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ABSTRACT	
	
THE	 INVESTIGATION	 OF	 AT7519	 (CDK	 INHIBITOR)	 AND	 AT13387	 (HSP90	
INHIBITOR)	AS	NOVEL	THERAPIES	FOR	THE	TREATMENT	OF	PANCREATIC	DUCTAL	
ADENOCARCINOMA	
Author:	Amy	Jayne	Thomas	MBChB,	MRCS	(Eng)	
	
BACKGROUND:	 Pancreatic	 ductal	 adenocarcinoma	 (PDAC)	 is	 usually	 a	 systemic	
disease	 and	 so	 requires	 chemotherapy	 even	 when	 surgical	 resection	 is	 possible.	
Current	agents	such	as	gemcitabine	are	only	effective	in	a	minority	of	patients	and	
chemoresistance	 is	 an	 important	 issue	 faced	 in	 pancreatic	 cancer.	 	 There	 is	 an	
urgent	 need	 for	more	 effective	 therapies;	 Novel	 agents	may	 offer	 an	 avenue	 for	
this.	 The	 CDK	 family	 of	 protein	 kinases	 are	 pivotal	 in	 cell	 cycle	 regulation	 that	 is	
often	 deranged	 in	 cancer.	 HSP90	 is	 a	molecular	 chaperone	 affecting	multiple	 key	
cellular	signaling	pathways	of	importance	in	pancreatic	cancer.	
OBJECTIVES:	 To	 determine	 the	 efficacy	 of	 AT7519,	 a	 novel	 CDK	 inhibitor,	 and	
AT13387,	a	novel	HSP90	 inhibitor	 in	pancreatic	cancer	models	 in	vivo	and	 in	vitro	
both	as	single	agents	and	in	combination	with	gemcitabine.	
METHODS:	 Cell	 proliferation	 was	 measured	 using	 the	 EZ4U	 assay.	 	 Cell	 cycle	
analysis	 was	 performed	 with	 flow	 cytometry.	 	 Apoptosis	 analysis	 was	 using	 the	
Caspase-Glo	3/7	luminescent	assay.	Western	blotting	assessed	expression	of	client	
proteins	and	phosphorylation.	A	murine	xenograft	model	was	employed	assessing	
tumour	volumes	with	external	calipers.		Experiments	were	performed	using	AT7519	
and	AT13387	as	single	agents	and	in	combination	with	gemcitabine.	
RESULTS:	 AT7519	 inhibited	 proliferation	 in	 cell	 lines	 including	 a	 gemcitabine	
resistant	 line	 (SUIT-2	GR)	with	 IC50	 values	 ranging	 5-2000nM.	 	 Cell	 cycle	 analysis	
showed	actions	 in	 line	with	CDK	 inhibition.	 	At	24	hours	 induction	of	 caspase	3/7	
was	significantly	 increased	in	AT7519	treated	cells	compared	with	those	in	control	
media	(p=0.01).		Phosphorylation	of	client	proteins	were	inhibited.		Isobolar	analysis	
of	 AT7519	 combined	with	 gemcitabine	 suggested	 an	 additive	 effect.	 AT7519	was	
tolerated	 as	 a	 single	 agent	 and	 in	 combination	 with	 gemcitabine	 in	 a	 xenograft	
model	and	resulted	in	slowed	tumour	growth	compared	to	control	(p	=	0.0446).			
AT13387	 inhibited	 proliferation	 of	 all	 cell-lines	 with	 IC50	 values	 of	 29nM-325nM	
including	 a	 cell	 line	with	 acquired	 gemcitabine	 resistance.	 	 AT13387	 treated	 cells	
accumulated	 in	G0/G1	and	G2/M	phases	of	 the	cell	 cycle	 (p<0.05).	Late	apoptosis	
was	seen	after	40	hours	post	treatment	with	At13387.		AT13387	treatment	resulted	
in	 down-regulation	 of	 HSP90	 client	 proteins	 and	 up-regulation	 of	 the	 HSP70	 co-
chaperone.		AT13387	was	tolerated	and	moderately	efficicacous	as	a	singe	agent	in	
a	 murine	 xenograft	 model	 but	 was	 poorly	 tolerated	 in	 combination	 with	
gemcitabine	and	conferred	no	benefit	over	single	agents.	
CONCLUSIONS:	AT7519	is	a	promising	agent	for	combination	therapy	in	pancreatic	
cancer,	as	acquired	resistance	to	gemcitabine	does	not	give	AT7519	resistance.	
AT13387	 showed	promising	effects	 in	 vitro	but	was	poorly	 tolerated	 in	an	 in	 vivo	
combination	with	 standard	 therapy	 therefore	may	offer	 a	 therapeutic	 avenue	 for	
non-responders	to	conventional	therapies.	
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CHAPTER	1:	INTRODUCTION	
	
	
1.1	EPIDEMIOLOGY	
Pancreatic	cancer	continues	to	a	pose	significant	health	problem	being	the	5th	most	
common	cause	of	cancer	death	in	the	UK.		Despite	current	research	and	advances	in	
understanding	pancreatic	cancer	biology,	imaging	detection	methods	and	improved	
surgical	outcomes,	the	prognosis	remains	poor	with	a	five-year	survival	of	between	
10-25%	 in	 resected	 disease(Richter,	 Niedergethmann	 et	 al.	 2003;	 Cress,	 Yin	 et	 al.	
2006).		The	mortality	roughly	equates	to	the	incidence;	in	2012	in	the	UK	there	were	
8,888	new	cases	of	pancreatic	cancer	and	8,622	deaths(UK	2014).		Despite	advances	
in	many	 other	 cancers	 resulting	 in	 improved	 survival	 the	 incidence	 and	mortality	
rates	for	pancreatic	cancer	have	not	seen	any	significant	improvement	over	the	last	
30	years	(Malvezzi,	Bertuccio	et	al.	2012).	
	
1.1.1	Age	
Advancing	age	is	associated	with	an	increased	incidence	of	pancreatic	cancer.		The	
peak	incidence	occurs	at	age	65-75(Lankisch,	Assmus	et	al.	2002),	less	than	0.3%	of	
cancers	occur	 in	those	under	40	years(Luttges,	Stigge	et	al.	2004).	 	Comparing	the	
incidence	in	different	age	groups	shows	in	those	over	the	age	of	80	incidence	is	100	
per	100	000	population	compared	to	2	per	100	000	for	those	between	40	and	44.	
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1.1.2	Gender	
Pancreatic	cancer	has	an	increased	incidence	in	the	male	population	compared	with	
females	 overall,	 though	 there	 is	 some	 geographical	 variation.	 	 For	 men	 the	 age-
standardised	worldwide	 rate	 is	 4.6	 per	 100	 000	 and	 3.3	 per	 100	 000	 for	 females	
(ratio	1.4:1)(Sahmoun,	D'Agostino	et	al.	2003).	
	
1.1.3	Geography	
Geographically	 the	 highest	 incidence	 for	 men	 is	 observed	 in	 Eastern	 Europe	 and	
North	 America,	 the	 lowest	 in	 southern/northern	 Africa	 and	 Southeast	 Asia.	 	 For	
women	 the	highest	 incidence	 is	 seen	 in	Northern	Europe	and	North	America,	 the	
lowest	is	the	same	as	males	in	Africa	and	Southeast	Asia	(7).	
	
1.2	AEITOLOGY	
Risk	factors	for	pancreatic	cancer	have	been	identified	that	include	both	genetic	and	
environmental	factors.		Approximately	10%	of	pancreatic	cancers	are	predominately	
due	 to	 a	 genetic	 predisposition	 associated	 with	 a	 range	 of	 syndromes	 and	
respective	 gene	mutations(Giardiello,	 Brensinger	 et	 al.	 2000;	 Lal,	 Liu	 et	 al.	 2000;	
McWilliams,	Rabe	et	al.	2005).	
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1.2.1	Familial	Pancreatic	Cancer	
A	 number	 of	 large	 epidemiological	 studies	 have	 established	 an	 increased	 risk	 of	
cancer	with	a	positive	family	history(Fernandez,	La	Vecchia	et	al.	1994;	Klein,	Brune	
et	al.	2004;	McWilliams,	Rabe	et	al.	2005).	Most	of	this	elevated	risk	is	probably	due	
to	 multigenetic	 factors,	 but	 there	 is	 evidence	 for	 a	 rare	 autosomal	 dominant	
condition	 (Familial	 Pancreatic	 Cancer).	 	 Early	 studies	 demonstrated	 families	 with	
increased	incidence	but	the	onset	of	cancer	was	not	early	and	histology	and	survival	
similar	 to	 sporadic	 cases	 (Ehrenthal,	 Haeger	 et	 al.	 1987;	 Ghadirian,	 Boyle	 et	 al.	
1991).	 	 	 	From	case-control	and	cohort	studies	 it	 is	clear	that	having	a	single-close	
relative	 with	 pancreatic	 cancer	 doubles	 an	 individuals	 lifetime	 risk	 of	 developing	
PDAC(Amundadottir,	 Thorvaldsson	 et	 al.	 2004;	 Hassan,	 Bondy	 et	 al.	 2007).	
Epidemiological	 studies	 have	 also	 shown	 that	 patients	 with	 a	 family	 history	 of	
pancreatic	cancer	also	have	an	increased	risk	of	extra	pancreatic	malignancies,	but	
this	 is	 not	 necessarily	 true	 in	 the	 autosomal	 dominant	 syndrome.	 	 Wang	 et	 al	
demonstrated	 that	 relatives	 of	 patients	 with	 cases	 of	 pancreatic	 cancer	 have	 an	
increased	 risk	 of	 dying	 from	 breast	 cancer	 (RR1.66,	 95%	 CI	 1.15-2.34),	 ovarian	
cancer	(RR	2.05,	95%	CI	1.10-3.49)	and	bile	duct	adenocarcinoma	(RR	2.89,	95%	CI	
1.04-6.39)(Wang,	Brune	et	al.	2009).		
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1.2.2	Hereditary	Cancer	Syndromes		
In	 most	 individuals	 with	 a	 predisposition	 for	 cancer	 the	 gene	 involved	 remains	
unknown,	however	a	number	of	known	genetic	syndromes	show	associations	with	
increased	risk	of	pancreatic	cancer	summarised	in	table	1.1.		PDAC	is	seen	in	some	
breast	 cancer	 families	 with	 BRCA1	 and	 BRCA	 2	 mutations(Couch,	 Johnson	 et	 al.	
2007)	 and	 BRCA2	 may	 account	 for	 up	 to	 5%	 of	 all	 pancreatic	 cancers(Goggins,	
Schutte	 et	 al.	 1996).	 	 Patients	 with	 familial	 atypical	 multiple	 mole	 melanoma	
(FAMM)	due	to	p16	gene	mutations	have	a	9	to	47-fold	increased	risk	of	developing	
pancreatic	cancer	and	pancreatic	cancer	is	the	second	most	common	cancer	in	this	
syndrome(Lynch	 and	 Fusaro	 1991;	 Vasen,	 Gruis	 et	 al.	 2000).	 	 Peutz-Jeghers	
syndrome	 is	 an	 autosomal	 dominant	 syndrome	 characterised	 by	 harmartomatous	
polyps	of	the	GI	tract	and	melanocytic	macules	of	the	oral	mucosa	and	lips.		Patients	
with	 Peutz-Jeghers	 syndrome	have	 a	 high	 risk	 of	 developing	 pancreatic	 cancer	 as	
well	 as	 other	 malignancies	 of	 the	 gastrointestinal	 tract	 and	 breast	
cancer(Boardman,	 Thibodeau	 et	 al.	 1998;	 Hearle,	 Schumacher	 et	 al.	 2006).		
Hereditary	 pancreatitis	 is	 a	 rare	 autosomal	 dominant	 condition	 characterised	 by	
recurrent	and	severe	attacks	of	acute	pancreatitis	at	a	young	age.		Mutations	in	the	
PRSS1	gene	have	been	shown	to	be	causative	in	hereditary	pancreatitis	and	patients	
have	a	lifetime	risk	of	developing	pancreatic	cancer	of	up	to	40%(Whitcomb,	Gorry	
et	al.	1996;	Lowenfels,	Maisonneuve	et	al.	1997).	
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Syndrome	 Gene	defect	 Increased	 risk	
of	PDAC	
Hereditary	 breast	 and	 ovarian	
cancer	
BRCA2,	FANC-C,	FANC-G,	PALB2	 3.5-10	fold	
FAMM	 P16	 9	to	47	fold	
Hereditary	pancreatitis	 PRSS1,	SPINK1	 50	to	80	fold	
Peutz-Jeghers	 STK11	 132-fold	
Li-Fraumeni	 P53	 unknown	
Cystic	fibrosis	 7q31	 2-61-fold	
Table	1.1	Table	showing	the	hereditary	cancer	syndromes	affecting	the	pancreas	
with	known	gene	defects	and	the	noted	increased	risk	of	pancreatic	cancer.	
	
1.2.3	Chronic	Pancreatitis	
Chronic	 pancreatitis	 is	 a	 well-recognised	 risk	 factors	 for	 the	 development	 of	
pancreatic	cancer.	 	The	cumulative	25-year	 risk	of	pancreatic	cancer	 in	 individuals	
with	chronic	pancreatitis	has	been	quoted	at	around	4%(Lowenfels,	Maisonneuve	et	
al.	 1993).	 	 	 Lowenfels	 et	 al	 looked	 a	 large	 cohort	 of	 patients	 with	 chronic	
pancreatitis	 and	 showed	 a	 six	 times	 greater	 risk	 of	 development	 of	 pancreatic	
cancer	in	affected	individuals(Lowenfels,	Maisonneuve	et	al.	1993).	In	another	large	
case-control	 study	a	history	of	chronic	pancreatitis	or	acute	pancreatitis	 for	seven	
years	 or	more	 confirmed	 an	 increased	 risk	 of	 pancreatic	 cancer	 (RR	 2.03,	 95%	 CI	
1.53-2.72)(Bansal	and	Sonnenberg	1995).	
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1.2.4	Diabetes	Mellitus	
The	 association	 between	 pancreatic	 cancer	 and	 diabetes	 mellitus	 has	 been	
investigated	in	depth	as	both	a	causative	factor	and	a	feature	of	early	disease.	Large	
prospective	cohort	study	in	US	investigated	the	independent	association	with	post-
load	plasma	glucose	 concentration	 and	 risk	 of	 pancreatic	 cancer	mortality	 among	
individuals	without	 self	 reported	 diabetes.	 	 This	 study	 concluded	 that	 the	 factors	
associated	with	 abnormal	 glucose	metabolism	may	 play	 an	 important	 role	 in	 the	
aetiology	of	PDAC	(Gapstur,	Gann	et	al.	2000).	A	early	meta	analysis	found	a	relative	
risk	of	2.0	for	pancreatic	cancer	in	patients	with	at	least	a	5	year	history	of	diabetes	
mellitus	 compared	with	 non-diabetics(Everhart	 and	Wright	 1995).	 	 A	 recent	meta	
analysis	concluded	that	DM	is	both	an	early	manifestation	of	pancreatic	cancer	and	
an	etiologic	factor(Ben,	Xu	et	al.	2011).	
	
1.2.5	Smoking	
The	causal	link	between	smoking	and	pancreatic	cancer	has	been	demonstrated	in	a	
number	 of	 studies	 dating	 back	 almost	 as	 far	 as	 30	 years(Gordis	 and	 Gold	 1984;	
Hirayama	1989).		There	is	a	clear	dose	response	noted	(Falk,	Pickle	et	al.	1988)	and	
risk	can	be	reduced	after	a	period	of	abstinence(Howe,	Ghadirian	et	al.	1992).	 	 In	
some	 case-control	 studies	 the	 risk	 of	 PDAC	 rises	with	 excessive	 lifetime	 cigarette	
consumption.		Being	a	smoker	and	having	a	first	degree	relative	with	PDAC	further	
increased	 the	overall	 relative	 risk	 (RR6.02,	95%	CI	1.98-18.29)(Ghadirian,	 Lynch	et	
al.	2003).	
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Smoking	and	chronic	pancreatitis	have	also	been	shown	to	be	significant	risk	factors	
for	 the	 development	 of	 pancreatic	 cancer(Lowenfels,	 Maisonneuve	 et	 al.	 1993;	
Nilsen	and	Vatten	2000).			
	
1.2.6	Alcohol	intake	
The	 association	 between	 acute	 and	 chronic	 pancreatitis	 and	 heavy	 alcohol	
consumption	has	been	well	recognised	but	its	link	definitively	to	pancreatic	cancer	
has	 been	 somewhat	 elusive.	 	 	 The	 study	 evidence	 was	 reviewed	 by	 a	 panel	 of	
experts	in	2009	convened	by	the	Agency	for	research	on	cancer	(Secretan,	Straif	et	
al.	 2009).	 Previous	 studies	 including	 cohort	 studies	 and	 meta-analyses	 of	
prospective	studies	reported	significant	association	between	pancreatic	cancer	risk	
and	 alcohol	 consumption(Heuch,	 Kvale	 et	 al.	 1983;	 Heinen,	 Verhage	 et	 al.	 2009;	
Michaud,	 Vrieling	 et	 al.	 2010;	 Tramacere,	 Scotti	 et	 al.	 2010)	 but	 others	
demonstrated	no	association(Isaksson,	Jonsson	et	al.	2002;	Rohrmann,	Linseisen	et	
al.	2009).		These	previous	studies	lacked	convincing	evidence	owing	to	a	number	of	
factors	 including	design	of	 studies,	 potential	 confounding	 factors	namely	 smoking	
and	the	associations	limited	in	a	number	of	studies	by	sample	size,	potential	recall	
bias	and	selection	bias.		In	2011	the	Cancer	prevention	study	II	published	its	findings	
into	the	relationship	between	alcohol	consumption	and	pancreatic	cancer.		This	was	
a	large	prospective	cohort	study	with	data	from	approximately	1.2	million	subjects	
in	the	USA.		This	study	confirmed	that	consumption	of	3	or	more	drinks	per	day	was	
associated	 with	 pancreatic	 cancer	 mortality	 in	 both	 non	 smokers	 and	 smokers	
specifically	in	spirit	consumption	but	not	wine	or	beer(Gapstur,	Jacobs	et	al.	2011).		
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This	 study	 is	 the	 clearest	 to	 date	 to	 suggest	 heavy	 alcohol	 intake	 is	 associated	
independently	with	pancreatic	cancer	mortality.	
	
1.2.7	Nutrition	
Some	 studies	 have	 reported	 dietary	 factors	 as	 possible	 risk	 factors	 for	 the	
development	 of	 PDAC.	 Increased	 intake	 of	meat,	 dairy	 products,	 eggs,	milk,	 fried	
food	and	salt	have	been	suggested	though	thus	far	an	 independent	causative	role	
has	not	been	proven	not	least	owing	to	the	difficulties	of	isolating	nutritional	factors	
as	independent	causative	agents	(Ghadirian,	Lynch	et	al.	2003).		
	
1.2.8	Obesity	
There	 have	 been	 large	 cohort	 studies	 investigating	 the	 relationship	 between	
pancreatic	cancer	and	obesity.		Results	have	shown	that	a	Body	mass	index	of	30	or	
greater	had	an	increased	risk	of	cancer	compared	with	patients	with	a	BMI	of	23	(RR	
1.72,	CI	95%	1.19-2.48)	(Michaud,	Giovannucci	et	al.	2001).		In	a	UK	meta	analysis	by	
cancer	 research	 there	 was	 a	 weak	 association	 between	 obesity	 and	 pancreatic	
cancer	(RR1.19,	95%	CI	1.1-1.29)(Berrington	de	Gonzalez,	Sweetland	et	al.	2003).	
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1.2.9	Previous	surgery	
Studies	into	the	link	between	previous	surgery	and	pancreatic	cancer	has	provided	
conflicting	 evidence.	 	 One	 study	 showed	 an	 increased	 risk	 of	 PDAC	 after	
gastrectomy	for	peptic	ulcer	disease	(RR1.8,	95%	CI	1.3-2.6)	but	no	association	was	
evident	in	another	Italian	study(Tascilar,	van	Rees	et	al.	2002)	
	
1.3	HISTOPATHOLOGY	
Over	 recent	 times	 there	 has	 been	 research	 that	 has	 provided	 a	 greater	
understanding	 of	 the	 molecular	 basis	 of	 pancreatic	 cancer	 and	 histopathological	
processes	underpinning	its	development.	
	
1.3.1	PanIN	Lesions		
The	 development	 of	 pancreatic	 cancer	 has	 been	 well	 described	 as	 a	 stepwise	
process	 involving	 precursor	 lesions	 named	 pancreatic	 intraepithelial	 neoplasia	
(PanIN)	which	has	resulted	in	a	model	of	progression	of	these	lesions	to	pancreatic	
ductal	adenocarcinoma	shown	in	figure	1.1.		A	classification	based	on	morphologic	
features	 as	 been	developed	with	 three	 grades	 of	 PanIN	 lesions:	 PanIN-1,	 PanIN-2	
and	PanIN-3,	it	as	been	noted	that	PanIN-3	lesions	occur	in	association	with	PDAC	in	
around	 half	 of	 cases	 histologically	 examined,	 supporting	 the	 concept	 that	 high-
grade	PanIN	lesions	are	precursor	lesions	for	PDAC.	PanIN	lesions	are	found	in	the	
smaller	 pancreatic	 ducts	 (<5mm)	where	 the	 usual	 cuboidal	 flat	 epithelial	 lining	 is	
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replaced	by	columnar	mucinous	cells.		PanIN-1	lesions	are	classified	as	PanIN-1A	or	
PanIN-1B.	 	 In	 PanIN-1A	 the	mucinous	 epithelium	 is	 flat	 and	 in	 PanIN-1B	 papillary	
mucinous	 epithelium	 is	 present,	 both	 have	 minimal	 cytonuclear	 atypical	
appearances.		In	PanIN-2	lesions	there	is	a	greater	degree	of	cytonuclear	atypia	and	
appearances	 consistent	 with	 low-grade	 dysplasia	 and	 in	 PanIN-3	 lesions	 complex	
papillary	architecture,	mitotic	figures,	nuclear	pleomorphism	and	at	times	necrosis	
resulting	in	appearances	consistent	with	high-grade	dysplasia	or	carcinoma	–in-situ.		
In	PanIN-3	lesions	there	is	no	invasive	growth	and	the	lesion	is	still	combined	within	
the	basement	membrane(Hruban,	Adsay	et	al.	2001).			
	
Figure	 1.1	 Figure	 showing	 the	 progression	 model	 of	 pancreatic	 cancer	 (Klein,	
Hruban	et	al.	2002)	
	
	
Evidence	for	PanIN	lesions	being	precursor	lesions	for	PDAC	comes	from	histological	
analysis	 and	 common	 genetic	 mutations	 in	 these	 lesions	 and	 PDAC.	 	 In	 autopsy	
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studies	 an	 increased	 prevalence	 of	 PanINs	 was	 documented	 with	 increasing	 age	
corresponding	with	 increased	 rates	of	PDAC(Cubilla	and	Fitzgerald	1976).	 	 Further	
studies	examined	resection	specimens	of	PDAC	revealing	presence	of	PanINs	in	the	
area	surrounding	a	tumour.	PanIN-1	were	found	in	75%,	PanIN-2	in	65%	and	PanIN-
3	in	50%(Andea,	Sarkar	et	al.	2003)	and	Brat	et	al	presented	3	cases	of	patient	with	
documented	 PanIN	 lesions	 that	 went	 on	 to	 develop	 PDAC(Brat,	 Lillemoe	 et	 al.	
1998).	 	 The	 genetic	 and	 epigenetic	 mutations	 commonly	 found	 in	 PDAC	 are	
discussed	in	later	chapters	but	it	is	noted	that	common	mutations	occur	in		PanINs.		
Kras2	mutations	are	found	in	up	to	85%	of	PanIN-3	lesions(Lohr,	Kloppel	et	al.	2005)	
and	 mutation	 of	 the	 important	 tumour	 suppressor	 gene	 p16	 has	 also	 been	
documented	 in	 PanIN	 lesions(Wilentz,	 Geradts	 et	 al.	 1998).	 	 Positive	
immunostaining	 has	 been	 shown	 as	 a	 surrogate	 marker	 of	 mutation	 and	
inactivation	 of	 the	 p53	 tumour	 suppressor	 gene	 and	 has	 been	 demonstrated	 in	
PanIN	 lesions(Baas,	 Mulder	 et	 al.	 1994;	 Maitra,	 Adsay	 et	 al.	 2003)	 and	 SMAD4	
tumour	suppressor	gene	mutations	and	BRCA2	mutations	have	also	been	identified	
in	PanIN-3	lesions(Wilentz,	Iacobuzio-Donahue	et	al.	2000).	
	
The	transition	of	high-grade	PanIN	to	PDAC	is	still	an	area	of	 investigation	and	the	
genetic	 alterations	 that	 may	 play	 a	 role	 in	 this	 transition	 are	 still	 not	 clearly	
understood	or	mostly	unknown(Murphy,	Hart	et	al.	2013).		Investigation	of	genetic	
data	 has	 suggested	 there	 is	 nearly	 a	 12	 year	window	 from	 the	 earliest	 precursor	
lesion	 changes	 to	 PDAC	 in	 a	 mathematical	 model(Iacobuzio-Donahue	 2012)	 so	
clearly	this	raises	the	possibility	of	changing	genetics	of	lesions	as	they	develop	and	
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also	suggests	a	significant	window	of	opportunity	to	modify	these	changes	as	they	
are	further	understood	in	the	future(Brosens,	Hackeng	et	al.	2015).	
		
1.3.2	PDAC	
Pancreatic	 ductal	 adenocarcinoma	 is	 the	most	 common	malignancy	 found	 in	 the	
pancreas.	 	 Solid	 tumours	with	poorly	demarcated	edges	being	characteristic.	 	 The	
majority	of	PDAC	tumours	are	well	to	moderately	differentiated	formed	by	tubular	
or	 duct-like	 structures	 resulting	 from	 mucinous	 columnar	 cells.	 	 The	 tubular	
structures	are	lined	by	a	single	layer	of	epithelia	cells	sometimes	showing	papillary	
projections.		Macroscopically	this	demonstrates	poorly	demarcated	nodular	growth	
with	areas	of	necrosis	or	haemorrhage	and	a	marked	desmoplastic	reaction	 in	the	
surrounding	 tissues.	 In	 moderately	 and	 poorly	 differentiated	 tumours	 there	 is	
increasing	 cellular	 irregularity	 poorly	 formed	 glands	 and	 decreased	 mucous	
production.	 	There	are	 further	malignant	 tumour	 types	of	 the	pancreas	which	are	
closely	 related	 to	 PDAC	 and	 considered	 variants	 of	 PDAC	 though	 these	 are	 less	
common,	 as	 well	 as	 other	 malignant	 solid	 and	 cystic	 neoplasms	 all	 with	 varying	
prognoses.		Table	1.2	summaries	the	various	histological	types	seen.		
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Histological	tumour	type	 Frequency	 Prognosis	
Solid	Tumours	
Ductal	adenocarcinoma	and	variants	 90%	 Poor	
Acinar	cell	carcinoma	 1%	 Poor	
Pancreatoblastoma	 <1%	 Poor	
Endocrine	tumours	 2%	 Intermediate*	
Non-epithelial	tumours	 Rare	 Intermediate*	
Cystic	tumours	
Intraductal	papillary	mucinous	
neoplasms	
2%	 favourable	
Mucinous	cystic	neoplasms	 1%	 favourable	
Serous	cystic	neoplasms	 1%	 favourable	
Solid	psuedopapillary	neoplasm	 <1%	 favourable	
Other	cystic	tumours	 1%	 Intermediate*	
Nonepithetial	lesions	and	tumours	 Rare	 Intermediate*	
*dependent	on	subtype	
Table	1.2	The	general	features	of	pancreatic	tumours.		Adapted	from	the	pancreas	
an	 integrated	 textbook	 of	 basic	 science,	 medicine	 and	 surgery	 second	 edition	
Beger	et	al	Blackwell	publishing	2008(Beger	2008).	
	
At	the	time	of	diagnosis	there	is	often	local	dissemination	of	disease	with	perineural	
invasion	 and	 spread	 to	 the	 peripancreatic	 fatty	 tissue	 almost	 universal	 and	
commonly	invasion	of	lymphatic	vessels,	veins	and	nerves.	
	
Histological	analysis	of	tumours	can	be	undertaken	with	cytokines	7,	8,	18	and	19,	
CEA	and	MUC1,	these	remain	important	though	not	specific	to	PDAC	and	conversely	
negative	 staining	 for	neuroendocrine	markers	and	pancreatic	enzymes	are	helpful	
diagnostically(Batge,	 Bosslet	 et	 al.	 1986;	 Takeda,	 Nakao	 et	 al.	 1991).	 	 Genetic	
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mutations	 in	Kras,	p16,	p53	and	SMAD4	can	often	be	demonstrated	 (discussed	 in	
section	 1.4)	 as	 well	 as	 overexpression	 of	 EGFR	 and	 HER2	 and	 less	 commonly	
VEGF(Apple,	Hecht	et	al.	1999;	Sipos,	Weber	et	al.	2002)	
	
1.3.3	Histopathological	grading	and	staging		
Kloppel	et	al	developed	a	system	of	grading	pancreatic	tumours	that	encompassed	
the	 variable	 histological	 characteristic	 of	 tumours	 between	 tumours	 and	 within	
individual	 tumours	 initially	 in	 1985(Kloppel,	 Lingenthal	 et	 al.	 1985).	 	 Since	 then	
other	grading	systems	have	been	employed.		The	Japan	Pancreas	society	described	
a	 more	 complex	 system	 assigning	 grades	 for	 a	 variety	 of	 tissue	 structures	
(mizumoto	1996).			
	
The	 UICC	 recommendation	 is	 that	 the	 least	 favourable	 grade	 recorded	 in	 an	
individual	 tumour	 should	 be	 that	 assigned(Sobin	 and	 Fleming	 1997)	 and	 the	
International	 pancreatic	 cancer	 study	 group	 has	 recommended	 that	 the	
predominant	grade	and	any	other	observed	should	be	recorded.		From	the	various	
recommendations	it	remains	true	that	all	areas	of	the	tumour	should	be	examined	
as	accurate	grading	 remains	 important	and	can	give	prognostic	 information	 (table	
1.3).	
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Histopathological	grading		
GX	 Grade	of	differentiation	cannot	be	assessed	
G1	 Well	differentiated	
G2	 Moderately	differentiated	
G3	 Poorly	differentiated	
G4	 Undifferentiated	
Table	1.3	The	histological	grading	of	PDAC,	adapted	from	Guzman	et	al	(Guzman	G	
2007)	
	
The	 American	 Joint	 Committee	 on	 Cancer	 (AJCC)	 TNM	 classification	 is	 the	 most	
widely	 used	 system	 to	 stage	 PDAC	 and	 describes	 the	 anatomical	 extent	 of	 the	
cancer	 in	 relation	 to	 the	 local	 tumour,	 lymph	 node	 metastasis	 and	 any	 distant	
metastasis(Wolfgang,	Herman	et	al.	2013)	(table	1.4).	
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T	-	Primary	Tumour	
TX	 Primary	tumour	cannot	be	assessed	
T0	 No	evidence	of	primary	tumour	
Tis	 Carcinoma	in	situ*	
T1	 Tumour	limited	to	pancreas,	2cm	or	less	in	greatest	dimension	
T2	 Tumour	limited	to	pancreas,	more	than	2cm	in	greatest	dimension	
T3	
Tumour	extends	beyond	pancreas,	but	without	involvement	of	coeliac	axis	
or	superior	mesenteric	artery	
T4	 Tumour	involves	coeliac	axis	or	superior	mesenteric	artery	
N	-	Regional	Lymph	Nodes	
NX	 Regional	lymph	nodes	cannot	be	assessed	
N0	 No	regional	lymph	node	metastasis	
pN0	
Lymph	nodes	negative	but	number	ordinarily	examined	are	not	met	(10	or	
more)	
N1	 Regional	lymph	node	metastasis	
M	–	Distant	Metastasis	
M0	 No	distant	metastasis	
M1	 Distant	metastasis	
pM1	 Distant	metastasis	microscopically	confirmed	
Note:	*Tis	also	includes	the	'PanIN-III'	classification.	
Note:	The	MX	category	 is	considered	to	be	 inappropriate	as	clinical	assessment	of	
metastasis	can	be	based	on	physical	examination	alone.	(The	use	of	MX	may	result	
in	exclusion	from	staging).	
Table	1.4	Table	showing	thr	TNM	and	pTNM	classification	of	PDAC	which	provides	
a	 general	 anatomical	 staging	 of	 disease,	 adapted	 from	National	 Comprehensive	
Cancer	Network	
http://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	
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The	TNM	staging	describes	 the	cancer	without	considering	 treatment,	 this	 staging	
can	be	supplemented	with	the	R	classification	which	describes	tumour	status	after	
treatment	therefore	reflecting	the	effects	of	therapy	and	giving	a	stronger	predictor	
of	prognosis	(table	1.5).	
	
In	 PDAC	 lymph	 node	 involvements	 has	 been	 shown	 as	 a	 negative	 prognostic	
indicator	 in	 multivariate	 analysis(Ferrone,	 Finkelstein	 et	 al.	 2006;	 Shimada,	
Sakamoto	et	al.	2006;	Winter,	Cameron	et	al.	2006;	Schnelldorfer,	Ware	et	al.	2008).	
Resection	margin	involvement	is	also	considered	of	prognostic	significance	in	PDAC.		
In	the	literature	R1	rate	(positive	resection	margins)	vary	significantly	and	the	rates	
of	margin	involvement	and	local	recurrence	often	variable	(Benassai,	Mastrorilli	et	
al.	2000;	Jarufe,	Coldham	et	al.	2004;	Han,	Jang	et	al.	2006;	Moon,	An	et	al.	2006;	
Sierzega,	Popiela	et	al.	2006).	 	Guidance	from	the	royal	college	of	pathologists	has	
stated	for	PDAC	when	there	is	carcinoma	present	less	than	1mm	from	the	resection	
margin	the	margin	should	be	considered	positive	i.e.	R1	and	for	the	anterior	surface	
of	the	pancreas	0mm	would	be	appropriate	as	this	is	an	anatomical	surface	rather	
than	 a	 surgical	 resection	 margin(Campbell,	 Smith	 et	 al.	 2009;	 Van	 den	 Broeck,	
Sergeant	et	al.	2009).	
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Residual	Tumour	(R)	Classification*	
RX	 Presence	of	residual	tumour	cannot	be	assessed	
R0	 No	residual	tumour	
R1	 Microscopic	residual	tumour	
R2	 Macroscopic	residual	tumour	
RX	 Presence	of	residual	tumour	cannot	be	assessed	
Note:	*some	consider	the	R	classification	to	apply	only	to	the	primary	tumour	and	
its	 local	or	regional	extent.	Others	have	applied	 it	more	broadly	to	 include	distant	
metastasis.	The	specific	usage	should	be	indicated	when	the	R	is	used	
Table	 1.5	 The	 residual	 tumour	 (R)	 classification	 of	 pancreatic	 tumours	 which	
classifies	cancer	status	after	treatment,	adapted	from	Wittekind	et	al	 (Wittekind	
CH	2003).	
	
	
An	 overall	 staging	 of	 disease	 based	 on	 the	 TNM	 status	 provides	 a	 standardized	
classification	 system	 to	 determine	 appropriate	 treatment	 options	 and	 provide	
prognostic	information	from	the	time	of	diagnosis	(table	1.6).			Resectable	disease	is	
classed	as	stage	II,	borderline	stage	III	and	I	and	unresectable	or	advanced	is	stage	
IV.	 	 This	 classification	 system	 allows	 clinician	 to	 determine	 the	 best	 treatment	
options	moving	forward	and	also	prognostic	information.	
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Stage	Grouping	
Stage	0	 Tis	 N0	 M0	
Stage	IA	 T1	 N0	 M0	
Stage	IB	 T2	 N0	 M0	
Stage	IIA	 T3	 N0	 M0	
Stage	IIB	 T1,	T2,	T3	 N1	 M0	
Stage	III	 T4	 Any	N	 M0	
Stage	IV	 Any	T	 Any	N	 M1	
Table	1.6	 table	 showing	 the	overall	 stage	groupings	of	PDAC	based	on	 the	TNM	
classification,	 adapted	 from	 National	 Comprehensive	 Cancer	 Network	
http://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf	
	
	
1.4	CANCER	MOLECULAR	BIOLOGY	
	
1.4.1	Alterations	in	oncogenic	pathways	in	pancreatic	cancer	
Known	molecular	pathways	 in	pancreatic	cancer	that	promote	tumourigenesis	are	
related	to	a	number	of	oncogenes	and	tumour	suppressor	genes.	
	
1.4.2	Kras	mutations	
The	most	common	mutation	found	in	PDAC	is	that	of	the	oncogene	KRAS,	reported	
mutated	in	up	to	90%	of	pancreatic	cancers(Almoguera,	Shibata	et	al.	1988;	Hruban,	
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van	 Mansfeld	 et	 al.	 1993).	 	 Mutations	 of	 KRAS	 affect	 codon	 12	 primarily	 but	
aberrations	 have	 also	 been	 found	 in	 codons	 13	 and	 61	 (19).	 	 The	 mutant	 KRAS	
expresses	a	protein	(Kras)	that	does	not	self	 inactivate	and	so	 is	suspended	 in	the	
GTP-bound	state	which	stimulates	a	number	of	downstream	signalling	cascades	 in	
the	development	and	progression	of	PDAC(Malumbres	and	Barbacid	2003).	
	
1.4.3	Growth	factor	receptors			
Inappropriate	expression	of	 a	 variety	of	 growth	 factor	 receptors	 are	also	deemed	
important	 in	 PDAC.	 	 Epidermal	 growth	 factor	 receptor	 is	 a	 member	 of	 the	 ErbB	
family	 of	 receptor	 tyrosine	 kinases	 that	 has	 been	 demonstrated	 to	 be	 over	
expressed	in	PDAC(Korc,	Chandrasekar	et	al.	1992)	along	with	the	principal	natural	
ligands	for	EGFR,	epidermal	growth	factor	and	transforming	growth	factor-α.		EGFR	
causes	receptor	homo	or	heterodimerisation	by	binding	ligands	to	the	extracellular	
domain.	 This	 results	 in	 phosphorylation	 of	 tyrosine	 residues	 on	 the	 intracellular	
domain	 providing	 docking	 sites	 for	 mediators	 activating	 downstream	 signalling	
pathways:	 including	 PI3K/Akt	 signalling	 pathway	 (mediating	 cell	 cycle	 progression	
and	 survival);	 Ras-Raf-MEK	 pathway	 (transmitting	 growth	 signals)	 and	 other	
pathways	 that	 facilitate	 a	 number	 of	 functions	 advantageous	 for	 cancer	 cell	
survival(Marshall	2006).		A	variety	of	other	growth	factor	receptors	and	their	ligands	
are	 expressed	 in	 PanIN	 lesions	 and	 PDAC	 including	 insulin-like	 growth	 factor	 and	
vascular	 endothelial	 growth	 factor	 (VEGF)	 receptor	 promoting	 endothelial	 cell	
proliferation	and	survival,	thereby	enhancing	tumour	angiogenesis.	VEGF	expression	
	 21	
(mainly	 VEGF-A)	 is	 noted	 in	 up	 to	 90%	 of	 pancreatic	 cancers	 and	 confers	 poor	
survival	when	at	moderate/high	levels(Seo,	Baba	et	al.	2000).	
	
1.4.4	p16	
Aberrant	 p16	 expression	 and	 namely	 alterations	 in	 the	 p16INK4A/retinoblastoma	
protein	 pathway	 affecting	 tumour	 suppressor	 genes	 has	 also	 been	 identified	 in	
PDAC.	 	 In	 PDAC	 the	 pathway	 is	 abrogated	 through	 functional	 inactivation	 of	 the	
INK4A	gene,	this	results	 in	a	 lack	of	 the	normal	suppression	of	phosphorylation	of	
Rb	 that	 blocks	 entry	 into	 S	 phase	 and	 mitogenic	 signals	 in	 the	 cell	 cycle(Caldas,	
Hahn	et	al.	1994;	Rozenblum,	Schutte	et	al.	1997).	
	
1.4.5	p53	
The	 TP53	 tumour	 suppressor	 gene	 is	 the	 most	 commonly	 inactivated	 gene	 in	
cancers	 in	general	and	more	than	50%	of	pancreatic	cancers	 (Waddell,	Pajic	et	al.	
2015)..	 	 p53	 is	 usually	 activated	 in	 response	 to	 a	 range	 of	 cellular	 stresses	 and	
regulates	 transcription	 leading	 to	cell	 cycle	arrest	or	apoptosis.	 	Mutations	of	p53	
are	thought	to	occur	 in	the	 latter	PanIN	 lesions	and	aberrant	p53	to	contribute	to	
the	 extensive	 genetic	 instability	 that	 characterises	 PDAC(Hingorani,	 Wang	 et	 al.	
2005).	
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1.4.6	Smad4	
Mutations	 of	 SMAD4,	 originally	 identified	 as	 a	 tumour	 suppressor	 gene	 in	
pancreatic	cancer	are	more	common	in	this	setting	than	in	any	other	cancer.	Smad4	
lies	downstream	to	the	polypeptide	growth	factor	TGF-β	which	affects	cell	growth,	
differentiation,	angiogenesis	and	invasion.	 	Loss	of	Smad4	has	been	shown	to	lead	
to	amelioration	of	TGF-β	tumour	suppressive	functions	and	maintenance	of	TGF-β	
mediated	tumour-promoting	functions(Levy	and	Hill	2005).	
	
1.4.7	Notch	pathway	
The	 Notch	 pathway,	 which	 is	 important	 developmentally	 in	 the	 pancreas,	 is	 also	
activated	 in	 the	 early	 stages	 of	 PDAC	 and	 is	 important	 in	 invasion(Leach	 2005;	
Lomberk,	Fernandez-Zapico	et	al.	2005).		Cell	surface	notch	receptors,	activated	by	
transmembrane	 ligands	 of	 the	 Delta	 and	 Jagged	 families,	 expressed	 on	
neighbouring	 cells,	 direct	 cell	 fate	 decisions	 and	 promotes	 vascularisation	 of	
tumours	when	activated(Rehman	and	Wang	2006).	
	
1.4.8	Hedgehog	pathway	
The	 Hedgehog	 pathway	 has	 a	 significant	 role	 in	 the	 development	 and	 growth	 of	
PDAC	as	well	as	the	tumour	microenvironment.		The	pathway	includes		the	ligands,	
Sonic	hedgehog,	Indian	hedgehog	and	desert	hedgehog	and	their	receptor	proteins	
smoothened	(smo)	and	patched	(ptc).		Research	has	shown	abnormal	expression	of	
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components	 of	 this	 pathway	 in	 PDAC	 that	 affects	 tumour	 growth	 as	 well	 as	
induction	 of	 stromal	 desmoplasia	 in	 PDAC,	 which	 contributes	 to	 the	
chemoresistance	 of	 PDAC(Kayed,	 Kleeff	 et	 al.	 2006;	 Bailey,	 Swanson	 et	 al.	 2008;	
Yauch,	Gould	et	 al.	 2008).	 	Although,	 trials	 of	 the	Hedgehog	 inhibitor	Vismodegib	
have	 so	 far	 proved	 unsuccessful	 in	 sensitising	 PDAC	 to	 gemcitabine	 (Catenacci,	
Junttila	et	al.	2015)	
	
1.4.9	Pathways	in	PDAC	
Jones	et	al(Jones,	Zhang	et	al.	2008)	performed	a	global	genomic	analysis	in	human	
PDAC	 specimens	 to	 reveal	 the	 key	 pathways	 that	 are	 frequently	 mutated	 in	
pancreatic	cancer	shown	in	figure	1.2.	 	This	 important	work	revealed	12	pathways	
that	are	commonly	mutated,	with	some	cancers	having	mutations	in	all	of	these	and	
most	displaying	mutation	of	at	 least	9.	 	The	identification	of	theses	core	pathways	
has	 facilitated	 further	 understanding	 of	 the	 pathogenesis	 of	 PDAC	 as	 well	 as	
highlighting	possible	avenues	for	new	therapy.	
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Figure	 1.2	 The	 12	 pathways	 and	 processes	 where	 component	 genes	 were	
genetically	 altered	 in	 the	 majority	 of	 pancreatic	 cancers	 identified	 on	 genomic	
analysis	of	24	samples	from	Advanced	PDAC	(adapted	from	Jones	et	al).	
	
1.4.10	Tumour	microenvironment	and	stroma	
One	 of	 the	 characteristics	 of	 pancreatic	 cancer	 is	 the	 formation	 of	 stroma	
surrounding	 the	 cancer	 termed	 a	 desmoplastic	 reaction(Chu,	 Kimmelman	 et	 al.	
2007).		This	stroma	surrounding	pancreatic	cancer	cells	is	often	poorly	vascularised	
and	contains	a	mixture	of	cellular	and	non-cellular	components.		Pancreatic	stellate	
cells	are	a	key	component	of	stroma	and	have	a	critical	role	in	the	development	and	
maintenance	 of	 the	 tumour	microenvironment.	When	 in	 a	 quiescent	 state	 these	
cells	 are	 characterised	 by	 the	 expression	 of	 desmin,	 glial	 fibrillary	 acidic	 proteins	
(GFAP)	 and	 vitamin	 A	 enriched	 intracellular	 fat	 droplets.	 	 When	 stimulated	 by	
growth	factors	such	as	TGF-β,	platelet	derived	growth	factor	or	 	 fibroblast	growth	
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factor	 the	 fat	 droplets	 disappear;	 the	 stellate	 cells	 then	 express	 alpha-smooth	
muscle	actin	and	produce	collagen	fibres	that	make	up	a	dense	matrix	surrounding	
the	tumour(Mahadevan	and	Von	Hoff	2007).	 	This	not	only	provides	a	mechanical	
barrier	 to	 the	 tumour	 but	 also	 results	 in	 a	 relatively	 hypoxic	 poorly	 vascularised	
tumour;	both	of	 these	 factors	provide	a	 therapeutic	challenge(Erkan,	Reiser-Erkan	
et	al.	2009;	Masamune	and	Shimosegawa	2009).		Further	features	of	these	stromal	
cells	 have	 been	 associated	 with	 poor	 prognosis	 and	 resistance	 to	 treatment.		
Stromal	 cells	 are	 known	 to	 express	 PDGF	 receptor,	 vascular	 endothelial	 growth	
factor,	 chemokines,	 intergrins	 and	 hedgehog	 pathway	 components	 all	 of	 which	
contribute	 to	 the	poor	prognosis	and	 relative	 therapeutic	 resistance	of	pancreatic	
cancers(Zhang,	Erkan	et	al.	2007).	
	
1.5	CURRENT	THERAPY	
	
1.5.1	Therapy	in	resectable	disease	
Surgical	resection	continues	to	be	the	only	intervention	for	potential	cure	in	15-20%	
of	 patients(Alexakis,	 Halloran	 et	 al.	 2004),	 the	 remainder	 presenting	 with	
unresectable	 disease.	 	 Even	 following	 a	 potentially	 curative	 resection,	 recurrence	
rates	are	high	owing	 to	 residual	macroscopic	disease(Sperti,	Pasquali	et	al.	 1997).			
In	 an	 effort	 to	 improve	 survival,	 more	 radical	 approaches	 to	 surgical	 resections	
including	 extended	 lymphadenectomy	 and	 total	 pancreatectomy	 have	 been	
attempted,	 however,	 these	 have	 failed	 to	 prove	 any	 demonstrable	 survival	
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benefit(Fortner,	Klimstra	et	al.	1996;	Pedrazzoli,	DiCarlo	et	al.	1998;	Yeo,	Cameron	
et	al.	2002;	Farnell,	Pearson	et	al.	2005;	Muller,	Friess	et	al.	2007).			
	
The	 basis	 of	 current	 therapies	 for	 PDAC	 involves	 targeting	 of	 DNA	 replication	 by	
inhibition	 of	 thymidylate	 synthase	 and	 incorporation	 of	 fluorouridine	 derivatives	
into	 nascent	 DNA	 strands.	 	 The	 agents	 that	 are	 used	 are	 5-FU,	 capcetabine	 and	
gemcitabine	and	also	have	an	effect	on	transcription	and	DNA	methylation.		These	
therapies	 are	 used	 in	 both	 the	 adjuvant	 and	 advanced	 disease	 setting	 based	 on	
previous	trial	evidence.			
	
The	 ESPAC-1	 trial	 was	 instrumental	 in	 providing	 clear	 evidence	 for	 the	 role	 of	
adjuvant	chemotherapy	and	the	 lack	of	benefit	 from	chemoradiation	 in	 improving	
survival	following	resection	in	pancreatic	cancer(Neoptolemos,	Stocken	et	al.	2004).	
The	main	 finding	 from	 this	 study	was	a	median	 survival	of	20.1	months	 for	 those	
that	 received	 chemotherapy	 and	 15.5	months	 in	 those	 that	 did	 not	 (hazard	 ratio	
0.71,	 p=0.009).	 	 The	 results	 of	 CONKO-001	 trial	 has	 added	 more	 weight	 to	 this	
argument	 which	 randomised	 patients	 to	 adjuvant	 gemcitabine	 or	 observation	
following	 surgery,	 patients	 that	 received	 chemotherapy	 had	 a	 improvement	 in	
overall	median	survival	of	22.8	months	compared	to	20.2	months	in	the	observation	
group	 (p=0.005)(Oettle,	Post	et	al.	 2007).	 The	ESPAC-3(v2)	 trial	has	demonstrated	
that	there	is	no	significant	survival	difference	between	adjuvant	gemcitabine	and	5-
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FU,	and	that	the	toxicity	profiles	of	each	would	indicate	that	gemcitabine	should	be	
recommended	above	bolus	5FU/FA.(Neoptolemos,	Stocken	et	al.	2010).	
	
The	use	of	fluorinated	pyrimidine	S-1	(an	oral	5-flurouracil)	as	an	adjuvant	therapy	
in	 pancreatic	 cancer	 has	 been	 investigated	 and	 its	 use	 compared	 to	 gemcitabine.		
The	 JASPAC-01	trial	was	a	 randomised	controlled	study	that	enrolled	385	patients	
between	2007	and	to	2010.	 	The	use	of	adjuvant	gemcitabine	was	compared	to	S-
1(Maeda,	 Boku	 et	 al.	 2008).	 	 In	 2012	 interim	 results	 were	 published	 showing	 an	
overall	 2-year	 survival	 of	 53%	 for	 the	 gemcitabine	 group	 and	 70%	 for	 the	 S-1	
group(Fukutomi	2013).		The	disease	free	survival	was	also	noted	to	be	superior	for	
S-1	 at	 49%	 compared	 to	 29%	 in	 the	 gemcitabine	 arm.	 	 From	 this	 study	 the	
consideration	of	S-1	as	standard	adjuvant	treatment	was	suggested	and	is	now	the	
case	in	Japan	though	this	has	not	been	adopted	in	the	western	world,	this	is	due	to	
the	 metabolic	 differences	 in	 the	 population	 treated	 and	 the	 observed	
gastrointestinal	side	effects	being	greater	in	Caucasian	populations	leading	to	lower	
tolerated	doses	of	S-1	(Antoniou,	Kountourakis	et	al.	2014).	
	
In	 2008	 Boeck	et	 al	published	 a	 systematic	 review	 and	meta-analysis	 of	 adjuvant	
chemotherapy	 in	 pancreatic	 cancer(Boeck,	 Ankerst	 et	 al.	 2007).	 	 Five	 trials	 were	
identified	 suitable	 to	 be	 included	 in	 the	 meta-analysis	 (Bakkevold,	 Arnesjo	 et	 al.	
1993;	Takada,	Amano	et	al.	2002;	Neoptolemos,	Stocken	et	al.	2004;	Kosuge,	Kiuchi	
et	al.	2006;	Oettle,	Post	et	al.	2007)	identifying	a	total	of	482	treated	patients	and	
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469	controls.		Median	survival	was	increased	by	3	months	(95%	CI	0.3–5.7	months,	
p	=	0.03)	in	the	adjuvant	chemotherapy	group.		There	was	a	small	increase	of	3.1%	
in	5-year	survival	in	the	adjuvant	chemotherapy	group	compared	with	controls	(95%	
CI	 –4.6	 to	 10.8%,	 p<0.05).	 	 The	 authors	 supported	 the	 use	 of	 adjuvant	
chemotherapy	 from	 this	 meta-analysis	 noting	 the	 statistically	 significant	
improvement	in	median	survival.	
	
The	most	recent	meta-analysis	into	adjuvant	therapy	explored	the	overall	survival	in	
patients	receiving	gemcitabine	(n=774)	or	5-FU	(n=876)	versus	observation	(n=670).		
This	 study	 concluded	 adjuvant	 therapy	 with	 either	 agent	 conferred	 a	 survival	
benefit	compared	to	observation	alone	(Hazard	ratios	0.68,	95%	CI:	0.44-1.07,	and	
0.62,	95%	CI:	0.42-0.88,	respectively).		It	was	noted	however	that	the	grade	3-4	non	
haematological	 toxicity	was	 far	greater	an	 issue	with	5-FU	 than	Gemcitabine(Liao,	
Chien	et	al.	2013).	
	
Currently	 the	 results	 of	 ESPAC4	 are	 set	 to	 change	 standard	 therapy	 after	 being	
released	 at	 the	American	 Society	 of	 Clinical	 oncology.	 	 ESPAC	 4	 is	 a	 international	
randomised	 control	 trial	 of	 combination	 adjuvant	 therapy	 (gemcitabine	 and	
capecitabine)	 versus	 single	 agent	 adjuvant	 therapy	 (gemcitabine).	 	 Although	 the	
median	 survival	 benefit	 was	modest	 in	 the	 combination	 group	 the	 overall	 5-year	
survival	for	this	group	was	double	that	of	the	gemcitabine	alone	cohort	(28.8%	vs.	
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16.3%).	 	 This	 study	 supports	 the	 notion	 that	 combining	 agents	 used	 in	 PDAC	will	
offer	the	most	promising	therapeutic	targets	in	the	future(Neoptolemos	2016).	
	
1.5.2	Therapy	in	advanced	disease		
In	 the	advanced	setting	 the	 initial	 standard	of	care	was	5-FU.	 	Evidence	 that	5-FU		
was	superior	to	best	supportive	care	was	demonstrated	by	a	meta-analysis	of	trials	
performed	between	1970	and	2003(Fung,	Takayama	et	al.	2003).		Subsequently	trial	
evidence	 supported	 the	 use	 of	 gemcitabine	 and	 its	 superior	 benefits	 in	 the	
advanced	 setting.	 	Burris	et	al	 showed	while	having	a	modest	 survival	 advantage,	
gemcitabine	 	 gave	better	 alleviation	of	 symptoms	 than	5-FU	 (Burris,	Moore	et	 al.	
1997).	 	 	 Sultana	et	al	 reviewed	 randomised	 control	 trials	 for	 advanced	pancreatic	
cancer	that	included	gemcitabine	or	5-FU	monotherapy,	gemcitabine	versus	5-FU	or	
gemcitabine/5-FU	 combination	 therapy	 with	 other	 chemotherapy.	 	 This	 meta-
analysis	 concluded	 that	 chemotherapy	 improved	 survival	 compared	 to	 best	
supportive	 care	 (hazard	 ratio	 =0.64,	 95%	 CI	 0.42-0.98),	 5-FU	 based	 combination	
therapy	was	not	superior	to	5-FU	alone,	there	was	no	significant	survival	difference	
between	 gemcitabine	 or	 5-FU	 but	 a	 definite	 improvement	 in	 survival	 from	
gemcitabine	combination	therapy	compared	with	gemcitabine	alone	(HR=0.91,	95%	
CI	 0.85-0.97).	 	 This	 meat-analysis	 supported	 the	 concept	 that	 gemcitabine	 based	
combination	 therapy	 would	 provide	 the	 most	 improvements	 in	 survival	 in	 the	
advanced	setting(Sultana,	Smith	et	al.	2007).	
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Capecitabine	 (xeloda)	 was	 developed	 to	 be	 an	 orally	 available	 form	 of	
fluoropryrimidine	 chemotherapy.	 Cunningham	 et	 al	 were	 able	 to	 show	 that	 a	
combination	 of	 capecitabine	 and	 gemcitabine	 (GEM-CAP)	 performed	 better	 than	
gemcitabine	 alone	with	 advanced	 disease,	 giving	 a	 genuine	 survival	 advantage	 in	
best-response	rates	(19.1%	v	12.4%,	p=0.03)	and	progression	free	survival	(HR	0.78;	
CI,	 0.66-0.93;	 x2	 LR=8.1;	 p=0.004).	 	 There	 was	 even	 a	 trend	 to	 improved	 overall	
survival	in	the	GEM-CAP	group	although	this	was	not	statistically	significant	(p=.0.8)	
(Cunningham,	Chau	et	al.	2009).	
	
Further	 combinations	 with	 gemcitabine	 have	 been	 explored	 without	 improved	
efficacy.	 Gemcitabine	 and	 oxaliplatin	 or	 gemcitabine	 with	 cisplatin	 have	 been	
investigated	 in	 phase	 III	 trials	 though	 no	 statistically	 significant	 improvements	 in	
survival	 have	 been	 noted(Louvet,	 Labianca	 et	 al.	 2005;	 Colucci,	 Labianca	 et	 al.	
2010).	
A	 regimen	 referred	 to	 as	 GTX	 (docetaxel	 and	 capecitabine	 in	 addition	 to	
gemcitabine)	 has	 demonstrated	 some	 activity	 in	 the	 advanced	 disease	 setting	
though	with	a	degree	of	toxicity.	 	Phase	II	trials	showed	median	survival	of	25	and	
11	months	 for	patients	with	 locally	advanced	and	metastatic	disease	 respectively.		
Though	 not	 standard	 first	 line	 therapy	 this	 combination	 could	 be	 considered	 for	
patients	 with	 a	 good	 performance	 status	 seeking	 combination	 therapy(De	 Jesus-
Acosta,	Oliver	et	al.	2012).	
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Further	 combinations	 of	 gemcitabine	 with	 targeted	 therapies	 have	 yielded	 only	
small	(gemcitabine	plus	erlotinib)	or	no	survival	benefits	(cetuximab	or	bevacizumab	
plus)	with	 notably	 increased	 toxicities	 therefore	 currently	 these	 combinations	 are	
not	 used	 in	 standard	 therapy	 and	 offer	 no	 real	 benefit	 over	 gemcitabine	
alone(Moore,	 Goldstein	 et	 al.	 2007;	 Kindler,	 Niedzwiecki	 et	 al.	 2010;	 Philip,	
Benedetti	et	al.	2010).	
	
Recently	 there	 has	 been	 investigation	 of	 the	 FOLFIRINOX	 regimen	 in	 advanced	
pancreatic	 cancer	 (consisting	 of	 oxaliplatin,	 irinotecan,	 fluorouracil	 and	
leucovorin)(Conroy,	 Desseigne	 et	 al.	 2011).	 	 In	 this	 study	 the	 overall	 survival	was	
significantly	 better	 in	 the	 FOLFIRINOX	 group	 at	 11.1	 months	 compared	 to	 6.8	
months	 in	 the	gemcitabine	group	 (HR	0.57,	95%	CI	0.45-0.73,	p<0.001).	 	However	
more	 adverse	 event	 were	 noted	 in	 the	 FOLFIRINOX	 arm	 which	 had	 a	 significant	
effect	on	quality	of	 life	scores	making	the	combination	questionable	 in	the	setting	
of	advanced	pancreatic	 cancer	owing	 to	unacceptable	 toxicity	 in	 the	absence	of	a	
good	performance	status.	
	
1.5.3	Neoadjvant	therapy	
The	 use	 of	 neoadjuvant	 therapy	 to	 improve	 the	 outcome	 for	 these	 patients	 by	
down-staging	 disease,	 increasing	 resection	 rates	 and	 R0	 resection	margins(Gillen,	
Schuster	et	 al.	 2010)	 has	 been	 evaluated	 in	 small	 studies	 and	 not	 in	 a	 successful	
phase	III	randomized	trial	so	far.	Some	studies	suggest	an	increase	in	resection	rate	
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by	around	a	third(Greer,	Pipas	et	al.	2008;	Gillen,	Schuster	et	al.	2010).	A	number	of	
studies	 demonstrate	 an	 increase	 in	 survival	 rate	 comparable	 with	 resectable	
disease(Gillen,	Schuster	et	al.	2010;	Stokes,	Nolan	et	al.	2011;	Takahashi,	Kinoshita	
et	al.	2011;	Motoi,	Ishida	et	al.	2013).	
	
Neoadjuvant	 therapy	 may	 offer	 a	 survival	 benefit	 to	 those	 with	 borderline	
resectable	disease	by	downstaging	tumours,	improving	resection	rates	and	negative	
margins,	however	role	of	neoadjuvant	therapy	in	BR	disease	has	been	investigated	
thus	far	in	small	phase	I/II	trials(Brown,	Siripurapu	et	al.	2008;	Landry,	Catalano	et	
al.	2010;	McClaine,	Lowy	et	al.	2010;	Patel,	Hoffe	et	al.	2011;	Sahora,	Kuehrer	et	al.	
2011;	Barugola,	Partelli	et	al.	2012).		It	appears	that	neoadjuvant	therapy	may	have	
no	benefit	or	even	a	detrimental	effect	in	those	initially	classified	resectable,	but	in	
borderline	 resectable	 groups	 improvements	 in	 survival	 of	 up	 to	 a	 third	 are	
suggested.	 	 Studies	 to	 date	 consistently	 demonstrate	 an	 improved	 survival	 in	
borderlines	 receiving	 neoadjuvant	 therapy	 over	 non-resectable	 cases	 and	 even	
comparable	 survival	 to	 resectable	 cases	 which	 was	 supported	 in	 recent	 meta-
analyses(Gillen,	 Schuster	 et	 al.	 2010;	 Assifi,	 Lu	 et	 al.	 2011;	 Laurence,	 Tran	 et	 al.	
2011;	Andriulli,	 Festa	et	 al.	 2012).	A	 recent	prospective	 study	of	 a	 small	 group	of	
patients	 by	 Lee	 et	 al	 suggested	 curative	 resection	 is	 possible	 in	 patients	 with	
borderline	 resectable	 disease	 who	 undergo	 neoadjuvant	 therapy	 (Lee,	 Kim	 et	 al.	
2012).	
	
Further	 potential	 benefits	 of	 neoadjuvant	 therapy	 include	 possible	 increased	
efficacy	 of	 chemoradiation	 and	 chemotherapy	 to	 a	 well-vascularized	 and	
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oxygenated	tumour	as	well	as	identifying	patients	who	have	aggressive	disease	as	in	
this	 group	 of	 patients	 it	 has	 been	 demonstrated	 that	 surgery	 after	 neoadjuvant	
therapy	 offers	 no	 real	 improvement	 in	 survival(Evans,	 Rich	 et	 al.	 1992;	 Pisters,	
Abbruzzese	et	al.	1998).	
	
1.5.4	Chemoresistance	in	PDAC	
Despite	 the	 demonstrated	 survival	 benefits	 recurrence	 rates	 in	 resected	 disease	
remain	high	and	in	all	disease	settings	long-term	survival	remains	poor	due	in	part	
to	 chemoresistance.	 	 Cancer	 cells	 become	 resistant	 to	 therapy	 by	 a	 number	 of	
hypothesised	 means:	 by	 exclusion	 of	 drugs	 from	 the	 cancer	 cells,	 by	 changes	 in	
enzymes	 metabolising	 drug	 or	 by	 becoming	 resistant	 to	 apoptosis	 and	 cellular	
stress.		Further	increases	in	survival	should	be	possible	by	targeting	these	areas	that	
lead	 to	 resistance	 or	 targeting	 multiple	 pathways	 in	 combination	 with	 standard	
therapy.			
	
The	 lack	 of	 efficacy	 of	 current	 treatment	 may	 be	 explained	 by	 inadequate	 drug	
delivery	 to	 the	 cancer	 cells	 leading	 to	 ineffective	 concentrations.	 	 This	 may	 be	
attributable	 to	 the	 tumour	microenvironment	consisting	of	a	 stromal	extracellular	
matrix	protecting	cancer	 cells	or	 transport	of	 fluoropyrimidines	across	 the	plasma	
membrane	of	cancer	cells.		It	may	be	these	agents	are	not	transported	into	resistant	
cells	or	moved	out	more	 rapidly.	 	 There	are	 two	 types	of	nucleoside	 transporters	
that	 transport	 gemcitabine	 across	 the	 plasma	 membrane,	 namely	 equilabratitive	
(eNTs)	 and	 concentrative	 (cNTs)	 and	 there	 has	 been	 investigation	 into	 these	
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transporters	and	their	relationship	to	gemcitabine	resistance	although	cell	line	data	
has	 been	 inconclusive.	 	Gemcitabine	 is	 transported	by	 hENT1,	 hENT2	 and	hCNT1.	
Once	 gemcitabine	 enters	 a	 cell	 via	 eNTs	 it	 reaches	 equilibrium	 between	 the	
intracellular	 and	 extracellular	 compartments,	 cNTs	 increase	 the	 concentration	 of	
the	 drug	 intracellularly	 by	 accumulation	 against	 the	 concentration	 gradient.		
Marechal	et	al	observed	that	either	high	expression	of	eNT1	or	cNT	resulted	in	the	
best	overall	survival(Marechal,	Mackey	et	al.	2009)	and	the	high	expression	of	eNT1	
and	 the	 positive	 effect	 on	 survival	 was	 again	 supported	 in	 the	 RTOG-9704	
trial(Farrell,	Elsaleh	et	al.	2009).		However	contrary	finding	were	reported	by	Tsujie	
et	 al	 who	 demonstrated	 a	 direct	 liner	 relationship	 between	 the	 levels	 of	 eNT1	
mRNA	 and	 the	 IC50	 for	 gemcitabine	 and	 5-FU(Tsujie,	 Nakamori	 et	 al.	 2007).			
Interestingly	 in	 the	 research	 setting	 pancreatic	 cancer	 cell	 lines	 are	 sensitive	 to	
gemcitabine	 and	 5-FU	 regardless	 of	 eNT	 status	when	 adequate	 concentrations	 of	
drug	are	delivered	 to	 the	cell	membrane	which	goes	some	way	 to	explaining	why	
xenograft	 models	 show	 a	 good	 response	 to	 these	 agents.(Olive,	 Jacobetz	 et	 al.	
2009).		Conversely	in	transgenic	mouse	models	pancreatic	cancer	shows	resistance	
to	gemcitabine	similar	to	what	is	observed	in	the	clinical	setting	ad	this	seems	to	be	
a	 consequence	 of	 the	 inability	 of	 drug	 to	 penetrate	 the	 tumour	 stroma(Olive,	
Jacobetz	et	al.	2009;	Grippo	and	Tuveson	2010;	Neesse,	Michl	et	al.	2011)	an	issue	
not	just	for	these	agents	but	many	agents	used	in	pancreatic	cancer.	
	
Owing	 to	 the	 observed	 relative	 chemoresistance	 of	 pancreatic	 cancer	 to	 current	
therapy	and	the	knowledge	of	the	underlying	molecular	biology	in	PDAC	there	has	
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been	investigation	into	novel	therapies	both	as	monotherapies	and	in	combination	
with	gemcitabine.	
	
1.6	NOVEL	THERAPY	IN	PDAC	
As	previously	discussed	Kras	mutations	are	the	single	most	common	genetic	change	
observed	 in	 PDAC(Almoguera,	 Shibata	 et	 al.	 1988).	 	 The	 effects	 of	 farnesylation	
inhibitors	has	been	 investigated	owing	 to	 the	 fact	 that	 the	 ras	protein	undergoes	
farnesylation	 in	 order	 to	 adhere	 it	 to	 the	 plasma	 membrane.	 In	 early	 xenograft	
models	 promising	 effects	were	 observed.	 	Manumycin,	 one	 such	 agent,	 inhibited	
growth	in	a	xenograft	model	of	pancreatic	cancer	without	toxicity(Ito,	Kawata	et	al.	
1996).	 	 SCH	 66336,	 a	 small	 molecule	 farnesyl	 protein	 transferase	 inhibitor,	 was	
investigated	 in	 tumour	 xenograft	 models	 of	 colon,	 lung,	 pancreas,	 prostate	 and	
bladder	cancers.		In	these,	potent	oral	activity	was	observed	leading	to	a	reduction	
in	 tumour	 burden.	 	 The	 investigators	 went	 on	 to	 a	 transgenic	mouse	model	 and	
observed	 significant	 tumour	 regression	 in	 a	 therapeutic	 model	 associated	 with	
increased	 apoptosis	 and	 decreased	 DNA	 synthesis	 in	 tumours(Liu,	 Bryant	 et	 al.	
1998).	 	 Unfortunately,	 when	 entered	 into	 clinical	 trials	 these	 agents	 have	 so	 far	
been	ineffective(Macdonald,	McCoy	et	al.	2005).	This	may	be	due	to	the	fact	that	in	
cells	 treated	with	 the	 agents	 Kras	 is	 geranylgeranylated	 thus	 allowing	membrane	
attachment.	Subsequently	newer	agents	are	being	developed	and	tested	in	mouse	
models	and	phase	I/II	trials(Campbell,	Boufaied	et	al.	2010).	
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Another	common	change	seen	in	pancreatic	cancer	 is	the	expression	of	epidermal	
growth	 factor	 and	 there	 are	 readily	 available	 inhibitors	 such	 as	 elrotinib	 and	
cetuximab.	In	retrospective	studies	a	significantly	reduced	median	survival	has	been	
observed	for	patients	expressing	high	levels	of	epidermal	growth	factors	providing	a	
biological	rationale	for	treatment(Yamanaka,	Friess	et	al.	1993).		The	SWOG	S0205	
study	reported	finding	on	gemcitabine	plus	cetuximab	versus	gemcitabine	alone	at	
ASCO	2007	(look	at	(Philip,	Benedetti	et	al.	2010)).		Patients	with	locally	advanced	or	
metastatic	PDAC	were	enrolled	 into	each	arm.	 	 In	 the	primary	endpoint	of	overall	
survival	 there	was	no	 significant	benefit	 to	 combination	 therapy	 (HR	1.09,	95%	CI	
0.93-1.27,	 p=0.14)	 nor	 in	 secondary	 endpoints	 of	 Progression	 Free	 Survival	 (PFS)	
and	 response	 (philip	 2007).	 In	 clinical	 trails	 with	 pancreatic	 cancer	 erlotinib	 in	
combination	with	 gemcitabine	 showed	a	modest	 survival	 benefit	 in	 the	 setting	of	
advanced	cancer(Moore,	Goldstein	et	al.	2007).	
A	potential	target	in	pancreatic	cancer	is	that	of	VEGF	receptor	inhibitors.		One	such	
inhibitor	 is	 avastin	 (bevacizumab),	 which	 was	 studied	 in	 a	 phase	 II	 trial	 in	
combination	 with	 ertloinib	 and	 gemcitabine.	 	 The	 primary	 endpoint	 of	 6	months	
survival	 was	 not	 reached	 for	 most	 patients	 but	 stable	 disease	 was	 achieved	 for	
more	than	2	cycles	of	treatment	for	22.2%	of	the	patients(Ko,	Venook	et	al.	2010).		
A	 phase	 III	 trial	 into	 bevacizumab	 in	 combination	 with	 gemcitabine	 and	 erlotinib	
was	conducted.		Patients	with	metastatic	PDAC	were	assigned	to	gemcitabine	plus	
erlotinib	and	bevacizumab	or	placebo	with	the	primary	endpoint	of	overall	survival.		
In	 the	group	 that	 received	all	active	agents	 the	OS	was	not	 significantly	 improved	
compared	to	gem,	erlotinib	plus	placebo	but	the	therapy	was	well	tolerated	and	the	
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secondary	 endpoint	 of	 progression	 free	 survival	 was	 improved	 (HR	 0.73;	 CI	
95%0.61-0.86,	p=0.0002)(Van	Cutsem,	Vervenne	et	al.	2009).	
	
As	 previously	 discussed	 the	 relative	 resistance	 to	 current	 therapy	 may	 be	 the	
deficiency	in	apoptotic	features	in	cancer	cells.		Platinum	based	therapies	have	been	
shown	 to	 strongly	 stimulate	 apoptosis(Saif	 and	 Kim	 2007).	 	 Studies	 of	 platinum	
agents	in	pancreatic	cancer	have	shown	significant	benefit	when	these	are	used	in	
combination	with	gemcitabine.	 	The	combination	of	cisplatin	and	gemcitabine	has	
been	 shown	 synergistic	 in	 vitro	 and	 in	 a	 phase	 II	 study	 improvements	 where	
observed	 in	 disease	 free	 survival	 and	 response	 although	 there	was	 no	 significant	
difference	in	overall	survival	when	compared	to	gemcitabine	monotherapy(Colucci,	
Giuliani	et	al.	2002).		Another	such	phase	II	study	of	a	cisplatin	analog,	carboplatin,	
combined	with	 gemcitabine	 showed	 an	 encouraging	 1-year	 survival	 of	 28%(Xiros,	
Papacostas	et	al.	2005).		Combinations	with	both	gemcitabine	and	5-FU	have	been	
investigated	 with	 oxaliplatin	 and	 shown	 synergy	 in	 the	 pre-clinical	 setting.	 	 In	
patients	 with	 pancreatic	 cancer	 refractory	 to	 gemcitabine	 monotherapy,	 GEMOX	
has	 shown	 promising	 survival	 benefit(Demols,	 Peeters	 et	 al.	 2006).	 	 A	 similar	
suggestion	of	improved	survival	in	gemcitabine	refractory	tumours	has	been	shown	
with	the	combination	of	oxaliplatin	and	5-FU,	FOLFOX(Yoo,	Hwang	et	al.	2009).		In	a	
meta-analysis	 of	 novel	 combination	 therapy	 in	 PDAC,	 platinum	 agent	 based	
combinations	 showed	 the	 highest	 response	 rates	 overall(Sultana,	 Ghaneh	 et	 al.	
2008).	
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Targeting	 proteins	 that	 feature	 in	 the	 tumour	 stroma	 may	 also	 provide	 another	
therapeutic	 avenue.	 	 A	 study	 by	 Olive	 et	 al	 investigated	 a	 mouse	 model	 of	
pancreatic	cancer	 targeting	 the	stromal	hedgehog	pathway.	 	They	used	KPC	mice,	
which	conditionally	express	mutant	Kras	and	p53	in	PDAC	and	develop	tumours	that	
resemble	human	PDAC	 in	both	molecular	and	pathophysiological	 features.	 	 In	 the	
study	the	tumours	developed	were	poorly	vascularised	and	delivery	and	efficacy	of	
gemcitabine	also	poor,	in	line	with	clinical	observations.		They	went	on	to	inhibit	the	
hedgehog	pathway	using	IPI-926,	a	derivative	of	cyclopamine	that	potently	inhibits	
Smo,	this	resulted	in	increased	tumour	vascularisation	and	therefore	the	delivery	of	
chemotherapeutic	 agents	 to	 the	 tumour(Olive,	 Jacobetz	 et	 al.	 2009).	 However,	 a	
clinical	 trial	 of	 hedgehog	 inhibition	 showed	 no	 improvement	 over	 gemcitabine	
alone		(Catenacci,	Junttila	et	al.	2015)	
	
As	 indicted	by	Hanahan	and	Weinberg	unlimited	proliferation	 is	a	 trait	 intrinsic	 to	
the	survival	of	cancer	cells(Hanahan	and	Weinberg	2011).		In	humans	there	are	cell-
autonomous	features	that	limit	replicative	potential	and	induce	cellular	senescence.		
Cell	senescence	serves	as	a	barrier	to	limitless	proliferation	and	is	dependent	on	the	
p53	 and	 RB	 tumour	 suppressor	 pathways.	 	 With	 mutations	 in	 these	 pathways	
cancer	cells	overcome	checkpoints	and	the	genomic	instability	experienced	can	be	
attributed	 to	 the	 attrition	 of	 telomeres.	 	 In	 contrast	 to	 normal	 cells,	 cancer	 cells	
show	telomersase	activity	and	inhibition	can	lead	to	rapid	telomere	shortening	and	
apoptosis,	 providing	 a	 rationale	 for	 therapy.	 	 A	 number	 of	 studies	 have	
demonstrated	up	regulation	of	telomerase	in	pancreatic	cancer(Hiyama,	Kodama	et	
	 39	
al.	1997;	Suehara,	Mizumoto	et	al.	1997).		There	has	been	investigation	into	the	use	
if	 immune	technology	to	target	and	ameliorate	telomerase	positive	cells.	 	GV1001	
has	 been	 shown	 to	 elicit	 T	 cell	 response	 in	 lung	 cancer	 without	 bone	 marrow	
suppression(Brunsvig,	 Aamdal	 et	 al.	 2006)	 and	 there	 was	 a	 phase	 I/II	 study	
conducted	 in	 unresectable	 pancreatic	 cancer	 to	 investigate	 safety	 and	
tolerability(Bernhardt,	 Gjertsen	 et	 al.	 2006).	 	 In	 this	 study	 a	 significant	 immune	
response	was	observed	in	75%	of	the	group	receiving	therapy.	The	vaccine	was	well	
tolerated	with	no	significant	adverse	effects.		In	this	study	overall	survival	was	not	a	
primary	 endpoint	 though	 a	 significant	 correlation	 was	 observed	 with	 median	
survival	 of	 8.6	 months	 in	 patients	 receiving	 a	 moderate	 dose	 compared	 to	 4.5	
months	in	those	receiving	a	low	or	high	dose.		After	300	days	all	surviving	patients	
had	 demonstrated	 an	 immune	 response	 to	 the	 vaccine.	 	 The	 TeloVac	 trial	 is	 the	
largest	study	of	GV1001	in	pancreatic	cancer	to	date	and	examined	gemcitabine	and	
capecitabine	 therapy	with	 concurrent	or	 sequential	GV1001	 treatment	 in	patients	
with	 locally	 advance	 or	 metastatic	 disease.	 This	 showed	 no	 significant	 survival	
benefit	with	the	vaccine	(Middleton,	Silcocks	et	al.	2014).	
	
MEK	inhibition	has	also	been	investigated	in	pancreatic	cancer.		Mitogen-activated	
extracellular	 signal	 regulated	 kinase	 is	 a	 crucial	 component	 of	 the	 RAS-RAF-MEK-
extracellular	 signal	 regulated	 kinase	 (ERK)	 that	 has	 a	 role	 in	 several	 cellular	
processes	 and	 known	 to	 be	 aberrant	 in	 a	 number	 of	 cancers	 including	 pancreas,	
breast,	lung	and	colon(Hoshino,	Chatani	et	al.	1999).		A	MEK1/2	inhibitor,	CI-1040,	
demonstrated	 anti-proliferative	 activity	 in	 a	 xenograft	 model	 of	 pancreatic	
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cancer(Allen,	 Sebolt-Leopold	 et	 al.	 2003).	 	 In	 a	 phase	 I	 study	 of	 patients	 with	
advanced	malignancies	 including	 pancreatic	 cancer	 it	 was	 well	 tolerated(Lorusso,	
Adjei	et	al.	2005).			In	this	phase	I	study	it	was	noted	that	one	of	the	patients	with	
pancreatic	cancer	demonstrated	a	partial	response	but	on	progression	to	a	phase	II	
study	no	significant	antitumor	activity	was	seen	and	the	study	abandoned.	
	
Gastrin	inhibition	has	also	been	investigated	in	pancreatic	cancer,	as	expression	of	
cholecystokinin	 (CCK)/gastrin	 receptor	 and	 the	 gastrin	 precursor,	 progastrin,	 have	
been	 observed	 frequently	 in	 pancreatic	 tumours(Caplin,	 Savage	 et	 al.	 2000).		
Gastrin	 stimulates	 the	 proliferation	 of	 pancreatic	 cancer	 that	 can	 be	 inhibited	 by	
antisense	 oligonucleotides	 to	 gastrin(Smith,	 Fantaskey	 et	 al.	 1995;	 Smith,	
Verderame	 et	 al.	 1999).	 	 Gastrazole,	 a	 gastrin	 receptor	 antagonist	was	 studied	 in	
two	trials	in	pancreatic	cancer	compared	to	placebo	first	then	with	5-FU.		Compared	
to	placebo	median	survival	was	significantly	 improved	with	gastrazole	(7.9	months	
vs.	 4.5	 months)	 but	 there	 was	 no	 significant	 difference	 when	 compared	 to	 5-
FU(Chau,	Cunningham	et	al.	2006).	
	
Targeting	 the	 enzymes	 that	 allow	 cells	 to	 degrade	 their	 surrounding	 matrix	
therefore	 facilitating	 metastasis	 has	 provided	 another	 area	 of	 investigation	 in	
pancreatic	cancer.		Matrix	Metalloproteinase	(MMPs)	are	proteolytic	enzymes	that	
are	 involved	 in	 the	 degradation	 of	 the	 extracellular	 matrix	 and	 an	 association	
between	MMP	expression	 and	 tumour	 progression	 has	 been	 described(Chambers	
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and	 Matrisian	 1997).	 	 In	 pancreatic	 cancer	 MMP-2,-7,-8,-9	 and	 -11	 are	
overexpressed	 and	 high	 MMP-7	 levels	 correlate	 with	 a	 poor	 survival(Jones,	
Humphreys	et	al.	2004)	.		In	preclinical	models	MMP	inhibitors	have	shown	efficacy.		
SC44463,	 a	 novel	 MMP	 inhibitor	 prevented	 metastases	 in	 an	 early	 mouse	
model(Reich,	 Thompson	 et	 al.	 1988).	 	 A	 further	 MMP	 inhibitor	 Batimastat	 was	
investigated	in	a	orthotopic	murine	model	of	pancreatic	cancer	and	demonstrated	
reduced	metastasis	 and	 significantly	 prolonged	 overall	 survival	 as	 a	monotherapy	
and	 in	 combination	with	 gemcitabine(Zervox,	 Franz	 et	 al.	 2000).	 	 In	 clinical	 trials	
however,	 results	 were	 not	 as	 promising.	 	 A	 trial	 of	 patients	 with	 advanced	
pancreatic	 cancer	 treated	 with	 Tanomastat	 was	 terminated	 early	 as	 patients	
experience	 a	 significantly	 worse	 survival	 than	 those	 receiving	 placebo(Moore,	
Hamm	et	al.	2003).	Marimastat	has	been	extensively	investigated	in	human	trials	of	
pancreatic	cancer.		A	phase	II	study	showed	an	acceptable	toxicity	profile	and	some	
symptomatic	 improvement	 in	patients(Evans,	 Stark	et	al.	 2001)	 and	as	 a	 result	 of	
this,	 two	 randomised	phase	 III	 trials	were	 conducting	 comparing	gemcitabine	and	
Marimastat	 in	 patients	 with	 unresectable	 PDAC.	 	 In	 both	 of	 these	 no	 significant	
survival	benefit	was	seen	and	there	was	no	significant	improvement	in	combination	
therapy	 with	 gemcitabine	 when	 compared	 to	 gemcitabine	 alone(Bramhall,	
Rosemurgy	 et	 al.	 2001;	 Bramhall,	 Schulz	 et	 al.	 2002).	 	 It	 may	 be	 that	 this	 agent	
merits	 further	 investigation	 as	 study	 design	 was	 flawed:	 patients	 enrolled	 had	
advanced	 disease	 and	 the	 evidence	 from	 preclinical	 data	 in	 reducing	 progression	
suggests	 that	patients	with	early	disease	may	derive	 the	most	benefit	 from	 these	
types	of	agents.	
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Another	line	of	 investigation	into	potential	novel	therapy	is	that	of	COX	inhibition.		
COX-2	 plays	 a	 principal	 role	 in	 the	 metabolism	 of	 prostaglandins	 therefore	
mediating	 resistance	 to	 apoptosis,	 adhesion,	 motility,	 immunosuppression	 and	
angiogenesis	 (Trifan	 and	Hla	 2003)and	 has	 been	 shown	 to	 be	 expressed	 in	 up	 to	
90%	of	pancreatic	cancers(Okami,	Yamamoto	et	al.	1999).	Results	on	the	efficacy	of	
these	 agents	 in	 pancreatic	 cancer	 have	 been	 variable.	 	 In	 a	 phase	 I	 study	 of	
celecoxib	 with	 a	 gemcitabine-radiation	 regimen	 increased	 efficacy	 as	 well	 as	
significant	 toxicity	was	 observed(Crane,	Mason	 et	 al.	 2003).	 	 In	 another	 study	 by	
Milella	 et	 al	 no	 demonstrable	 clinical	 benefit	 was	 derived	 from	 the	 addition	 of	
celecoxib	 to	5-FU	therapy	 in	gemcitabine	refractory	disease(Milella,	Gelibter	et	al.	
2004).	 	 In	 a	 phase	 II	 trial	 in	 advanced	 patients	 of	 combination	 therapy	 with	
gemcitabine	and	celecoxib	median	survival	was	6.2	months	and	the	toxicity	profile	
was	acceptable.	A	further	phase	II	trial	found	a	median	survival	of	9.1	months	with	
this	combination,	also	in	advanced	disease	(El-Rayes,	Zalupski	et	al.	2005).		Though	
the	 data	 thus	 far	 is	 conflicting	 the	 promising	 results	 that	 have	 been	 observed	
suggests	further	investigation	of	these	agents	in	pancreatic	cancer	is	warranted.	
	
Inhibitors	 of	 PI3K/AKT	 pathway	 have	 been	 suggested	 as	 potential	 agents.	 	 It	 has	
been	demonstrated	that	inhibition	of	the	AKT	pathway	in	pancreatic	cancer	induces	
apoptosis	and	restores	gemcitabine	chemosensitivity	in	vitro	offering	an	interesting	
therapeutic	 strategy(Ng,	 Tsao	 et	 al.	 2000;	 Bondar,	 Sweeney-Gotsch	 et	 al.	 2002).	
Targeting	 downstream	 of	 AKT	 has	 been	 investigated	 using	 mTOR	 inhibition.	 	 In	
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preclinical	studies	CCI-779,	an	mTOR	inhibitor	supressed	proliferation	in	pancreatic	
cancer	cell	lines	and	induced	apoptosis(Asano,	Yao	et	al.	2005).		
	
Most	of	these	therapies	have	as	a	virtue	the	specificity	of	the	agent	for	a	particular	
target	 (from	KRAS	to	ribonucleotide	reductase	via	AKT	and	MMP-7).	 It	has	been	a	
struggle	 to	 achieve	 such	 specificity	 and	 success	 has	 been	 marginal.	 Perhaps	 it	 is	
worth	considering	whether	this	apparent	virtue	is	truly	desirable.	
	
As	 previously	mentioned	 Jones	et	 al	 identified	12	 common	pathways	which	were	
commonly	affected	 in	advanced	cancer,	but	with	multiple	possible	mutations	and	
considerable	heterogeneity.	 	Clearly	this	underpins	the	complex	genetic	anomalies	
that	exist	in	PDAC	and	supports	the	concept	that	targeting	single	genes	or	proteins	
will	likely	be	ineffective.		Therapy	that	targets	multiple	pathways	at	different	levels	
in	 combination	 with	 standard	 therapy	 may	 offer	 the	 most	 chance	 of	 making	
significant	 differences	 to	 survival	 of	 patients.	 	 A	 protein	 that	 appears	 on	multiple	
pathways	commonly	mutated	in	PDAC	is	Heat	Shock	Protein	(HSP)	90	and	may	offer	
a	 possible	 target	 for	 future	 therapy.	 	 Genetic	 mutations	 that	 arise	 in	 pancreatic	
cancer	often	have	effect	on	crucial	checkpoints	within	the	cell	cycle	and	CDKs,	being	
pivotal	to	cell	cycle	regulation,	could	offer	another	target	for	inhibition	in	pancreatic	
cancer.		Targeting	HSP90	and	CDK	inhibition	could	offer	future	promise	for	therapy	
in	PDAC.	
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The	 key	 to	 the	 future	 of	 chemotherapy	 in	 pancreatic	 cancer	 will	 be	 the	
identification	 of	 novel	 and	 effective	 agents,	 better	 biomarker	 technology	
underpinned	by	translational	research,	which	will	inform	the	design	of	future	trials.	
Ultimately	this	will	ensure	that	patients	will	be	able	to	receive	targeted	therapy	to	
achieve	the	most	benefit.	
	
1.7	CYCLIN	DEPENDANT	KINASES	AND	CANCER	
The	 replication	of	DNA	and	mitosis	 are	 reliant	on	 the	activity	of	 cyclin-dependant	
protein	kinase	(CDK)	enzymes.		CDK’s	are	heterodimers	of	a	catalytic	subunit	with	a	
cyclin	subunit	whose	activity	governs	cell	cycle	regulation.			
	
1.7.1	Structure	
Protein	kinases	have	a	tertiary	structure	consisting	of	a	small	amino-terminal	 lobe	
and	a	larger	carboxy-terminal	 lobe	(figure	1.3).	 	ATP	fits	between	these	lobes	with	
phosphates	directed	outwards	towards	where	the	protein	substrate	binds.		There	is	
then	 transfer	 of	 the	 terminal	 γ-phosphate	of	ATP	 to	hydroxyl	 residues.	 	 CDKs	 are	
inactive	 in	 the	 absence	 of	 cyclin	 via	 two	modifications	 when	 compared	 to	 other	
protein	kinases.		Firstly,	in	CDKs	a	T-loop	or	activation	loop	arises	from	the	carboxy-
terminal	 lobe	thereby	blocking	the	binding	of	protein	substrate	at	the	entrance	to	
the	active	cleft	site.		Secondly	there	are	several	important	amino-acid	side	chains	in	
the	inactive	CDK	that	are	incorrectly	positioned	so	that	the	ATP	phosphates	are	not	
well	oriented	for	the	kinase	reaction.		As	a	result	of	these	two	factors	CDK	activation	
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requires	structural	change	in	the	active	site.		This	is	facilitated	by	interaction	of	the	
a1	helix	of	the	upper	lobe	with	a	cyclin,	this	results	in	reorientation	of	the	residues	
that	interact	with	the	phosphates	of	ATP.		The	reconfiguration	is	also	facilitated	by	
the	 small	 L12	 helix	 that	 changes	 structure	 to	 become	 a	 beta	 strand	 during	 cyclin	
binding.	
Figure	1.3	The	structure	and	conformity	of	a	cyclin	dependant	kinase	molecule.	
	
1.7.2	The	cell	cycle	
Progression	 through	 the	 cell	 cycle	 involves	 changing	abundance	of	 specific	 cyclins	
with	subsequent	changes	in	the	nature	of	CDK	activity.			
CDK$ Cyclin$
ATP$ P$
Substrate$(target$
proteins)$
Ac:vates$
Binds$the$
substrate$
Phosphorlya:on$
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The	cell	cycle	is	an	ordered	sequence	of	events	resulting	in	cell	growth	and	division	
into	 two	daughter	 cells.	 	During	 S	phase	 chromosome	 replication	 takes	place	and	
during	M	phase	(mitosis)	segregation	of	the	replicated	chromosomes	occurs.		There	
are	 two	Gap	phases:	 the	phase	prior	 to	S	 is	G1	and	prior	 to	M	 is	G2.	 	The	double	
helix	 structure	of	DNA	unwinds	 in	 S	 phase	producing	 two	 templates	 used	 for	 the	
synthesis	of	two	new	DNA	strands.		In	G2	a	bipolar	spindle	is	formed	and	the	DNA	
helix	 molecules	 making	 up	 each	 replicated	 chromosome	 condense	 and	 during	
metaphase	move	to	the	centre	of	the	spindle	and	orientate	towards	opposite	poles,	
to	be	segregated	at	cell	division.	 	The	ordered	cycling	that	occurs	 is	dependent	on	
CDKs	and	their	 formation	of	CDK-cyclin	complexes	and	each	CDK	acts	at	a	specific	
point	 in	 the	 cell	 cycle.	 CDK4	 and	 6	 interact	 with	 cyclin	 D,	 CDK2	 with	 cyclin	 E,	
allowing	passage	through	the	G1	restriction	point	into	S	phase.		Phosphorylation	of	
Rb	 via	 cyclin	 D-CDK4/6	 late	 in	 G1	 phase	 results	 in	 the	 components	 necessary	 for	
DNA	 replication.	 	 Cyclin	 E-CDK2	 leads	 to	 further	 phosphorylation	 of	 pRb	 that	
facilitates	entry	to	S	phase.		Cyclin	A-CDK2	(and	then	CDK1)	prevents	re-initiation	of	
DNA	synthesis.	Completion	of	DNA	replication	 in	S	phase	 is	 followed	by	G2,	 there	
are	 3	 checkpoints	 that	 need	 to	 be	 passed	 in	 order	 to	 begin	 segregation	 of	
chromosomes	 at	 anaphase.	 First	 a	 checkpoint	 to	 ensure	 that	 there	 is	 no	 DNA	
damage	(the	DNA	checkpoint),	then	a	checkpoint	to	ensure	centrosome	segregation	
and	 correct	 spindle	 formation	 (the	 CHFR	 checkpoint)	 and	 then	 a	 checkpoint	 to	
ensure	that	the	chromosomes	are	correctly	orientated	at	the	metaphase	plate	(the	
spindle	 or	 tension	 checkpoint).	 These	 are	 controlled	 by	 cyclin	 B-CDK1,	 gradual	
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increase	 in	activity	allowing	metaphase	 to	be	achieved	and	 rapid	decline	allowing	
passage	 into	 anaphase.	 	 CDC25	 phosphatase	 dephosphorylates	 cyclin	 B-CDK1	
facilitating	its	activation	during	metaphase,	subsequently	cyclin	B	is	degraded	by	the	
proteasome	as	a	result	of	ubiquitination	by	the	anaphase-promoting	complex	(APC).		
A	feedback	loop	results	in	phosphorylation	of	APC	by	cyclin	B-CDK1	that	is	necessary	
for	 cyclin	 B	 proteolysis	 and	 subsequent	 transition	 into	 anaphase.	 The	 cyclins	 and	
their	CDKs	with	points	of	action	 in	 the	 cell	 cycle	are	 summarised	 in	 table	1.7	and	
figure	1.4.	
	
Phase	 Cyclin	 CDK	
G1	 D,	E	 CDK	4,	6,	2	
S	 A,	E	 CDK	2	
G2	 A	 CDK	2,	1	
M	 B	 CDK	1	
Table	 1.7	 Table	 showing	 cyclins	 and	 CDK’s	 and	 their	 points	 of	 action	 in	 the	 cell	
cycle.	
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Figure	 1.4	 The	 cell	 cycle	 with	 CDK/cyclin	 complexes	 at	 points	 where	 they	 are	
known	to	act,	adapted	from	Suryadinata	et	al	((Suryadinata,	Sadowski	et	al.	2010)	
	
CDKs	were	identified	as	enzymes	that	control	cell	cycle	events,	though	members	of	
the	CDK	family	are	involved	in	other	cellular	processes.		In	human	cells	CDK	1,	2,	4,	
and	6	are	directly	involved	in	cell	cycle	control	and	CDK	7	works	indirectly	by	acting	
as	a	CDK-activating	kinase	 (CAK)	phosphorylating	other	CDKs.	 	CDK	7,	8	and	9	are	
involved	in	gene	transcription	and	CDK	5	in	the	differentiation	of	nerve	cells.	
	
1.7.3	CDKs	and	Cancer	
Cancer	cells,	by	definition,	are	prone	to	 inappropriate	cell	division	and	the	activity	
of	 CDKs	 and	 cyclins	 are	 frequently	 deranged	 in	 cancer.	 	 This	 may	 be	 due	 to	
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amplification	of	genes	encoding	for	specific	CDKs	or	cyclins,	but	it	is	more	common	
to	 have	 loss	 of	 expression	 of	 a	 CDK	 inhibitor	 such	 as	 p16INK4a(Malumbres	 and	
Barbacid	 2001).	 	 Proteins	 involved	 in	 CDK	 regulation	 and	 downstream	 substrates	
have	also	been	linked	to	tumour	development.	Common	deregulated	cyclins,	CDKs	
and	endogenous	CDK	inhibitors	are	summarised	in	table	1.8	with	the	cancers	they	
are	associated	with.	
	
Genetic	 alterations	 in	 CDKs	 themselves	 are	 not	 that	 common	 but	 have	 been	
observed	in	some	human	cancers.		Mutations	and	amplifications	in	CDK4	have	been	
noted	 in	 some	 tumours	 including	 melanomas,	 breast	 carcinomas,	 gliomas	 and	
sarcomas	(He,	Allen	et	al.	1994;	Wolfel,	Hauer	et	al.	1995;	Kanoe,	Nakayama	et	al.	
1998;	 An,	 Beckmann	 et	 al.	 1999).	 	 CDK6	 has	 been	 found	 amplified	 in	 lung	
tumours(Zhao,	Weir	et	al.	2005)	and	translocated	in	melanoma(Okamoto,	Pirker	et	
al.	2005).	
	
Deregulated	 expression	 of	 cyclins	 is	 a	 feature	 in	 human	 cancer,	 cyclin	 D1	 is	 of	
particular	 note	 and	has	 been	 identified	 in	 haematological	malignancies	 as	well	 as	
breast	cancers,	the	overexpression	of	cyclin	D1	is	involved	in	aberrant	Rb	pathways	
in	 cancer	 (Barbareschi,	 Pelosio	 et	 al.	 1997;	 Malumbres	 and	 Barbacid	 2001).		
Overexpression	of	cyclin	E	is	seen	in	many	tumour	types	and	has	been	evaluated	as	
a	potential	prognostic	marker	owing	to	its	correlation	with	clinical	response(Hwang	
and	Clurman	2005).	
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Relationships	between	CDK’s	cell	cycle	regulation	and	tumour	suppressor	genes	are	
critical	in	cancer.		Aberrant	pRb	signalling	pathways	are	common	in	the	majority	of	
human	cancers	resulting	in	unchecked	entry	into	S	phase.		Overexpression	of	cyclin	
D1	 or	 deletion	 of	 p16INK4A	 activates	 the	 pRb	 pathway	 in	 this	 manner.	 	 p53	 is	 an	
essential	 regulator	 of	 the	 G1	 and	 G2	 checkpoints	 and	 arrests	 growth	 through	
induction	 of	 p21	 (a	 CDK	 inhibitor)	 and	 G2	 arrest	 by	 promoting	 transcription	 of	
GADD45	that	inhibits	cyclin	B-CDK1	activation.	
	
In	 pancreatic	 cancer	 a	 number	 of	 genetic	 abnormalities	 have	 been	 identified	
including	those	that	rely	on	or	are	closely	involved	in	cyclins	and	CDKs.		This	includes	
inactivation	of	 p16,	 a	 endogenous	CDK	 inhibitor.	 	 Cyclin	D	 synthesis	 and	 coupling	
with	 CDK	 partners	 is	 stimulated	 by	 growth	 factor	 signalling,	 under	 normal	
conditions	 p16	 normally	 prevents	 cell	 cycle	 progression	 by	 binding	with	 CDK	 and	
preventing	 the	 CDK	 phosphorylation	 of	 Rb.	 	 The	 drive	 into	 S	 phase	 is	 finally	
permitted	when	p16	 is	 sequestered	by	 the	production	of	 cyclin	D-CDK	 complexes	
allowing	 Rb	 phosphorylation	 and	 deactivation.	 	 This	 pathway	 (p16/Cyclin	 D/Rb)is	
critical	 in	 tumorigenesis(Sherr	 1996).	 	Mutation	of	 p16	 are	 frequent	 in	 pancreatic	
cancers	 the	majority	being	nonsense	mutations	 in	a	 single	allele	with	 silencing	by	
methylation	 of	 the	 other	 allele,	 the	 second	most	 common	 form	of	 inactivation	 is	
homozygous	deletions.			p15	activity	has	also	been	investigated	in	pancreatic	cancer	
and	 its	 inactivation	 been	 found	 in	 up	 to	 60%	 of	 patients(Goggins,	 Shekher	 et	 al.	
1998).		This	alteration	in	p15	activity	may	be	in	part	responsible	for	the	resistance	to	
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TGF-β	inhibitory	effects	that	pancreatic	cancer	displays	(TGF-β	inhibits	epithelial	cell	
growth)(Villanueva,	Garcia	et	al.	1998).	 	Under	normal	conditions	the	downstream	
cell	cycle	inhibitor	p15	forms	a	complex	with	CDK4	and	6	resulting	in	cell	cycle	arrest	
which	is	one	of	the	mechanisms	by	which	TGF-β	inhibits	growth(Hannon	and	Beach	
1994).	
	
Kras	 mutations	 are	 frequent	 and	 almost	 universal	 in	 pancreatic	 adenocarcinoma	
and	activity	of	ras	appears	central	to	pancreatic	tumorigenesis.	 	The	expression	of	
cyclin	 D1	 is	 regulated	 by	 ras,	 the	 elevated	 cyclin	 D1	 levels	 along	 with	 the	
aforementioned	 disruption	 of	 the	 Rb/p16	 pathway	 allows	 the	 maintenance	 of	
proliferative	drivers	in	pancreatic	cancer(Ji,	Tsou	et	al.	2009).	
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Target	 Oncogenic	change	 Associated	tumours	
a)							
Cyclin	D1	
Gene	amplification	
Overexpression	
translocation	
40-80%	breast	carcinomas	
70%	familial	polyposis	
50%	B	cell	lymphoma	
35%	head	and	neck	carcinomas	
25-50%	oesophageal	carcinomas	
25%	bladder	tumours	
 
Cyclin	E	 Overexpression	
Gene	amplification	
90%	colorectal	carcinomas	
30-80%	breast	carcinomas	
70%	prostate	carcinomas	
18%	ovarian	carcinomas	
Cyclin	E2	 Overexpression	 Breast	carcinoma	
Small-cell	lung	carcinoma	
Cervical	carcinoma	
Cyclin	B1	 Overexpression	
 
90%	colorectal	carcinoma	
Cyclin	A	 Amplification	or	
overexpression	
Hepatocelluar	carcinoma	
CDK2	 Overexpression	 Colorectal	carcinomas	
 
CDK4	 Amplification	
 
Sarcomas,	gliomas	
b)											
p15	
	
Deletions	
	
pancreatic	
p16	 Mutation	
Deletion	
Epigenetic	
Pancreatic	carcinoma	
Melanoma	
Gilomas	
Bladder	
Head	and	neck	
Non	small	cell	lung	
Lymphoma/leukaemia	
p21	 Mutation	
Downregulation	
Mislocalisation	
Oral	
Oesophageal	
Breast	
p27	 Mutations/deletion	rare	
downregulation	
 
Breast	
Colon	
prostate	
Table	 1.8	 Table	 showing	 a)	 deregulated	 cyclins	 and	 CDKs	 and	 their	 associated	
tumours	 b)	 deregulated	 endogenous	 CDK	 inhibitors	 and	 associated	
tumours(Benson,	Kaye	et	al.	2005)	
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1.7.4	CDK	inhibition	in	cancer	
	
The	role	of	aberrant	CDK	activity	and	potential	 inhibition	has	been	 investigated	 in	
many	human	cancers.	
	
Flavopiridol	 is	 broad-spectrum	CDK	 inhibitors	with	 proven	 activity	 in	 vitro	 against	
CDK1,	 2,	 4	 and	 6	 and	 cell	 effects	 including	 inhibition	 of	 growth	 and	proliferation,	
induction	of	apoptosis	and	 inhibition	of	angiogenesis.	 	 In	mouse	studies	poor	oral	
bioavailability	was	evident	and	subsequent	parenteral	dosing	did	result	in	some	GI	
and	marrow	 suppressive	 toxic	 effects	 but	 there	 was	 significant	 antitumor	 effects	
and	significantly	synergistic	effects	with	other	chemotherapeutics.	 	Phase	 I	clinical	
trials	 have	 been	 completed	 with	 flavopiridol	 as	 a	 monotherapy	 in	 refractory	
tumours	 with	 GI	 dose	 limiting	 toxicity	 being	 the	main	 issue.	 	 Phase	 II	 trials	 have	
yielded	significant	effects	in	non-small	cell	lung	cancer	that	has	resulted	in	a	phase	II	
trial	comparing	flavopiridol	to	standard	therapy(Shapiro	2004).		
	
Yu	 et	 al	 performed	 a	 range	 of	 experiments	 concerning	 cyclin	 D-CDK4	 activity	 in	
Breast	 cancer.	 	 Initially	 they	 demonstrated	 that	 mice	 lacking	 in	 cyclin	 D1	 are	
resistant	to	breast	cancers	triggered	by	Erb-2	oncogene(Yu,	Geng	et	al.	2001)	then	
developed	 this	 hypothesis	 proposing	 that	 the	 ability	 of	 cyclin	 D	 to	 activate	 CDK4	
underpinned	 the	 oncogenic	 potential	 of	 Erb-2-driven	 breast	 neoplasia.	 	 This	 was	
tested	by	crossing	CDK4-null	mice	with	a	transgenic	strain	 in	which	the	expression	
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of	 Erb-2	 gene	was	 driven	 by	 a	mammary	 specific	mouse	mammary	 tumour	 virus	
enhancer.	 	 The	 result	 of	 this	 was	 complete	 protection	 against	 breast	 cancers(Yu,	
Sicinska	et	al.	2006).		Interestingly	the	normal	physiological	development	of	breast	
tissue	 in	the	CDK4-null	mice	was	unimpeded	suggesting	the	requirement	for	CDK4	
activity	 in	 neoplasia	 but	 not	 normal	 mammary	 development.	 	 These	 conclusions	
were	 supported	 by	 Landis	 et	 al	 (Landis,	 Pawlyk	 et	 al.	 2006)	 again	 supporting	 the	
concept	that	CDK’s	offer	an	attractive	target	in	cancer	therapy.	
	
Work	 on	 CDK2	 targeting	 has	 not	 provided	 such	 promising	 results.	 	 Testu	 et	 al	
investigated	CDK2	inhibition	and	noted	 its	activity	 is	 indispensible	for	both	colonic	
neoplasia	 and	 other	 cancer	 cell	 types	 including	 cervical	 and	 osteosarcoma(Tetsu	
and	McCormick	2003).		Despite	this	there	have	been	reports	of	successful	targeting	
of	CDK2	in	other	tumour	types.		Du	et	al	demonstrated	CDK2	activity	was	critical	for	
melanoma	cell	proliferation	demonstrating	that	specific	CDKs	may	offer	therapeutic	
targets	in	specific	tumour	types(Du,	Widlund	et	al.	2004).	
	
Novel	CDK	inhibitors	have	also	been	investigated	in	PDAC.		Brasca	et	al	reported	on	
a	novel	CDK	inhibitor	PHA-793887	and	its	effects	in	a	xenograft	model	of	pancreatic	
cancer	using	the	tumour	line	Bx-PC3.		The	agent	was	well	tolerated	and	resulted	in	
significant	tumour	growth	inhibition	(Brasca,	Albanese	et	al.	2010).	
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The	 effects	 of	 the	 CDK	 inhibitor	Dinaciclib	 (SCH727965;	MK-7965)	 in	 combination	
with	an	AKT	inhibitor	(MK-2206)	were	investigated	in	orthotopic	and	subcutaneous	
xenograft	models	of	pancreatic	cancer.		In	this	study	tumour	growth	and	metastases	
were	 blocked	 in	 the	models	 used	 and	 several	 complete	 responses	were	 noted	 in	
this	combination,	a	phase	I	trial	for	pancreatic	cancer	is	now	ongoing	(Hu,	Dadon	et	
al.	2015).	
	
1.7.5	AT7519-	A	novel	CDK	inhibitor	
AT7519	is	a	general	CDK	inhibitor	developed	by	Astexs	pharmaceuticals	(Cambridge,	
UK).	 	 This	 compound	 was	 developed	 using	 fragment-based	 X-ray	 crystallographic	
screening.	 	 Fragments	 are	 low-molecular	 weight	 compounds	 with	 low	 binding	
affinities	 and	 screening	 using	 X-ray	 crystallography	 yields	 small	 libraries	 of	
compounds	 that	 have	 much	 greater	 probability	 of	 yielding	 complimentary	
fragments	and	targets(Hartshorn,	Murray	et	al.	2005).		Astexs	developed	a	panel	of	
molecules	and	investigated	pharmacokinetic	properties	leading	to	the	identification	
of	 AT7519,	 its	 chemical	 structure	 shown	 in	 figure	 1.5	 (Wyatt,	 Woodhead	 et	 al.	
2008).	
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Figure	1.5	The	structure	of	AT7519	adapted	from	Squires	et	al		(Squires,	Feltell	et	
al.	2009).	
	
	
AT7519	is	a	potent	inhibitor	of	CDK1,2,	4	,	6	and	9	and	also	inhibits	CDK	3	and	7	to	a	
lesser	 degree.	 	 Initial	 in	 vitro	 experiments	 across	 a	 range	 of	 cancer	 cell	 lines	
confirmed	 the	 antiproliferative	 (table	 1.9)	 activity	 of	 AT7519	 and	 TUNEL	 staining	
assays	 and	 colony	 formation	 confirmed	 induction	 of	 apoptosis	 in	 colonic	 and	
ovarian	cancer	cell	 lines,	 interestingly	an	exposure	equivalent	or	greater	 than	one	
cell	cycle	was	required	for	induction	of	apoptosis	suggesting	that	AT7519	needed	to	
be	present	during	certain	points	in	the	cell	cycle(Squires,	Feltell	et	al.	2009).		In	this	
initial	investigation	a	xenograft	model	using	HCT116	(a	colonic	cancer	cell	line)	was	
carried	 out	 that	 showed	 delayed	 tumour	 growth	 and	 tumour	 regression	 in	 an	
advanced	cancer	model	compared	to	controls	(p<0.05).		CDK2	substrates	were	also	
tested	from	this	xenograft	model,	namely	the	phosphorylation	of	NPM	and	Rb	and	
were	shown	to	decrease	after	certain	time	points	post	dose.	
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Origin	 Cell	Line	 AT7519	
IC50	
(nM)	
Colon	Carcinoma	 HCT116	 82	
HT-29	 170	
SW620	 940	
Ovarian	carcinoma	 A2789	 350	
SK-OV-3	 400	
Lung	Carcinoma	 A549	 310	
NCI-H69	 330	
NCI-H596	 690	
NCI-H82	 230	
Breast	Carcinoma	 MCF-7	 40	
BT-20	 320	
MDA-MB-468	 340	
SK-BR3	 140	
HCC1937	 460	
Uterine	sarcoma	 MESSA	 660	
Leukaemia	 HL60	 230	
K562	 310	
MOLT-4	 310	
F36-P	 390	
Kasumi-1	 250	
MOLM-13	 170	
MV4-11	 170	
PL-21	 160	
Lymphoma	 Granta-519	 160	
JEKO-1	 670	
Ramos	 720	
Fibroblast	 MRC-5	 980	
MRC-5	
(nonproliferating)	
>10,000	
Table	1.9	The	anti-proliferative	activity	of	AT7519	in	a	range	of	human	cancer	cell	
lines	adapted	from	Squires	et	al	(Squires,	Feltell	et	al.	2009).		
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Since	its	initial	description	AT7519	has	been	investigated	in	the	preclinical	setting	in	
a	range	of	malignancies,	efficacy	has	also	been	demonstrated	in	multiple	myeloma,	
leukaemia		and	neuroblastoma	cell	lines(Santo,	Vallet	et	al.	2010)	(Squires,	Cooke	et	
al.	2010;	Dolman,	Poon	et	al.	2015).	
	
Phase	I	studies	have	characterised	the	toxicity	profile	of	this	agent	and	shown	initial	
promise	 regarding	 efficacy.	 	 Patients	with	 refractory	 solid	 organ	 tumours	 or	 non-
Hodgkin’s	 lymphoma	were	enrolled	 and	 treated	with	 an	escalated	dose	based	on	
the	 toxicity	 assessment	 observed.	 	 Dose-limiting	 toxicities	 included	 febrile	
neutropenia,	rash,	mucosisits	and	hypokalaemia.		The	initial	phase	I	study	reported	
significant	QTc	prolongations	resulting	in	one	grade	5	toxicity	but	further	work	has	
established	a	safe	tolerated	dose	without	this	important	toxicity	and	phase	II	trials	
are	on	going(Mahadevan,	Plummer	et	al.	2011)	(Chen,	Hotte	et	al.	2014).	
	
1.7.6	Conclusion	
The	 role	 of	 CDKs	 and	 their	 inhibition	 in	 cancer	 including	 pancreatic	 cancer	 has	
shown	therapeutic	promise.		AT7519	a	general	CDK	inhibitor	has	shown	efficacy	in	a	
range	 of	 tumours	 in	 the	 pre	 clinical	 setting	 and	 therefore	 is	 agent	 that	 warrants	
evaluation	 in	 PDAC	 as	 an	 agent	 that	 may	 offer	 further	 therapeutic	 promise	
particularly	against	the	inherent	gemcitabine	resistance	seen.			
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1.8	HSP90	
Heat	Shock	Protein	90	(HSP90)	is	one	of	the	most	abundant	molecular	chaperones	
crucial	 in	 the	 function	 and	 survival	 of	 eukaryotic	 cells.	 	 HSP90	 is	 required	 for	 the	
stability	and	function	of	a	number	of	signalling	proteins	and	other	key	regulators	of	
the	cell	cycle.	It	facilitates	the	final	activation	of	selected	client	proteins	rather	than	
de	novo	protein	folding	and	therefore	does	not	only	function	in	relation	to	protein	
folding	but	also	contributes	 in	a	host	of	other	 cellular	processes	 including	protein	
degradation,	 signal	 transduction	 and	 intracellular	 transport.	 	 There	 are	 two	main	
genes	that	encode	HSP90	protein	(α	and	β),	α	is	induced	in	times	of	cellular	stress		
and	β	is	mainly	involved	in	regulating	clients	under	normal	conditions.		This	means	
that	α	is	of	particular	relevance	to	the	cancer	environment	where	stresses	such	as	
hypoxia,	nutrient	deprivation	and	acidosis	exist	(Taipale,	Jarosz	et	al.	2010)	(Nathan,	
Vos	et	al.	1997).			
	
1.8.1	Structure	of	HSP90	
HSP90	acts	as	a	homodimer	with	three	flexibly	linked	functional	regions	including	an	
N-terminal	ATP-binding	domain	(N-domain),	a	middle	domain	(M-domain)	and	a	C-
terminal	dimerization	domain	(C-domain)	and	resides	primarily	in	the	cytoplasm	of	
eukaryotic	cells;	although,	there	are	organelle	specific	HSP90	variants	such	as	TRAP1	
in	 the	mitochondria	and	GRP94	 in	 the	endoplasmic	 reticulum(Sreedhar,	Kalmar	et	
al.	2004).		The	ATP-binding	site	and	structural	conformity	is	conserved	from	bacteria	
to	man	 aside	 from	 a	 cross	 link	 between	 the	 N-terminal	 and	M-domain.	 	 The	M-
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domain	 is	 active	 in	ATP-hydrolysis	 and	 contains	 catalytic	 components	 for	 forming	
the	 ATPase	 site	 (Meyer,	 Prodromou	 et	 al.	 2004).	 	 The	 C-domain	 is	 essential	 for	
dimerizastion	(Ratzke,	Mickler	et	al.	2010).				
	
1.8.2	Functional	conformity	
HSP90	 is	 a	 ATP-dependant	molecular	 chaperone	 functioning	 in	 a	 cycle	 associated	
with	ATP	binding	and	hydrolysis.	Structurally	HSP90	adopts	two	distinct	 functional	
conformities	that	are	 in	a	dynamic	equilibrium.	 	 In	the	 inactive	unbound	state	the	
protein	is	in	an	open	V-shaped	conformation.		The	binding	of	ATP	triggers	a	number	
of	 conformational	 changes	 and	HSP90	 reaches	 its	 compact,	 closed	 state.	 The	 fact	
that	these	states	are	in	dynamic	equilibrium	remains	important	functionally	as	this	
may	allow	HSP90	to	adapt	to	different	client	proteins	 (Li	and	Buchner	2013).	 	The	
protein	 binding	 region	 is	 located	 towards	 the	 C-terminal,	 it	 is	 the	 ATP	 hydrolysis	
that	 drives	 the	 conformational	 changes	 above	 described	 that	 govern	 the	
appearance	of	the	protein	binding	site	(Grenert,	Sullivan	et	al.	1997).	 	 In	the	open	
confirmation	HSP90	has	some	hydrophobic	residues	exposed	that	recruit	unfolded	
or	misfolded	proteins	with	the	same	areas.		Once	the	bound	substrate	is	in	position	
the	ATP	hydrolysis	near	the	N-terminal	 results	 in	 the	conformational	changes	that	
clamp	 down	 onto	 the	 substrate.	 	 This	 ability	 of	 HSP90	 allows	 several	 functions	
including	 protein	 folding	 assistance,	 aggregation	 prevention	 and	 as	 a	 transport	
mechanism	 (Wegele,	 Muller	 et	 al.	 2004).	 HSP90	 functions	 as	 part	 of	 a	
multichaperone	complex	 in	association	with	cochaperones	and	client	proteins.	 	 In	
the	 open	 state	 a	 client	 protein	 is	 clamped	 onto	 HSP90	 with	 the	 assistance	 of	
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cochapernes,	for	example	HSP70	and	HSP40.		Moving	to	the	closed	state	Cdc37,	p23	
and	immunophilins	replace	the	original	cochaperones	to	facilitate	maturation	of	the	
conformation	of	the	client	and	therefore	maintain	the	protein	in	its	active	state	in	
order	to	exert	a	function(Prodromou	and	Pearl	2003).		The	structure	and	functional	
conformity	of	HSP90	is	summarised	in	figure	1.6.		
	
Figure	1.6	The	structure	and	functional	conformity	of	HSP90.	
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1.8.3	HSP90	in	cancer	biology	
In	 cancer	 biology	 client	 proteins	 have	 been	 identified	 that	 associate	with	 HSP90,	
those	described	 include	EGF	receptors,	MET,	Raf-1	kinase,	AKT,	mutant	p53,	CDK4	
and	 Bcr-abl(Maloney	 and	 Workman	 2002;	 Neckers	 and	 Ivy	 2003).	 	 These	 client	
proteins	 rely	on	HSP90	 for	 stabilisations	and/or	maturation	and	 contribute	 to	 the	
hallmarks	 of	 cancer,	 as	 described	 by	 Hanahan	 and	 Weinberg	 (Hanahan	 and	
Weinberg	 2000;	 Hanahan	 and	 Weinberg	 2011).	 	 The	 hallmarks	 include	 self-
sufficiency	 in	 growth	 signalling,	 insensitivity	 to	 anti-growth	 signalling,	 evading	
apoptosis,	sustained	angiogenesis,	metastasis	and	unlimited	proliferative	potential.		
In	pancreatic	cancer	12	pathways	that	are	routinely	mutated	have	been	described,	
observations	 showed	 some	 cancer	 had	 mutations	 in	 all	 these	 pathways	 and	 the	
majority	 had	 mutations	 in	 at	 least	 9	 (Jones,	 Zhang	 et	 al.	 2008).	 	 It	 follows	 that	
proteins	appearing	on	more	than	one	of	these	pathways	provide	interesting	targets	
for	therapy	and	it	is	noted	that	HSP90	is	required	for	all	of	these	pathways(Xu	and	
Neckers	 2007;	 Taldone,	 Gozman	 et	 al.	 2008).	 Pancreatic	 cancer	 remains	 a	
complicated	disease	possessing	multiple	 genetic	 changes.	Over	 90%	of	 pancreatic	
ductal	 adenocarcinomas	 have	 a	 mutation	 in	 the	 KRAS	 gene	 that	 restricts	 self-
inactivation	 (Eser,	 Schnieke	 et	 al.	 2014),	 its	 protein	 that	 can	 affect	 both	 the	
PI3K/AKT	and	MAP	kinase	pathways.	HSP90	client	proteins	AKT,	and	EGFR	are	both	
over-expressed,	amplified	or	activated	in	60%	(AKT2)	and	70%	of	pancreatic	cancers	
respectively(Ghaneh,	 Costello	 et	 al.	 2007).	 More	 generally	 both	 the	 MAP	 kinase	
pathway	 and	 the	 PI3K/AKT	 pathways	 have	 been	 associated	 in	 pancreatic	 cancer	
(Jones,	 Zhang	 et	 al.	 2008)	 (Reichert,	 Saur	 et	 al.	 2007).	 Additionally	 pancreatic	
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cancer,	in	common	with	many	cancer,	have	increased	levels	of	HSP90	and	may	rely	
more	heavily	on	the	HSP90	protein	to	stabilize	the	mutated	and	activated	proteins	
on	which	they	depend.		HSP90	has	been	found	to	be	expressed	6-	to	7-fold	higher	in	
human	pancreatic	cancer	than	in	normal	tissue	(Ogata,	Naito	et	al.	2000).		Thus	the	
targeting	of	multiple	pathways	through	the	inhibition	of	HSP90	is	a	more	attractive	
target	than	that	of	a	single	molecule	in	the	treatment	of	such	a	complex	disease	as	
pancreatic	cancer.	Table	1.10	summarises	the	HSP90	client	proteins	associated	with	
oncogenesis.	
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HSP90	client	proteins	associated	with	oncogenesis	
Kinases	 Akt/PKB	
Bcr-Abl	
CDK4,	CDK6,	CDK9	
Death	domain	kinase	RIP	
ErbB2	(and	mutant	EGF	receptor)	
C-MET	
IGFR	
MEK	
MOK,	MAK,	MRK	
PDK	1	
Pim-1	
Plk	1	
FAK	
Pp60v-src,	c-src	
Raf-1,	B-Raf,	Ste	11	
trkB	
VEGFR2	
Weel,	Swel	
Transcription	factors	
Steroid	receptors	(GR,	MR,	ER,	PR,	AR)	
HSF-1	
p53	
Stat3	
Others	 Apaf-1	
Mdm2	
Proteasome	
Ral-binding	protein	1	
Survivin	
SV40	large		T	antigen	
Telomerase	
Table	 1.10	 A	 table	 showing	 HSP90	 client	 proteins	 associated	 with	 oncogenesis,		
adapted	from	(Zhang	and	Burrows	2004).	
	
	
1.8.4	Inhibition	of	HSP90	
The	desirable	feature	of	HSP90	as	a	target	for	cancer	therapy	stem	from	its	position	
on	multiple	cancer	related	pathways(Workman	2004).	The	fact	that	 its	actions	are	
multifactorial	(figure	1.7)	should	also	significantly	reduce	the	opportunity	for	cancer	
cells	to	become	resistant	to	HSP90	inhibition.	
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Figure	 1.7	 The	 multiple	 signalling	 pathways	 disrupted	 by	 HSP90	 inhibition	
disrupting	 both	 anti-apoptotic	 signalling	 and	 cell	 cycle	 progression.	 	 Targets	 of	
HSP90	 inhibitors	 	 are	 circled.	 	 Adapted	 from	 Blagosklonny	 et	 al.(Blagosklonny	
2002).	
	
It	 is	obviously	a	concern	that	HSP90	is	pivotal	not	only	cancer	but	also	normal	cell	
function:	 i.e.	 toxicity	 may	 be	 an	 issue.	 	 The	 therapeutic	 selectivity	 of	 HSP90	
inhibition	in	cancer	relies	on	a	number	of	factors	(Workman,	Burrows	et	al.	2007).		
Firstly	 the	 fact	 that	 cancer	 cells	 become	 reliant	 on	 the	 oncogenic	 pathways	 that	
drive	the	malignancy,	 in	turn	depleting	oncoproteins	has	a	much	greater	effect	on	
cancer	cells	than	normal	tissue	(Weinstein	and	Joe	2006).		Secondly,	oncoproteins	in	
cancer	often	exist	in	their	mutated	form	and	are	much	more	reliant	on	HSP90	than	
in	 their	 normal	 state	 (Grbovic,	 Basso	 et	 al.	 2006).	 The	 cancer	 microenvironment	
IGF,%EGF,%PDGF%
PI)3K % % %%%%Ras % % %GF#R% % %Src#
Raf)1%
MEK%
Erk%
(MAPK)%
Cyclin%D%
CDK4#
Rb % % %pp)Rb % %G1/S%transi,on%
G1%arrest%
Bcr-Abl#
Akt#
Apoptosis%
	 66	
(including	 acidosis	 and	hypoxia)	 is	 heavily	 influenced	by	molecular	 chaperones,	 in	
such	an	environment	HSP90	is	often	involved	in	large	muticomplexes	as	opposed	to	
the	 uncomplexed	 HSP90	 found	 in	 healthy	 cells.	 	 The	 inhibitors	 developed	 can	
specifically	 target	 the	 bound	 form	 of	 HSP90,	 such	 as	 17-AAG	 (Kamal,	 Thao	 et	 al.	
2003).	
	
Geldanamycin	 and	 its	 derivatives	 17-allyamino-geldamycin	 (17AAG)	 and	 17-
(dimethylaminoethylamino)-17-demethoxygeldanamycin	 (DMAG)	 are	 HSP90	
inhibitors	that	 initiated	 interest	 in	the	 inhibition	of	HSP90	as	a	strategy	for	cancer	
treatment.		Geldanamycin	is	a	benzoquinone	asamycin	that	has	been	shown	to	bind	
directly	with	HSP90	interfering	with	the	heterocomplex	formation	and	ATP	binding	
to	 the	 N-terminal	 resulting	 in	 ubiquitin	mediated	 proteasomal	 degradation	 of	 its	
client	 proteins(Workman,	 Burrows	et	 al.	 2007)	 (Whitesell,	Mimnaugh	et	 al.	 1994)	
(Grenert,	 Sullivan	 et	 al.	 1997).	 	 	 Despite	 the	 potent	 anti-tumour	 effects	
demonstrated	 by	 Geldamycin	 and	 17AAG	 their	 use	was	 limited	 by	 hepatotoxicity	
and	water	 solubility	 (Usmani2009)	 (Banerji,	 O'Donnell	 et	 al.	 2005).	 	 	 17-AAG	 has	
been	 investigated	 in	 prostate	 cancer	 and	 melanoma	 in	 a	 Phase	 II	 study	 but	 no	
objective	clinical	responses	were	seen	with	the	dose	and	scheduling	deemed	safe	in	
phase	I	studies	(Heath,	Hillman	et	al.	2008)	(Solit,	Osman	et	al.	2008).			17-DMAG	is	
a	 geldanamycin	 derivative	 with	 substitution	 of	 the	 C-17	 methoxy	 group	 that	
resulted	 in	 increased	water	 solubility	and	bioavailability	 (Hollingshead,	Alley	et	al.	
2005).	 	 In	phase	 I	 trials	clinical	responses	or	stable	disease	have	been	observed	 in	
prostate,	 melanomas	 and	 renal	 cell	 carcinomas	 but	 again	 drug-related	 toxicities	
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were	 observed	 limiting	 its	 role	 moving	 forward	 (Pacey,	 Wilson	 et	 al.	 2011)	
(Kummar,	Gutierrez	et	al.	2010).			
	
Another	mechanism	for	HSP90	inhibition	is	disruption	of	the	bond	between	HSP90	
and	 its	 co-chaperone	 Cdc37.	 This	was	 investigated	 by	 Zhang	et	 al	using	 celastrol,	
they	 demonstrated	 inhibition	 of	 cell	 division	 and	 induction	 of	 apoptosis	 in	
pancreatic	 cancer	 cells	 lines.	 	 In	 an	 in	 vivo	 model	 celastrol	 inhibited	 pancreatic	
tumour	growth	by	up	to	80%	(p	<0.001)	(Zhang,	Hamza	et	al.	2008).	
	
Structure	based	approaches	have	also	been	employed	in	the	development	of	HSP90	
inhibitors.		Based	on	the	purine	scaffold	PU3	was	designed	and	reported	on	as	the	
first	synthetic	HSP90	inhibitor	(Chiosis,	Timaul	et	al.	2001).		Since	its	development	a	
number	 of	 other	 agents	 have	 been	 developed	 based	 on	 this	 initial	 prototype	
molecule	and	advanced	 to	clinical	 trials.	 	CNF2024/BIIB021	as	one	such	agent	has	
been	 investigated	 in	 phase	 I	 and	 II	 clinical	 trials	 in	 advanced	 solid	 organ	
malignancies,	 toxicities	 included	 grade	 3	 and	 4	 fatigue,	 hyponatreamia	 and	
hypoglycaemia	and	efficacy	investigation	demonstrated	stable	disease	in	11	of	the	
16	patients	studied	(Saif,	Takimoto	et	al.	2014).	
Another	 HSP90	 inhibitor	 that	 has	 been	 investigated	 is	 novobiocin	 although	 this	
inhibition	 	 was	 an	 additional	 effect	 not	 originally	 expected.	 	 Novobiocin	 is	 a	
aminocoumarin	antibiotic	 that	acts	 through	 the	 inhibition	of	DNA	gyrase	and	was	
originally	investigated	as	an	agent	for	the	treatment	of	bacterial	infections(Samuels	
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and	Garon	1993).		It	has	also	been	shown	to	provide	a	degree	of	HSP90	inhibition	by	
binding	to	the	HSP90	C-terminal	binding	site	and	subsequently	induce	degradation	
of	 client	 proteins(Donnelly	 and	 Blagg	 2008).	 	 The	 activity	 of	 novobiocin	 itself	 in	
relation	 to	 HSP90	 inhibition	 was	 weak	 therefore	 a	 number	 of	 analogues	 were	
developed	that	have	shown	more	promising	anti-cancer	activity	(Burlison,	Neckers	
et	 al.	 2006).	 	 Montori	 et	 al	 demonstrated	 one	 such	 analogues	 activity	 in	 breast	
cancer	 cell	 lines(Montoir,	 Barille-Nion	 et	 al.	 2016)	 as	 well	 as	 other	 literature	
demonstrating	 novobiocin	 analogues	 activity	 in	 lung	 and	 breast	 cancer	 cell	
lines(Hall,	Seedarala	et	al.	2016)	
	
The	 investigation	of	HSP90	 inhibitors	 and	 issues	experienced	have	 resulted	 in	 the	
development	of	compounds	that	are	less	toxic	more	water-soluble	and	have	better	
pharmacodynamics	including	AT13387	(woodhead2010).		
	
1.8.5	AT13387-	A	novel	HSP90	inhibitor	
AT13387	is	a	small-molecule	inhibitor	of	HSP90	developed	by	Astex	Pharmaceuticals	
Inc.	via	fragment	based	drug	discovery	(figure	1.8).		Fragment	based	drug	discovery	
is	a	process	based	on	identifying	small	chemical	fragments	that	bind	to	a	biological	
target	 then	 combining	or	 growing	 them	 to	produce	a	 lead	 compound	with	a	high	
affinity	for	the	proposed	target.	 	The	resulting	compounds	have	benefits	of	higher	
ligand	efficiency	with	low	molecular	weight	compounds	(Murray,	Carr	et	al.	2010).		
Fragment	screening	using	NMR	and	high	throughput	X-ray	crystallography	was	used	
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to	develop	AT13387	as	a	novel	inhibitor	of	HSP90.		It	was	demonstrated	to	have	a	
high	 affinity	 for	 HSP90	 binding	 at	 the	 ATPase	 site	 of	 the	 N-terminal	 which	 was	
demonstrated	to	have	inhibitive	activity	against	a	range	of	human	cancer	cell	 lines	
(table	1.11)	and	cytostatic	activity	 in	a	xenograft	model	(Woodhead,	Angove	et	al.	
2010).			
	
	
Figure	1.8	The	 structure	of	an	AT13387	molecule	adapted	 from	Woodhead	et	al		
(Woodhead,	Angove	et	al.	2010)		
	
There	has	already	been	published	data	on	its	efficacy	in	a	range	of	cancers	from	in	
vitro	 and	 in	 vivo	models.	 	 Smyth	et	 al	 investigated	AT13387	 activity	 against	 an	 in	
vitro	and	in	vivo	gastrointestinal	stromal	tumour	model	and	found	it	effective	both	
in	 Imatinib	 (standard	 therapy)	 sensitive	 and	 resistant	 cell	 lines,	 notably	 AT13387	
was	effective	in	cell	lines	resistant	to	17-AAG,	an	alternative	HSP90	inhibitor	(Smyth,	
Van	Looy	et	al.	2012).			As	a	result	of	these	initial	investigations	a	randomised	phase	
II	 study	 of	 patients	 with	 advanced	 GIST	 tumours	 who	 have	 progressed	 following	
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standard	therapy	has	been	completed	using	AT13387	both	as	a	single	agent	and	in	
combination	with	Imatinib,	the	results	are	yet	to	be	published.			
	
Graham	et	al	demonstrated	AT13387	efficacy	 in	 	a	xenograft	model	of	 	 refractory	
non-small	 cell	 lung	 cancers	 demonstrating	 significant	 reduction	 in	 tumour	 growth	
compared	to	controls	and	noted	a	long	duration	of	action	both	 in	vitro	and	 in	vivo	
(Graham,	 Curry	 et	 al.	 2012).	 	 Currently	 phase	 I	 and	 II	 clinical	 trials	 have	 been	
completed	 in	 Gastrointestinal	 Stromal	 Tumours	 (GIST)	 (Mahadevan	 2013)and	 a	
phase	I	trial	completed	in	refractory	solid	organ	tumours	demonstrating	tolerability	
only	grade	2	adverse	events	(Mahadevan	2012).			
	
More	 recently	AT13387	has	been	demonstrated	 to	overcome	 issues	 in	melanoma	
relating	 to	 clinical	 resistance	 to	 BRAF	 inhibitors	 in	 pre-clinical	 studies	 (Smyth,	
Paraiso	et	al.	2014)	and	further	drug	safety	in	a	phase	I	clinical	trial	of	patient	with	
advanced	 solid	 organ	 tumours	 has	 demonstrated	 safety	 and	 tolerability	 with	
preliminary	 anti-tumour	 activity	 (Shapiro,	 Kwak	 et	 al.	 2014).	 	 Current	 phase	 II	
studies	 continue	 in	 the	 treatment	 of	 non-small	 cell	 lung	 cancer	 and	 BRAF	
melanoma.	
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Origin	 Cell	Line	 AT13387	
GI50	(nM)	
Normal	Prostate	 PNT2	 480	
Colon	Carcinoma	 HCT116	 48	
HT-29	 78	
SW620	 210	
Lung	Carcinoma	 A549	 22	
NCI-H1975	 27	
NCI-H1993		 63	
NCI-H1650	 13	
Breast	Carcinoma	 MCF-7	 53	
MDA-MB-231	 260	
MDA-MB-468	 25	
SK-BR3	 63	
T47D	 29	
BT474	 13	
Multiple		Myeloma	 U266	 58	
RPMI	8226	 70	
Hepatoma	 Huh-7	 22	
Prostate	Carcinoma	 DU145	 94	
PC3	 120	
LNCaP	 77	
22Rv1	 46	
Uterine	Sarcoma	 MES-SA	 53	
MES-SA/Dx5	 42	
Ovarian	 SKOV3	 44	
Leukaemia	 HL60	 22	
K562	 47	
MV4-11	 13	
Melanoma	 A375	 18	
SkMel	28	 44	
Cholangiocarcinoma	 TFK-1	 19	
Table	1.11	A	table	showing	the	anti-proliferative	effect	of	AT13387	on	a	panel	of	
human	tumour	cell	lines	with	a	notable	absence	of	any	description	of	PDAC	lines,	
adapted	from	Graham	et	al		(Graham,	Curry	et	al.	2012)	
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1.8.6	Conclusion	
Targeting	HSP90	inhibition	offers	a	promising	therapeutic	avenue	in	PDAC	owing	to	
the	 complex	 molecular	 events	 seen	 in	 this	 disease.	 	 AT13387	 as	 a	 novel	 HSP90	
inhibitor	 presents	 a	 new	 agent	 that	 warrants	 investigation	 in	 PDAC	 in	 the	 pre-
clinical	 setting,	 it	 offers	new	 treatment	 that	may	be	able	 to	enhance	 the	gains	of	
current	therapy	and	overcome	the	innate	gemcitabine	resistant	seen	in	this	disease.	
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1.9	STUDY	DESIGN	AND	OBJECTIVES	
	
1.9.1	Aims	
The	 aim	 of	 this	 study	 was	 to	 evaluate	 two	 novel	 agents	 in	 pancreatic	 cancer,	
AT7519,	 a	 general	CDK	 inhibitor,	 and	AT13387,	 a	HSP90	 inhibitor	as	 single	agents	
and	in	combination	with	standard	therapy	(gemcitabine).		The	actions	of	each	agent	
alone	and	 in	 combination	with	 standard	 chemotherapy	 (gemcitabine)	 in	 vitro	was	
investigated	 in	 pancreatic	 cancer	 cell	 lines	 (including	 a	 gemcitabine	 resistant	 cell	
line),	and	their	efficacy	in	vivo	was	evaluated.	
	
1.9.2	Study	design	in	vitro	
1. Standard	pancreatic	cancer	cell	lines	were	cultured	as	well	as	a	gemcitabine	
resistant	line	for	in	vitro	experimentation.	
2. The	IC50	of	AT7519,	AT13387	and	gemcitabine	was	determined	on	a	range	
of	pancreatic	cancer	cell	lines	using	MTS	assay.	
3. The	 effects	 on	 the	 cell	 cycle	 by	 each	 agent	 (and	 AT7519/AT13387	 in	
combination	with	standard	therapy)	was	investigated	using	flow	cytometry.	
4. Evidence	of	induction	of	apoptosis	of	AT7519	and	AT13387	was	investigated	
using	the	caspase	3/7	assay.	
5. Isobolar	analysis	of	AT7519	+	gemcitabine	and	AT13387	+	gemcitabine	was	
undertaken	using	MTS	assay.	
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6. Western	 blotting	 was	 undertaken	 to	 measure	 biomarkers	 related	 to	
assumed	 drug	 actions	 for	 both	 single	 agents	 (AT7519	 or	 AT13387)	 and	
agents	in	combination	with	standard	therapy	(gemcitabine)	
	
1.9.3	Study	design	in	vivo	
1. Subcutaneous	xenografts	of	Suit2	and	Miapaca-2	cell	lines	were	established	
in	nude	mice	and	the	cell	 line	 that	produced	tumours	most	amenable	 to	a	
xenograft	model	was	taken	forward	to	further	studies.	
2. AT7519,	 AT13387	 and	 gemcitabine	were	 assessed	 for	 tolerability	 as	 single	
agents.	
3. Responses	 to	 AT13387,	 AT7519	 and	 gemcitabine	 were	 assessed	 as	 single	
agents	against	control	animals	measured	by	tumour	volume.	
4. AT7519	 +	 gemcitabine	 and	 AT13387	 +	 gemcitabine	 were	 assessed	 for	
tolerability	in	combination.	
5. Responses	 to	AT7519	and	AT13387	 in	 combination	with	gemcitabine	were	
assessed	 for	 efficacy	 against	 control	 animals	 using	 tumour	 volume	 as	 the	
primary	endpoint.	
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CHAPTER	2:	MATERIALS	AND	METHODS	IN	VITRO	
	
2.1	DRUG	TREATMENTS	
	
2.1.1	Gemcitabine	
Gemcitabine	 for	 in	 vitro	 experiments	 was	 derived	 from	 a	 master	 stock	 already	
available	in	the	department	(diluted	by	K	Dajani).	 	Powered	gemcitabine	had	been	
purchased	from	Eli	lilly	Ltd	(Basingstoke,	UK)	and	a	stock	solution	of	0.1M	was	made	
with	Dulbecco’s	Phosphate	Buffered	Saline	(PBS)	(Sigma,	Poole,	UK).		This	was	filter	
sterilized	and	stored	at	-80ºc	in	0.5ml	aliquots.			
	
2.1.2	AT7519	
AT7519	was	provided	by	Astex	Pharmaceuticals	 (Cambridge,	UK).	 	 Powered	agent	
was	 diluted	 in	Dimethyl	 sulfoxide	 (DMSO)	 	 (Sigma,	 Poole,	UK)	 to	 a	 stock	 solution	
concentration	 of	 10	mM	and	 kept	 in	 20-50µl	 aliquots	 at	 room	 temperature	 for	 a	
maximum	of	6	weeks	(as	recommended	by	Astex	Pharmaceuticals).			
	
2.1.3	AT13387	
AT13387	was	provided	by	Astex	Pharmaceuticals(Cambridge,	UK)	 .	Powered	agent	
was	diluted	in	DMSO	into	a	stock	solution	of	10	mM	and	kept	in	20-50µl	aliquots	at	
room	 temperature	 for	 a	 maximum	 of	 6	 weeks	 (as	 recommended	 by	 Astex	
Pharmaceuticals).			
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2.1.4	Dilution	of	stock	solutions	
When	required	for	experimentation	further	dilutions	of	the	master	stock	solutions	
were	 performed	 with	 Roswell	 Park	 Memorial	 Institute	 medium	 (RPMI)	 (Sigma,	
Poole,	UK)	tissue	culture	media	for	all	agents.	
	
	
2.2		IN	VITRO	CELL	STUDY	
	
2.2.1	Standard	cell	lines	
The	 pancreatic	 cancer	 cell	 lines	 used,	 their	 origin	 and	 source	 for	 this	 study	 are	
detailed	in	table	2.1.	
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Cell	line	 Origin	 Sourced	from	
	 	 	
SUIT-2	 metastatic	liver	tumour	of	human	
PDAC	
Stores	in	department	of	
molecular	and	clinical	
cancer	medicine	
	 	 	
Miapaca-2	 PDAC	obtained	from	a	65-year-old	
Caucasian	male	
Stores	in	department	of	
molecular	and	clinical	
cancer	medicine	
	 	 	
Panc-1	 PDAC	from	a	56-year-old	Caucasian	
male	
	
ATCC	via	LGC	standards	
(Middlesex,	UK)	
CFPac	 metastatic	liver	lesion	of	PDAC	in	a	26	
year	old	Caucasian	male	with	cystic	
fibrosis	(CF)	
	
Stores	in	department	of	
molecular	and	clinical	
cancer	medicine	
Fampac	
	
	
poorly	differentiated	PDAC	in	a	43-
year-old	Caucasian	female	with	a	
familial	predisposition	to	pancreatic	
carcinoma	
	
Stores	in	department	of	
molecular	and	clinical	
cancer	medicine	
	
Table	2.1		A	table	of	the	pancreatic	cancer	cell	lines	used	in	experiments	with	their	
original	origin	and	the	supplier	used.	
	
These	pancreatic	cancer	cell	lines	have	been	characterised	and	information	on	their	
genetic	alterations	are	detailed	in	table	2.2.	
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Cell	line	 KRAS	
alteration	
and	product		
p53	
alteration	
and	product	
p16	alteration	and	
product	
Tumour	marker	
Expression	
SUIT-2	 Mutant	
ASP	12	
Mutant	
His	273	
69	GAG-TAG	
Glu-stop	
Ca19-9	
CEA	
Miapaca-2	 Mutant	
12	cys	
Mutant	
248	trp	
Homozygous	
deletion	
No	product	
	
Panc-1	 Mutant	
Asp	12	
Mutant	
His	273	
Homozygous	
deletion	
No	product	
	
CFPac	 Mutant	
Val	12	
Mutant	
Arg	242	
Methylated	
No	product		
Ca19-9	
CEA	
Fampac	 Mutant	
Gly	>	Val	12	
Mutant	 Homozygous	
deletion	
No	product	
	
Table	2.2	A	table	demonstrating	the	pancreatic	cancer	cell	lines	genetic	mutations	
and	tumour	marker	expression.	
	
2.2.2	Gemcitabine	resistant	cell	line	
A	gemcitabine	resistant	cell	line,	SUIT-2	(GR),	was	established	in	the	department	by	
Khaled	 Dajani	 (Department	 of	 Molecular	 and	 Clinical	 cancer	 medicine)	 and	 a	
subsequent	 clonal	 population	 developed	 by	 Elisabeth	 Shaw	 (Cancer	 Research	
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Centre	 UK,	 Liverpool).	 	 SUIT-2	 cells	 were	 rendered	 gemcitabine	 resistant	 by	 sub-
culturing	with	progressively	 increasing	concentrations	of	gemcitabine	 to	a	plateau	
of	 5	 mM	 for	 maintenance.	 	 This	 provided	 a	 mixed	 population	 of	 adaptive	 and	
clonally	resistant	cells.			
The	clonal	population	was	separated	by	growing	small	numbers	of	cells	 in	96	well	
plates	and	on	going	culture	of	those	that	maintained	a	large	cell	population	in	5µM	
of	gemcitabine.		These	cells	were	tested	for	on	going	gemcitabine	resistance	by	sub-
culturing	in	the	absence	of	gemcitabine	and	MTS	assays	performed	to	establish	the	
IC50	value.		
	
	
	2.3	TISSUE	CULTURE	
All	 tissue	culture	work	was	undertaken	 in	a	 class	 II	hood	with	 laminar	 flow	which	
was	cleaned	with	70%	ethanol	prior	to	use.	 	Tissue	culture	reagents	(RPMI	media,	
PBS	and	Trypsin,	all	from	Sigma,	Poole,	UK)	were	warmed	in	a	37oC	water	bath	for	
15	minutes	prior	 to	use	and	bottles	cleaned	with	70%	ethanol	prior	 to	transfer	 to	
the	hood.	 	All	 tissue	culture	work	was	performed	using	a	no	 touch	technique	and	
asepsis	ensured	as	feasible.	
	
2.3.1	Defrosting	cells	
Vials	of	the	required	cell	line	pellet	were	retrieved	from	either	-80oC	stores	or	liquid	
nitrogen	stores.		The	vial	of	cell	pellet	was	rapidly	defrosted	and	spun	in	a	centrifuge	
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at	500	revolutions	per	minute	(rpm)	for	5	minutes	to	remove	DMSO.		The	resultant	
cell	pellet	was	then	diluted	into	standard	RPMI	media	to	10ml	and	transferred	to	a	
T25	 flask(Sigma,	 Poole,	 UK).	 	 Once	 cells	 were	 growing	 adequately	 they	 were	
transferred	to	T75(Sigma,	Poole,	UK)	flasks	on	subsequent	splits.	
	
2.3.2	Sub-culturing	cells	
Cells	 contained	 in	a	T25	or	T75	 flask	had	RPMI	media	 removed	and	 the	adherent	
cells	were	 lavaged	with	 10ml	 of	warmed	 PBS,	which	was	 subsequently	 discarded	
into	virkon.	 	Trypsin	was	 then	 introduced	 into	 the	 flask,	1ml	per	T25	and	2ml	per	
T75,	 and	 the	 flask	 returned	 to	 the	 incubator	 for	 the	 time	 required	 to	 lift	 the	
adherent	 cells	 from	 the	 surface.	 	 	 After	 this	 period	 of	 time	 flasks	 were	 removed	
from	the	incubator	back	to	the	hood	and	trypsin	diluted	with	RPMI	media	to	make	a	
total	volume	of	10ml	(i.e.	9ml	of	media	per	T25	and	8ml	of	media	per	T75).	 	Cells	
were	 then	 dispensed	 into	 new	 flasks	 at	 the	 desired	 concentration.	 	 	 Fresh	 RPMI	
media	was	then	added	to	make	a	total	volume	of	10ml	per	T25	and	20ml	per	T75.	
The	routine	practices	for	each	cell	line	used	are	detailed	in	table	2.3.	
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Cell	line	 Time	for	trypsining	cells	
(minutes)	
Routine	sub-culture	split	
SUIT-2	 3	 1	in	10	
Miapaca-2	 3	 1	in	10	
CFPAC-1	 5	 1	in	5	
Panc-1	 1	 1	in	5	
Fampac	 5	 1	in	5	
SUIT-2	(GR)	 3	 1	in	10	
Table	 2.3	 A	 table	 showing	 the	 pancreatic	 cancer	 cell	 lines	 average	 times	 for	
trypsinising	and	the	sub-culture	spilt	routinely	used	for	cell	line	maintenance.	
	
2.3.3	Freezing	cell	stocks	
Adherent	cells	 in	a	T75	flask	at	approximately	80%	confluence	were	used	to	make	
frozen	cell	stocks.		Cells	were	firstly	lavaged	with	10ml	of	PBS	that	was	subsequently	
discarded	into	virkon.		2ml	of	trypsin	was	added	to	each	flask	and	the	flask	returned	
to	the	incubator	for	the	desired	time	to	lift	adherent	cells.	 	After	this	time	the	cell	
flask	was	returned	to	the	hood	and	trypsin	diluted	in	8ml	of	media	to	make	a	total	
volume	of	10ml.		The	10ml	cell	solution	was	then	transferred	into	a	15ml	eppendof	
(Sigma,	 Poole,	 UK)	 and	 spun	 in	 a	 centrifuge	 at	 500rpm	 for	 5	minutes.	 	 Next	 the	
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media	was	removed	from	the	resultant	cell	pellet	and	then	this	was	resuspended	in	
10ml	 of	 PBS	 and	 spun	 for	 a	 further	 5	 minutes	 at	 500rpm.	 	 The	 PBS	 was	 then	
removed	and	the	cell	pellet	mixed	with	5-10ml	of	freezing	media	(dependent	on	the	
size	of	cell	pellet	obtained	at	this	stage).			The	cell	solution	was	then	transferred	to	
labelled	cryotubes	in	1ml	aliquots.		Cryotubes	(Sigma,	Poole,	UK)	were	left	on	ice	for	
1	 hour	 then	 transferred	 to	 -80oC	 for	 48	 hours	 and	 subsequently	 liquid	 nitrogen	
stores	(if	for	long	term	storage).	
	
2.3.4	Authentication	and	Mycoplasma	screening	
All	 cells	 lines	 used	 were	 verified	 as	 the	 correct	 line	 by	 genotyping	 via	 PCR	
(powerplex16,	 promega,	 Southampton,	 UK)	 by	 E.	 Shaw.	 	 Cells	 were	 regularly	 (	
approximately	3	monthly)	screened	for	mycoplasma	using	PCR	by	E.	Shaw.	
	
2.4	MTS	ASSAY	
In	order	to	determine	the	optimal	seeding	density	of	cells	on	Corning	96	well	plates	
(Sigma,	Poole,	UK)	as	well	as	the	IC50	of	the	drug	treatment	and	effects	of	drugs	in	
combination	 the	 EZ4U	 (Biomedica,	 Oxford,	 UK)	 assay	 was	 used.	 	 EZ4U	 is	 a	 non-
radioactive	cell	proliferation	and	cytotoxicity	assay	that	measures	the	cells	ability	to	
convert	the	yellow	coloured	tetrazolium	compound	into	its	red	formazan	derivative.		
This	is	an	active	process	that	requires	functioning	mitochondria	therefore	the	assay	
is	a	measure	of	cell	vitality	and	an	indirect	measure	of	cell	death.	The	kit	consists	a	
SUB	Substrate	power,	1	vial	of	which	 is	enough	solution	 for	2	96	well	plates	with	
100µl	per	well	and	ACT	activator	solution.		2.5ml	of	activator	solution	that	was	pre-
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warmed	to	37oC	was	added	to	one	vial	of	SUB	substrate	power,	which	dissolved	to	
yield	a	straw	coloured	solution	and	was	used	immediately.		10µl	of	the	dye	solution	
was	 added	 to	 each	 100µl	 well	 and	 absorbance	 readings	 were	 taken	 from	 0	 to	 4	
hours	 at	 hourly	 intervals	with	 incubation	 at	 37oC	 between	 readings.	 	 These	were	
taken	on	a	microtiterplate	reader	set	at	450nm	with	620nm	as	a	reference	used	to	
correct	any	non-specific	background	values.	 	 The	plates	were	 shaken	by	 the	plate	
reader	prior	to	each	reading	in	a	standard	fashion.	
	
The	numerical	values	produced	for	each	well	were	averaged	across	wells	with	the	
same	conditions	and	used	 to	give	a	difference	compared	 to	 the	control	wells	and	
corrected	against	blank	wells	(i.e.	those	containing	no	cells).	
	
2.4.1	IC50	determination	
Determination	of	optimum	seeding	density	(the	density	to	reach	approximately	80%	
confluence	 in	 24	 hours)	 to	 commence	 experiments	 for	 each	 cell	 line	 was	 first	
determined	by	seeding	cells	at	variable	densities	on	a	96	well	plate	then	performing	
MTS	assays	at	24,	48,	36,	72	and	96	hours.		Once	the	optimum	seeding	density	was	
established	for	each	cell	line	cytotoxicity	assays	were	performed.	Cells	were	seeded	
at	 the	 required	 density	 in	 100µl	 in	 96	 well	 plates	 and	 incubated	 for	 24	 hours.	
Subsequently	the	media	was	removed	a	fresh	media	with	varying	concentrations	of	
drug	were	added	and	plates	then	incubated	for	24,	48,	36,	72	and	96	hours	at	which	
points	 MTS	 assays	 were	 performed	 	 A	 typical	 example	 of	 a	 plate	 for	 these	
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experiments	is	shown	in	figure	2.1.			IC50’s	for	each	cell	line	were	done	in	triplicate.		
The	IC50	for	each	experiment	was	determined	by	plotting	the	average	growth	curve	
for	well	across	each	plate	compared	to	the	percentage	controls	and	the	50%	point	
of	cell	growth	was	determined	and	the	IC50	derived.	
	
Figure	 2.1	 A	 figure	 showing	 a	 96-well	 plate	 configuration	 to	 determine	 the	
cytotoxicity	of	agents	against	pancreatic	cancer	cell	lines.	
	
2.4.2	Isobolar	analysis	of	drug	combinations	
Isobolar	 analysis	 of	 drug	 combination	were	 completed	 for	Gemcitabine	 +	AT7519	
and	Gemcitabine	+	AT13387.	 	The	concentrations	of	agent	used	were	determined	
from	 the	 single	 agent	 IC50’s	 and	 the	 IC50	 was	 used	 as	 the	 0.25x	 or	 0.5x	
concentration	 on	 the	 isobolar	 plates	 (i.e.	 the	 1x	 concentration	 was	 4x	 or	 2x	 the	
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IC50).	 	 Cells	 were	 seeded	 in	 96	 well	 plates	 at	 previously	 determined	 optimum	
seeding	densities	 then	24	hours	 later	media	removed	and	drug	media	 introduced.		
Variable	dosing	schedules	in	combination	were	used	as	in	table	2.4	and	assays	were	
completed	with	a	48	and	72	hour	MTS	reading.	
	
	
	
Day	0	 Day	1	 Day	2	 Day	3	 Day	4	
Design	1	 seeding	
cells	
agent	1	
+agent	2	
introduced	
	
MTS	assay	
(48	hours)	
	
Design	2	 seeding	
cells	
agent	1	
introduced	
agent	1	
+agent	2	
introduced	
	
MTS	assay	
(48	hours)	
Design	3	 seeding	
cells	
agent	2	
introduced	
agent	1	
+agent	2	
introduced	
	
MTS	assay	
(48	hours)	
Table	2.4	The	timeline	for	3	experimental	designs	of	isobolar	analysis.	
	
Isobolar	plates	were	prepared	in	a	standard	format,	an	example	of	which	is	shown	
in	figure	2.2.	
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Figure	2.2	The		96-well	plate	configuration	for	isobolar	analysis.	
	
	
	
2.5	CELL	CYCLE	ASSAYS	
Cell	 cycle	 analysis	was	 completed	 on	 pancreatic	 cancer	 cell	 lines	 using	 untreated	
cells	 and	 drug	 treated	 cells	 performed	 using	 propidium	 iodide	 (PI)	 (Sigma,	 Poole,	
UK)	staining	and	flow	cytometry.		
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2.5.1	Cell	preparation	
Suit2	cells	were	seeded	onto	6	well	plates	at	2.5	x	105	cells	per		well	in	RPMI	media	
and	incubated	for	24	hours.		
	
2.5.2	Drug	treatment	
After	24	hours	incubation	RPMI	media	was	removed	and	cell	treated	with	AT7519,	
AT13387,	 gemcitabine,	 a	 combination	 of	 Gemcitabine	 +	 AT13387,	 Gemcitabine	 +	
AT7519	or	control	(0.1%	DMSO	or	PBS).		Experiments	were	completed	with	varying	
drug	doses	and	times	of	treatment.	
	
2.5.3	Cell	preparation	for	PI	staining	
Both	 adherent	 and	 floating	 cells	were	 collected	 and	washed	with	 twice	with	 PBS	
prior	 to	 fixation	 in	 70%	 ethanol	 overnight	 before	 staining	 with	 PI	 (50ug/ml)	 for	
15minutes	at	room	temperature.		
	
2.5.4	Assay	measurement	
	Propidium	 iodide	 incorporation	was	 using	 assessed	 using	 a	 CyAn™	 ADP	 Analyzer	
(Beckman	 Coulter,	 High	 Wycombe,	 UK).	 Duplicates	 were	 formed	 each	 time	 and	
experiments	were	repeated	in	duplicate	on	different	days.		The	resultant	data	was	
statically	analysed	using	statview	calculating	mann-whitney	generated	p	values.	
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2.6	APOPTOSIS	ASSAYS	
To	 determine	 the	 timing	 and	 mechanism	 of	 cell	 death	 caspase	 3/7	 activity	 was	
assessed	using	the	Caspase-Glo	3/7	luminescent	assay	Promega,	Southampton,	UK).			
	
2.6.1	Cell	preparation	
Miapaca-2	pancreatic	cancer	cell	line	were	seeded	in	96	well	plates	at	5000	cells	per	
well	and	incubated	for	24	hours	to	adhere	to	the	plate	in	RPMI	media.	
	
2.6.2	Treatment	of	cells	
RPMI	 media	 was	 removed	 and	 fresh	 media	 with	 either	 10μM	 AT7519,	 1μM	
AT13387	 or	 0.1%	 DMSO	 control	 was	 introduced	 and	 cells	 were	 incubated	 for	 a	
further	6,	16,	24,	40,	48	or	72	hours.		
	
2.6.3	Caspase	3	assay	
Caspase-Glo	 reagent	 was	 added,	 as	 detailed	 in	 the	manufacturers	 protocol	 using	
100ul	 volumes	 and	 incubated	 for	 1	 hour.	 Luminescence	was	 then	measured	 in	 a	
microplate	 reader	 and	 normalised	 to	 untreated	 control.	 A	 single	 experiment	was	
performed	with	6	replicates	for	each	time	point.		Differences	between	control	and	
treated	cells	were	examined	statistically	using	mann-whitney	p	values	via	statview.	
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2.7	WESTERN	BLOTTING	
Western	 blot	 analysis	 was	 completed	 on	 pancreatic	 cancer	 cell	 line	 lysates.		
Western	 blots	 were	 completed	 on	 untreated	 cells	 and	 drug	 treated	 cells	 with	
variable	drug	concentrations,	sampled	at	variable	time	points.			
	
2.7.1	Antibodies	
The	 antibodies	 used	 as	 potential	 downstream	 markers	 in	 western	 blotting	 were	
supplied	by	Cell	 Signalling	 Technology	 via	New	England	Biolabs	 ltd,	Hertfordshire,	
UK.	
The	antibodies	used	for	AT7519	were	cdc2,	pp1-α,	phospho-pp1-α,	Rb,	phospho-Rb,	
NPM	and	phospho-NPM	 (table	 2.5).	 	 Cdc2	 antibody	detects	 endogenous	 levels	 of	
cdc2	protein,	which	encodes	 for	CDK1.	 	Pp1-α	and	 its	phosphorylated	version	are	
involved	 in	 cell	 cycle	 regulation.	 	 Pp1-α	 dephosphorylates	 Rb	 and	 cdc25	 during	
mitosis	 and	 its	 cell-cycle	 dependant	 phosphorylation	 by	 cdc2	 kinase	 inhibits	 its	
activity.		Retinoblastoma	tumour	suppressor	protein	(Rb)	regulates	proliferation	by	
controlling	the	restriction	point	within	the	G1	phase	of	the	cell	cycle	and	cell	cycle	
dependant	phosphorylation	by	CDKs	inhibits	its	activity,	therefore	allowing	cell	cycle	
progression.		Nucleophosmin	(NPM)	is	a	phosphor	protein	abundant	primarily	in	the	
nucleus	 and	 an	 elevated	 level	 is	 often	 found	 in	 tumour	 cells.	 	 NPM	had	multiple	
functions	 including	 centresome	 duplication	 as	 a	 substrate	 of	 CDK2/cyclinE,	 its	
phosphorylation	 is	a	prerequisite	 step	 for	centrosome	to	 initiate	duplication.	 	The	
Antibodies	used	for	AT13387	were	HSP70,	S6,	phospho-S6,	CDK	4,	Akt,	phospho-Akt	
and	Raf-1	(table	2.6).	
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Target	 Size	 Antibody	
code	
species	 Dilution	 Antibody	
incubated	in	
(TBS)	
Blocking	
agent	
(TBS)	
Cdc2	 34kDa	 9112	 Rabbit	 1	in	
2000	
5%	BSA	 5%	BSA	
Pp1α	 38kDa	 2582	 Rabbit	 1	in	
1000	
5%	BSA	 5%	BSA	
phospho-
pp1α	
38kDa	 2581S	 Rabbit	 1	in	
1000	
5%	BSA	 5%	BSA	
Rb	 110kDa	 9309	 Mouse	 1	in	
1000	
5%	Milk	 5%	Milk	
Phospho-
Rb	
120kDa	 44-574G	 Rabbit	 1	in	
1000	
5%	BSA	 5%	BSA	
NPM	 38kDa	 3542	 Rabbit	 1	in	
2000	
5%	Milk	 5%	Milk	
Phospho-
NPM	
38kDa	 3541	 Rabbit	 1	in	
1000	
5%	BSA	 5%	BSA	
	Table	2.5	A	table	showing	the	primary	antibodies	used	for	AT7519	experiments.	
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Target	 Size	 Antibody	
code	
species	 dilution	 Antibody	
incubated	in	
(TBS)	
Blocking	in	
(TBS)	
HSP70*	 70kDa	 SPA-811	 Rabbit	 1	in	
1000	
5%	BSA	 5%	BSA	
S6	 32kDa	 2317	 Rabbit	 1	in	1000	 5%	Milk	 5%	Milk	
Phospho-
S6	
32kDa	 4838	 Rabbit	 1	in	1000	 5%	Milk	 5%	Milk	
CDK	4	 30kDa	 2906	 Mouse	 1	in	1000	 5%	Milk	 5%	Milk	
Akt	 60kDa	 9272	 Rabbit	 1	in	1000	 5%	BSA	 5%	BSA	
Phospho-
Akt	
60kDa	 4058	 Rabbit	 1	in	1000	 5%	BSA	 5%	BSA	
Raf-1**	 80kDa	 Sc-133	 Rabbit	 1	in	1000	 5%	BSA	 5%	BSA	
*HSP70	supplied	by	Enzo	Life	Sciences	Ltd,	Exeter,	UK,		
**Raf-1	supplied	by	Santa	Cruz	Biotechnology	Inc,	Heidelberg,	Germany.	
Table	2.6		A	table	showing	the	primary	antibodies	used	for	AT13387	experiments.	
	
	
2.7.2	Preparation	of	cell	lysate	
Cells	for	western	blotting	were	incubated	for	the	appropriate	time	and	conditions	to	
the	cell	line	in	T75	flasks.		Subsequently	the	media	was	removed	and	adherent	cells	
washed	with	10ml	of	PBS	then	trypsinised	with	2mls	of	trypsin	for	the	appropriate	
period	of	time	at	37oC.		The	trypsin	was	then	neutralised	with	8ml	of	media	and	the	
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cells	 in	media	 transferred	 into	a	 falcon	 tube	and	 spun	 for	2	minutes	ay	1000rpm.		
The	media	was	removed	from	the	cell	pellet	and	this	was	resuspended	in	PBS	and	
transferred	 to	 a	 1.5ml	 eppindorf	 tube.	 	 This	 was	 centrifuged	 at	 1000rpm	 for	 2	
minutes,	the	PBS	was	then	removed	and	the	cell	pellet	resuspended	in	50-100µl	of	
SDS	lysis	buffer	dependant	on	the	size	of	the	cell	pellet	obtained.		The	cell	lysis	was	
then	 sonicaded	 at	 13	 amps	 for	 10	 seconds.	 	 If	 the	 cell	 lysis	 was	 not	 used	
immediately	it	was	stored	at	-20oC.	
	
2.7.3	Determining	protein	concentration	
Protein	concentration	of	the	cell	lysates	produced	was	measured	using	the	Bradford	
assay.	 	 The	 Bradford	 assay	 is	 a	 colorimetric	 protein	 assay	 which	 is	 based	 on	 the	
absorbance	 of	 the	 dye	 coomassie	 brilliant	 blue	 G-250,	 the	 amount	 of	 complex	
present	is	indicated	by	the	depth	of	blue	colour	of	the	solution	and	is	a	measure	of	
protein	concentration	that	can	be	quantitated	by	an	absorbance	reading.	
	
Initially	 to	 standardise	 readings	 controls	 were	 made	 up	 of	 solutions	 with	 known	
concentrations	of	Bovine	Serum	Albumin	(BSA).		A	stock	of	BSA	was	made	up	using	
0.005g	of	bovine	albumin	diluted	into	1ml	of	dH2O.		The	dilutions	detailed	in	table	
2.7	were	then	performed.	
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Concentration	 Volume	 of	 stock	 BSA	
solution	(µl)	
Volume	of	dH2O	(µl)	
10	 100	 0	
7	 70	 30	
5	 50	 50	
2	 20	 80	
1	 10	 90	
Table	2.7	A	table	of	the	dilutions	of	BSA	used	for	the		Bradford	assay.	
	
These	 standards	 and	 the	 cell	 lysates	 to	 be	 analysed	 were	 then	 placed	 in	 to	
eppendofs		with	2µl	of	the	sample,	200µl	of	Bradford	assay	and	798µl	of	dH2O.	 	A	
blank	 with	 800µl	 of	 dH2O	 and	 200µl	 of	 Bradford	 assay	 was	 also	 made	 and	 was	
measured	 first	 to	 calibrate	 the	 machine	 then	 the	 standards	 and	 samples	 were	
measured	using	a	spectrophotometer	set	at	562nm.		The	BSA	standards	were	then	
plotted	 in	 a	 standard	 curve	 and	 a	 R2	 value	 of	 greater	 than	 0.7	 indicated	 a	 valid	
result.		A	formula	was	then	applied	to	the	samples	to	give	the	protein	concentration	
per		µl		and	subsequently	the	volume	of	lysate	needed	to	load	20µg	of	protein	per	
lane.	
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2.7.4	Preparation	of	protein	for	loading	
Once	the	protein	concentration	of	samples	had	been	determined	the	samples	were	
prepared	ready	to	be	loaded	into	each	lane.		This	was	performed	either	on	the	day	
of	 western	 or	 the	 day	 before	 and	 stored	 at	 -20oC	 overnight.	 	 The	 determined	
volume	 of	 cell	 lysate	 was	 added	 to	 3µl	 of	 loading	 buffer	 (sample	 loading	 buffer	
ingredients	given	below	in	table	2.8)	and	a	variable	volume	of	1xRBS	(dependent	on	
the	volume	of	cell	lysate	used)	to	make	a	total	volume	of	15µl	in	a	100µl	eppendof.		
Each	 sample	was	 then	 centrifuged	 to	 13.3g	 and	warmed	 at	 96oC	 for	 15	minutes,	
followed	by	a	further	run	in	the	centrifuge	to	13.3g.	
	
Sample	loading	buffer	(1x	concentration)	
2%	SDS	
10%	glycerol	
60mM	of	Tris-HCL	(pH	6.8)	
0.001%	bromophenol	blue	
200mM	DDT	
Table	2.8	A	table	showing	the	1x	final	concentration	of	sample	loading	buffer.	
	
2.7.5	Gels	
Tris-glycine	 based	 Sodium	 Dodecyl	 Sulfate	 (SDS)	 polyacrylamide	 gels	 were	 cast	
between	biorad	0.75mm	plates	using	approximately	5ml	of	resolving	gel	and	1ml	of	
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stacking	gel	per	gel	produced.		A	variable	%	of	resolving	gel	was	used	dependant	on	
the	size	of	protein	band	expected	(table	2.9).	
	
	
%	resolving	gel	 Molecular	weight	of	band	(kDa)	
8	 25-200	
10	 15-100	
12	 10-70	
Table	2.9	A	table	showing	the	percentage	gels	used	for	differing	molecular	weight	
bands.	
	
Initially	plates	were	cleaned	with	ethanol	and	water	 then	air	dried.	 	The	resolving	
gel	was	pipette	between	the	plates	 leaving	approximately	1	 inch	at	the	top	of	the	
plates.	 	 200µl	 of	 Isopropanol	 was	 then	 pipetted	 on	 top	 of	 the	 resolving	 gel	 to	
prevent	bubbles	and	an	uneven	surface	and	the	gel	left	to	set	for	approximately	20	
minutes.		Isopropanol	was	then	removed	with	blotting	paper	and	1ml	of	stacking	gel	
was	pipetted	on	top	of	the	resolving	gel,	a	12	well	comb	introduced	then	left	to	set	
for	 a	 further	 20	minutes	 approximately.	 	 Gels	 were	made	 fresh	 the	 day	 prior	 to	
running	 a	 western	 blot	 and	 stored	 at	 4oC	 overnight	 saturated	 in	 dH2O.	 	 The	
components	of	resolving	and	stacking	gels	are	detailed	below	in	table	2.10.	
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10%		resolution	solution	for	Tris-glycine	
SDS-	polyacrylamide	gel	
5%	 stacking	 solution	 for	 Tris-glycine	
SDS-Polyacrylamide	gel	
To	cast	one	gel	(5ml)	
1.9ml	distilled	water	 1.4ml	distilled	water	
1.7ml	30%	acrylamide	mix	 0.33ml	30%	acrylamide	mix	
1.3ml	1.5M	Tris	(pH	8.8)	 0.25ml	1.0M	Tris	(pH	6.8)	
0.05ml	10%	SDS	 0.01ml	10%	SDS	
0.05ml	10%	ammonium	persulfate	 0.01ml	10%	ammonium	persulfate	
0.005ml	TEMED	 0.005ml	TEMED	
Table	2.10	A	table	showing	the	components	of	resolving	and	stacking	gels	used	for		
protein	electrophoresis.	
	
2.7.6	Electrophoresis	
Gels	were	loaded	into	running	chambers	(mini	protean	II	electrophoresis	chamber,	
Bio-Rad)	with	lanes	facing	inward	and	immersed	in	running	buffer.		Prior	to	loading	
protein	 into	 lanes	 samples	were	placed	 in	 a	warmer	 at	 96oC	 for	 15	minutes	 then	
centrifuged	to	a	maximum	of	13.3g	and	placed	into	ice	ready	for	loading.	
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5ul	 of	 protein	 ladder	 was	 loaded	 into	 that	 far	 left	 lane	 then	 samples	 loaded	
alongside	 from	 left	 to	 right.	 	 Samples	were	 then	 allowed	 to	 run	 on	 the	 gel	 using	
35Amp	output	for	approximately	1.5	hours	until	the	proteins	had	run	down	to	the	
bottom	of	the	gel.	
Gels	 were	 then	 removed	 from	 the	 glass	 plates	 and	 loaded	 into	 a	 cassette	 for	
transfer	onto	a	nitrocellulose	membrane	abutted	by	filter	paper	and	sponge	either	
side.		Cassettes	were	then	loaded	into	a	transfer	chamber	and	immersed	in	transfer	
buffer	and	run	for	30-60	minutes	(dependant	on	the	size	of	chamber)	at	110V.	
	
The	 membrane	 was	 then	 removed	 and	 washed	 in	 TBS/PBS	 dependant	 on	 the	
individual	antibody	protocol.	
	
2.7.7	Immunoblotting	
Membranes	were	 blocked	 in	 the	 appropriate	 blocking	 agent	 for	 1.5	 hours,	 10mls	
per	box.		This	was	then	exchanged	for	the	primary	antibody	diluted	into	8ml	of	the	
appropriate	carriage	solution	and	incubated	overnight	in	a	cold	room	(4oC).	
	
Primary	antibody	was	then	removed	and	membranes	washed	in	Tris-Buffered	Saline	
(TBS)/PBS	for	1	hour	changing	the	wash	every	15	minutes.			
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Species-specific	 secondary	 antibody	 was	 then	 introduced	 and	 incubated	 for	 1.5	
hours.	 	 After	 this	 a	 further	 1	 hour	 wash	 with	 changes	 every	 15	 minutes	 was	
performed.	
	
2.7.8	Detection	
Membranes	 were	 immersed	 in	 5ml	 of	 Enhanced	 Chemiluminescence	 (ECL)	
detection	solution	for	5	minutes.	 	This	was	then	removed	and	membranes	blotted	
dry	and	loaded	into	a	Kodak	light	safe	exposure	cassette	and	exposed	onto	medical	
X-ray	 film	 in	 a	 dark	 room	 and	 subsequently	 immersed	 in	 Kodak	 developer	 then	
fixative	solution,	washed	and	allowed	to	air	dry.		
	
	
2.7.9		β	actin	
β-actins	 were	 performed	 on	 all	 membranes	 to	 control	 for	 protein	 loading.		
Previously	exposed	membranes	were	soaked	in	stripping	buffer	(see	recipe	in	table	
2.11)		then	wrapped	in	clingfilm	and	left	at	75oC	for	30	minutes.	
Stripping	buffer	was	then	removed	and	4	15	minute	washes	in	PBS	performed.		Next	
blocking	 in	 5%	milk	 was	 carried	 out	 for	 1.5	 hours	 and	 subsequently	 membranes	
were	immersed	in	β-actin	mouse	primary	in	5%	milk/PBS	at	the	concentration	of	1	
in	5000	and	incubated	overnight	a	4oC.	
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Stripping	buffer	
20ml	10%	SDS	
12.5ml	1M	Tris-HCL	pH	6.5	
0.7ml	β-mercaptoethanol	
Table	2.11	A	table	showing	the	stripping	buffer	recipe	used.	
The	primary	antibody	was	then	removed	and	membranes	were	washed	with	PBS	4	
times,	 15	 minutes	 per	 wash.	 	 Secondary	 anti-mouse	 Horseradish	 Peroxidase-
Conjugated	(HRP)	antibody	was	introduced	in	5%	milk/PBS	at	a	concentration	of	1	in	
3000	for	1.5	hrs.		A	further	round	of	4	15	minute	PBS	washes	were	then	performed	
and	 detection	 of	 the	 β-actin	 band	 using	 the	 standard	 ECL	 detection	 method	 as	
detailed	in	section	2.7.8.	
	
2.7.10	Analysis	
Western	blots	were	examined	using	direct	visualisation	and	descriptive	comments	
on	 up	 or	 down	 regulation	 made	 where	 blots	 had	 adequate	 β-actins	 on	 direct	
visualisation.	
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CHAPTER	3:	MATERIALS	AND	METHODS	IN	VIVO	
	
A	 mouse	 xenograft	 model	 with	 pancreatic	 cancer	 cell	 lines	 was	 planned	 to	 test	
AT7519,	AT13387	and	gemcitabine	as	single	agents	and	the	combination	of	AT7519	
+	 gemcitabine	 and	 AT13387	 +	 gemcitabine.	 	 The	 animal	 licensee	 course	 was	
undertaken	(University	of	Liverpool)	and	a	personal	licence	obtained	(PIL	40/9684).		
The	experiments	where	carried	out	in	accordance	with	project	licence	PPL40/3320	
and	 all	 experiments	 designed	 under	 the	 obligations	 of	 the	 Animals	 in	 scientific	
procedures	 act	 set	 out	 by	 the	 home	 office	 with	 the	 principles	 of	 replacement,	
reduction	and	refinement	as	well	as	the	United	Kingdom	Co-ordinating	Committee	
on	Cancer	Research	guidelines	(UKCCCR)(Workman	1998).	
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3.1	CELL	PREPARATION	
	
3.1.1	Establishing	stocks	
Pancreatic	cancer	cell	lines	were	frozen	down	with	adequate	stocks	to	complete	all	
experiments	 in	 the	 xenograft	 model.	 	 As	 the	 initial	 experiment	 would	 be	
establishing	 the	 optimum	 cell	 line	 for	 xenograft	 studies	 stocks	 of	 SUIT-2	 and	
Miapaca-2	were	created.		Cells	were	stored	at	-150oC.	
	
3.1.2	Restoring	cell	lines	
For	 each	 experiment	 cells	 used	 to	 generate	 xenografts	 were	 prepared	 in	 a	
standardise	manner	and	underwent	the	same	number	of	passages.		The	number	of	
vials	defrosted	depended	on	the	number	of	tumours	required,	approximately	1	flask	
for	every	tumour	required,	an	excess	of	10%	was	prepared	each	time.	 	Cells	were	
tested	for	mycoplasma		once	growth	was	re-established.	
	
Vials	of	cell	 line	were	obtained	from	-150oC	stores	and	underwent	a	rapid	defrost.		
They	were	 suspended	 in	10ml	of	warmed	RPMI	media	 and	 spun	 in	 a	15ml	 falcon	
tube	 at	 200rpm	 for	 5	minutes.	 	 The	media	was	 then	 removed	 and	 the	 cell	 pellet	
resuspended	 into	 20ml	 of	 RPMI	media	 and	 incubated	 in	 a	 T75	 flask.	 	 Cells	 were	
incubated	 for	 4	days	 at	 37oC	 in	5%	CO2	and	 then	 split	 to	1	 in	10	 in	 the	 standard	
method	 described	 in	 section	 2.3.2.	 	 The	 day	 before	 planned	 injections	 cells	
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underwent	 a	 further	 split	 of	 1	 in	 2	 to	 achieve	 70-80%	 confluence	 on	 the	 day	 of	
harvest.	
	
On	the	day	of	injection	cells	were	prepared.		Initially	they	underwent	2	PBS	washes	
then	were	 trypsinised	with	 2ml	 of	 trypsin	 per	 T75	 flask.	 	Once	 trypinsied	 6mls	 of	
media	was	added	 to	each	 flask	 to	make	a	 total	 volume	of	8ml.	 	 Flasks	were	 then	
combined	 into	50ml	 falcon	 tubes	and	spun	at	200	 rpm	for	5	minutes.	 	The	media	
was	then	removed	from	the	cell	pellet	and	the	cell	pellet	 in	each	50ml	falcon	was	
resuspended	in	20ml	of	cold	PBS	and	spun	at	200	rpm	for	5	minutes.		Subsequently	
the	PBS	was	removed	and	the	resultant	cell	pellet	resuspended	in	10ml	of	cold	PBS	
and	kept	on	ice.	
	
Cells	were	counted	using	20µl	of	the	stock	into	a	haemocytometer		to	make	a	final	
concentration	of	1x	107/ml	(this	usually	required	a	further	spin	down	at	200rpm	for	
5	minutes	to	reach	the	desired	concentration).		The	resultant	stock	solution	of	cells	
was	 combined	with	 the	 same	 volume	 of	Matrigel	 HESC	Matrix	 (Bectin	 Dickinson,	
Oxford,	UK)	which	had	undergone	a	slow	defrost	overnight	on	ice	and	the	mixture	
gently	 agitated.	 	 	 The	 cell	 suspension	 was	 kept	 on	 ice	 and	 injected	 as	 soon	 as	
possible	after	preparation	in	200µl	aliquots	per	tumour	at	1x	106	per	tumour.	
	
	
	 103	
3.2	MICE	
Nude	 mice	 were	 supplied	 by	 Charles	 River	 UK,	 BALB/c-Nude	 mice	 CAnN.Cg-
Foxn1nu/Crl.		This	strain	of	immunodeficient	mouse	was	developed	through	crosses	
and	 backcrosses	 between	 BalB/caBom-nu	 and	 BalB/cannCrj-nu	 at	 Charles	 River	
Japan	 in	1985.	 	The	homozygous	strain	of	animal	 lacks	a	 thymus,	and	 is	 therefore	
unable	to	produce	T	cells	and	immunodeficient.			For	all	studies	male	6-8	weeks	old	
animals	were	used.			
	
During	the	experimental	protocol	animals	were	given	1	week	to	acclimatise	prior	to	
commencing	 the	 study	 and	 then	 ear	 punched	 to	 differentiate	 between	 animals	
(figure	3.1).		They	were	weighed	daily	and	monitored	for	any	changes	in	behaviour	
that	might	indicate	poor	health.		In	tolerability	studies	animals	were	not	dosed	with	
agents	 if	 they	 had	 >15%	weight	 loss	 compared	with	 animal	weight	 on	 day	 0	 and	
were	culled	 if	 they	had	sustained(72	hrs.)	weight	 loss	of	>20%.	 	 In	efficacy	studies	
(and	 therefore	 tumour	bearing	animals)	mice	were	not	dosed	 if	>15%	weight	 loss	
and	culled	if	they	had	sustained	weight	loss	(72	hrs.)	of	>15%	(see	full	explanation	of	
reasons	for	cull	below).	
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Figure	 3.1	 A	 figure	 showing	 the	 rodent	 ear	 punch	 identification	 map	 used	 for	
experiments.	
	
In	 the	 xenograft	 model	 tumours	 were	 measured	 thrice	 weekly	 with	 external	
callipers,	 taking	measurements	of	 length,	width	 and	height.	 	Measurements	were	
standardised	 by	 being	 taken	 by	 only	 one	 individual	 through	 all	 studies	 and	
compared	with	 animal	 handling	 officer’s	measurements	 and	 compared	 to	 ex	 vivo	
tumour	measurements.		Tumour	volumes	were	then	calculated	using	the	equation:	
	
	 	 (Length	x	width	x	height)	x	0.5236	=	tumour	volume	
	
Once	the	animal	was	culled	they	underwent	necropsy	for	organs	(heart,	lungs,	liver,	
kidneys	and	 spleen)	which	were	 suspended	 in	 formaldehyde	 for	H	&	E	 staining	 in	
tumour	bearing	mice	tumours	were	resected	also.		The	tumours	were	measured	in	
vivo	 and	 ex	 vivo	 and	 weighed	 ex	 vivo.	 	 The	 tumours	 were	 then	 divided	 in	 half	
through	 the	 midline.	 	 The	 inferior	 portion	 was	 suspended	 in	 formaldehyde	 for	
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histopathology	and	the	superior	portion	snap	frozen	in	liquid	nitrogen	for	western	
blotting.				
	
Animals	were	 culled	 by	 a	 schedule	 1	method	 (CO2	 asphyxiation)	 at	 the	 specified	
experimental	end	point	or	when	the	following	circumstances	arose:	
• Animals	 demonstrated	 abnormal	 behaviour	 (failure	 to	 take	 food/drink,	
depressed	mobility/lack	of	interaction)	
• Animals	developed	large	ascites	(>10%	of	body	weight)	
• Large	local	tumours	or	distant	spread	of	cancer	cells	
• Weight	loss	of	20%	body	weight	sustained	over	72	hours	
• If	the	tumour	reaches	over	17mm	diameter	or	impairs	the	movement	of	the	
animal	
• If	the	tumour	starts	to	ulcerate	
	
3.3	ESTABLISHING	THE	CELL	LINE	FOR	TUMOUR	GROWTH	
	
In	order	to	establish	the	most	appropriate	cell	line	to	use	for	forward	experiments	a	
tumour	growth	experiment	was	performed.	 	SUIT-2	and	Miapaca-2	cell	 lines	were	
tested.	 	Cell	 lines	were	prepared	for	 injection	as	per	the	methodology	of	restoring	
cell	 lines	 detailed	 in	 section	 3.1.2.	 	 4	 mice	 per	 cell	 line	 were	 inoculated	 with	
tumours	 to	 both	 left	 and	 right	 shoulders	 with	 200ul	 of	 the	 tumour	 suspension.		
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Mice	 were	 observed	 daily	 and	 once	 palpable	 tumours	 were	 established	
measurements	were	undertaken	of	 length,	width	and	height	of	 the	tumours.	 	The	
volume	of	tumours	was	established	as	below:	
	
	 	 (Length	x	width	x	height)	x	0.5236	=	tumour	volume	
	
Weight	measurements	 and	 general	 well-being	 observations	 were	 also	 performed	
daily.	 	 The	 experimental	 endpoints	 were	 tumours	 reaching	 the	 maximum	 mean	
diameter	 of	 17mm	 or	 28	 days	 from	 inoculation	 with	 tumours.	 	 Post	 culling	 the	
animals	 ex	 vivo	measurements	 of	 tumour	 volume	with	 callipers,	 tumour	 weights	
and	collection	of	specimens	for	histopathology	were	performed.	
	
	
3.4	PREPARING	AGENTS	
AT7519	and	AT13387	 for	 in	vivo	 studies	were	provided	by	Astex	Pharmaceuticals,	
Cambridge,	 UK.	 	 Gemcitabine	 was	 bought	 from	 LC	 laboratories	 MA,	 USA	 as	
Gemcitabine	hydrochloride	salt	(2g,	G-4177).	
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3.4.1	AT7519	
AT7519	was	provided	as	 the	methanesulphonic	 salt	of	 the	 compound.	 	Doses	are	
quoted	as	 the	base	 so	 there	was	a	 correction	 factor	applied	 to	derive	 the	correct	
dose	for	dilution.		The	base	molecular	weight	is	493.7	and	the	salt	molecular	weight	
589.8,	therefore	the	correction	factor	was	1.19.	
	
Calculations	 of	 doses	 were	 based	 on	 a	 20g	mouse	 and	 enough	 agent	 for	 7	 days	
treatment	 was	 made	 up	 on	 each	 occasion.	 	 One	 injection	 at	 7.5mg/kg	 was	
0.1875mg	 per	 100ul	 for	 the	 base	 and	 0.223mg	 per	 100ul	 for	 the	 salt.	 	 The	 salt	
weight	was	multiplied	by	the	number	of	injections	required	and	the	amount	of	salt	
required	was	established.		An	excess	of	50%	was	added	to	this	weight	to	account	for	
losses	 and	 the	 volume	 of	 saline	 required	 for	 dilution	 calculated	 by	 dividing	 this	
weight	by	the	salt	molecular	weight	multiplied	by	100µl.	 	The	volume	required	for	
each	injection	was	then	calculated	by	multiplying	the	mouse	weight	by	5.	 	AT7519	
salt	was	diluted	in	normal	saline.		The	drug	was	stored	at	room	temperature	as	per	
recommendations	
	
Example:	
-calculation	based	on	20g	mouse	(6	mice	per	group,	120	doses	in	two	weeks)	
-for	one	injection	0.15mg	per	100ul	(for	base)	=	0.1785mg	per	100ul	(for	salt)	(factor	
1.19)	
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-	0.1875	x	120	=	21.42mg		(for	120	injections)	(in	15ml	falcon	tube)	
-each	injection	volume	100ul	(assuming	a	20g	mouse)	
-to	 account	 for	 loss,	 need	 extra	 50%,	weigh	 at	 least	 32mg	 	 -	 too	much	 for	 15ml	
falcon	tube	
Therefore	weigh	two	lots	of	at	least	16mg	(two	falcon	tubes)	
-Weight/0.1875	x	0.1ml	=	volume	in	ml	to	dissolve	in	(saline)	
-aliquot	1.5ml	per	2ml	tube	(i.e.	for	12	injections	–	AM	and	PM	separately)		
For	injections:	
-volume	per	mouse	is		5x	mouse	weight	in	grams	
	
3.4.2	AT13387	
AT13387	was	provided	as	the	lactate	salt	of	the	compound	and	the	dose	of	80mg/kg	
quoted	as	the	compound	base.	 	 	The	base	weight	is	409.58	and	the	salt	molecular	
weigh	499.67,	thus	correction	factor	was	1.22.		One	injection	at	80mg/kg	was	1.6mg	
per	 100µl	 for	 the	 base	 and	 1.95mg	 per	 100µl	 for	 the	 salt.	 	 	 2-Hydroxypropyl)-β-
cyclodextrin	powder	 (Sigma-aldrich,	Dorset,	UK)	was	 	diluted	 in	sterilised	water	to	
make	a	17.5%	solution	of	cyclodextrin	which	AT13387	was	diluted	in.		The	drug	was	
stored	at	room	temperature	as	per	recommendations.	
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Example:	
-calculation	based	on	20g	mouse	(6	mice	per	group,	2	injections	per	mouse)	
-for	one	injection	1.6	mg	per	100ul	(for	base)	=	1.95	mg	per	100ul	(for	salt)	(factor	
1.22)	
-	1.95	x	12	=	23.4mg		(for	12	injections)	(in	15ml	falcon	tube)	
-each	injection	volume	100ul	(assuming	a	20g	mouse)	
-to	 account	 for	 loss,	 need	 extra	 50%,	weigh	 at	 least	 36mg	 	 -	 too	much	 for	 15ml	
falcon	tube	
Therefore	weight	two	lots	of	at	least	18mg	(two	falcon	tubes)	
-Weight/01.95	x	0.1ml	=	volume	in	ml	to	dissolve	in	(cyclodextrin)	
-single	aliquot	each	week	
For	injections:	
-volume	per	mouse	is		5x	mouse	weight	in	grams	
	
3.4.3	Gemcitabine	
A	stock	of	powered	salt	was	purchased	from	LC	 laboratories	and	diluted	 in	saline.		
Again	a	correction	against	base	and	salt	was	required	of	1.14	and	the	calculations	
made	 as	 detailed	 below.	 The	 drug	 was	 stored	 at	 room	 temperature	 as	 per	
recommendations.		
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Example:	
-calculation	based	on	20g	mouse	(6	mice	per	group,	24	doses	in	two	weeks)	
-for	one	 injection	0.5mg	per	100ul	 (for	base)	=	0.57mg	per	100ul	 (for	 salt)	 (factor	
1.14)	
-	0.57	x	24	=	13.68mg		(for	24	injections)	(in	15ml	falcon	tube)	
-each	injection	volume	100ul	(assuming	a	20g	mouse)	
-to	account	for	loss,	need	extra	50%,	weigh	at	least	21mg	
-Weight/0.57	x	0.1ml	=	volume	in	ml	to	dissolve	in	(saline)	
-aliquot:	split	volume	equally	in	4	aliquots	of	at	least	1ml	each	
	
For	injections:	
-volume	per	mouse	is		5x	mouse	weight	in	grams	
	
3.5	SINGLE	AGENT	TOLERABILITY	EXPERIMENTS	
In	order	to	establish	the	maximum	tolerated	dose	of	agents	prior	 to	each	efficacy	
study	 a	 tolerability	 experiment	 was	 performed.	 	 Drug	 doses	 for	 AT13387	 and	
AT7519	tested	were	established	after	advice	from	Astex	pharmaceuticals	based	on	
previous	animal	models	in	other	cancers.		Doses	tested	of	gemcitabine	were	based	
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on	 current	 literature.	 	 Tolerability	 experiments	 were	 performed	 in	 non-tumour	
bearing	mice.			
	
3	 mice	 per	 group	 were	 given	 intra-peritoneal	 injections	 of	 agents	 and	 had	 daily	
monitoring	 of	 weight	 and	 behaviour	 to	 establish	 tolerability.	 Gemcitabine	 was	
tested	at	100mg/kg	twice	per	week,	AT7519	at	7.5mg/kg	twice	daily	for	5	days	and	
AT13387	at	80mg/kg	once	weekly;	all	for	2	weeks	(table	3.1).		Drugs	were	deemed	
tolerated	 if	 animals	 did	 not	 experience	weight	 loss	 or	 side	 effects	 that	 precluded	
further	dosing	or	made	culling	the	animal	necessary.	
	
	
	
	
Table	3.1	A	table	showing	the	single	agent	tolerability	experiments	schedule	with	
the	drug	dosing	for	Gemcitabine,	AT7519	and	AT13387.	
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3.6	SINGLE	AGENT	EFFICACY	OF	GEMCITABINE,	AT7519	AND	AT13387	
Animals	 were	 injected	 with	 Miapaca2	 pancreatic	 cancer	 cell	 lines	 into	 the	 right	
shoulder	 as	 in	 section	 3.1.2.	 	 Once	 tumours	were	 palpable	 thrice	weekly	 calliper	
measurements	 were	 undertaken.	 	 	 Drug	 injections	 commenced	 one	 week	 after	
measurements	began.		Animals	were	treated	for	3	weeks.	 	Each	group	constituted	
of	six	animals	and	each	drug	was	tested	against	a	vehicle	control	group.		All	agents	
were	 dosed	 at	 the	 previously	 determined	maximum	 tolerated	 dose;	 Gemcitabine	
100mg/kg	twice	weekly,	AT13387	80mg/kg	once	weekly	and	AT7519	7.5mg/kg	BD	
for	 5	 of	 7	 days.	 	 Vehicle	 control	 groups	 included	 saline	 BD	 for	 5	 of	 7	 days	 and	
cyclodextrin	 once	weekly.	 	 Table	 3.2	 summaries	 the	 treatment	 groups	 used.	 	 The	
experimental	 endpoint	 was	 tumours	 reaching	 the	 maximum	 mean	 diameter	 of	
15mm,	weight	 loss	 of	 >20%	 sustained	 over	 72	 hours	 or	 completion	 of	 treatment	
(these	 animals	 were	 usually	 retained	 for	 a	 maximum	 of	 4	 days	 after	 treatment	
ceased).	 	 Tumour	 volumes	 were	 calculated	 in	 excel	 and	 regression	 analysis	 of	
tumour	growth	performed	in	statview.	
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Table	3.2	A	table	showing	the	single	agent	efficacy	experiments	for	gemcitabine,	
AT7519,	AT13387	and	vehicle	controls	days	of	dosing	and	number	of	mice	used.	
	
	
	
3.7	TOLERABILITY	COMBINATIONS	
In	order	to	establish	the	maximum	tolerated	dose	of	agents	prior	 to	each	efficacy	
study	 a	 tolerability	 experiment	 was	 performed.	 	 Tolerability	 experiments	 were	
performed	 in	 non	 tumour	 bearing	 mice.	 	 	 3	 mice	 per	 group	 were	 given	 intra-
peritoneal	injections	of	agents	and	had	daily	monitoring	of	weight	and	behaviour	to	
establish	tolerability.		Agents	were	deemed	tolerated	if	animals	did	not	experience	
weight	loss	or	side	effects	that	precluded	further	dosing	or	made	culling	the	animal	
necessary.	
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AT7519	and	gemcitabine	were	tested	in	combination	with	the	dose	7.5mg/kg	twice	
daily	for	5	days	of	AT7519	and	50mg/kg	twice	weekly	of	gemcitabine	(table	3.3).		
	
Table	3.3	A	table	demonstrating	the	dosing	regimen	for	the	AT7519	+	Gemcitabine	
tolerability	combination	experiments.	
		
	
AT13387	 and	 gemcitabine	 were	 tested	 in	 combination	 three	 times	 with	 varying	
dosing	and	schedule	 in	order	 to	 find	 the	best	 tolerated	experimental	design(table	
3.4).	
	
	
	
	
	 115	
	
	
	
Table	 3.4	 A	 table	 showing	 the	 three	 tolerability	 combination	 experiments	
performed	for	AT13387	and		gemcitabine.	
	
3.8	COMBINATION	EFFICACY	STUDIES	
In	 combination	 efficacy	 experiments	 4	 groups	 of	 6	 animals	 each	were	 compared.		
Theses	consisted	of	one	group	being	given	both	agents,	two	groups	with	one	agent	
and	the	other	agents	vehicle	control	and	vice	versa	and	a	control	group	given	both	
agents	vehicle	controls	(table	3.5	and	3.6).	
Xenografts	were	generated	as	in	section	2.1.2	and	measurements,	observations	and	
endpoints	reached	as	in	section	2.3.	
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Table	 3.5	 A	 table	 showing	 the	 dosing	 regime	 of	 the	 	 AT7519	 +	 Gemcitabine	
combination	efficacy	experiments.	
	
Table	 3.6	 A	 table	 showing	 the	 dosing	 regime	 of	 the	 AT13387	 +	 Gemcitabine	
combination	efficacy	experiments.	
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3.9	PROCESSING	OF	ANIMAL	TISSUES	
3.9.1	H	and	E	staining	
Sections	of	tumour	and	organs	including	heart,	lungs,	liver,	kidneys	and	spleen	were	
extracted	 from	 animals	 at	 necropsy	 and	 immediately	 fixed	 in	 paraformaldehyde.		
Later	 these	 tissue	 sections	 were	 dehydrated	 further	 with	 successive	 ethanol	
washes,	embedded	 in	paraffin	and	sectioned	with	a	microtome	(by	pathologist	Dr	
Fiona	Campbell).		Sections	were	stained	with haematoxylin and eosin	and	mounted	
onto	glass	slides.		Histopathology	specimens	were	review	by	a	pathologist	(Dr	Fiona	
Campbell).		
	
3.10		STATISTICAL	ANALYSIS	
Results	 were	 maintained	 on	 excel	 spreadsheets	 and	 statistical	 analysis	 was	
performed	using	excel	 and	 statsbase.	Median	 tumour	volume	between	 treatment	
groups	 were	 compared	 using	 Mann	 Whitney.	 Differences	 in	 the	 co-efficient	 of	
tumour	volume	were	compared	between	treatment	groups	using	fishers	R-Z.	
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CHAPTER	4:	RESULTS	IN	VITRO	STUDIES	
	
4.1	TREATMENT	OF	PANCREATIC	CANCER	CELL	LINES	
Initial	 experiments	 performed	 were	 to	 establish	 the	 ability	 of	 agents	 to	 inhibit	
growth	of	pancreatic	cancer	cell	lines	in	vitro.		The	results	of	novel	agents	AT7519,	
AT13387	and	the	standard	therapy	gemcitabine	are	included.		Inhibition	of	growth	
was	 determined	 by	 obtaining	 IC50	 values	 using	 an	 MTS	 assay.	 Work	 using	 the	
Fampac	cell	line	was	performed	by	Elisabeth	Shaw.	
	
4.1.1	IC50	FOLLOWING	TREATMENT	WITH	GEMCITABINE	
The	ability	of	gemcitabine	to	inhibit	growth	was	assessed	in	6	pancreatic	cancer	cell	
lines.	 	 The	 half	 maximal	 inhibitory	 concentration	 (IC50)	 was	 determined,	 as	 a	
quantitative	measure	of	how	much	of	the	drug	was	needed	to	inhibit	cell	growth	by	
half	using	MTS	assay	as	a	measure	of	cell	viability.		Cells	were	cultured	at	a	seeding	
density	 of	 1.5	 x	 104,	 incubated	 for	 24	 hours	 and	 then	 treated	 with	 increasing	
concentrations	 of	 Gemcitabine	 (500nM	 –	 1nM,	 1000nM	 –	 5nM	 for	 SUIT-2	 GR	
experiments).	 	 Cell	 viability	 assays	 were	 performed	 at	 24,	 48	 and	 72	 hours	 post	
treatment.		Experiments	had	6	replicates	and	were	performed	in	triplicate,	growth	
curves	were	plotted	to	determine	the	IC50.				
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Table	4.1	shows	the	IC50	values	of	gemcitabine	for	each	pancreatic	cancer	cell	line	
tested.	 	 IC50	 values	 ranged	 from	625nM	 to	 5nM.	 	 In	 a	Gemcitabine	 resistant	 cell	
line,	SUIT-2	(GR),	IC50	values	obtained	were	markedly	increased	compared	with	the	
other	 cell	 lines	 tested	 confirming	 this	 to	 be	 a	 resistant	 line.	 	 	 Figures	 4.1	 and	 4.2	
show	 the	 growth	 curves	 for	 the	parent	 line	 SUIT-2	 and	 gemcitabine	 resistant	 line	
SUIT-2	 (GR).	 	 Cell	 photography	 shown	 in	 figure	 4.3	 again	 demonstrates	 the	
inhibition	of	 cell	 growth	when	 treated	with	 gemcitabine	 in	 comparison	 to	 control	
plates,	regardless	of	replenishment	or	removal	of	gemcitabine.		
Cell	line	 IC50	Gemcitabine	
SUIT-2	 10nM	
SUIT-2	(GR)	 625nM	
Miapaca-2	 25nM	
Panc-1	 150nM	
CFpac	 180nM	
FamPac	 5.5nM	
Table	4.1	A	Table	 showing	 the	anti-proliferative	activity	of	 gemcitabine	 in	 vitro;	
IC50	values	are	shown	in	a	range	of	pancreatic	cancer	cell	 lines.	The	IC50	ranged	
from	5nM	to	625nM.		
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Figure	4.1	A	Growth	curve	of	cell	viability	corrected	 for	controls	after	 treatment	
with	variable	concentrations	of	gemcitabine	to	establish	IC50	in	SUIT-2	pancreatic	
cancer	cell	line.	The	X-axis	shows	the	gemcitabine	concentration	(the	plotted	data	
points	 represent	 the	 gemcitabine	 concentration	 used),	 the	 Y-axis	 shows	 the	
percentage	of	 viable	 cells	 compared	 to	 controls.	 	MTS	assay	data	at	48	hours	 is	
shown.		
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Figure	4.2	A	graph	 showing	growth	curves	of	 cell	 viability	 corrected	 for	 controls	
after	 treatment	 with	 variable	 concentrations	 of	 gemcitabine	 in	 SUIT-2	 (GR)	
pancreatic	 cancer	cell	 line.	The	X-axis	 shows	 the	gemcitabine	concentration	 (the	
plotted	data	points	represent	the	gemcitabine	concentration	used,	error	bars	are	
shown),	 the	 Y-axis	 shows	 the	 percentage	 of	 viable	 cells	 compared	 to	 controls.		
This	graph	shows	two	MTS	assay	experiments	with	readings	taken	at	48	hours	and	
one	with	readings	at	72	hours.		
	
	
	
	
	
	
IC#50#values#–#Suit21GR#cells#
EZ4U#assay#
IC50#–#625nm#
IC50#–#700nm# IC50#–#60nm#
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[1]	
	
[2]	
	
Figure	4.3	Pictures	showing	cell	photography	of	SUIT-2	cells	in	96-well	plates	at	
seeding	density	1.5	x	104		(By	Elisabeth	Shaw)	Cell	photography	was	performed	at	
24	hours,	48	hours	and	5	days.		
[1]	Treated	with	10nM	of	Gemcitabine	[2]	In	DMSO	0.1%	as	control																									
A:	drug	or	control	introduced	at	0	time	point.																																																																			
B:	drug	or	control	introduced	at	0	time	point	then	replenished	at	24	and	48	hrs.					
C:	drug	or	control	introduced	at	0	time	point	and	then	removed	at	48	hrs.											
	
	
24#hrs### 48#hrs### Day#5###GEMCITABINE#
drug#at#zero#<me#
drug#at#zero#<me#and##replenished#24#&#48hr#
drug##at#zero#<me#medium#removed#at#48hrs#
A#
B#
C#
24	hrs			 48	hrs			 Day	5			
MEDIUM		only	at	zero	6me	
MEDIUM	only	at	zero	6me	and	replenished	at	24	&	48hrs	
MEDIUM		only	at	zero	6me	medium	removed	at	48hrs	
control	A	
B	
C	
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CONCLUSION	
Gemcitabine	 was	 effective	 in	 inducing	 growth	 inhibition	 across	 a	 range	 of	
pancreatic	cancer	cell	lines.		The	IC50	value	for	a	gemcitabine	resistant	cell	line	was	
60-fold	higher	than	that	of	the	parent	line	(625nM	in	SUIT-2	(GR),	10nM	in	SUIT-2).		
	
	
4.1.2	IC50	OF	PANCREATIC	CANCER	CELL	LINES	FOLLOWING	TREATMENT				
WITH	AT7519	
The	 ability	 of	 AT7519	 to	 inhibit	 growth	 was	 assessed	 in	 6	 pancreatic	 cancer	 cell	
lines.	 	 After	 seeding	 in	 96-well	 plates	 cells	 were	 cultured	 with	 increasing	
concentrations	of	AT7519	(50nM-5000nM)	and	MTS	assay	was	performed	on	plates	
at	 24,	 48	 and	 72	 hours.	 	 Experiments	 had	 6	 replicates	 and	 were	 performed	 in	
triplicate	and	growth	 curves	plotted	 to	determine	 the	 IC50.	 	 The	72	hour	 reading	
IC50	values	are	shown	in	Table	4.2.		Growth	curves	and	determined	IC50	values	are	
shown	 in	 figures	4.4	and	4.5	 	 	Cell	photography	shown	 in	 figure	4.6	demonstrates	
the	 inhibition	 of	 cell	 growth	when	 treated	with	 AT7519	 in	 comparison	 to	 control	
plates.	
	
The	 IC50	 values	 obtained	 ranged	 from	 180nM	 to	 2000nM.	 	 The	 gemcitabine	
resistant	cell	line	SUIT-2	GR	had	comparable	sensitivity	to	AT7519	and	gemcitabine	
(table	4.3).	 	SUIT-2	GR	was	notably	more	sensitive	to	treatment	with	AT7519	than	
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the	 parent	 line	 SUIT-2	 (700nM	 versus	 2μM)	 the	 converse	 was	 observed	 after	
treatment	with	gemcitabine	(625nM	versus	10nM).	
Cell	line	 IC50	AT7519	
SUIT-2	 2μM	
SUIT-2	(GR)	 700nM	
Miapaca-2	 390nM	
Panc-1	 275nM	
CFpac	 180nM	
FamPac	 210nM	
Table	 4.2	 A	 able	 showing	 the	 anti-proliferative	 activity	 of	 AT7519	 in	 vitro;	 IC50	
values	at	72	hours	after	treatment	with	AT7519	are	shown	in	a	range	of	pancreatic	
cancer	cell	lines.			
	
Cell	line	 IC50	AT7519	 IC50	Gemcitabine	
SUIT-2	 2μM	 10nM	
SUIT-2	(GR)	 700nM	 625nM	
Table	4.3	Table	showing	the	anti-proliferative	activity	of	AT7519	and	gemcitabine	
as	 single	 agents	 in	 vitro;	 IC50	 values	 are	 shown	 for	 treatment	 with	 AT7519	 or	
gemcitabine	in	pancreatic	cancer	cell	lines	SUIT-2	and	SUIT-2(GR).	
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Figure	4.4	Graph	showing	a	growth	curve	of	cell	vitality	corrected	for	controls	
after	treatment	with	variable	concentrations	of	AT7519	in	SUIT-2	pancreatic	
cancer	cell	line.		X-axis	shows	AT7519	concentration	(plotted	data	points	
represent	AT7519	concentration	use,	concentration	range	250nM	-	50mM),	Y-axis	
shows	percentage	of	viable	cells	compared	to	controls.	The	72	hour	reading	is	
shown.		
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Figure	 4.5	 Graph	 showing	 growth	 curves	 of	 cell	 viability	 corrected	 for	 controls	
after	 treatment	 with	 variable	 concentrations	 of	 AT7519	 in	 SUIT-2	 (GR).	 X	 axis	
shows	AT7519	concentration	(plotted	data	points	represent	AT7519	concentration	
used,	 error	 bars	 shown),	 Y	 axis	 shows	 percentage	 of	 viable	 cells	 compared	 to	
controls.	Shows	two	experiments	with	readings	at	48	hours	and	one	with	reading	
at	72	hours.		
	
	
	
IC#50#values#–#Suit21GR#cells#
EZ4U#assay#
IC50#–#625nm#
IC50#–#700nm# IC50#–#60nm#AT7519	uM 
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Figure	4.6	Pictures	of	cell	photography	of	SUIT-2	cells	in	96-well	plates	at	seeding	
density	1.5	x	104	(By	Elisabeth	Shaw)	The	upper	row	is	control	cells	left	to	grow	in	
media	with	photography	at	24,	48	hours	and	5	days	(media	introduced	at	0	hours).		
The	 lower	 row	 shows	 cells	 treated	 with	 10μM	 of	 AT7519	 at	 0	 hours	 then	 cell	
photography	at	24,	48	hours	and	5	days.		
	
	
CONCLUSION	
AT7519	 inhibited	 proliferation	 across	 a	 range	 of	 pancreatic	 cancer	 cell	 lines	 with	
IC50	values	ranging	from	180nM	to	2μM.		The	gemcitabine	resistant	line	SUIT-2	(GR)	
was	more	sensitive	than	the	parent	 line	to	AT7519	offering	encouraging	results	to	
overcome	 the	 issue	 of	 gemcitabine	 resistance	 in	 pancreatic	 cancer	 (IC50	 700nM	
versus	2μM).	
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4.1.3	IC50	OF	AT13387	TREATMENT	OF	PANCREATIC	CANCER	CELL	LINES		
The	 ability	 of	 AT13387	 to	 inhibit	 growth	was	 assessed	 in	 7	 pancreatic	 cancer	 cell	
lines.		After	seeding	in	96-well	plates	at	1.5	x	104	cells	were	cultured	with	increasing	
concentrations	of	AT13387	(5mM	-	5nM)	and	MTS	assay	was	performed	on	plates	at	
24,	 48	 and	 72	 hours.	 	 The	 72	 hour	 reading	 IC50	 values	 are	 shown	 in	 table	 4.4.		
Growth	curves	and	determined	IC50	values	are	shown	in	figures	4.7	and	4.8.				
	
The	IC50	values	obtained	ranged	from	42nM	to	100nM.		The	gemcitabine	resistant	
cell	 line	 SUIT-2	 (GR)	 and	 the	 parent	 line	 SUIT-2	 had	 comparable	 sensitivity	 to	
AT13387.	 	SUIT-2	(GR)	was	significantly	more	sensitive	to	treatment	with	AT13387	
than	gemcitabine.	 	 	Experiments	had	6	replicates	and	were	performed	in	triplicate	
and	 growth	 curves	 plotted	 to	 determine	 the	 IC50.	 	 	 Cell	 photography	 shown	 in	
figure	4.9	demonstrates	the	inhibition	of	cell	growth	when	treated	with	AT13387	in	
comparison	 to	 control	 plates.	 	When	 experiments	 were	 performed	 removing	 the	
treatment	 after	 48	 hours	 cell	 re-growth	 was	 observed.	 	 This	 pointed	 towards	 a	
cytostatic	rather	than	cytotoxic	effect	of	AT13387	on	the	cell	lines.			
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Cell	line	 IC50	AT13387	
SUIT-2	 63nM	
SUIT-2	(GR)	 60nM	
Miapaca-2	 58nM	
Panc-1	 50nM	
CFpac	 100nM	
FamPac	 42nM	
Table	4.4	A	table	showing	the	anti-proliferative	activity	of	AT13387	 in	vitro;	 IC50	
values	are	shown	for	treatment	with	AT13387	in	a	range	of	pancreatic	cancer	cell	
lines.		IC50	ranged	from	29nM	to	325nM.			
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Figure	4.7	A	graph	showing	a	growth	curve	of	cell	viability	corrected	for	controls	
after	treatment	with	variable	concentrations	of	AT13387	 in	SUIT-2	cell	 line.	 	The		
72	hour	 reading	 is	 shown.	The	X	axis	 shows	AT7519	concentration	 (plotted	data	
points	 represent	 AT13387	 concentration	 use,	 concentration	 range	 5nM	 -	 5mM),	
the	Y	axis	shows	percentage	of	viable	cells	compared	to	controls.		
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Figure	 4.8	 A	 graph	 of	 growth	 curves	 of	 cell	 vitality	 corrected	 for	 controls	 after	
treatment	with	 variable	 concentrations	 of	 AT13387	 in	 SUIT-2	 (GR)	 cell	 line.	 	 An	
MTS	assay	was	performed	at	2,	24,	48	and	72	hours.	The	X	axis	 shows	AT13387	
concentration	 (plotted	data	points	 represent	AT13387	 concentration	used,	error	
bars	shown),	the	Y	axis	shows	percentage	of	viable	cells	compared	to	controls.		
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[1]	
	
[2]	
	
Figure	4.9	Pictures	of	cell	photography	(By	Elisabeth	Shaw),	showing	SUIT-2	cells	
in	96-well	plates	at	seeding	density	1.5	x	104			Cell	photography	was	performed	at	
24	hours,	48	hours	and	5	days.			
[1]	Treated	with	250nM	of	AT13387	[2]	In	DMSO	0.1%	as	control																																
A:	drug	or	control	introduced	at	0	time	point.																																																																			
B:	drug	or	control	introduced	at	0	time	point	then	replenished	at	24	and	48	hrs.					
C:	drug	r	control	introduced	at	0	time	point	and	then	removed	at	48	hrs.		
	
	
	
	
24#hrs### 48#hrs### Day#5###HSP90#inhibitor#A#
B#
C#
drug#at#0hr#
drug#at#0,#24#&#48hr#
drug##at#0hr#removed#at#48#hr#
24	hrs			 48	hrs			 Day	5			
MEDIUM		only	at	zero	6me	
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B	
C	
	 133	
CONCLUSION	
AT13387	 inhibited	 proliferation	 in	 a	 range	 of	 pancreatic	 cancer	 cell	 lines	 and	 the	
sensitivity	of	a	gemcitabine	resistant	line	SUIT-2	GR	was	comparable	to	that	of	the	
parent	 line	 in	 contrast	 with	 the	 marked	 resistance	 to	 gemcitabine	 observed	
previously.	 	 From	 cell	 photography	 a	 cytostatic	 rather	 than	 cytotoxic	 effect	 of	
AT13387	was	observed.			
	
4.2	CELL	CYCLE	ANALYSIS	
In	order	to	examine	the	effects	on	the	cell	cycle	from	each	of	these	novel	agents	in	
pancreatic	cancer	cell	 lines	cell	cycle	analysis	was	performed	via	propidium	 iodide	
(PI)	 staining	 and	 flow	 cytometry	 (experiments	 primarily	 performed	 by	 Elisabeth	
Shaw	with	my	assistance).	
	
4.2.1	Cell	cycle	analysis		gemcitabine		
SUIT-2	cells	were	seeded	onto	6	well	plates	at	2.5	x	105	cells	per	well	in	RPMI	media	
and	incubated	for	24	hours.		Gemcitabine	250nM	was	introduced	and	cells	further	
incubated	for	7,	24	and	48	hours	before	performing	the	assay.	
	
Cell	cycle	analysis	showed	gemcitabine	produced	a	G1/S	phase	cell	cycle	arrest	in	
line	with	expected	action	from	literature		(see	figure	4.10	and	4.11).	
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Figure	4.10	A	figure	showing	the	cell	cycle	distribution	of	SUIT-2	pancreatic	cancer	
cell	 line	 untreated	 (media	 only)	 and	 treated	with	 gemcitabine	 (250nm)	 at	 7,	 24	
and	48	hours.		
	
	
Figure	 4.11	Bar	 chart	 of	 percentage	of	 SUIT-2	 cells	 at	G1	peak	phase	of	 the	 cell	
cycle	untreated	or	treated	with	gemcitabine	at	7,	24	and	48	hours.	X	axis	shows	
cells	 in	 groups	 untreated	 or	 treated	 with	 gemcitabine	 (250nM),	 Y	 axis	 shows	
percentage	of	cells	seen	 in	G1	peak.	 	Legend	shows	cells	at	different	time	point,	
blue	at	7	hours,	red	at	24	hours	and	green	at	48	hours.	Significant	difference	in	the	
number	of	cells	at	G1	peak	between	untreated	and	gemcitabine	treated	cells	at	7	
hours.	
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CONCLUSION	
Cell	 cycle	analysis	 showed	gemcitabine	produced	a	G1/S	phase	cell	 cycle	arrest	 in	
line	with	expected	action	from	literature.	
	
4.2.2	Cell	cycle	analysis	AT7519	
Suit-2	cells	were	used	to	analyze	the	cytotoxic	effects	of	AT7519	on	the	cell	cycle.		
Suit2	cells	were	seeded	onto	6	well	plates	at	2.5	x	105	cells	per	well	in	RPMI	media	
and	incubated	for	24	hours	before	treatment	with	AT7519	(10μM)	or	media	control.		
Cell	cycle	analysis	was	performed	at	4,	7,	24	and	48	hours.			
	
Following	24	hours	 treatment	with	AT7519	 there	was	 clear	 arrest	 in	G2/M	phase	
and	 a	 reduction	 in	 the	 proportion	 of	 cells	 in	 G0/G1	 and	 S	 phase	 compared	 to	
untreated	cells	(p=<0.001)	(see	figure	4.12,	4.13	and	4.14).	
	
When	AT7519	was	combined	with	gemcitabine	cell	cycle	distributions	resulted	in	an	
accumulation	of	 cells	 in	 S	phase	 in	 keeping	with	 the	effects	of	 gemcitabine	alone	
but	with	a	more	marked	effect	than	gemcitabine	as	a	single	agent	(shown	in	figure	
4.15).	
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Figure	4.12	A	figure	showing	the	cell	cycle	distribution	of	SUIT-2	pancreatic	cancer	
cell	line	untreated	(media	only)	and	treated	with	AT7519	(10μM)	at	4,	7,	24	and	48	
hours.		
	
	
Figure	 4.13	A	 bar	 chart	 of	 percentage	 of	 SUIT-2	 cells	 in	 phases	 of	 the	 cell	 cycle	
treated	 with	 AT7519	 (10μM)	 versus	 untreated	 control	 cells	 7	 hours	 after	 drug	
addition.	The	X-axis	 shows	phase	of	cell	 cycle	G1,	S	phase	and	G2/M,	 the	Y-axis	
represents	percentage	of	cells	seen	in	each	phase.		**	p<0.01.	
 ** 
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4hrs&
CDK$inhibitor$
Hsp90$inhibitor$
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Figure	4.14	A	bar	chart	of	percentage	of	SUIT-2	cells	in	different	phases	of	the	cell	
cycle	 treated	with	AT7519	 (10μM)	 versus	 untreated	 control	 cells	 24	 hours	 after	
drug	addition.		The	x-axis	shows	phase	of	cell	cycle	G1,	S	phase	and	G2/M,	the	y-
axis	represents	percentage	of	cells	seen	in	each	phase.	**	p<0.01.		
	
	
	
	
 ** 
 ** 
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Figure	4.15	A	figure	showing	the	cell	cycle	distribution	of	SUIT-2	pancreatic	cancer	
cell	 line	untreated	(media	only	)	and	 	treated	with	AT7519	(2μM)	+	Gemcitabine	
(10nm)	at	4,	7,	13.5,	24	and	48	hours.	
	
	
CONCLUSION	
Cell	 cycle	analysis	 showed	a	marked	 reduction	of	 cells	 in	 the	G0/G1	and	S	phases	
with	 an	 increase	 in	 cells	 in	 G2/M	 phase	 following	 treatment	with	 AT7519.	When	
AT7519	was	combined	with	gemcitabine	the	effects	observed	were	in	line	with	that	
of	gemcitabine	alone	with	an	accumulation	of	cells	in	S	phase.	
	
4.2.3	Cell	cycle	analysis	AT13387	
The	effect	of	AT13387	 treatment	on	cell	 cycle	progression	was	assessed	 in	SUIT-2	
cells.	SUIT-2	cells	were	seeded	onto	6	well	plates	at	2.5	x	105	cells	per	well	in	RPMI	
media	 and	 incubated	 for	 24	 hours	 before	 treatment	 with	 AT13387	 (250nM)	 or	
media	control.		Cell	cycle	analysis	was	performed	at	4,	7,	24	and	48	hours.	
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Following	 24hrs	 of	 treatment	with	AT13387	 cells	 showed	 a	 significant	 increase	 in	
cells	in	the	G0/G1	(P<0.01)	and	G2/M	(P<0.05)	phases	of	the	cell	cycle	compared	to	
vehicle	treated	controls	(figure	4.16	and	4.17).	
	
Cells	 treated	with	both	AT13387	and	Gemcitabine	showed	a	marked	difference	to	
single	 drug	 treatment	with	 an	 increase	 in	 cells	 in	 the	 s-phase	 of	 the	 cell	 cycle	 in	
keeping	with	the	effects	of	Gemcitabine	alone	but	more	perturbed	(figure	4.18).	
	
Figure	4.16	A	figure	showing	the	cell	cycle	distribution	of	SUIT-2	pancreatic	cancer	
cell	line	untreated	(media	only)	and	treated	with	AT13387	(250nm)	at	4,	7,	24	and	
48	hours.		
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Figure	4.17	A	bar	 chart	of	 the	percentage	of	 cells	 in	different	phases	of	 the	 cell	
cycle	treated	with	AT13387	versus	untreated	control	SUIT-2	cells	at	24	hour	time	
point.	 The	 x-axis	 shows	 phase	 of	 cell	 cycle	 G1,	 S	 phase	 and	 G2/M,	 the	 y-axis	
represents	percentage	of	cells	seen	in	each	phase.		*	p<0.05.		**	p<0.01.	
	
	
Figure	4.18	A	figure	showing	the	cell	cycle	distribution	of	SUIT-2	pancreatic	cancer	
cell	line	untreated	(media	only)	and	treated	with	AT13387	(63nM)	+	Gemcitabine	
(10nM)	at	4,	7,	13.5,	24	and	48	hours.	
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CONCLUSION	
AT13387	 treatment	 leads	 to	 cell	 cycle	 arrest	 in	 G0/G1	 and	 G2/M	 phases	 of	 cell	
cycle.	 	 In	combination	with	gemcitabine	AT13387	showed	S	phase	accumulation	in	
line	with	gemcitabine	action	but	more	marked.	
	
4.3	APOPTOSIS	ASSAYS	
Experiments	in	this	section	were	performed	by	Elisabeth	Shaw.	
	
4.3.1	Apoptosis	assays	gemcitabine	
Evidence	 of	 induction	 of	 apoptosis	 by	 gemcitabine	 was	 tested	 in	 Miapaca-2	
pancreatic	 cancer	 cell	 line	by	 investigation	of	 caspase-3	activity.	 	 The	 caspase-Glo	
3/7	luminescent	assay	was	performed	on	cells	treated	with	250nM	of	Gemcitabine	
or	0.1%	DMSO	control	at	6,	16,	24,	40,	48	and	72	hours.	 	At	40,	48	and	72	hours	
induction	 of	 caspase	 3/7	 was	 significantly	 increased	 in	 gemcitabine	 treated	 cells	
compared	with	those	in	control	media	(p=0.01)	(figure	4.19).	
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Figure	4.19	A	bar	chart	showing	caspase-3/7	activity	of	untreated	and	gemcitabine	
(250nM)	 treated	Miapaca-2	 pancreatic	 cancer	 cells	 at	 6,	 16,	 24,	 40,	 48	 and	 72	
hours.		The	x-axis	shows	the	time	point	of	the	assay	and	the	y-axis	shows	Relative	
Light	Units	(RLU)-normalised	to	untreated	control	cells.	**	p=0.01.	
	
CONCLUSION	
Apoptosis	 was	 demonstrated	 after	 treatment	 with	 gemcitabine	 in	 vitro	 by	 the	
surrogate	marker	caspase-3.		
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4.3.2	Apoptosis	assays	AT7519	
Evidence	of	 induction	of	apoptosis	by	AT7519	was	 tested	 in	Miapaca-2	pancreatic	
cancer	 cell	 line	 by	 investigation	 of	 caspase-3	 activity.	 	 The	 caspase-Glo	 3/7	
luminescent	 assay	was	 performed	on	 cells	 treated	with	 10μM	of	AT7519	or	 0.1%	
DMSO	control	at	6,	16,	24,	40,	48	and	72	hours.	
	
At	24	hours	induction	of	caspase	3/7	was	significantly	increased	in	AT7519	treated	
cells	 compared	with	 those	 in	 control	media	 (p=0.01),	upregulation	of	 caspase	3/7	
was	also	noted	at	16	and	40	hour	time	points	(figure	4.20).	
	
Figure	4.20	A	bar	chart	showing	the	caspase-3/7	activity	of	untreated	and	AT7519	
(10μM)	treated	Miapaca-2	pancreatic	cancer	cells	at	6,	16,	24,	40,	48	and	72	hours.		
The	 x-axis	 shows	 time	 point	 of	 assay	 and	 the	 y-axis	 shows	 RLU-normalised	 to	
untreated	control	cells.	**	p=0.01		
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CONCLUSION	
Apoptosis	was	demonstrated	after	treatment	with	AT7519	in	vitro	by	the	surrogate	
marker	caspase-3.	
	
4.3.3	Apoptosis	assays	AT13387	
Treatment	of	AT13387	had	already	proven	inhibition	of	growth	and	cell	cycle	arrest	
but	 this	 does	 not	 necessarily	 equate	 to	 cell	 death	 therefore	 investigation	 was	
undertaken	 to	establish	 if	 apoptosis	was	occurring	using	 caspase	3/7	activity	 as	 a	
marker	of	this.		After	treating	Miapaca-2	cells	with	1μM	of	AT13387	or	0.1%	DMSO	
control	 the	 caspase-glo	 3/7	 luminescent	 assay	 was	 performed	 at	 time	 points	
including	6,	16,	24,40,48	and	72	hours	(experiment	performed	by	ES).	At	40,	48	and	
72	hours	there	was	a	substantial	increase	in	caspase	3/7	activity	(figure	4.21).	
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Figure	 4.21	 A	 bar	 chart	 showing	 the	 caspase-3	 activity	 of	 untreated	 and	
AT13387(1μM)	treated	Miapaca-2	pancreatic	cancer	cells	at	6,	16,	24,	40,	48	and	
72	 hours.	 The	 x-axis	 shows	 time	 point	 of	 assay	 after	 treatment	 and	 the	 y-axis	
shows	RLU-normalised	to	untreated	control	cells.	**	p<0.01.	
	
This	 observed	 evidence	 of	 apoptosis	 was	 further	 confirmed	 by	 the	 presence	 of	
cleaved	PARP	in	Miapaca-2	cells	at	30		and	48	hours	after	treatment	,	it	was	noted	
that	 cleaved	 PARP	 was	 evident	 in	 both	 adherent	 and	 floating	 cell	
populations(experiment	performed	by	ES,	data	not	shown).	
	
CONCLUSION	
The	 results	 from	 caspase	 3/7	 assays	 and	 evidence	 of	 cleaved	 PARP	 support	 the	
motion	that	AT13387	resulted	in	apoptosis	of	treated	pancreatic	cells.	
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4.4	ISOBOLAR	ANALYSIS	
After	 establishing	 the	 IC50	 values	 for	 gemcitabine,	 AT7519	 and	 AT1387	 as	 single	
agents	the	combinations	of	gemcitabine	+	AT7519	and	gemcitabine	+	AT13387	were	
investigated	using	 an	 isobolar	 analysis.	 	 In	 this	 experiment	 cells	were	plated	 then	
treated	with	both	agents	at	variable	concentrations	to	observe	any	changes	to	the	
established	IC50’s	of	each	agent	in	line	with	synergy	or	antagonism	when	the	agents	
were	used	in	combination.	
	
4.4.1	Isobolar	analysis	of	AT7519	and	gemcitabine	
Cells	were	seeded	in	96-well	plates	at	1.5	x	104	after	24	hours	culture	fresh	media	
was	 introduced	 with	 variable	 concentrations	 of	 gemcitabine	 (20nM-2.5nM)	 and	
AT7519	 (2μM	–	0.25μM)	with	wells	of	 combined	agents,	 single	 agents	 and	media	
controls.	 MTS	 assays	 were	 performed	 at	 24,	 48,	 36,	 72	 and	 96	 hours.	 	 IC50	
experiments	were	performed	in	triplicate	with	4	plates	per	experimental	run.	
	
When	gemcitabine	 and	AT7519	were	 added	 in	 combination	 the	 resulting	 isobolar	
curve	 generated	 showed	 an	 antagonistic	 effect.	 	 	 These	 initial	 results	 showed	
AT7519	 still	 had	 an	 effect	 at	 its	 recognized	 IC50	 regardless	 of	 the	 presence	 of	
gemcitabine	 however	 Gemcitabine	 was	 inhibited	 from	 reaching	 its	 IC50	 (figure	
4.22).	
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Figure	 4.22	A	 graph	 showing	 an	 isobolar	 analysis	 of	 the	 combination	of	AT7519	
and	gemcitabine.	Data	is	shown	from	6	96-well	plates	representing	the	average	of	
50%	 point	 of	 cell	 growth	 across	 plates	 adjusted	 for	 controls.	 	 The	 AT7519	
concentration	used		ranged	from	2-0.25	μM	and	gemcitabine	was	20-2nM.		Both	
agents	 were	 added	 to	 plates	 at	 the	 same	 time	 point.	 	 The	 x-axis	 shows	
gemcitabine	 concentration	 in	nM	and	 the	y-axis	 shows	AT7519	 concentration	 in	
μM.	 	Plotted	red	and	blue	points	represent	the	50%	 isoeffect	 i.e.	 the	amount	of	
each	agent	required	to	produce	a	50%	cell	growth	inhibition.	Points	plotted	along	
the	black	 line	would	 represent	 an	 additive	 effect,	 points	 above	 the	 line	 suggest	
antagonism		and	below	the	line	represent	synergy.	
	
In	 light	 of	 this	 results	 further	 experiments	were	 performed	 using	 sequential	 drug	
addition.		From	data	generated	after	discussion	it	was	decided	that	the	addition	of	
gemcitabine	 for	 24	 hours	 followed	 by	 combination	 therapy	 would	 be	 a	 rational	
dosing	regimen	owing	to	the	fact	that	cell	cycle	analysis	demonstrated	cells	need	to	
be	dividing	in	order	for	gemcitabine	to	have	an	effect.	
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Following	 this	 sequential	 addition	 of	 drugs	 and	 isobolar	 curve	 was	 generated	
showing	 at	 least	 an	 additive	 effect	 of	 gemcitabine	 and	 AT7519	 (figure	 4.23).	 	 No	
results	were	obtained	demonstrating	synergy.	
	
	
Figure	 4.23	A	 graph	 showing	 an	 isobolar	 analysis	 of	 the	 combination	of	AT7519	
and	gemcitabine	when	the	drugs	were	added	sequentially	(gemcitabine	treatment	
for	24	hours	then	the	combination	of	gemcitabine	and	AT7519	for	48	hours).	Data	
from	6	96-well	plates	representing	the	average	of	50%	point	of	cell	growth	across	
plates	adjusted	for	controls	is	shown.		The	AT7519	concentration	used	was	2-0.25	
μM	 and	 gemcitabine	 concentrations	 used	 were	 20-2nM.	 	 The	 x-axis	 shows	
gemcitabine	 concentration	 in	nM	and	 the	y-axis	 shows	AT7519	 concentration	 in	
μM.	 	Plotted	red	and	blue	points	represent	the	50%	 isoeffect	 i.e.	 the	amount	of	
each	agent	required	to	produce	a	50%	cell	growth	inhibition.	Points	plotted	along	
the	 black	 line	 would	 represent	 an	 additive	 effect,	 red	 line	 above	 shows	
antagonism	and	green	below	demonstrates	synergy.		
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CONCLUSION	
In	vitro	 the	combination	of	gemcitabine	and	AT7519	had	an	antagonistic	effect	on	
isobolar	 analysis,	 however	 when	 the	 scheduling	 of	 the	 agents	 was	 modified	 to	
sequential	 addition	 of	 gemcitabine	 then	 the	 combination	 of	 gemcitabine	 and	
AT7519	an	additive	effect	was	observed.		This	supports	the	cell	cycle	data	observes	
that	 demonstrates	 cells	 need	 to	 be	 dividing	 in	 order	 for	 gemcitabine	 to	 have	 an	
effect.			The	observation	of	at	least	an	additive	effect	supports	further	investigation	
of	this	agent	in	combination	with	gemcitabine.			
	
	
4.4.2	Isobolar	analysis	of	AT13387	and	gemcitabine	
Cells	were	seeded	 in	96-well	plates	at	1.5	x	104	cells	per	well	and	cultured	 for	24	
hours,	 fresh	 media	 was	 then	 introduced	 with	 variable	 concentrations	 of	
gemcitabine	 (2nM-	 40nM)	 and	 AT13387	 (15nM	 –	 125nM).	 MTS	 assays	 were	
performed	at	48	hours.		IC50	experiments	were	performed	in	triplicate	with	6	plates	
per	run.	
	
The	 combination	of	AT13387	 and	 gemcitabine	did	 not	 yield	 an	 adequate	 isobolar	
analysis.		In	one	run	of	the	experiment	gemcitabine	did	not	have	a	significant	effect	
as	a	single	agent	and	in	2	runs	AT13387	did	not	have	an	effect	as	a	single	agent,	this	
made	 isobolar	 interpretation	 impossible.	 	The	results	were	examined	 in	detail	and	
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some	observations	were	made	despite	this.	 	 In	the	presence	of	gemcitabine	there	
was	a	suggestion	of	enhanced	AT13387	activity	in	one	run	of	this	experiment	where	
AT13387	did	not	reach	its	IC50	as	a	single	agent.		This	was	observed	by	calculating	
the	 coefficients	 of	 the	 gradients	 produced	 but	 this	 data	was	 too	 extrapolated	 to	
give	a	definitive	result	to	comment	upon	regarding	these	agents	in	combination.			
	
CONCLUSION	
Isobolar	analysis	was	not	completed	with	AT13387	and	gemcitabine	but	there	was	a	
trend	that	AT13387	activity	was	enhanced	by	the	presence	of	gemcitabine.	
	
4.5	WESTERN	BLOTTING	
	
4.5.1	Western	blotting	of	downstream	targets	AT7519	
In	 order	 to	 establish	 the	 downstream	 targets/effects	 of	 treatment	 with	 AT7519	
western	 blotting	 was	 performed	 on	 a	 number	 of	 downstream	 targets	 both	 to	
demonstrate	activity	and	to	establish	any	potential	biomarkers	 for	the	AT7519.	 	A	
summary	of	 the	effects	on	protein	expression	are	 summarized	 in	 table	4.5	 at	 the	
end	of	this	section.	
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4.5.1.1	cdc2	(CDK1)	protein	expression	
Entry	of	cells	into	mitosis	is	regulated	by	cdc2	kinase	activation.		Cell	cycle	analysis	
supports	an	AT7519	G2/M	block	(as	expected	if	cdc2	activity	is	inhibited).			Western	
blot	analysis	was	undertaken	to	examine	cdc2	activity	after	various	treatments.				
	
After	 treatment	 with	 AT7519	 as	 a	 single	 agent	 (dose	 1μM-10μM)	 western	 blot	
analysis	 showed	no	 change	 in	 cdc2	 levels,	 supporting	 the	notion	 that	 activity	 and	
not	levels	of	CDK1	are	affected	by	AT7519	(figure	4.24	and	4.25).	
	
	
Figure	 4.24	 A	 figure	 showing	 the	 western	 blot	 assay	 of	 protein	 extracts	 from	
pancreatic	 cancer	 cell	 line	Miapaca-2	 treated	with	 AT7519	 (1μM-	 10μM)	media	
only	 or	 DMSO	 control	 for	 24	 hours.	 The	 blots	 were	 probed	 with	 cdc2	 (CDK1)	
antibody.		
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Figure	 4.25	 A	 figure	 showing	 a	 western	 blot	 assay	 of	 protein	 extracts	 from	
pancreatic	 cancer	 cell	 line	 Miapaca-2	 treated	 with	 AT7519	 (250nM	 –	 2μM)	 or	
Gemcitabine	(10nM-100nM)	or	vehicle	control.	The	blots	were	probed	with	cdc2	
(CDK1)	antibody.		
	
When	gemcitabine	and	AT7519	were	used	in	combination	this	decrease	in	cdc2	was	
again	observed	suggesting	AT7519	was	having	an	effect	but	not	gemcitabine.	This	
was	confirmed	by	sequential	addition	of	gemcitabine	alone	for	24	hours	followed	by	
variable	concentrations	of	AT7519,	cdc2	levels	remained	unchanged	supporting	the	
observation	that	gemcitabine	was	causing	an	s	phase	accumulation	and	the	notion	
that	 cells	need	 to	be	dividing	 in	order	 for	a	G2/M	block	 to	occur	 (figure	4.26	and	
4.27).	
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Figure	 4.26	 A	 figure	 showing	 combination	 treatment-	 a	 western	 blot	 assay	 of	
protein	extracts	 from	pancreatic	 cancer	cell	 line	Miapaca-2	 treated	with	AT7519	
(250nM	–	2μM)	and	gemcitabine	(25nM)	for	24	hours.	The	blots	were	probed	with	
cdc2	(CDK1)	antibody.		
	
	
	
Figure	4.27	A	figure	showing	sequential	addition-	a	western	blot	assay	of	protein	
extracts	 from	 pancreatic	 cancer	 cell	 line	 Miapaca-2	 treated	 with	 gemcitabine	
(25nM)	 +	 	 AT7519	 (250nM	 –	 2μM).	 	 Gemcitabine	 was	 given	 for	 24	 hours	 then	
AT7519	for	24	hours.	The	blot	was	probed	with	cdc2	(CDK1)	antibody.		
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CONCLUSION	
After	 treatment	 with	 AT7519	 as	 a	 single	 agent	 levels	 of	 cdc2	 activity	 were	
unchanged.	 In	 combination	 AT7519	 and	 gemcitabine	 displayed	 a	 cdc2	 decrease,		
when	 gemcitabine	 was	 given	 first	 cdc2	 levels	 were	 unchanged	 supporting	 the	
notion	that	cells	need	to	be	dividing	in	order	for	a	G2/M	block	to	occur.	
	
4.5.1.2	Rb/Phospho	Rb	protein	expression	
The	retinoblastoma	protein	(Rb)	is	a	tumour	suppressor	protein	that	is	known	to	be	
dysfunctional	 in	 cancer.	 	Rb	prevents	excessive	 cell	 growth	by	 inhibiting	 cell	 cycle	
progression	 from	G1	 to	 S	 phase	 until	 a	 cell	 is	 ready	 to	 divide	 at	which	 point	 it	 is	
phosphorylated.	 Rb	 phosphorylation	 is	 catalysed	 by	 cyclin-dependent	 kinases	 and	
therefore	it	was	hypothesized	potentially	inhibited	by	AT7519.			
	
From	western	blots	performed	Rb	phosphorylation	with	 increasing	concentrations	
of	 AT7519	 is	 almost	 eliminated	 despite	 minimal	 changes	 in	 Rb	 levels	 after	 drug	
treatment	(figure	4.28	and	4.29).	
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Figure	4.28	A	western	blot	 assay	of	protein	extracts	 from	pancreatic	 cancer	 cell	
line	Miapaca-2	treated	with	AT7519	(1μM-	10μM)	media	only	or	DMSO	control	for	
24	hours.	The	blot	was	probed	with	Rb	antibody.		
	
	
	
Figure	4.29	A	western	blot	 assay	of	protein	extracts	 from	pancreatic	 cancer	 cell	
line	Miapaca-2	treated	with	AT7519	(1μM-	10μM)	media	only	or	DMSO	control	for	
24	hours.	The	blot	was	probed	with	Phospho-Rb	antibody.			
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CONCLUSION	
Retinoblastoma	protein	phosphorylation	is	decreased	by	treatment	with	AT7519.	
	
4.5.1.3	pp1-α/Phospho	pp1-α	protein	expression	
Protein	 phosphatase	 type	 1	 (pp1)	 is	 one	 of	 the	 major	 cellular	 serine/threonine	
protein	phosphatases	and	has	a	crucial	role	in	cell	cycle	progression.		The	activity	of	
Rb	in	turn	is	regulated	by	phosphorylated	pp1-α.		 Its	phosphorylation	is	controlled	
by	CDK2.	 	 It	was	hypothesized	 that	 therefore	phosphorylation	of	 pp1-α	would	be	
inhibited	by	AT7519.	
	
On	western	blot	analysis	pp1-α	levels	were	unchanged	however	at	higher	AT7519	
concentrations	pp1-α	phosphorylation	was	inhibited	(figure	4.30	and	4.31).	
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Figure	4.30	A	western	blot	 assay	of	 protein	extracts	 from	pancreatic	 cancer	 cell	
line	Miapaca-2	treated	with	AT7519	(1μM-	10μM)	media	only	or	DMSO	control	for	
24	hours.	The	blot	was	probed	with	pp1-α	antibody.		
	
	
	
Figure	4.31	A	western	blot	 assay	of	protein	extracts	 from	pancreatic	 cancer	 cell	
line	Miapaca-2	treated	with	AT7519	(1μM-	10μM)	media	only	or	DMSO	control	for	
24	hours.	The	blot	was	probed	with	Phospho	pp1-α	antibody.		
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CONCLUSION	
The	phosphorylation	of	pp1-α	was	inhibited	by	AT7519	in	line	with	its	expected	
actions	on	this	protein.	
	
4.5.1.4	NPM/Phospho	NPM	protein	expression	
Nucleophosim	 (NPM)	 plays	 important	 roles	 in	 the	 regulation	 of	 cell	 proliferation	
and	apoptosis	and	has	been	found	abundant	in	tumour	cells.		The	phosphorylation	
of	 NPM	 is	 facilitated	 by	 cyclin	 E/CDK2	 which	 is	 a	 precursor	 step	 to	 centrosome	
duplication.	
	
Western	 blot	 analysis	 was	 performed	 with	 NPM	 and	 phosphor	 NPM	 antibodies	
using	 cells	 that	 had	 been	 treated	 with	 AT7519	 or	 gemcitabine	 (experiements	
performed	by	Owain	Jones).		Results	showed	whilst	NPM	levels	were	unchanged	by	
either	 AT7519	 or	 gemcitabine	 the	 phosphorylation	 of	 NPM	was	 reduced	 by	 both	
agents	(figure	4.32).	
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Figure	4.32	A	western	blot	 assay	of	protein	extracts	 from	pancreatic	 cancer	 cell	
line	 Miapaca-2	 treated	 with	 AT7519	 (250nM-2μM)	 or	 gemcitabine	 (10nM	 –	
100nM)	media	 only	 or	DMSO	 control	 for	 24	 hours.	 The	blots	were	probed	with		
NPM	and	Phospho	NPM	antibody.		
	
Further	investigation	was	performed	on	cells	treated	with	AT7519	and	gemcitabine	
in	combination.		Again	the	levels	of	NPM	were	unchanged.		When	AT7519	and	
gemcitabine	were	given	in	combination	the	levels	of	phosphor-NPM	were	markedly	
reduced,	when	cells	were	treated	with	gemcitabine	followed	by	AT7519	the	effects	
observed	were	similar	to	that	of	AT7519	alone	(figure	4.33).	
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Figure	4.33	Figure	showing	combination		and	sequential	addition	treatment-	A	
western	blot	assay	of	protein	extracts	from	pancreatic	cancer	cell	line	Miapaca-2	
treated	with	AT7519	(250nM	–	2μM)	and	Gemcitabine	(25nM)	for	24	hours.																																																																							
In	the	sequential	addition	experiment	gemcitabine	was		given	for	24	then	AT7519	
for	24	hours.	The	blots	were	probed	with	NPM	and	PhNPM	antibody.																																																																																																													
	
CONCLUSION	
Phosphorylation	of	NPM	was	 reduced	 in	cells	 treated	with	AT7519	and	 this	effect	
was	still	observed	when	cells	were	treated	with	both	AT7519	and	gemcitabine	but	
more	markedly	when	both	agents	were	used	simultaneously.		
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4.5.1.5	Summary	of	AT7519	treatment	effects	
Table	 4.5	 summarises	 the	 effects	 seen	 on	 the	 protein	 expression	 of	 those	 tested	
with	AT7519	or	the	combination	of	AT7519	and	gemcitabine.		
	
	
Protein	marker	
	
Effect	on	protein	
expression	with	AT7519	
	
Effect	on	protein	expression	with	
AT7519	+	Gemcitabine	
Cdc2	      çè	 çè	
Rb	 çè	 No	data	
Phospho	Rb	 ê	 No	data	
pp1-α	 çè	 No	data	
Phospho	pp1-α	 ê	 No	data	
NPM	 çè	 çè	
Phospho	NPM	 ê	 ê	
Table	4.5	A	summary	table	showing	the	protein	expression	effects	of	treatment	
with	AT7519	or	combination	treatment	with	AT7519	and	gemcitabine,	
(êrepresents	downregualtion	çè	represents	no	change	in	protein	expression).	
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4.5.2	Western	blotting	of	downstream	targets	AT13387	
Western	 blotting	 was	 performed	 in	 order	 to	 establish	 the	 downstream	
targets/effects	 of	 treatment	 with	 AT13387.	 	 A	 number	 of	 potential	 targets	 were	
explored	 both	 to	 demonstrate	 activity	 and	 establish	 any	 potential	 biomarkers	 for	
AT13387.	
	
Inhibition	of	Hsp90	has	been	shown	to	affect	a	number	of	oncogenes	and	proteins	
important	 for	 the	 growth	 and	 survival	 of	 cancer	 cells.	 This	 includes	 molecules	
involved	in	cell	survival,	growth	and	cell	cycle	progression.	We	examined	the	effect	
of	AT13387	inhibition	on	a	number	of	these	proteins	including	those	involved	in	the	
MAP	Kinase	and	PI3K	pathways.	 	A	 summary	of	 the	effects	on	protein	expression	
are	summarized	in	table	4.6	at	then	end	of	this	section.		Experiments	in	this	section	
were	performed	by	Elisabeth	Shaw.	
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4.5.2.1	Akt/Phospho	Akt	protein	expression	
Akt	is	a	downstream	effector	of	phosphoinositide	3-kinase	and	mediates	biological	
actions	 in	 respect	 to	 anti-apoptotic	 responses.	 	 HSP90	 binding	 to	 Akt	 reduces	
sensitivity	of	cells	to	apoptosis	 inducing	stimuli	therefore	 it	was	hypothesized	that	
AT13387	may	play	a	role	in	regulating	Akt	and	its	phosphorylation.	
	
Miapaca-2	 cells	 were	 treated	 with	 AT13387	 for	 18	 hours.	 	 This	 resulted	 in	
significantly	 decreased	 levels	 of	 phosphor	 Akt	 and	 decreased	 levels	 of	 Akt	 with	
increasing	concentrations	of	AT13387	(figure	4.34).	
	
Figure	4.34	A	western	blot	 assay	of	protein	 extracts	 from	pancreatic	 cancer	 cell	
line	Miapaca-2	 treated	with	 AT13387	 (10nM-	 1000nM)	 or	media	 control	 for	 18	
hours.	The	blots	were	probed	with	Akt	and	phospho	Akt	antibody.			
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• Administered as a single agent, AT13387 was tolerated in nude mice with no
mortality, persistent weight loss or other significant side effects.
• Although not significant the rate of tumour growth (as measured by coefficient of
exponential regression) was reduced with AT13387 treatment (n=6) compared to
vehicle treated controls (n=6) (p=0.073, pair T-test).
• AT13387 given in combination with Gemcitabine was also tolerated and on-going
experiments are investigating the inhibition of tumour growth with this
combination.
AT13387 inhibited the proliferation of a
number of pancreatic cancer cell lines.
• IC50 values for proliferation inhibition by
AT13387 ranged from 29 - 100nM (Table 1).
• Suit-2GR, a gemcitabine resistant cell line
derived from Suit-2 (with a gemcitabine IC50
value 60-fold higher than the parent cell-line)
had similar sensitivity to AT13387. Table 1: Anti-proliferative 
activity of AT13387 
• Treatment of pancreatic cancer cells with AT13387 resulted in significant
down-regulation of phospho-S6 ribosomal protein and Raf -1 (both P<0.01)
and Akt/PKB, CDK4, phosphorylated -Erk and phosphorylated-Akt (all
P<0.001).
• In vivo down-regulation of CDK, phospho-S6 ribosomal protein and Akt was
observed in tumours from mice 19hrs but not 2hrs after dosing.
• Significant up-regulation of co-chaperone Hsp70 was also observed following
treatment with AT13387 in vitro (P=0.02) and in vivo.
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METHODS
• Cell proliferation assays performed in triplicate using EZ4U assay (BioMedica), 48 or 72 hrs after  
treatment. 
• Cell cycle analysis was performed 4,7,24 and 48hrs after treatment of cells with 250nM AT13387 using 
flow cytometry to determine propidium iodide incorporation.
• Apoptosis was assessed using Annexin-FITC vs propidium iodide staining and flow cytometry 7,13,24 
and 48hrs after treatment of cells with 250nM AT13387.
• Western blot analysis was performed using standard methods with ECL detection.
• Tolerability and efficacy of AT13387 assessed in Xenograft model (BALB/c (CAnN.Cg-Foxn1nu/Cr) nude 
mice and miapaca2 cells). Tumour volumes measured with external callipers.
• Statistical analysis was performed in SPSS and Statview. P values reported from T-tests. 
Hsp90 inhibition leads to cell cycle arrest in G0/G1 and G2/M phases of 
the cell cycle, but no clear evidence of apoptosis. Hsp90 downstream biomarkers are altered, following treatment 
with AT13387.
Figure 4: Effects of AT13387 treatment on Hsp90
client proteins and co-chaperone Hsp70 in A)
Miapaca2 cells (18hrs after treatment) and B)
miapaca2 xenograft tumours: C1 and C2 cyclodextrin
control animals; T1, tumor removed 2hrs and T2,
tumour removed 19hrs, after 80mg/kg AT13387.
Cell line IC50 (nM)
Suit-2 63
Suit-2GR 60
MiaPaCa-2 58
FamPac 42
Paca2 29
CFpac 100
Panc-1 50
CONCLUSION
AT13387 inhibits growth of pancreatic cancer cell lines, including those
resistant to gemcitabine, and suppresses the expression of Hsp90 client
proteins. In vivo AT13387 slows tumour growth and further investigations
will determine if AT13387 can improve inhibition of tumour growth when
used in combination with gemcitabine.
Untreated 
AT13387
Figure 1:  The effects of AT13387 on cell cycle distribution in A) Suit-2 and B) Suit-2 GR cells.  C) 
Analysis of apoptosis 24hrs after AT13387 treatment of Suit-2 cells; similar results were observed 
at 7, 13, 48 hours post  drug treatment. 
AT13387 treatment slows tumour growth in vivo
A
B
Figure 2: AT13387 tolerability: daily weights of mice
treated with AT13387(A). Example of exponential
regression curves of tumour growth in animal treated
with AT13387(B), or with vehicle control(C). Drug
administered once weekly at 80mg/kg. Exponential
regression analysis was used to fit a curve to data points
before treatment and over the first 10 days of treatment
and assign coefficients. Treatment groups were compared
using paired T-test (6 mice per group). Arrow marks start of
treatment.
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BACKGROUND
• Pancreatic cancer continues to have a poor prognosis with over 7700 deaths in the
UK per year.
• Gemcitabine the main standard of treatment for pancreatic cancer is still relatively
ineffective.
• Heat shock protein 90 (Hsp90), a molecular chaperone required for the stability and
function of signalling proteins that promote growth and/or survival of cancer cells,
affects a number of key pathways identified to be important in cancer, including the
PI3K/Akt and MAPK pathways [1].
• AT13387 (Astex therapeutics), a novel Hsp90 inhibitor, has efficacy against
melanoma, AML, colon and lung carcinoma in xenograft models and in a variety of
cancer types in vitro (IC50 10-400nM) [2].
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AT13387 inhibited the proliferation of a
number of pancreatic cancer cell lines.
• IC50 values for proliferation inhibition by
AT13387 ranged from 29 - 100nM (Table 1).
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value 60-fold higher than the parent cell-line)
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down-regulation of phospho-S6 ribosomal protein and Raf -1 (both P<0.01)
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P<0.001).
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flow cytometry to determine propidium iodide incorporation.
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melanoma, AML, colon and lung carcinoma in xenograft models and in a variety of
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When	Miapaca-2	 cells	were	 treated	with	 AT13387	 plus	 gemcitabine	 it	was	 noted	
that	 decreased	 concentrations	 of	 Akt	were	 observed	 both	when	 the	 agents	were	
given	 together	 (figure	4.35)	 and	when	agents	were	added	 sequentially,	 the	effect	
was	less	marked	when	agents	added	sequentially	(figure	4.36).	
	
	
Figure	 4.35	 Figure	 showing	 combination	 treatment	 –	 A	 western	 blot	 assay	 of	
protein	extracts	from	pancreatic	cancer	cell	line	Miapaca-2	treated	with	AT13387	
(1.	 10nM,	 2.	 25nM,	 3.	 100nM,	 4.	 250nM,	 5.	 1000nM)	 or	 AT13387	 with	
Gemcitabine	 (500nM)	 for	 18	 hours.	 	 G	 represents	 treatment	 with	 gemcitabine	
500nM	alone.		The	blots	were	probed	with	Akt	antibody.			
	
	
		Without	gem	è 	with	gem	è 		
		0	1		2		3		4		5		0	1		2		3	4	5	G		
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Figure	4.36	A	 figure	showing	the	sequential	addition	of	agents	 	 -	A	western	blot	
assay	of	protein	extracts	from	pancreatic	cancer	cell	 line	Miapaca-2	treated	with	
AT13387	(1.	10nM,	2.	25nM,	3.	100nM,	4.	250nM,	5.	1000nM)	or	media	control	as	
a	 single	 agent	 or	 AT13387	 with	 Gemcitabine	 (500nM)	 for	 18	 hours.	 	 For	
combination	study	cells	were	 treated	with	gemcitabine	 for	24	hrs	 then	AT13387	
was	added	for	24hrs.	The	blots	were	probed	with	Akt	antibody.			
	
CONCLUSION	
Treatment	of	Miapaca-2	cells	with	AT13387	resulted	in	both	decreased	levels	of	Akt	
and	Phospho	Akt.	 	When	 cells	were	 treated	with	both	AT13387	 and	Gemcitabine	
Akt	 levels	 decreased	 irrespective	 of	 drug	 scheduling	 but	 was	 less	 marked	 when	
gemcitabine	was	given	prior	to	AT13387.	
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4.5.2.2	S6/Phospho	S6	protein	expression	
Phosphorylation	 of	 the	 S6	 ribosomal	 protein	 correlates	 with	 increases	 mRNA	
transcripts	 that	 encode	 for	 proteins	 involved	 in	 cell	 cycle	 progression	 and	 factors	
necessary	 for	 translation.	 Decreased	 phosphorylation	 of	 S6	 should	 correlate	with	
HSP90	inhibition.			
	
Miapaca-2	cells	treated	with	AT13387	showed	significant	decreases	of	phosph-S6	at	
18	hours	after	treatment,	levels	of	S6	were	unchanged	(figure	4.37).	
	
	
	
Figure	4.37	A	western	blot	 assay	of	protein	extracts	 from	pancreatic	 cancer	 cell	
line	Miapaca-2	 treated	with	 AT13387	 (10nM-	 1000nM)	 or	media	 control	 for	 18	
hours.	The	blots	were	probed	with	S6	and	phospho	S6	antibody.			
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When	cells	were	treated	with	AT13387	and	gemcitabine	concurrently	the	decreased	
phosphor	S6	was	also	observed	and	the	effect	was	more	marked	at	lower	doses	of	
AT13387	(figure	4.38).	 	This	was	also	true	of	sequential	scheduling	of	gemcitabine	
followed	by	AT13387	(figure	4.39).	
	
	
Figure	4.38	A	figure	showing	combination	treatment	with	agents	-	A	western	blot	
assay	of	protein	extracts	from	pancreatic	cancer	cell	 line	Miapaca-2	treated	with	
AT13387	(1.	10nM,	2.	25nM,	3.	100nM,	4.	250nM,	5.	1000nM)	or	media	control	as	
a	single	agent	or	AT13387	with	gemcitabine	(500nM)	for	18	hours.	G18	represents	
treatment	with	 gemcitabine	 500nM	alone.	 	 The	 blots	were	 probed	with	 S6	 and	
phospho	S6	antibody.		
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Figure	4.39	A	 figure	 showing	 the	sequential	addition	of	agents	–	A	western	blot	
assay	of	protein	extracts	from	pancreatic	cancer	cell	 line	Miapaca-2	treated	with	
AT13387	(1.	10nM,	2.	25nM,	3.	100nM,	4.	250nM,	5.	1000nM)	or	media	control	as	
a	 single	 agent	 or	 AT13387	 with	 gemcitabine	 (500nM)	 for	 18	 hours.	 	 For	
combination	study	cells	were	 treated	with	gemcitabine	 for	24	hrs	 then	AT13387	
was	added	for	24hrs.	The	blots	were	probed	with	S6	and	phospho	S6	antibody.			
	
CONCLUSION	
Treatment	with	AT13387	resulted	in	decreased	phosphorylation	of	S6,	this	was	also	
noted	 when	 AT13387	 was	 combined	 with	 gemcitabine	 regardless	 of	 dosing	
schedule	and	the	effect	was	noted	at	lower	doses	of	AT13387.	
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4.5.2.3	Raf-1	protein	expression	
HSP90	 is	 essential	 for	 raf-1	 protein	 stability	 and	 it	 localization	 in	 the	 cell.	 	 Raf-1	
activation	 initiates	 the	MAPK	 (mitogen-activated	 protein	 kinase)	 cascade	 that	 has	
critical	 regulatory	 functions	 in	 determining	 cell	 proliferation,	 differentiation,	
apoptosis	 and	 oncogenic	 transformation.	 	 It	 was	 hypothesized	 that	 AT13387	
treatment	would	result	in	decreased	levels	of	Raf-1.	
	
When	Miapaca-2	cells	were	treated	with	increasing	concentrations	decreased	levels	
of	Raf-1	were	noted	(figure	4.40).	
	
	
	
Figure	4.40	A	western	blot	 assay	of	protein	extracts	 from	pancreatic	 cancer	 cell	
line	Miapaca-2	 treated	with	 AT13387	 (10nM-	 1000nM)	 or	media	 control	 for	 18	
hours.	The	blot	was	probed	with	Raf-1	antibody.			
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The	 combination	 of	 gemcitabine	 and	 AT13387	 showed	 similar	 effects	 to	 that	 of	
AT13387	alone	 (4.41).	 	When	the	agents	were	given	sequentially	 (gemcitabine	 for	
24	hours	 followed	by	AT13387)	the	effects	on	decreasing	protein	expression	were	
more	marked	and	observed	at	lower	doses	of	AT13387	(figure	4.42).		This	supports	
the	notion	 that	gemcitabine	as	a	nucleoside	analogue	acts	mostly	on	dividing	and	
replicating	cells.	
	
	
	
Figure	 4.41	A	 figure	 showing	 combination	 treatment	 of	 agents	 -	 A	western	blot	
assay	of	protein	extracts	from	pancreatic	cancer	cell	 line	Miapaca-2	treated	with	
AT13387	(1.	10nM,	2.	25nM,	3.	100nM,	4.	250nM,	5.	1000nM)	or	media	control	as	
a	single	agent	or	AT13387	with	gemcitabine	 (500nM)	 for	18	hours.	G	 represents	
treatment	 with	 gemcitabine	 500nM	 alone.	 The	 blots	 were	 probed	 with	 Raf-1	
antibody.		
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Figure	4.42	A	 figure	 showing	 the	sequential	addition	of	agents	–	A	western	blot	
assay	of	protein	extracts	from	pancreatic	cancer	cell	 line	Miapaca-2	treated	with	
AT13387	(1.	10nM,	2.	25nM,	3.	100nM,	4.	250nM,	5.	1000nM)	or	media	control	as	
a	 single	 agent	 or	 AT13387	 with	 gemcitabine	 (500nM)	 for	 18	 hours.	 	 For	
combination	study	cells	were	 treated	with	gemcitabine	 for	24	hrs	 then	AT13387	
was	added	for	24hrs.	The	blots	were	probed	with	Raf-1	antibody.		
	
CONCLUSION	
In	 line	with	 its	expected	actions	AT13387	reduced	the	protein	expression	 levels	of	
Raf-1,	the	effect	on	protein	expression	was	more	marked	when	cells	were	treated	
sequentially	with	gemcitabine	followed	by	AT13387	and	observed	at	lower	doses	of	
AT13387.	
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4.5.2.4	CDK4	protein	expression	
	
CDK4	protein	 is	 a	member	of	 the	 cyclin	dependent	kinase	 family	of	enzymes	 that	
has	 been	 found	 to	 be	 associated	with	 tumourgenesis	 in	 a	 variety	 of	 cancers	 and	
forms	a	complex	with	HSP90	and	cdc37.	
	
When	 Miapaca-2	 cells	 were	 treated	 with	 AT13387	 significant	 decreases	 in	 CDK4	
protein	expression	were	noted	(figure	4.43).	
	
	
Figure	4.43	A	western	blot	 assay	of	protein	extracts	 from	pancreatic	 cancer	 cell	
line	Miapaca-2	 treated	with	 AT13387	 (10nM-	 1000nM)	 or	media	 control	 for	 18	
hours.	The	blots	were	probed	with	CDK4	antibody	
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• Administered as a single agent, AT13387 was tolerated in nude mice with no
mortality, persistent weight loss or other significant side effects.
• Although not significant the rate of tumour growth (as measured by coefficient of
exponential regression) was reduced with AT13387 treatment (n=6) compared to
vehicle treated controls (n=6) (p=0.073, pair T-test).
• AT13387 given in combination with Gemcitabine was also tolerated and on-going
experiments are investigating the inhibition of tumour growth with this
combination.
AT13387 inhibited the proliferation of a
number of pancreatic cancer cell lines.
• IC50 values for proliferation inhibition by
AT13387 ranged from 29 - 100nM (Table 1).
• Suit-2GR, a gemcitabine resistant cell line
derived from Suit-2 (with a gemcitabine IC50
value 60-fold higher than the parent cell-line)
had similar sensitivity to AT13387. Table 1: Anti-proliferative 
activity of AT13387 
• Treatment of pancreatic cancer cells with AT13387 resulted in significant
down-regulation of phospho-S6 ribosomal protein and Raf -1 (both P<0.01)
and Akt/PKB, CDK4, phosphorylated -Erk and phosphorylated-Akt (all
P<0.001).
• In vivo down-regulation of CDK, phospho-S6 ribosomal protein and Akt was
observed in tumours from mice 19hrs but not 2hrs after dosing.
• Significant up-regulation of co-chaperone Hsp70 was also observed following
treatment with AT13387 in vitro (P=0.02) and in vivo.
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METHODS
• Cell proliferation assays performed in triplicate using EZ4U assay (BioMedica), 48 or 72 hrs after  
treatment. 
• Cell cycle analysis was performed 4,7,24 and 48hrs after treatment of cells with 250nM AT13387 using 
flow cytometry to determine propidium iodide incorporation.
• Apoptosis was assessed using Annexin-FITC vs propidium iodide staining and flow cytometry 7,13,24 
and 48hrs after treatment of cells with 250nM AT13387.
• Western blot analysis was performed using standard methods with ECL detection.
• Tolerability and efficacy of AT13387 assessed in Xenograft model (BALB/c (CAnN.Cg-Foxn1nu/Cr) nude 
mice and miapaca2 cells). Tumour volumes measured with external callipers.
• Statistical analysis was performed in SPSS and Statview. P values reported from T-tests. 
Hsp90 inhibition leads to cell cycle arrest in G0/G1 and G2/M phases of 
the cell cycle, but no clear evidence of apoptosis. Hsp90 downstream biomarkers are altered, following treatment 
with AT13387.
Figure 4: Effects of AT13387 treatment on Hsp90
client proteins and co-chaperone Hsp70 in A)
Miapaca2 cells (18hrs after treatment) and B)
miapaca2 xenograft tumours: C1 and C2 cyclodextrin
control animals; T1, tumor removed 2hrs and T2,
tumour removed 19hrs, after 80mg/kg AT13387.
Cell line IC50 (nM)
Suit-2 63
Suit-2GR 60
MiaPaCa-2 58
FamPac 42
Paca2 29
CFpac 100
Panc-1 50
CONCLUSION
AT13387 inhibits growth of pancreatic cancer cell lines, including those
resistant to gemcitabine, and suppresses the expression of Hsp90 client
proteins. In vivo AT13387 slows tumour growth and further investigations
will determine if AT13387 can improve inhibition of tumour growth when
used in combination with gemcitabine.
Untreated 
AT13387
Figure 1:  The effects of AT13387 on cell cycle distribution in A) Suit-2 and B) Suit-2 GR cells.  C) 
Analysis of apoptosis 24hrs after AT13387 treatment of Suit-2 cells; similar results were observed 
at 7, 13, 48 hours post  drug treatment. 
AT13387 treatment slows tumour growth in vivo
A
B
Figure 2: AT13387 tolerability: daily weights of mice
treated with AT13387(A). Example of exponential
regression curves of tumour growth in animal treated
with AT13387(B), or with vehicle control(C). Drug
administered once weekly at 80mg/kg. Exponential
regression analysis was used to fit a curve to data points
before treatment and over the first 10 days of treatment
and assign coefficients. Treatment groups were compared
using paired T-test (6 mice per group). Arrow marks start of
treatment.
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BACKGROUND
• Pancreatic cancer continues to have a poor prognosis with over 7700 deaths in the
UK per year.
• Gemcitabine the main standard of treatment for pancreatic cancer is still relatively
ineffective.
• Heat shock protein 90 (Hsp90), a molecular chaperone required for the stability and
function of signalling proteins that promote growth and/or survival of cancer cells,
affects a number of key pathways identified to be important in cancer, including the
PI3K/Akt and MAPK pathways [1].
• AT13387 (Astex therapeutics), a novel Hsp90 inhibitor, has efficacy against
melanoma, AML, colon and lung carcinoma in xenograft models and in a variety of
cancer types in vitro (IC50 10-400nM) [2].
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Figure 3: Inhibition of HSP90 leads to
inhibition of multiple signalling pathways
simultaneously and disrupts both anti-
apoptotic signalling and cell cycle
progression. Targets of HSP90 inhibitors
shown circled in red. Adapted from
Blagosklonny 2002, Leukemia 16: 455–
462.
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experiments are investigating the inhibition of tumour growth with this
combination.
AT13387 inhibited the proliferation of a
number of pancreatic cancer cell lines.
• IC50 values for proliferation inhibition by
AT13387 ranged from 29 - 100nM (Table 1).
• Suit-2GR, a gemcitabine resistant cell line
derived from Suit-2 (with a gemcitabine IC50
value 60-fold higher than the parent cell-line)
had similar sensitivity to AT13387. Table 1: Anti-proliferative 
activity of AT13387 
• Treatment of pancreatic cancer cells with AT13387 resulted in significant
down-regulation of phospho-S6 ribosomal protein and Raf -1 (both P<0.01)
and Akt/PKB, CDK4, phosphorylated -Erk and phosphorylated-Akt (all
P<0.001).
• In vivo down-regulation of CDK, phospho-S6 ribosomal protein and Akt was
observed in tumours from mice 19hrs but not 2hrs after dosing.
• Significant up-regulation of co-chaperone Hsp70 was also observed following
treatment with AT13387 in vitro (P=0.02) and in vivo.
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METHODS
• Cell proliferation assays performed in triplicate using EZ4U assay (BioMedica), 48 or 72 hrs after  
treatment. 
• Cell cycle analysis was performed 4,7,24 and 48hrs after treatment of cells with 250nM AT13387 using 
flow cytometry to determine propidium iodide incorporation.
• Apoptosis was assessed using Annexin-FITC vs propidium iodide staining and flow cytometry 7,13,24 
and 48hrs after treatment of cells with 250nM AT13387.
• Western blot analysis was performed using standard methods with ECL detection.
• Tolerability and efficacy of AT13387 assessed in Xenograft model (BALB/c (CAnN.Cg-Foxn1nu/Cr) nude 
mice and miapaca2 cells). Tumour volumes measured with external callipers.
• Statistical analysis was performed in SPSS and Statview. P values reported from T-tests. 
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Figure 4: Effects of AT13387 treatment on Hsp90
client proteins and co-chaperone Hsp70 in A)
Miapaca2 cells (18hrs after treatment) and B)
miapaca2 xenograft tumours: C1 and C2 cyclodextrin
control animals; T1, tumor removed 2hrs and T2,
tumour removed 19hrs, after 80mg/kg AT13387.
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CONCLUSION
AT13387 inhibits growth of pancreatic cancer cell lines, including those
resistant to gemcitabine, and suppresses the expression of Hsp90 client
proteins. In vivo AT13387 slows tumour growth and further investigations
will determine if AT13387 can improve inhibition of tumour growth when
used in combination with gemcitabine.
Untreated 
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Figure 1:  The effects of AT13387 on cell cycle distribution in A) Suit-2 and B) Suit-2 GR cells.  C) 
Analysis of apoptosis 24hrs after AT13387 treatment of Suit-2 cells; similar results were observed 
at 7, 13, 48 hours post  drug treatment. 
AT13387 treatment slows tumour growth in vivo
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Figure 2: AT13387 tolerability: daily weights of mice
treated with AT13387(A). Example of exponential
regression curves of tumour growth in animal treated
with AT13387(B), or with vehicle control(C). Drug
administered once weekly at 80mg/kg. Exponential
regression analysis was used to fit a curve to data points
before treatment and over the first 10 days of treatment
and assign coefficients. Treatment groups were compared
using paired T-test (6 mice per group). Arrow marks start of
treatment.
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BACKGROUND
• Pancreatic cancer continues to have a poor prognosis with over 7700 deaths in the
UK per year.
• Gemcitabine the main standard of treatment for pancreatic cancer is still relatively
ineffective.
• Heat shock protein 90 (Hsp90), a molecular chaperone required for the stability and
function of signalling proteins that promote growth and/or survival of cancer cells,
affects a number of key pathways identified to be important in cancer, including the
PI3K/Akt and MAPK pathways [1].
• AT13387 (Astex therapeutics), a novel Hsp90 inhibitor, has efficacy against
melanoma, AML, colon and lung carcinoma in xenograft models and in a variety of
cancer types in vitro (IC50 10-400nM) [2].
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The	 combination	 of	 AT13387	 and	 gemcitabine	 showed	 similar	 effects	 to	 that	 of	
AT13387	 alone	 (figure	 4.44).	 	 Again	 when	 gemcitabine	 and	 AT13387	 were	 given	
sequentially	 the	 same	 decreased	 protein	 expression	 was	 observed	 but	 this	 was	
noted	at	decreased	concentrations	of	AT13387	(figure	4.45).	
	
Figure	 4.44	A	 figure	 showing	 the	 combination	 treatment	 of	 agents	 –	 A	western	
blot	assay	of	protein	extracts	 from	pancreatic	cancer	cell	 line	Miapaca-2	treated	
with	 AT13387	 (1.	 10nM,	 2.	 25nM,	 3.	 100nM,	 4.	 250nM,	 5.	 1000nM)	 or	 media	
control	 as	 a	 single	 agent	or	AT13387	with	 gemcitabine	 (500nM)	 for	 18	hours.	G	
represents	treatment	with	gemcitabine	500nM	alone.	The	blots	were	probed	with	
CDK4	antibody.		
	
CDK4%
					Without	gem	è 										with	gem	è 		
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Figure	4.45	A	 figure	 showing	 the	sequential	addition	of	agents	–	A	western	blot	
assay	of	protein	extracts	from	pancreatic	cancer	cell	 line	Miapaca-2	treated	with	
AT13387	(1.	10nM,	2.	25nM,	3.	100nM,	4.	250nM,	5.	1000nM)	or	media	control	as	
a	 single	 agent	 or	 AT13387	 with	 Gemcitabine	 (500nM)	 for	 18	 hours.	 	 For	
combination	study	cells	were	 treated	with	gemcitabine	 for	24	hrs	 then	AT13387	
was	added	for	24hrs.	The	blot	was	probed	with	CDK4	antibody.			
	
CONCLUSION	
AT13387	 reduced	 the	 protein	 expression	 levels	 of	 CDK4,	 the	 effect	 on	 protein	
expression	 was	 more	 marked	 when	 cells	 were	 treated	 sequentially	 with	
gemcitabine	followed	by	AT13387	and	observed	at	lower	doses	of	AT13387.	
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4.5.2.5	HSP70	protein	expression	
	
HSP70	is	a	heat	shock	protein	that	as	a	molecular	chaperone	accumulates	in	cells	at	
times	 of	 cellular	 stresses,	 including	 oncogenic	 transformation.	 	 HSP70	 is	 a	 co	
chaperone	to	HSP90	inhibition.	
	
A	 significant	 increase	 in	 HSP70	 was	 observed	 following	 treatment	 with	 AT13387	
(figure	4.46).	
	
	
Figure	4.46	A	western	blot	 assay	of	protein	extracts	 from	pancreatic	 cancer	 cell	
line	Miapaca-2	 treated	with	 AT13387	 (10nM-	 1000nM)	 or	media	 control	 for	 18	
hours	which	was	probed	with	HSP70	antibody.		
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• Administered as a single agent, AT13387 was tolerated in nude mice with no
mortality, persistent weight loss or other significant side effects.
• Although not significant the rate of tumour growth (as measured by coefficient of
exponential regression) was reduced with AT13387 treatment (n=6) compared to
vehicle treated controls (n=6) (p=0.073, pair T-test).
• AT13387 given in combination with Gemcitabine was also tolerated and on-going
experiments are investigating the inhibition of tumour growth with this
combination.
AT13387 inhibited the proliferation of a
number of pancreatic cancer cell lines.
• IC50 values for proliferation inhibition by
AT13387 ranged from 29 - 100nM (Table 1).
• Suit-2GR, a gemcitabine resistant cell line
derived from Suit-2 (with a gemcitabine IC50
value 60-fold higher than the parent cell-line)
had similar sensitivity to AT13387. Table 1: Anti-proliferative 
activity of AT13387 
• Treatment of pancreatic cancer cells with AT13387 resulted in significant
down-regulation of phospho-S6 ribosomal protein and Raf -1 (both P<0.01)
and Akt/PKB, CDK4, phosphorylated -Erk and phosphorylated-Akt (all
P<0.001).
• In vivo down-regulation of CDK, phospho-S6 ribosomal protein and Akt was
observed in tumours from mice 19hrs but not 2hrs after dosing.
• Significant up-regulation of co-chaperone Hsp70 was also observed following
treatment with AT13387 in vitro (P=0.02) and in vivo.
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METHODS
• Cell proliferation assays performed in triplicate using EZ4U assay (BioMedica), 48 or 72 hrs after  
treatment. 
• Cell cycle analysis was performed 4,7,24 and 48hrs after treatment of cells with 250nM AT13387 using 
flow cytometry to determine propidium iodide incorporation.
• Apoptosis was assessed using Annexin-FITC vs propidium iodide staining and flow cytometry 7,13,24 
and 48hrs after treatment of cells with 250nM AT13387.
• Western blot analysis was performed using standard methods with ECL detection.
• Tolerability and efficacy of AT13387 assessed in Xenograft model (BALB/c (CAnN.Cg-Foxn1nu/Cr) nude 
mice and miapaca2 cells). Tumour volumes measured with external callipers.
• Statistical analysis was performed in SPSS and Statview. P values reported from T-tests. 
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Figure 4: Effects of AT13387 treatment on Hsp90
client proteins and co-chaperone Hsp70 in A)
Miapaca2 cells (18hrs after treatment) and B)
miapaca2 xenograft tumours: C1 and C2 cyclodextrin
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CONCLUSION
AT13387 inhibits growth of pancreatic cancer cell lines, including those
resistant to gemcitabine, and suppresses the expression of Hsp90 client
proteins. In vivo AT13387 slows tumour growth and further investigations
will determine if AT13387 can improve inhibition of tumour growth when
used in combination with gemcitabine.
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AT13387
Figure 1:  The effects of AT13387 on cell cycle distribution in A) Suit-2 and B) Suit-2 GR cells.  C) 
Analysis of apoptosis 24hrs after AT13387 treatment of Suit-2 cells; similar results were observed 
at 7, 13, 48 hours post  drug treatment. 
AT13387 treatment slows tumour growth in vivo
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B
Figure 2: AT13387 tolerability: daily weights of mice
treated with AT13387(A). Example of exponential
regression curves of tumour growth in animal treated
with AT13387(B), or with vehicle control(C). Drug
administered once weekly at 80mg/kg. Exponential
regression analysis was used to fit a curve to data points
before treatment and over the first 10 days of treatment
and assign coefficients. Treatment groups were compared
using paired T-test (6 mice per group). Arrow marks start of
treatment.
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BACKGROUND
• Pancreatic cancer continues to have a poor prognosis with over 7700 deaths in the
UK per year.
• Gemcitabine the main standard of treatment for pancreatic cancer is still relatively
ineffective.
• Heat shock protein 90 (Hsp90), a molecular chaperone required for the stability and
function of signalling proteins that promote growth and/or survival of cancer cells,
affects a number of key pathways identified to be important in cancer, including the
PI3K/Akt and MAPK pathways [1].
• AT13387 (Astex therapeutics), a novel Hsp90 inhibitor, has efficacy against
melanoma, AML, colon and lung carcinoma in xenograft models and in a variety of
cancer types in vitro (IC50 10-400nM) [2].
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When	 Miapaca-2	 cells	 were	 treated	 with	 AT13387	 plus	 gemcitabine	 the	 same	
effects	 were	 observed.	 	 There	 was	 no	 noted	 difference	 between	 combination	
therapy	and	sequential	addition	of	agents	(figure	4.47	and	4.48).	
	
	
	
Figure	4.47	A	figure	showing	the	combination	experiments-		A	western	blot	assay	
of	 protein	 extracts	 from	 pancreatic	 cancer	 cell	 line	 Miapaca-2	 treated	 with	
AT13387	(1.	10nM,	2.	25nM,	3.	100nM,	4.	250nM,	5.	1000nM)	or	media	control	as	
a	single	agent	or	AT13387	with	gemcitabine	(500nM)	for	18	hours.	G18	represents	
treatment	 with	 gemcitabine	 500nM	 alone.	 The	 blots	 were	 probed	 with	 HSP70	
antibody.			
	
	
	
HSP70&
&
Β(ac+n&
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Figure	4.48	A	 figure	 showing	 the	sequential	addition	of	agents	–	A	western	blot	
assay	of	protein	extracts	from	pancreatic	cancer	cell	 line	Miapaca-2	treated	with	
AT13387	(1.	10nM,	2.	25nM,	3.	100nM,	4.	250nM,	5.	1000nM)	or	media	control	as	
a	 single	 agent	 or	 AT13387	 with	 gemcitabine	 (500nM)	 for	 18	 hours.	 	 For	
combination	study	cells	were	 treated	with	gemcitabine	 for	24	hrs	 then	AT13387	
was	added	for	24hrs.	The	blots	were	probed	with	HSP70	antibody.			
	
CONCLUSION	
Cells	 treated	 with	 AT13387	 showed	 upregulation	 of	 HSP70	 protein	 compared	 to	
control,	 the	 same	 effect	 of	 upregulation	 was	 observed	 in	 combination	 with	
gemcitabine	regardless	of	drug	scheduling.	
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4.5.2.6	Summary	of	AT13387	effects	
The	 table	 below	 summarises	 the	 effects	 seen	 on	 the	 protein	 expression	 of	 those	
tested	with	AT13387	or	the	combination	of	AT13387	and	gemcitabine.	
	
	
Protein	Marker	
	
Effect	on	protein	
expression	with	AT13387	
	
Effect	on	protein	expression	with	
AT13387	+	Gemcitabine	
Akt	 ê	 ê	
Phospho	Akt	 ê	 ê	
S6	 çè	 çè	
Phospho	S6	 ê	 êê	
Raf-1	 ê	 êê	
CDK4	 ê	 êê	
HSP70	 é	 é	
Table	4.6	A	summary	table	showing	the	protein	expression	effects	of	treatment	
with	AT13387	or	combination	treatment	with	AT13387	and	gemcitabine	(		ê	
represents	downregulation,		é	represents	upregulation,		çè	represents	no	
change	in	protein	expression).	
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CHAPTER	5:	RESULTS	IN	VIVO	
	
In	vivo	studies	with	agents	AT7519,	AT13387,	gemcitabine	and	matched	treatment	
controls	 were	 undertaken	 using	 6-8	 week	 old	 BALB/c-Nude	 mice.	 	 Experiments	
examined	tumour	growth,	tolerability	and	efficacy	of	treatment.		
	
5.1	TUMOUR	GROWTH	EXPERIMENTS	
	
Initial	experiments	were	performed	to	establish	the	optimal	cell	line	to	take	forward	
into	the	xenograft	model.		Cell	line	characteristics	deemed	desirable	included	those	
which	would	 generate	 a	measurable	 tumour	 that	would	 grow	over	 an	 acceptable	
time	 frame	 in	 order	 to	 allow	 observations	 and	 detect	 any	 differences	 between	
control	groups	and	treatment	groups.	
	
The	cell	lines	tested	were	SUIT-2	and	Miapaca-2	from	stocks	frozen	down	as	per	the	
methodology	 section	 3.1.2.	 	 Four	 mice	 per	 group	 were	 inoculated	 with	
subcutaneous	tumours	to	each	shoulder	(see	table	5.1	and	5.2).	
	
Mice	 were	 injected	 on	 day	 0	 and	 observed	 for	 up	 to	 28	 days.	 	 Tumour	
measurements	 were	 performed	 by	 a	 single	 observer	 using	 calipers	 measuring	
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length,	 width	 and	 height	 of	 tumours,	 to	 establish	 tumour	 volume	 using	 the	
equation:	
	
(length	x	width	x	height)	x	0.5236	=	tumour	volume	
	
Mice	were	also	weighed	daily	and	general	observations	on	behavior	were	made.	
	
Both	cell	lines	produced	palpable	and	measurable	tumours	that	increased	in	size	in	
an	exponential	manner	(see	figure	5.1,	5.2	and	5.3).	Experiments	were	terminated	
when	experimental	end	points	were	reached:	tumours	exceeding	17mm	diameter,	
sustained	 weight	 loss	 (72	 hrs.)	 of	 >20%,	 displayed	 adverse	 behaviour/physical	
condition	 or	 the	 planned	 number	 of	 days	 reached	 relevant	 to	 the	 experiment	
(detailed	in	section	3.2).	
	
Of	 the	 4	 SUIT-2	mice,	 2	 were	 sacrificed	 at	 day	 19	 owing	 to	 tumour	 volume	 and	
tumour	ulceration,	one	was	sacrificed	on	day	23	owing	to	tumour	volume	and	the	
last	sacrificed	at	the	experimental	endpoint	of	day	28,	the	tumour	was	noted	to	be	
ulcerated	at	this	point.	
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Of	the	4	Miapaca-2	mice	three	were	sacrificed	on	day	23	owing	to	tumour	volumes	
and	one	reached	28	days.	
Subject	 Right	shoulder	 Left	shoulder	 Notes	
Mouse	1	 200μl	injection	 200μl	injection	 Hematoma	from	right	
injection	
	
Mouse	2	 200μl		injection	 200μl	injection	
	
	
	
Mouse	3	 200μl	injection	 200μl	injection	 Small	loss	left	
	
	
Mouse	4	 200μl	injection	 200μl	injection	 Small	loss	left	
	
	
Table	5.1	A	table	showing	the	injections	of	Miapaca-2	tumours	of	4	mice	of	200μl	
per	tumour.	The	site	of	injections,	volumes	and	any	notes/complications	shown.	
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Subject	 Right	shoulder	 Left	shoulder	 Notes	
Mouse	1	 200μl	injection	 200μl	injection	
	
	
	
Mouse	2	 200μl	injection	 200μl	injection	 Small	loss	both	sides	
	
	
Mouse	3	 200μl	injection	 175μl	injection	 Bleed	on	injection	to	left,	
last	15μl	not	injected	
	
Mouse	4	 150μl	injection	 150μl	injection	 Not	enough	tumour	
suspension	left	therefore	
150μl	both	sides	
Table	5.2	A	table	showing	the	injections	of		SUIT-2	tumours	of	4	mice	of	200μl	per	
tumour.	The	site	of	injections,	volumes	and	any	notes/complications	shown.	
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Figure	5.1	A	graph	showing	the	individual	tumour	growth	of	8	tumours	(four	mice,	
2	 tumours	 per	mouse)	 generated	 from	 SUIT-2	 tumour	matrix.	 The	 x-axis	 shows	
time	from	injection	of	cells	in	days,	the	y-axis	shows	the	tumour	volumes	in	mm3.		
Each	 green	 dashed	 line	 represents	 an	 individual	 tumour.	 	 The	 graph	 shows	
tumours	becoming	measurable	at	day	6	and	growth	of	tumours,	the	majority	in	an	
exponential	manner.	
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	Figure	 5.2	 A	 graph	 showing	 the	 individual	 tumour	 growth	 of	 8	 tumours	 (four	
mice,	2	tumours	per	mouse)	generated	from	Miapaca-2	tumour	matrix.	The	x-axis	
shows	time	from	injection	of	cells	in	days,	the	y-axis	shows	the	tumour	volumes	in	
mm3.		Each	green	dashed	line	represents	an	individual	tumour.		The	graph	shows	
tumours	becoming	measurable	at	day	13	and	growth	of	tumours	in	an	exponential	
manner.	
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Figure	 5.3	 A	 graph	 showing	 the	mean	 tumour	 growth	 of	 all	 tumours	 generated	
from	Miapaca-2		and	SUIT-2	tumour	matrix	injections.		The	x-axis	shows	time	from	
injection	 of	 cells	 in	 days,	 the	 y-axis	 shows	 tumour	 volume	 in	 mm3.	 The	 graph	
shows	 exponential	 tumour	 growth	 demonstrated	 by	 both	 tumour	 cell	 lines	 and	
SUIT-2	 cells	 becoming	 measurable	 around	 day	 6	 whilst	 Miapaca-2	 tumours	
became	measurable	at	day	13.		
	
	
Post	 sacrifice	 tumours	 were	 harvested	 and	 examined	 by	 a	 pathologist	 (Dr	 F	
Campbell)	to	examine	tumour	characterisitics.	
	
SUIT-2	tumours	grew	in	a	fashion	generating	more	rounded	tumours	with	a	greater	
height	 compared	 to	 miapaca	 tumours.	 	 This	 allowed	 earlier	 detection	 and	
mesurements	 to	 be	 performed	 at	 6-7	 days	 post	 injection.	 	 At	 the	 later	 stages	 of	
tumour	 growth	 tumours	 became	 more	 fluctuant	 centrally	 with	 collapse	 that	
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effected	 tumour	 measurements.	 	 In	 the	 SUIT-2	 group	 2	 animals	 needed	 to	 be	
sacrificed	owing	to	 this	phenomenon	 leading	to	 tumour	ulceration.	 	On	dissection	
there	 was	 a	 central	 exudate	 (ranging	 from	 pus	 like	 to	 watery),	 tumours	 were	
centrally	hollow	with	largely	peripheral	vascularisation.		Histologically	necrosis	was	
observed	(see	figure	5.4,	slide	A).	
	
Miapaca-2	 tumours	 grew	 in	 a	 flatter	 more	 nodular	 manner	 compared	 to	 SUIT-2	
tumours.		Each	tumour	was	composed	of	multiple	smaller	growths	that	were	firmily	
adhered	to	each	other	as	shown	in	figure	5.4,	slide	B.		Some	nodules	grew	at	a	small	
distance	 from	 the	 central	 tumours.	 	 After	 dissection	 less	 necrosis	 was	 observed	
compared	to	SUIT-2	tumours	with	an	absence	of	central	necrosis.	
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Figure	5.4		Photographs	of	histopathology	slides	of	the	tumours	generated.	
A)	A	SUIT-2	tumour	showing	central	tumour	necrosis	.	
B)	A	Miapaca-2	tumour	showing	tumours	consisting	of	multiple	nodules.	
	
	
CONCLUSION	
	
After	taking	into	account	the	characteristics	of	each	cell	line,	further	experiments	in	
the	xenograft	model	were	performed	using	the	Miapaca-2	cell	line.		This	was	owing	
to	the	more	uniform	growth	observed	without	necrosis	and	subsequent	depression	
of	tumours	that	could	effect	tumour	growth	calculations	in	future	experiments.		The	
characteristic	observed	in	the	SUIT-2	tumours	of	developing	ulceration	in	half	of	the	
subjects	was	also	deemed	undesirable	in	future	experiments.	
Suit2&Tumour&histopathology&MiaPaCa&
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5.2	VALIDATION	OF	TUMOUR	MEASUREMENT	
In	 order	 to	 ensure	 validity	 of	 tumour	measurements	 taken	 in	 subsequent	 studies	
comparison	was	made	between	measurements	of	tumours	performed	in	vivo	verses	
ex	vivo.			
	
	
Figure	 5.5	A	 graph	 showing	ex	 vivo	 correlation	of	 tumour	 volume	and	mass	 (16	
tumours	 total,	 8	 mice	 with	 2	 tumours	 per	 animal).	 The	 x-axis	 shows	 tumour	
volume	ex	 vivo	 in	mm3	and	 the	 y-axis	 shows	 tumour	mass	 in	 grams.	 	 Pearson’s	
correlation	data	shown.			
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Figure	5.6	A	graph	showing	correlation	of	tumour	volume	calculations	in	vivo	and	
ex	vivo	 (16	 tumours	 total,	 8	mice	with	2	 tumours	per	animal).	 The	x-axis	 shows	
tumour	volumes	ex	vivo	 in	mm3	and	the	y-axis	shows	tumour	volumes	 in	vivo	 in	
mm3,	Pearson’s	correlation	data	shown.		
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Figure	5.7	A	graph	showing	correlation	of	tumour	volume	calculations	in	vivo	with	
tumour	mass	ex	vivo	(16	tumours	total,	8	mice	with	2	tumours	per	animal).		The	x-
axis	shows	tumour	mass	ex	vivo	in	grams	and	the	y-axis	shows	tumour	volume	in	
vivo	in	mm3.		
	
The	comparative	 results	of	 in	vivo	measurements	with	ex	vivo	measurements	and	
weights	were	plotted	for	each	tumour	generated	and	the	Pearson	product-moment	
correlation	coefficient	was	calculated	to	measure	the	linear	correlation	between	the	
variables.	 	 The	 ex	 vivo	measurements	 of	 tumour	 volume	 correlated	with	 tumour	
mass	 ex	 vivo	 shown	 in	 figure	 5.5.	 	 The	 results	 showed	 a	 positive	 correlation	
between	the	in	vivo	measurements	and	both	the	ex	vivo	tumour	measurements	and	
weight	measurements	(shown	in	figure	5.6	and	5.7).		The	correlation	was	not	strong	
but	none-the	less	a	positive	correlation.	
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CONCLUSION	
Measurements	confirmed	that	there	was	a	positive	correlation	between	the	in	vivo	
measurements	 performed	 and	 the	 ex	 vivo	 measurements	 obtained.	 The	
relationship	between	mass	and	volume,	although	significant,	was	weak.	 Indicating	
the	 heterogeneity	 of	 the	 tumours,	 but	 this	 does	 not	 detract	 from	 validity	 of	 the	
caliper	 measurements,	 which	 on	 this	 basis	 can	 be	 considered	 to	 be	 a	 justified	
measure	 of	 the	 expansion	 of	 the	 tumour	 (albeit	 not	 the	 only	 way	 this	 could	 be	
assessed).	 To	 ensure	 minimal	 variation	 in	 the	 results	 obtained	 a	 single	 observer	
performed	caliper	measurements	throughout	all	experiments	(AT).	
	
5.3	SINGLE	AGENT	TOLERABILITY	STUDIES	
	
5.3.1	Gemcitabine	single	agent	tolerability	
	
The	 gemcitabine	 tolerability	 for	 this	 model	 was	 tested	 in	 3	 non	 tumour-bearing	
mice.		The	dose	of	gemcitabine	trialed	was	based	on	previous	literature	experience	
in	pancreatic	xenograft	models.		The	dose	of	100mg/kg	twice	per	week	was	tested	
for	a	total	treatment	period	of	14	days.		During	the	treatment	an	initial	fall	in	weight	
was	 observed	 that	 decreased	with	 further	 doses	 of	 gemcitabine	 (shown	 in	 figure	
5.8).		No	animal	had	to	be	sacrificed	due	to	this	weight	loss.		As	a	single	agent	this	
was	deemed	the	maximal	tolerated	dose	of	gemcitabine	but	owing	to	the	fact	that	
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gemcitabine	would	be	used	in	combination	studies	the	decision	was	made	to	use	a	
decreased	 dose	 of	 50mg/kg	 twice	 per	 week	 in	 future	 studies.	 This	 avoided	
significant	weight	loss	that	might	have	prevented	the	experimental	end	point	being	
reached.	
	
	
	
Figure	 5.8	 A	 graph	 showing	 gemcitabine	 tolerability:	 the	 x-axis	 shows	 time	 of	
experiment	 in	 days,	 the	 y-axis	 shows	 mouse	 weight	 in	 grams.	 	 The	 crosses	
represent	a	dose	of	gemcitabine.	 	Lines	of	best	fit	were	produced	with	a	2-point	
moving	 average.	 3	 mice	 were	 dosed	 at	 100mg/kg	 twice	 per	 week	 with	
gemcitabine.		
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CONCLUSION	
Gemcitabine	was	tolerated	 in	the	nude	mice	tested.	 	The	dose	of	100mg/kg	twice	
per	week	did	result	in	a	non-sustained	drop	in	weight	of	the	3	mice.		Initial	weight	
loss	was	observed	that	became	less	marked	with	subsequent	dosing.	No	weight	loss	
exceeded	 greater	 than	 20%	 body	weight,	 which	would	 have	 necessitated	 subject	
sacrifice.	
	
5.3.2	AT7519	single	agent	tolerability	
The	tolerability	of	AT7519	treatment	was	established	in	non-tumour	bearing	mice.		
3	mice	per	group	were	used.		The	maximum	dose	and	dosing	regimen	was	used	as	
per	 the	 experience	 of	 Astex	 pharmaceuticals	 in	 other	 in	 vivo	models	 of	 AT7519;	
7.5mg/kg	(Saline	vehicle)	twice	per	day	for	5	days	per	7	day	treatment	period.		The	
total	treatment	time	was	14	days.		Animal	sacrifice	was	performed	after	the	14	day	
treatment	period,	or	sooner	if	animals	lost	weight	of	>20%	sustained	over	72	hours,	
or	 if	 they	 experienced	 significant	 side	 effects.	 	 	 One	 animal	 died	 on	 day	 6	 of	
treatment.	 	 Necropsy	 performed	 established	 an	 intra-abdominal	 hemorrhage,	
therefore	this	animal	died	owing	to	an	iatrogenic	injury	from	IP	injection	rather	than	
a	drug	effect.		There	were	no	other	significant	side	effects	or	adverse	events.	
On	analysis	of	the	data	AT7519	at	this	dosing	was	well	tolerated	with	no	significant	
weight	loss	(shown	in	figure	5.9).	
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Figure	 5.9	 A	 graph	 showing	 AT7519	 tolerability:	 The	 x-axis	 shows	 time	 of	
experiment	 in	 days,	 the	 y-axis	 shows	 mouse	 weight	 in	 grams.	 	 The	 crosses	
represent	 a	 dose	 of	 AT7519.	 	 Lines	 of	 best	 fit	 were	 produced	 with	 a	 2-point	
moving	average.	3	mice	were	dosed	at	7.5mg/kg	BD	for	5	days	per	7	day	period	
with	AT7519.		
	
CONCLUSION	
AT7519	was	well	 tolerated	with	no	weight	 loss	observed	at	7.5mg/kg	5	 times	per	
week.		This	dose	was	deemed	appropriate	to	take	forward	into	single	agent	efficacy	
studies.		
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ASSESSMENT OF THE CDK INHIBITOR AT7519 IN A XENOGRAFT 
MODEL OF PANCREATIC CANCER 
•  Pancreatic cancer continues to have a poor prognosis with over 70 000 deaths reported in Europe (2008). 
•  Chemotherapy is the treatment of choice in advanced disease and has a proven role in the adjuvant setting 
though current clinical agents, such as gemcitabine,  only prolong survival by a matter of weeks;  highlighting 
the need for more effective novel therapies 
•  The Cyclin Dependent Kinase (CDK)  family of protein kinases are pivotal 
  in cell cycle regulation 
•  AT7519 is a selective CDK inhibitor providing potent inhibition of CDK 1, 2, 4, 5 and 9 (Astex Therapeutics).  
Figures 3: Tumour volumes in mice treated with vehicle control (A), AT7519 (B) and 
gemcitabine (C).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 
AT7519 group than the control group (p=0.045). 
Initial xenograft experiments of AT7519 as a single agent showed 
a significant reduction in tumour growth compared with vehicle 
control 
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Figure 1: Individual mice weights (g) for 3 mice 
dosed at  7.5mg/kg twice daily, weekdays for 2 
weeks with 7519.  
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Figure 2: Individual mouse weights (g) for 3 mice dosed 
with  50mg/kg of gemcitabine twice per week and 
7.5mg/kg of AT7519 twice daily for 5 days.  Total 
treatment of 2 weeks. 
METHODS 
•  Cell proliferation assays  and isobolar analysis were performed in triplicate using 
EZ4U assay (BioMedica), measured 48 h or 72 h after drug treatment.  
•  Cell cycle analysis was performed 4 h,7 h,24 h and 48h after treatment of cells 
with 10mM AT7519, using flow cytometry to determine propidium iodide 
incorporation. 
•  Western blot analysis was performed using standard methods with ECL 
detection. 
•  Statistical analysis was performed using SPSS. 
•  In vivo studies using a murine xenograft model, BALB/c (CAnN.Cg-Foxn1nu/Cr) 
nude mice with MiaPaCa2 pancreatic cancer cells, tumour volumes measured 
with external callipers.!
A xenograft model of AT7519 in combination with gemcitabine showed 
superior reduction in tumour growth compared with gemcitabine and 
AT7519 as single agents and vehicle control 
   AT7519 inhibited the proliferation 
of a range of pancreatic cancer cell 
lines with  IC50 values from 0.2– 
2uM    
Figure 7: Anti-proliferative activity of 
AT17519 
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Cell! lines! resistant! to! gemcitabine! do! not! appear! to! be!
resistant!to!AT7519:!SuitT2!GR!(a!gemcitabine!resistant!cell!
line)! has! a! 60! fold! higher! gemcitabine! IC50! and! an!
equivalent!IC50!with!AT7519.!
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CFpac! 180nM! 180nM!
FamPac! 210nM! 5.5nM!
Paca!2! 250nM! 5nM!
   Cell cycle analysis displayed a marked reduction 
of cells in the G0/G1 and S phases with an 
increase of cells in G2/M phase following 
treatment with AT7519 compared to 
untreated(p<0.0001) 
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Figure 8: Effects of AT7519 on cell cycle distribution of 
Suit-2 pancreatic cancer cell line. 
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 Isobolar analysis of AT7519 combined 
with gemcitabine suggested an additive 
effect 
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Figure 9: Isobolar graph of cells treated with 
gemcitabine for 24 h followed by combination of 
gemcitabine + AT7519 for 48 h.  
The line represents an additive effect.  The area 
under the curve would be lower if there was 
synergy and greater if there was antagonism. 
CONCLUSIONS(
Pancrea7c!cancer!cell!lines!develop!resistance!to!gemcitabine!(standard!chemotherapy)!aZer!rela7vely!brief!exposure!to!the!drug.!!!AT7519!inhibited!growth!
in!a!range!of!pancrea7c!!cancer!cell!lines!including!one!that!has!acquired!gemcitabine!resistance!and!was!eﬀec7ve!in!combina7on!with!gemcitabine.!
In!vivo!AT7519!was!eﬀec7ve!as!a!single!agent!in!a!xenograZ!model!and!had!superior!eﬀect!in!combina7on!with!gemcitabine!oﬀering!possible!future!
combina7on!therapy.!
AT7519(is((a(promising(agent(for(further(invesSgaSon(to(overcome(the(problem(of(acquired(gemcitabine(resistance(in(pancreaSc(cancer.!!!
!
PhosphoTpp1Tα!
Rb!
PhospoTRb!
0 0+
D
M
S
O
 
1u
M
  
2u
M
  
5u
M
  
10
uM
  
Example!βTac7n!
• Cell!cycle!analysis!supports!an!AT7519!G2/M!block!(as!!expected!if!cdc2!
ac7vity!is!inhibited).!!!
!
• CDK1!levels!were!unchanged,!but!phosphoryla7on!of!!pp1Ta!was!inhibited!
(shown!to!result!in!mito7c!collapse!!aZer!nuclear!envelope!breakdown)!
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Figure 10: Effects of 
AT7519 on Suit- 2 
cells treated with 
AT7519 for 48 h. 
Western blot analysis demonstrated the effect 
on downstream targets of AT7519 
pp1Tα!
AT7519 was well tolerated as a single 
agent and in combination with 
gemctiabine in nude mice with no 
significant morbidity or mortality 
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Figures 5: Tumour volumes in mice treated with Saline vehicle control(A) and Gemcitabine 
+ AT7519 (B).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 
combination treatment  group than the control group (p=0.0041). 
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ASSESSMENT OF THE CDK INHIBI OR AT7519 IN A XENOGRAFT 
MODEL OF PANCREATIC CANCER 
•  Pancreatic cancer continues to have a poor prognosis with over 70 000 deaths reported in Europe (2008). 
•  Chemotherapy is the treatment of choice in advanc d disease and has a proven role in the adjuvant setting 
though current clinical agents, such as gemcitabin ,  only prolong survival by a matter of weeks;  highlighting 
the need for more effective novel therapies 
•  The Cyclin Dependent Kinase (CDK)  family of protein kinases are pivotal 
  in cell cycle regulation 
•  AT 519 is a selective CDK inhibito  providin  pot nt in ibition of CDK 1, 2, 4, 5 and 9 (Astex Therapeutics).  
Figures 3: Tumour volumes in mice treated with vehicle control (A), AT7519 (B) and 
gemcitabine (C).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 
AT7519 group than the control group (p=0.045). 
Initial xenograft experiments of AT7519 as a single agent showed 
a significant reduction in tumour growth compared with vehicle 
control 
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Figure 1: Individual mice weights (g) for 3 mice 
dosed at  7.5mg/kg twice daily, weekdays for 2 
weeks with AT7519.  
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Figure 2: Individual mouse weights (g) for 3 mice dosed 
with  50mg/kg of gemcitabine twice per week and 
7.5mg/kg of AT7519 twice daily for 5 days.  Total 
treatment of 2 weeks. 
METHODS 
•  Cell proliferation assays  and isobolar analysis were performed in triplicate using 
EZ4U assay (BioMedica), measured 48 h or 72 h after drug treatment.  
•  Cell cycle analysis was performed 4 h,7 h,24 h and 48h after treatment of cells 
with 10mM AT7519, using flow cytometry to determine propidium iodide 
incorporation. 
•  Western blot analysis was performed using standard methods with ECL 
detection. 
•  Statistical analysis was performed using SPSS. 
•  In vivo studies using a murine xenograft model, BALB/c (CAnN.Cg-Foxn1nu/Cr) 
nude mice with MiaPaCa2 pancreatic cancer cells, tumour volumes measured 
with external callipers.!
A xenograft model of AT7519 in combination with gemcitabine showed 
superior reduction in tumour growth compared with gemcitabine and 
AT7519 as single agents and vehicle control 
   AT7519 inhibited the proliferation 
of a range of pancreatic cancer cell 
lines with  IC50 values from 0.2– 
2uM    
Figure 7: Anti-proliferative activity of 
AT17519 
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Cell! lines! resistant! to! gemcitabine! do! not! appear! to! be!
resistant!to!AT7519:!SuitT2!GR!(a!gemcitabine!resistant!cell!
line)! has! a! 60! fold! higher! gemcitabine! IC50! and! an!
equivalent!IC50!with!AT7519.!
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Figure 8: Effects of AT7519 on cell cycle distribution of 
Suit-2 pancreatic cancer cell line. 
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Figure 9: Isobolar graph of cells treated with 
gemcitabine for 24 h followed by combination of 
gemcitabine + AT7519 for 48 h.  
The line represents an additive effect.  The area 
under the curve would be lower if there was 
synergy and greater if there was antagonism. 
CONCLUSIONS(
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Figure 10: Effects of 
AT7519 on Suit- 2 
cells treated with 
AT7519 for 48 h. 
Western blot analysis demonstrated the effect 
on downstream targets of AT7519 
pp1Tα!
AT7519 was well tolerated as a single 
agent and in combination with 
gemctiabine in nude mice with no 
significant morbidity or ortality 
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Figures 5: Tumour volumes in mice treated with Saline vehicle control(A) and Gemcitabine 
+ AT7519 (B).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 
combination treatment  group than the control group (p=0.0041). 
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MODEL OF PANCREATIC CANCER 
•  Pancreatic cancer continues to have a poor prognosis with over 70 000 deaths reported in Europe (2008). 
•  Chemotherapy is the treatment of choice in advanced disease and has a proven role in the adjuvant setting 
though current clinical agents, such as gemcitabine,  only prolong survival by a matter of weeks;  highlighting 
the need for more effective novel therapies 
•  The Cyclin Dependent Kinase (CDK)  family of protein kinases are pivotal 
  in cell cycle regulation 
•  AT7519 is a selective CDK inhibitor providing potent inhibition of CDK 1, 2, 4, 5 and 9 (Astex Therapeutics).  
Figures 3: Tumour volumes in mice treated with vehicle control (A), AT7519 (B) and 
gemcitabine (C).   
Log regression analysis gave coefficients that declined after tr atment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 
AT7519 group than the control group (p=0.045). 
Initial xenograft experiments of AT7519 as a single agent showed 
a significant reduction in tumour growth comp red with vehicle 
control 
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Figure 4: Mean difference in growth coefficients 
for treatments and controls. 
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Figure 1: Individual mice weights (g) for 3 mice 
dosed at  7.5mg/kg twice daily, weekdays for 2 
weeks with AT7519.  
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Figure 2: Individual mouse weights (g) for 3 mice dosed 
with  50mg/kg of gemcitabine twice per week and 
7.5mg/kg of AT7519 twice daily for 5 days.  Total 
treatment of 2 weeks. 
METHODS 
•  Cell proliferation assays  and isobolar analysis were performed in triplicate using 
EZ4U assay (BioMedica), measured 48 h or 72 h after drug treatment.  
•  Cell cycle analysis was performed 4 h,7 h,24 h and 48h after treatment of cells 
with 10mM AT7519, using flow cytometry to determine propidium iodide 
incorporation. 
•  Western blot analysis was performed using standard methods with ECL 
detection. 
•  Statistical analysis was performed using SPSS. 
•  In vivo studies using a murine xenograft model, BALB/c (CAnN.Cg-Foxn1nu/Cr) 
nude mice with MiaPaCa2 pancreatic cancer cells, tumour volumes measured 
with external callipers.!
A xen graft mo el of AT7519 in combination with gemcitabine showed 
superior reduction in tumour growth compared with gemcitabine and 
AT7519 as single agents and vehicle control 
   AT7519 inhibited the proliferation 
of a range of pancreatic cancer cell 
lines with  IC50 values from 0.2– 
2uM    
Figure 7: Anti-proliferative activity of 
AT17519 
!!!!
Cell! lines! resistant! to! gemcitabine! do! not! appear! to! be!
resistant!to!AT7519:!SuitT2!GR!(a!gemcitabine!resistant!cell!
line)! has! a! 60! fold! higher! gemcitabine! IC50! and! an!
equivalent!IC50!with!AT7519.!
Cell(line( IC50(AT7519( IC50(
G m itabine(
SuitT2! 2000nM! 10nM!
SuitT2!(GR)! 700nM! 625nM!
MiapacaT2! 390nM! 25nM!
PancT1! 275nM! 150nM!
CFpac! 180nM! 180nM!
FamPac! 210nM! 5.5nM!
Paca!2! 250nM! 5nM!
   Cell cycle analysis displayed a marked reduction 
of cells in the G0/G1 and S phases with an 
increase of cells in G2/M phase following 
treatment with AT7519 compared to 
untreated(p<0.0001) 
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Figure 8: Effects of AT7519 on cell cycle distribution of 
Suit-2 pancreatic cancer cell line. 
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 Isobolar analysis of AT7519 combined 
with gemcitabine suggested an additive 
effect 
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Figure 9: Isobolar graph of cells treated with 
gemcitabine for 24 h followed by combination of 
gemcitabine + AT7519 for 48 h.  
The line represents an additive effect.  The area 
under the curve would be lower if there was 
synergy and greater if there was antagonism. 
CONCLUSIONS(
Pancrea7c!cancer!cell!lines!develop!resistance!to!gemcitabine!(standard!chemotherapy)!aZer!rela7vely!brief!exposure!to!the!drug.!!!AT7519!inhibited!growth!
in!a!rang !of!pancrea7c!!cancer!cell!lines!including!one!that!has!acquired!gemcitabine!resistance!and!was!eﬀec7ve!in!combin 7on!with!gemcitabine.!
In!vivo!AT7519!was!eﬀec7ve!as!a!single!agent!in!a!xenograZ!model!and!had!superior!eﬀect!in!combina7on!with!gemcitabine!oﬀering!possible!future!
combina7on!therapy.!
AT7519(is((a(promising(agent(for(further(invesSgaSon(to(overcome(the(problem(of(acquired(gemcitabine(resistance(in(pancreaSc(cancer.!!!
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• Cell!cycle!analysis!supports!an!AT7519!G2/M!block!(as!!expected!if!cdc2!
ac7vity!is!inhibited).!!!
!
• CDK1!levels!were!unchanged,!but!phosphoryla7on!of!!pp1Ta!was!inhibited!
(shown!to!result!in!mito7c!collapse!!aZer!nuclear!envelope!breakdown)!
!
Figure 10: Effects of 
AT7519 on Suit- 2 
cells treated with 
AT7519 for 48 h. 
Western blot analysis demonstrated the effect 
on downstream targets of AT7519 
pp1Tα!
AT7519 was well tolerated as a single 
agent and in combination with 
gemctiabine in nude mice with no 
significant morbidity or mortality 
!
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5.3.3	AT13387	single	agent	tolerability	
The	 tolerability	 of	 AT13387	 was	 established	 in	 3	 non-tumour	 bearing	mice.	 	 The	
dose	 used	 was	 80mg/kg	 once	 per	 week	 based	 on	 the	 experiments	 of	 Astexs	
pharmaceuticals	in	other	in	vivo	solid	organ	malignancy	studies.	The	total	treatment	
time	 was	 14	 days.	 	 Animal	 sacrifice	 was	 performed	 after	 the	 14	 day	 treatment	
period	 or	 sooner	 if	 animals	 lost	 weight	 of	 >20%	 sustained	 over	 72	 hours,	 or	
experienced	significant	side	effects.				
There	was	no	significant	weight	loss	or	adverse	events	experienced	with	this	dosing	
regime.	 	 The	dose	of	 80mg/kg	once	weekly	was	 tolerated	 in	 non	 tumour	 bearing	
mice	(data	shown	in	figure	5.10).	
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Figure	 5.10	 A	 graph	 showing	 AT13387	 tolerability:	 the	 x-axis	 shows	 time	 of	
experiment	 in	 days,	 the	 y-axis	 shows	 mouse	 weight	 in	 grams.	 	 The	 crosses	
represent	 a	 dose	 of	 AT13387.	 	 Lines	 of	 best	 fit	 were	 produced	 with	 a	 2	 point	
moving	average.	3	mice	were	dosed	at	80mg/kg	once	weekly	with	AT7519.		
	
CONCLUSION	
AT13387	 was	 well	 tolerated	 at	 80mg/kg	 once	 per	 week	 in	 non-tumour	 bearing	
animals	 therefore	 was	 deemed	 acceptable	 to	 take	 forward	 to	 future	 efficacy	
studies.	
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• Administered as a single agent, AT13387 was tolerated in nude mice with no
mortality, persistent weight loss or other significant side effects.
• Although not significant the rate of tumour growth (as measured by coefficient of
exponential regression) was reduced with AT13387 treatment (n=6) compared to
vehicle treated controls (n=6) (p=0.073, pair T-test).
• AT13387 given in combination with Gemcitabine was also tolerated and on-going
experiments are investigating the inhibition of tumour growth with this
combination.
AT13387 inhibited the proliferation of a
number of pancreatic cancer cell lines.
• IC50 values for proliferation inhibition by
AT13387 ranged from 29 - 100nM (Table 1).
• Suit-2GR, a gemcitabine resistant cell line
derived from Suit-2 (with a gemcitabine IC50
value 60-fold higher than the parent cell-line)
had similar sensitivity to AT13387. Table 1: Anti-proliferative 
activity of AT13387 
• Treatment of pancreatic cancer cells with AT13387 resulted in significant
down-regulation of phospho-S6 ribosomal protein and Raf -1 (both P<0.01)
and Akt/PKB, CDK4, phosphorylated -Erk and phosphorylated-Akt (all
P<0.001).
• In vivo down-regulation of CDK, phospho-S6 ribosomal protein and Akt was
observed in tumours from mice 19hrs but not 2hrs after dosing.
• Significant up-regulation of co-chaperone Hsp70 was also observed following
treatment with AT13387 in vitro (P=0.02) and in vivo.
REFERENCES
[1] P. Workman, Cancer Letters 2004; 206, 149-157
[2] J. Lyons et al., EJC Supplements 2008; 6, 47
METHODS
• Cell proliferation assays performed in triplicate using EZ4U assay (BioMedica), 48 or 72 hrs after  
treatment. 
• Cell cycle analysis was performed 4,7,24 and 48hrs after treatment of cells with 250nM AT13387 using 
flow cytometry to determine propidium iodide incorporation.
• Apoptosis was assessed using Annexin-FITC vs propidium iodide staining and flow cytometry 7,13,24 
and 48hrs after treatment of cells with 250nM AT13387.
• Western blot analysis was performed using standard methods with ECL detection.
• Tolerability and efficacy of AT13387 assessed in Xenograft model (BALB/c (CAnN.Cg-Foxn1nu/Cr) nude 
mice and miapaca2 cells). Tumour volumes measured with external callipers.
• Statistical analysis was performed in SPSS and Statview. P values reported from T-tests. 
Hsp90 inhibition leads to cell cycle arrest in G0/G1 and G2/M phases of 
the cell cycle, but no clear evidence of apoptosis. Hsp90 downstream biomarkers are altered, following treatment 
with AT13387.
Figure 4: Effects of AT13387 treatment on Hsp90
client proteins and co-chaperone Hsp70 in A)
Miapaca2 cells (18hrs after treatment) and B)
miapaca2 xenograft tumours: C1 and C2 cyclodextrin
control animals; T1, tumor removed 2hrs and T2,
tumour removed 19hrs, after 80mg/kg AT13387.
Cell line IC50 (nM)
Suit-2 63
Suit-2GR 60
MiaPaCa-2 58
FamPac 42
Paca2 29
CFpac 100
Panc-1 50
CONCLUSION
AT13387 inhibits growth of pancreatic cancer cell lines, including those
resistant to gemcitabine, and suppresses the expression of Hsp90 client
proteins. In vivo AT13387 slows tumour growth and further investigations
will determine if AT13387 can improve inhibition of tumour growth when
used in combination with gemcitabine.
Untreated 
AT13387
Figure 1:  The effects of AT13387 on cell cycle distribution in A) Suit-2 and B) Suit-2 GR cells.  C) 
Analysis of apoptosis 24hrs after AT13387 treatment of Suit-2 cells; similar results were observed 
at 7, 13, 48 hours post  drug treatment. 
AT13387 treatment slows tumour growth in vivo
A
B
Figure 2: AT13387 tolerability: daily weights of mice
treated with AT13387(A). Example of exponential
regression curves of tumour growth in animal treated
with AT13387(B), or with vehicle control(C). Drug
administered once weekly at 80mg/kg. Exponential
regression analysis was used to fit a curve to data points
before treatment and over the first 10 days of treatment
and assign coefficients. Treatment groups were compared
using paired T-test (6 mice per group). Arrow marks start of
treatment.
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BACKGROUND
• Pancreatic cancer continues to have a poor prognosis with over 7700 deaths in the
UK per year.
• Gemcitabine the main standard of treatment for pancreatic cancer is still relatively
ineffective.
• Heat shock protein 90 (Hsp90), a molecular chaperone required for the stability and
function of signalling proteins that promote growth and/or survival of cancer cells,
affects a number of key pathways identified to be important in cancer, including the
PI3K/Akt and MAPK pathways [1].
• AT13387 (Astex therapeutics), a novel Hsp90 inhibitor, has efficacy against
melanoma, AML, colon and lung carcinoma in xenograft models and in a variety of
cancer types in vitro (IC50 10-400nM) [2].
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Figure 3: Inhibition of HSP90 leads to
inhibition of multiple signalling pathways
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apoptotic signalling and cell cycle
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5.4	SINGLE	AGENT	EFFICACY	STUDIES	
	
5.4.1	Gemcitabine	single	agent	efficacy	
Gemcitabine	was	tested	as	a	single	agent	for	efficacy	in	this	xenograft	model.		Initial	
efficacy	 experiments	 with	 gemcitabine	 were	 performed	 in	 tumour	 bearing	 mice	
using	 the	 tolerated	 dose	 of	 100mg/kg	 twice	 a	week.	 Treatment	was	 commenced	
once	palpable	and	measurable	 tumours	were	established	and	 tumours	were	 then	
measured	 3	 times	 per	 week.	 	 Each	 mouse	 was	 inoculated	 with	 one	 shoulder	
tumour.	Daily	weights	and	observations	were	performed.		Treatment	was	continued	
for	 up	 to	 three	weeks.	 	 Experiments	 were	 performed	 in	Miapaca-2	 bearing	mice	
with	6	mice	in	the	treatment	group	and	6	mice	in	the	saline	control	group	(see	table	
5.3).		Saline	controls	were	given	a	dosing	regime	in	line	with	AT7519	treatment.			
	
Groups	 No	of	mice	 Dosing	regimen	
group	1	 6	 Vehicle	control	saline	7.5mg/kg	twice	
per	day	for	5	of	7	days	each	week	
group	2	 6	 Gemcitabine	100mg/kg	twice		a	week		
	
Table	5.3	A	 table	 showing	groups,	numbers	of	mice	and	dosing	 regime	used	 for	
the	gemcitabine	tolerability	experiment	 (the	vehicle	control	dosing	regime	given	
was	as	per	AT7519	treatment	as	this	was	the	maximal	dosing	used).	
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Figure	 5.11	 A	 graph	 showing	 the	 tumour	 volume	 for	 6	 mice	 treated	 with	
gemcitabine	 100mg/kg	 twice	 per	 week	 for	 3	 weeks.	 The	 x-axis	 shows	 days	 in	
relation	to	starting	treatment,	the	y-axis	shows	tumour	volume	in	mm3.		Volumes	
for	6	individual	mice	are	shown.		
	
Figure	 5.12	A	 graph	 showing	 the	 tumour	 volume	 for	 6	mice	 treated	with	 saline	
control	7.5mg/kg	BD	for	5	of	7	days	per	week	for	3	weeks.	The	x-axis	shows	days	
in	 relation	 to	 starting	 treatment,	 the	 y-axis	 shows	 tumour	 volume	 in	 mm3.		
Volumes	for	6	individual	mice	are	shown.		
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Figure	5.13	A	graph	showing	the	total	mean	tumour	volumes	for	groups	1	and	2	
treated	with	gemcitabine	or	vehicle	control	(saline)	respectively.	The	x-axis	shows	
days	of	treatment,	day	0	represents	the	commencement	of	treatment.	The	y-axis	
shows	tumour	volume	in	mm3.		
	
The	tumours	grew	in	an	exponential	manner	and	the	mean	tumours	volumes	
observed	in	the	gemcitabine	group	were	noted	to	be	less	than	in	the	matched	saline	
vehicle	control	(see	figure	5.11,	5.12	and	5.13).		The	data	produced	was	further	
analysed.	
	
As	 observed	 tumour	 growth	 occurs	 in	 an	 exponential	 manner	 therefore	 a	 log	
regression	 analysis	 was	 performed	 to	 examine	 any	 difference	 in	 the	 gradients	 of	
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growth	observed	before	 and	after	 treatment.	 	 This	 further	 exemplified	 any	effect	
the	agent	had	as	complete	tumour	regression	was	not	observed.	
	
During	 the	 single	 agent	 efficacy	 study,	 gemcitabine	 significantly	 reduced	 the	
exponential	 tumour	 growth	 (p=0.0038)	 compared	 with	 the	 saline	 vehicle	 control	
shown	in	table	5.4,	figure	5.14	and	5.15.	
	
Treatment	
Mean	
coefficient	difference	
N	 P	value	
Group	1	-	Vehicle	
control	saline	
0.162	 6	 0.502	
Group	2-
Gemcitabine	
0.445	 6	 0.038	
Table	5.4	A	table	of	the	log	regression	analysis	coefficients	mean	difference	after	
treatment	for	each	group	with	p	values	of	significance	in	difference.		
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Figure	5.14	A	graph	showing	the	tumour	volume	of	a	mouse	treated	with	saline	
vehicle	control	with	log	regression	analysis	co-efficient	plotted.	The	x-axis	shows	
time	from	injection	of	tumour	cells	and	the	y-axis	shows	tumour	volumes	in	mm3.		
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Figure	 5.15	 A	 graph	 showing	 the	 tumour	 volume	 of	 a	 mouse	 treated	 with	
gemcitabine	 100mg/kg	 twice	 weekly	 with	 log	 regression	 analysis	 co-efficient	
plotted.	The	x-axis	shows	time	from	injection	of	tumour	cells	and	the	y-axis	shows	
tumour	volumes	in	mm3.		
	
	
All	 animals	 had	 been	 sacrificed	 by	 day	 17	 post	 commencing	 treatment.	 In	 the	
control	group	only	one	animal	reached	day	17,	the	5	other	mice	were	culled	earlier	
owing	to	tumour	volume	(this	accounts	for	the	fall	in	tumour	volume	seen	in	figure	
5.12).	
	
In	the	gemcitabine	treated	group	one	animal	reached	17	days,	2	mice	were	culled	
secondary	to	tumour	volume	on	days	14	and	16	and	3	mice	were	culled	owing	to	
sustained	 weight	 loss	 (72hrs)	 of	 greater	 than	 20%	 on	 days	 14	 and	 15.	 	 This	
accounted	for	half	of	the	group	lost	to	unacceptable	weight	loss	(again	this	accounts	
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for	 the	 fall	 in	mean	 tumour	 volume	 rather	 than	 treatment	 exemplified	 in	 figures	
5.12	and	5.13).	
	
Because	 of	 the	 weight	 loss	 observed	 in	 non-tumour	 bearing	 animals	 in	 previous	
tolerability	 experiments	 and	 the	 weight	 loss	 observed	 in	 this	 first	 efficacy	
experiment,	 two	 reduced	 dosing	 regimens	 were	 tested	 in	 order	 to	 find	 a	
moderately	efficacious	dosing	regimen	to	progress	to	combination	studies.	
	
Experiments	 for	 gemcitabine	 single	 agent	 efficacy	 were	 performed	 with	
gemcitabine	with	a	 further	dosing	experiment	with	gemcitabine	at	50mg/kg	 twice	
weekly	(table	5.5).		
	
In	this	single	agent	efficacy	study,	gemcitabine	significantly	reduced	the	exponential	
tumour	growth	(p=0.0198)	compared	with	the	saline	vehicle	control	shown	in	table	
5.6,	figure	5.16	and	5.17.		This	dose	of	gemcitabine	was	deemed	to	be	an	efficaous	
dose	to	take	forward.	
	
	
	
	 204	
Groups	 No	of	mice	 Dosing	regimen	
Group	3	 4	 Gemcitabine	50mg/kg	twice	a	week	
(days	1	and	5)	
Group	4	 4	 Vehicle	control	saline	7.5mg/kg	twice	
per	day(days	1-5)	
Table	5.5	A	table	of	gemcitabine	single	agent	efficacy	studies:	groups,	numbers	of	
mice	 and	 dosing	 regime	 used	 for	 second	 experiment	 with	 gemcitabine	 dose	
reduced	to	50mg/kg	twice	weekly.	
	
	
Figure	 5.16	 A	 graph	 showing	 the	 tumour	 volume	 of	 a	 mouse	 treated	 with	
gemcitabine	 50mg/kg	 twice	 weekly	 with	 log	 regression	 analysis	 co-efficient	
plotted.	The	Xx-xis	shows	time	from	injection	of	tumour	cells	and	the	y-axis	shows	
tumour	volumes	in	mm3.		
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Figure	5.17	A	graph	showing	the	tumour	volume	of	a	mouse	treated	with	saline	
vehicle	control	7.5mg/kg	BD	for	5	of	7	days	treatment	with	log	regression	analysis	
co-efficient	plotted.	The	x-axis	shows	time	from	injection	of	tumour	cells	and	the	
y-axis	shows	tumour	volumes	in	mm3.	
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Treatment	
Mean	
coefficient	difference	
N	 P	value	
Group	3-	
Gemcitabine	
50mg/kg	twice	
weekly	
0.162	 6	 0.0198	
Group	4-	Vehicle	
control	
0.05	 6	 -	
Table	 5.6	 A	 table	 of	 the	 log	 regression	 analysis	 coefficients	 for	 groups	 3	 and	 4	
(gemcitabine	 50mg/kg	 twice	 weekly	 versus	 vehicle	 control	 saline	 respectively)	
mean	difference	 after	 treatment	 for	 each	 group	with	p	 values	 of	 significance	 in	
difference.		
	
In	 this	 experiment	 day	 17	 post	 treatment	 was	 the	 experimental	 endpoint.	 	 All	 4	
controls	and	2	mice	from	the	treatment	group	were	culled	on	day	16	due	to	tumour	
volume.		The	remaining	2	mice	in	the	treatment	group	were	culled	on	day	17	owing	
to	tumour	volume.		Importantly	no	mice	were	culled	secondary	to	significant	weight	
loss.	
	
CONCLUSION	
Gemcitabine	was	efficacious	 in	 this	mouse	model	 in	 reducing	exponential	 tumour	
growth	 when	 compared	 to	 saline	 control	 (p=0.0198).	 	 The	 initial	 dosing	 of	
gemcitabine	at	100mg/kg	twice	weekly	produced	unacceptable	adverse	effects	so	a	
lower	 dose	 was	 tested	 that	 also	 proved	 efficacious.	 	 In	 forward	 experiments	
Gemcitabine	50mg/kg	was	tested	in	line	with	the	findings.	
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5.4.2	AT7519	single	agent	efficacy	
The	efficacy	of	AT7519	was	examined	in	this	xenograft	model.		The	dosing	regime	of	
AT7519	 was	 based	 on	 the	 experience	 of	 Astex	 pharmaceuticals	 in	 previous	
xenograph	models	 they	 had	 employed	 in	 testing	 other	 solid	 organ	 tumour	 types.		
From	tolerability	experiments	performed	it	was	confirmed	the	dosing	regime	would	
be	 7.5mg/kg	 for	 5	 days	 per	 week	 (treatment	 groups	 shown	 in	 table	 5.7).	 	 There	
were	6	BALB-c	nude	mice	per	group	and	treatment	was	commenced	12	days	after	
tumour	cell	injections,	each	mouse	was	inoculated	with	one	shoulder	tumour.	Daily	
weights	and	observations	were	performed.		Once	palpable	and	measurable	tumours	
were	established	and	tumours	were	then	measured	3	times	per	week.	 	Treatment	
was	continued	for	up	to	three	weeks.			
	
Groups	 No	of	mice	 Dosing	regimen	
Group	1	 6	 Vehicle	control	saline	7.5mg/kg	twice	
daily	(days	1-5)	
Group	2	 6	 AT7519	7.5mg/kg	twice	daily		
(days	1-5)	
Table	 5.7	 A	 table	 showing	 the	 AT7519	 single	 agent	 efficacy	 study:	 groups,	
numbers	of	mice	and	dosing	regime	used.	
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During	the	single	agent	efficacy	study,	AT7519	significantly	reduced	the	exponential	
tumour	growth	(p=0.045)	compared	with	the	saline	vehicle	control	shown	in	table	
5.8,	figure	5.18	and	5.19.	
	
Figure	5.18	A	graph	showing	the	tumour	volume	of	a	mouse	treated	with	saline	
vehicle	control	with	the	log	regression	analysis	co-efficient	plotted.	The	x-axis	
shows	time	from	injection	of	tumour	cells	and	y-axis	shows	tumour	volumes	in	
mm3.		
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ASSESSMENT OF THE CDK INHIBITOR AT7519 IN A XENOGRAFT 
MODEL OF PANCREATIC CANCER 
•  Pancreatic cancer continues to have a poor prognosis with over 70 000 deaths reported in Europe (2008). 
•  Chemotherapy is the treatment of choice in advanced disease and has a proven role in the adjuvant setting 
though current clinical agents, such as gemcitabine,  only prolong survival by a matter of weeks;  highlighting 
the need for more effective novel therapies 
•  The Cyclin Dependent Kinase (CDK)  family of protein kinases are pivotal 
  in cell cycle regulation 
•  AT7519 is a selective CDK inhibitor providing potent inhibition of CDK 1, 2, 4, 5 and 9 (Astex Therapeutics).  
Figures 3: Tumour volumes in mice treated with vehicle control (A), AT7519 (B) and 
gemcitabine (C).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 
AT7519 group than the control group (p=0.045). 
Initial xenograft experiments of AT75 9 as a single agent showed 
a sig ficant r duction in tumour growth compared with vehicle 
control 
(A) Saline Control (B) AT7519 (C) Gemcitabine 
y"="6.8498e0.3135x
R²"="0.866
y"="78.46e0.1001x
R²"="0.937
0
200
400
600
800
1000
1200
0 5 10 15 20 25 30
Tu
m
o
u
r&
V
o
lu
m
e
&(m
m
3
)
Time&from&injection&of&cells&(days)
Before"Vehicle
After"Vehicle
y"="4.6953e0.3704x
R²"="0.9774
y"="229.8e0.0372x
R²"="0.9676
0
200
400
600
800
1000
1200
0 5 10 15 20 25 30
Tu
m
o
u
r&V
o
lu
m
e&
(m
m
3)
Time&from&injection&of&cells&(days)
Before"Gem
After"Gem
y"="11.745e0.2726x
R²"="0.9408
y"="121.58e0.0731x
R²"="0.9304
0
200
400
600
800
1000
1200
0 5 10 15 20 25
Tu
m
o
u
r&V
o
lu
m
e&
(m
m
3)
Time&from&injection&of&cells&(days)
Before"AT7519
After"AT7519
Treatment(
Mean((
coeﬃcient(
diﬀerence(
N( P(
AT7519! 0.29! 6! 0.045!
Gem! 0.445! 6! 0.038!
Vehicle! 0.162! 6! 0.502!
Figure 4: Mean difference in growth coefficients 
for treatments and controls. 
(+(((dose!of!gemcitbine!
 
!
!
!
!
!
!
!
!
Figure 1: Individual mice weights (g) for 3 mice 
dosed at  7.5mg/kg twice daily, weekdays for 2 
weeks with AT7519.  
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Figure 2: Individual mouse weights (g) for 3 mice dosed 
with  50mg/kg of gemcitabine twice per week and 
7.5mg/kg of AT7519 twice daily for 5 days.  Total 
treatment of 2 weeks. 
METHODS 
•  Cell proliferation assays  and isobolar analysis were performed in triplicate using 
EZ4U assay (BioMedica), measured 48 h or 72 h after drug treatment.  
•  Cell cycle analysis was performed 4 h,7 h,24 h and 48h after treatment of cells 
with 10mM AT7519, using flow cytometry to determine propidium iodide 
incorporation. 
•  Western blot analysis was performed using standard methods with ECL 
detection. 
•  Statistical analysis was performed using SPSS. 
•  In vivo studies using a murine xenograft model, BALB/c (CAnN.Cg-Foxn1nu/Cr) 
nude mice with MiaPaCa2 pancreatic cancer cells, tumour volumes measured 
with external callipers.!
A xenograft model of AT7519 in combination with gemcitabine showed 
superior reduction in tumour growth compared with gemcitabine and 
AT7519 as single agents and vehicle control 
   AT7519 inhibited the proliferation 
of a range of pancreatic cancer cell 
lines with  IC50 values from 0.2– 
2uM    
Figure 7: Anti-proliferative activity of 
AT17519 
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Cell! lines! resistant! to! gemcitabine! do! not! appear! to! be!
resistant!to!AT7519:!SuitT2!GR!(a!gemcitabine!resistant!cell!
line)! has! a! 60! fold! higher! gemcitabine! IC50! and! an!
equivalent!IC50!with!AT7519.!
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FamPac! 210nM! 5.5nM!
Paca!2! 250nM! 5nM!
   Cell cycle analysis displayed a marked reduction 
of cells in the G0/G1 and S phases with an 
increase of cells in G2/M phase following 
treatment with AT7519 compared to 
untreated(p<0.0001) 
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Figure 8: Effects of AT7519 on cell cycle distribution of 
Suit-2 pancreatic cancer cell line. 
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gemcitabine for 24 h followed by combination of 
gemcitabine + AT7519 for 48 h.  
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CONCLUSIONS(
Pancrea7c!cancer!cell!lines!develop!resistance!to!gemcitabine!(standard!chemotherapy)!aZer!rela7vely!brief!exposure!to!the!drug.!!!AT7519!inhibited!growth!
in!a!range!of!pancrea7c!!cancer!cell!lines!including!one!that!has!acquired!gemcitabine!resistance!and!was!eﬀec7ve!in!combina7on!with!gemcitabine.!
In!vivo!AT7519!was!eﬀec7ve!as!a!single!agent!in!a!xenograZ!model!and!had!superior!eﬀect!in!combina7on!with!gemcitabine!oﬀering!possible!future!
combina7on!therapy.!
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Figure 10: Effects of 
AT7519 on Suit- 2 
cells treated with 
AT7519 for 48 h. 
Western blot analysis demonstrated the effect 
on downstream targets of AT7519 
pp1Tα!
AT7519 was well tolerated as a single 
agent and in combination with 
gemctiabine in nude mice with no 
significant morbidity or mortality 
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Figures 3: Tumour volumes in mice treated with vehicle control (A), AT7519 (B) and 
gemcitabine (C).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 
AT7519 group than the control group (p=0.045). 
Initial xenograft exp riments of AT7519 as a single agent showed 
a significant reduction in tumour growth compared with vehicle 
control 
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Figure 1: Individual m ce weights (g) for 3 mice 
dosed at  7.5mg/kg twice daily, weekdays for 2 
weeks with AT7519.  
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Figure 2: Individual mouse weights (g) for 3 mice dosed 
with  50mg/kg of gemcitabine twice per week and 
7.5mg/kg of AT7519 twice daily for 5 days.  Total 
treatment of 2 weeks. 
METHODS 
•  Cell proliferation assays  and isobolar analysis were performed in triplicate using 
EZ4U assay (BioMedica), measured 48 h or 72 h after drug treatment.  
•  Cell cycle analysis was performed 4 h,7 h,24 h and 48h after treatment of cells 
with 10mM AT7519, using flow cytometry to determine propidium iodide 
incorporation. 
•  Western blot analysis was performed using standard methods with ECL 
detection. 
•  Statistical analysis was performed using SPSS. 
•  In vivo studies using a murine xenograft model, BALB/c (CAnN.Cg-Foxn1nu/Cr) 
nude mice with MiaPaCa2 pancreatic cancer cells, tumour volumes measured 
with external callipers.!
A xenograft model of AT7519 in combination with gemcitabine showed 
superior reduction in tumour growth compared with gemcitabine and 
AT7519 as single agents and vehicle control 
   AT7519 inhibited the proliferation 
of a range of pancreatic cancer cell 
lines with  IC50 values from 0.2– 
2uM    
Figure 7: Anti-proliferative activity of 
AT17519 
!!!!
Cell! lines! resistant! to! gemcitabine! do! not! appear! to! be!
resistant!to!AT7519:!SuitT2!GR!(a!gemcitabine!resistant!cell!
line)! has! a! 60! fold! higher! gemcitabine! IC50! and! an!
equivalent!IC50!with!AT7519.!
Cell(line( IC50(AT7519( IC50(
Gemcitabine(
SuitT2! 2000nM! 10nM!
SuitT2!(GR)! 700nM! 625nM!
MiapacaT2! 390nM! 25nM!
PancT1! 275nM! 150nM!
CFpac! 180nM! 180nM!
FamPac! 210nM! 5.5nM!
Paca!2! 250nM! 5nM!
   Cell cycle analysis displayed a marked reduction 
of cells in the G0/G1 and S phases with an 
increase of cells in G2/M phase following 
treatment with AT7519 compared to 
untreated(p<0.0001) 
24hrs!
48hrs!Untreated(SuitH2(
cells(
4hrs! 7hrs!
AT7519(treated(
SuitH2(cells(
Figure 8: Effects of AT7519 on cell cycle distribution of 
Suit-2 pancreatic cancer cell line. 
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gemcitabine for 24 h followed by combination of 
gemcitabine + AT7519 for 48 h.  
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synergy and greater if there was antagonism. 
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Figure 10: Effects of 
AT7519 on Suit- 2 
cells treated with 
AT7519 for 48 h. 
Western blot analysis demonstrated the effect 
on downstream targets of AT7519 
pp1Tα!
AT7519 was well tolerated as a single 
agent and in combination with 
gemctiabine in nude mice with no 
significant morbidity or mortality 
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y!=!3.058e0.2582x!
R²!=!0.91185!
y!=!6.6855e0.1947x!
R²!=!0.91905!
0!
100!
200!
300!
400!
500!
600!
700!
800!
0! 5! 10! 15! 20! 25! 30!
Before!
AZer!
7me!from!injec7on!of!cells(days)!
(A)!Saline!control!!
tu
mo
ur
!vo
lum
e!m
m3
!
Thomas A1, Shaw E1, Ghaneh P1, Greenhalf W1, Costello E1, Dejani K1, Davi s M1, Lyons J2, Sibson R1, Neoptolemos JP1 
! ! ! !1Department!of!Molecular!and!Clinical!Cancer!Medicine,!Ins7tute!of!Transla7onal!Medicine,!University!of!Liverpool!
! ! ! !2!Astex!Therapeu7cs,!Cambridge! ! ! ! ! ! ! ! !!!!!!!!!!!!!!!!!email: ajthomas@liv.ac.uk 
ASSESSMENT OF THE CDK INHIBITOR AT7 19 IN A XENOGRAFT 
MODEL OF PANCREATIC CANCER 
•  Pancreatic cancer continues to have a poor prognosis with over 70 000 deaths reported in Eur pe (2008). 
•  Chemotherapy is the treatment of choice in advanced disease and has a proven role in the adjuvant setting 
though current clinical agents, such as gemcitabine,  only prolong survival by a matter of weeks;  highlighting 
the n e  for more effective novel therapies 
•  The Cyclin Dependent Kinase (CDK)  family of protein kinases are pivotal 
  in cell cycle regulation 
•  AT7519 is a selective CDK inhibitor providing potent inhibition of CDK 1, 2, 4, 5 and 9 (Astex Therapeutics).  
Figures 3: Tumour volumes in mice treated with vehicle control (A), AT7519 (B) and 
gemcitabine (C).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 
AT7519 group than the control group (p=0.045). 
Initial xenograft experiments of AT7519 as a single agent showed 
a significant reduction in tumour growth compared with vehicle 
control 
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Figure 1: Individual mice weights (g) for 3 mice 
dosed at  7.5mg/kg twice daily, weekdays for 2 
weeks with AT7519.  
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Figure 2: Individual mouse weights (g) for 3 mice dosed 
with  50mg/kg of gemcitabine twice per week and 
7.5mg/kg of AT7519 twice daily for 5 days.  Total 
treatment of 2 weeks. 
METHODS 
•  Cell proliferation assays  and isobolar analysis were performed in triplicate using 
EZ4U assay (BioMedica), measured 48 h or 72 h after drug treatment.  
•  Cell cycle analysis was performed 4 h,7 h,24 h and 48h after treatment of cells 
with 10mM AT7519, using flow cytometry to determine propidium iodide 
incorporation. 
•  Western blot analysis was performed using standard methods with ECL 
detection. 
•  Statistical analysis was performed using SPSS. 
•  In vivo studies using a m rine xenograft model, BALB/c (CAnN.Cg-Foxn1nu/Cr) 
nude mice with MiaPaCa2 pancreatic cancer cells, tumour volumes measured 
with external callipers.!
A xenograft model of AT7519 in combination with gemcitabine showed 
superior reduction in tumour growth compared with gemcitabine and 
AT7519 as single agents and vehicle control 
   AT7519 inhibited the proliferation 
of a range f pancreatic cancer cell 
lines with  IC50 values from 0.2– 
2uM    
Figure 7: Anti-proliferative activity of 
AT17519 
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Cell! lines! resistant! to! gemcitabine! do! not! appear! to! be!
resistant!to!AT7519:!SuitT2!GR!(a!gemcitabine!resistant!cell!
line)! has! a! 60! fold! higher! gemcitabine! IC50! and! an!
equivalent!IC50!with!AT7519.!
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Figure 8: Effects of AT7519 on cell cycle distribution of 
Suit-2 pancreatic cancer cell line. 
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CONCLUSIONS(
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Figure 10: Effects of 
AT7519 on Suit- 2 
cells treated with 
AT7519 for 48 h. 
Western blot analysis demonstrated the effect 
on downstream targets of AT7519 
pp1Tα!
AT7519 was well tolerated as a single 
agent and in combination with 
gemctiabine in nude mice with no 
significant morbidity or mortality 
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Figures 5: Tumour volumes in mice treated with Saline vehicle control(A) and Gemcitabine 
+ AT7519 (B).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 
combination treatment  group than the control group (p=0.0041). 
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Figure	5.19	A	graph	showing	the	tumour	volume	of	a	mouse	treated	with	AT7519	
7.5mg/kg	 BD	 for	 5	 of	 7	 day	 treatment	 period,	 with	 total	 treatment	 of	 up	 to	 3	
weeks.	The	log	regression	analysis	co-efficients	are	plotted.	The	x-axis	shows	time	
from	injection	of	tumour	cells	and	the	y-axis	shows	tumour	volumes	in	mm3.		
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ASSESSMENT OF THE CDK INHIBITOR AT7519 IN A XENOGRAFT 
MODEL OF PANCREATIC CANCER 
•  Pancreatic cancer continues to have a poor prognosis with over 70 000 deaths reported in Europe (2008). 
•  Chemotherapy is the treatment of choice in advanced disease and has a proven role in the adjuvant setting 
though current clinical agents, such as gemcitabine,  only prolong survival by a matter of weeks;  highlighting 
the need for more effective novel therapies 
•  The Cyclin Dependent Kinase (CDK)  family of protein kinases are pivotal 
  in cell cycle regulation 
•  AT7519 is a selective CDK inhibitor providing potent inhibition of CDK 1, 2, 4, 5 and 9 (Astex Therapeutics).  
Figures 3: Tumour volumes in mice treated with vehicle control (A), AT7519 (B) and 
gemcitabine (C).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 
AT7519 group than the control group (p=0.045). 
Initial xenograft experiments of AT75 9 as a single agent showed 
a significant reduction in tumour growth compared with vehicle 
control 
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Figure 1: Individual mice weights (g) for 3 mice 
dosed at  7.5mg/kg twice daily, weekdays for 2 
weeks with AT7519.  
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Figure 2: Individual mouse weights (g) for 3 mice dosed 
with  50mg/kg of gemcitabine twice per week and 
7.5mg/kg of AT7519 twice daily for 5 days.  Total 
treatment of 2 weeks. 
METHODS 
•  Cell proliferation assays  and isobolar analysis were performed in triplicate using 
EZ4U assay (BioMedica), measured 48 h or 72 h after drug treatment.  
•  Cell cycle analysis was performed 4 h,7 h,24 h and 48h after treatment of cells 
with 10mM AT7519, using flow cytometry to determine propidium iodide 
incorporation. 
•  Western blot analysis was performed using standard methods with ECL 
detection. 
•  Statistical analysis was performed using SPSS. 
•  In vivo studies using a murine xenograft model, BALB/c (CAnN.Cg-Foxn1nu/Cr) 
nude mice with MiaPaCa2 pancreatic cancer cells, tumour volumes measured 
with external callipers.!
A xenograft model of AT7519 in combination with gemcitabine showed 
superior reduction in tumour growth compared with gemcitabine and 
AT7519 as single agents and vehicle control 
   AT7519 inhibited the proliferation 
of a range of pancreatic cancer cell 
lines with  IC50 values from 0.2– 
2uM    
Figure 7: Anti-proliferative activity of 
AT17519 
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resistant!to!AT7519:!SuitT2!GR!(a!gemcitabine!resistant!cell!
line)! has! a! 60! fold! higher! gemcitabine! IC50! and! an!
equivalent!IC50!with!AT7519.!
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Suit-2 pancreatic cancer cell line. 
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CONCLUSIONS(
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AT7519 on Suit- 2 
cells treated with 
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Western blot analysis demonstrated the effect 
on downstream targets of AT7519 
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AT7519 was well tolerated as a single 
agent and in combination with 
gemctiabine in nude mice with no 
significant morbidity or mortality 
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Figures 5: Tumour volumes in mice treated with Saline vehicle control(A) and Gemcitabine 
+ AT7519 (B).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 
combination treatment  group than the control group (p=0.0041). 
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Figures 3: Tumour volumes in mice treated with vehicle control (A), AT7519 (B) and 
gemcitabine (C).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 
AT7519 group than the control group (p=0.045). 
Initial xenograft exp riments of AT7519 as a single agent showed 
a significant reduction in tumour growth compared with vehicle 
control 
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Figure 4: Mean difference in growth coefficients 
for treatments and controls. 
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Figure 1: Individual m ce weights (g) for 3 mice 
dosed at  7.5mg/kg twice daily, weekdays for 2 
weeks with AT7519.  
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Figure 2: Individual mouse weights (g) for 3 mice dosed 
with  50mg/kg of gemcitabine twice per week and 
7.5mg/kg of AT7519 twice daily for 5 days.  Total 
treatment of 2 weeks. 
METHODS 
•  Cell proliferation assays  and isobolar analysis were performed in triplicate using 
EZ4U assay (BioMedica), measured 48 h or 72 h after drug treatment.  
•  Cell cycle analysis was performed 4 h,7 h,24 h and 48h after treatment of cells 
with 10mM AT7519, using flow cytometry to determine propidium iodide 
incorporation. 
•  Western blot analysis was performed using standard methods with ECL 
detection. 
•  Statistical analysis was performed using SPSS. 
•  In vivo studies using a murine xenograft model, BALB/c (CAnN.Cg-Foxn1nu/Cr) 
nude mice with MiaPaCa2 pancreatic cancer cells, tumour volumes measured 
with external callipers.!
A xenograft model of AT7519 in combination with gemcitabine showed 
superior reduction in tumour growth compared with gemcitabine and 
AT7519 as single agents and vehicle control 
   AT7519 inhibited the proliferation 
of a range of pancreatic cancer cell 
lines with  IC50 values from 0.2– 
2uM    
Figure 7: Anti-proliferative activity of 
AT17519 
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Cell! lines! resistant! to! gemcitabine! do! not! appear! to! be!
resistant!to!AT7519:!SuitT2!GR!(a!gemcitabine!resistant!cell!
line)! has! a! 60! fold! higher! gemcitabine! IC50! and! an!
equivalent!IC50!with!AT7519.!
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CFpac! 180nM! 180nM!
FamPac! 210nM! 5.5nM!
Paca!2! 250nM! 5nM!
   Cell cycle analysis displayed a marked reduction 
of cells in the G0/G1 and S phases with an 
increase of cells in G2/M phase following 
treatment with AT7519 compared to 
untreated(p<0.0001) 
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Figure 8: Effects of AT7519 on cell cycle distribution of 
Suit-2 pancreatic cancer cell line. 
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 Isobolar analysis of AT7519 combined 
with gemcitabine suggested an additive 
effect 
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Figure 9: Isobolar graph of cells treated with 
gemcitabine for 24 h followed by combination of 
gemcitabine + AT7519 for 48 h.  
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synergy and greater if there was antagonism. 
CONCLUSIONS(
Pancrea7c!cancer!cell!lines!develop!resistance!to!gemcitabine!(standard!chemotherapy)!aZer!rela7vely!brief!exposure!to!the!drug.!!!AT7519!inhibited!growth!
in!a!range!of!pancrea7c!!cancer!cell!lines!including!one!that!has!acquired!gemcitabine!resistance!and!was!eﬀec7ve!in!combina7on!with!gemcitabine.!
In!vivo!AT7519!was!eﬀec7ve!as!a!single!agent!in!a!xenograZ!model!and!had!superior!eﬀect!in!combina7on!with!gemcitabine!oﬀering!possible!future!
combina7on!therapy.!
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Figure 10: Effects of 
AT7519 on Suit- 2 
cells treated with 
AT7519 for 48 h. 
Western blot analysis demonstrated the effect 
on downstream targets of AT7519 
pp1Tα!
AT7519 was well tolerated as a single 
agent and in combination with 
gemctiabine in nude mice with no 
significant morbidity or mortality 
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Figures 5: Tumour volumes in mice treated with Saline vehicle control(A) and Gemcitabine 
+ AT7519 (B).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 
combination treatment  group than the control group (p=0.0041). 
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ASSESSMENT OF THE CDK INHIBITOR AT7 19 IN A XENOGRAFT 
MODEL OF PANCREATIC CANCER 
•  Pancreatic cancer continues to have a poor prognosis with over 70 000 deaths reported in Eur pe (2008). 
•  Chemotherapy is the treatment of choice in advanced disease and has a proven role in the adjuvant setting 
though current clinical agents, such as gemcitabine,  only prolong survival by a matter of weeks;  highlighting 
the n e  for more effective novel therapies 
•  The Cyclin Dependent Kinase (CDK)  family of protein kinases are pivotal 
  in cell cycle regulation 
•  AT7519 is a selective CDK inhibitor providing potent inhibition of CDK 1, 2, 4, 5 and 9 (Astex Therapeutics).  
Figures 3: Tumour volumes in mice treated with vehicle control (A), AT7519 (B) and 
gemcitabine (C).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 
AT7519 group than the control group (p=0.045). 
Initial xenograft experiments of AT7519 as a single agent showed 
a significant reduction in tumour growth compared with vehicle 
control 
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Figure 4: Mean difference in growth coefficients 
for treatments and controls. 
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Figure 1: Individual mice weights (g) for 3 mice 
dosed at  7.5mg/kg twice daily, weekdays for 2 
weeks with AT7519.  
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Figure 2: Individual mouse weights (g) for 3 mice dosed 
with  50mg/kg of gemcitabine twice per week and 
7.5mg/kg of AT7519 twice daily for 5 days.  Total 
treatment of 2 weeks. 
METHODS 
•  Cell proliferation assays  and isobolar analysis were performed in triplicate using 
EZ4U assay (BioMedica), measured 48 h or 72 h after drug treatment.  
•  Cell cycle analysis was performed 4 h,7 h,24 h and 48h after treatment of cells 
with 10mM AT7519, using flow cytometry to determine propidium iodide 
incorporation. 
•  Western blot analysis was performed using standard methods with ECL 
detection. 
•  Statistical analysis was performed using SPSS. 
•  In vivo studies using a m rine xenograft model, BALB/c (CAnN.Cg-Foxn1nu/Cr) 
nude mice with MiaPaCa2 pancreatic cancer cells, tumour volumes measured 
with external callipers.!
A xenograft model of AT7519 in combination with gemcitabine showed 
superior reduction in tumour growth compared with gemcitabine and 
AT7519 as single agents and vehicle control 
   AT7519 inhibited the proliferation 
of a range f pancreatic cancer cell 
lines with  IC50 values from 0.2– 
2uM    
Figure 7: Anti-proliferative activity of 
AT17519 
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Cell! lines! resistant! to! gemcitabine! do! not! appear! to! be!
resistant!to!AT7519:!SuitT2!GR!(a!gemcitabine!resistant!cell!
line)! has! a! 60! fold! higher! gemcitabine! IC50! and! an!
equivalent!IC50!with!AT7519.!
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of cells in the G0/G1 and S phases with an 
increase of cells in G2/M phase following 
treatment with AT7519 compared to 
untreated(p<0.0001) 
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Figure 8: Effects of AT7519 on cell cycle distribution of 
Suit-2 pancreatic cancer cell line. 
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 Isobolar analysis of AT7519 combined 
with gemcitabine suggested an additive 
effect 
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Figure 9: Isobolar graph of cells treated with 
gemcitabine for 24 h followed by combination of 
gemcitabine + AT7519 for 48 h.  
The line represents an additive effect.  The area 
under the curve would be lower if there was 
synergy and greater if there was antagonism. 
CONCLUSIONS(
Pancrea7c!cancer!cell!lines!develop!resistance!to!gemcitabine!(standard!chemotherapy)!aZer!rela7vely!brief!exposure!to!the!drug.!!!AT7519!inhibited!growth!
in!a!range!of!pancrea7c!!cancer!cell!lines!including!one!that!has!acquired!gemcitabine!resistance!and!was!eﬀec7ve!in!combina7on!with!gemcitabine.!
In!vivo!AT7519!was!eﬀec7ve!as!a!single!agent!in!a!xenograZ!model!and!had!superior!eﬀect!in!combina7on!wit !gemcitabine!oﬀering!possible!future!
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Figure 10: Effects of 
AT7519 on Suit- 2 
cells treated with 
AT7519 for 48 h. 
Western blot analysis demonstrated the effect 
on downstream targets of AT7519 
pp1Tα!
AT7519 was well tolerated as a single 
agent and in combination with 
gemctiabine in nude mice with no 
significant morbidity or mortality 
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Figures 5: Tumour volumes in mice treated with Saline vehicle control(A) and Gemcitabine 
+ AT7519 (B).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 
combination treatment  group than the control group (p=0.0041). 
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Treatment	
Mean	
coefficient	difference	
N	 P	value	
Group	1-	Vehicle	
control	saline	
0.162	 6	 0.502	
Group	2-	AT7519	
	
0.29	 6	 0.045	
Table	5.8	A	table	of	the	log	regression	analysis	coefficients	mean	difference	after	
treatment	for	each	group	with	p	values	of	significance	in	the	difference.		
	
	
All	 subjects	 in	 the	 AT7519	 group	 reached	 at	 least	 day	 14	 of	 treatment	 and	were	
culled	on	the	basis	of	tumour	volume,	there	were	no	adverse	effects	or	significant	
weight	loss	observed	(see	table	5.9).	
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Subject	
	
Day	of	treatment	 Reason	for	cull	
Mouse	2	 14	
	
Tumour	volume	
	Mouse	5	
Mouse	3	 	
15	
	
	
Tumour	volume	
	
Mouse	4	
Mouse	6	
Mouse	1	 18	 Experimental	end	point	
Table	 5.9	 A	 table	 of	 the	 day	 and	 reasoning	 for	 cull	 of	 mice	 in	 the	 AT7519	
treatment	group.		
	
CONCLUSION	
In	 this	 xenograft	model	 of	 pancreatic	 cancer	 AT7519	 as	 a	 single	 agent	 showed	 a	
significant	 reduction	 in	 tumour	 growth	 compared	 to	 vehicle	 control	 with	 no	
observed	significant	adverse	effects.	
	
5.4.3	AT13387	single	agent	efficiacy	
The	 efficacy	 of	 AT13387	 as	 a	 single	 agent	 was	 tested	 in	 this	 pancreatic	 cancer	
xenograft	model.		AT13387	was	dosed	as	per	the	tolerated	dosing	regimen	tested	at	
80mg/kg	 once	 weekly	 in	 BALB-c	 nude	 tumour	 bearing	 mice.	 	 Treatment	 was	
commenced	 on	 day	 13	 once	 palpable	 and	measurable	 tumours	were	 established	
and	tumours	were	then	measured	3	times	per	week.	 	Each	mouse	was	 inoculated	
with	 one	Miapaca-2	 cell	 shoulder	 tumour.	 	 Daily	 weights	 and	 observations	 were	
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performed.		Treatment	was	continued	for	up	to	three	weeks.	There	were	6	mice	in	
the	treatment	group	and	6	mice	in	the	cyclodextrin	vehicle	control	group	(see	table	
5.10).	
	
Groups	
	
No	of	mice	 Dosing	regimen	
Group	1		 6	 Vehicle	control	cyclodextrin	80mg/kg	
once	weekly		
Group	2	 6	 AT13387	80mg/kg	once	weekly		
	
Table	 5.10	 A	 table	 showing	 the	 AT13387	 single	 agent	 efficacy	 study:	 groups,	
numbers	of	mice	and	dosing	regime	used.	
	
There	was	a	trend	for	the	rate	of	tumour	growth	as	measured	by	coefficients	of	an	
exponential	regression	plot	being	reduced	by	treatment	with	AT13387	compared	to	
vehicle	treated	controls	(cyclodextrin),	this	was	not	statistically	significant	(p=0.073)	
(data	shown	in	table	5.11,	figure	5.20	and	figure	5.21).	
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Figure	5.20	A	graph	showing	the	tumour	volume	of	mouse	treated	with	
cyclodextrin	vehicle	control	with	log	regression	analysis	co-efficients	plotted.	The	
x-axis	shows	time	from	injection	of	tumour	cells	and	the	y-axis	shows	tumour	
volumes	in	mm3.		
	
AT13387'(single(agent(
Inhibition of tumour growth in a pancreatic cancer xenograft model by 
AT13387, a novel Hsp90 inhibitor.
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• Administered as a single agent, AT13387 was tolerated in nude mice with no
mortality, persistent weight loss or other significant side effects.
• Although not significant the rate of tumour growth (as measured by coefficient of
exponential regression) was reduced with AT13387 treatment (n=6) compared to
vehicle treated controls (n=6) (p=0.073, pair T-test).
• AT13387 given in combination with Gemcitabine was also tolerated and on-going
experiments are investigating the inhibition of tumour growth with this
combination.
AT13387 inhibited the proliferation of a
number of pancreatic cancer cell lines.
• IC50 values for proliferation inhibition by
AT13387 ranged from 29 - 100nM (Table 1).
• Suit-2GR, a gemcitabine resistant cell line
derived from Suit-2 (with a gemcitabine IC50
value 60-fold higher than the parent cell-line)
had similar sensitivity to AT13387. Table 1: Anti-proliferative 
activity of AT13387 
• Treatment of pancreatic cancer cells with AT13387 resulted in significant
down-regulation of phospho-S6 ribosomal protein and Raf -1 (both P<0.01)
and Akt/PKB, CDK4, phosphorylated -Erk and phosphorylated-Akt (all
P<0.001).
• In vivo down-regulation of CDK, phospho-S6 ribosomal protein and Akt was
observed in tumours from mice 19hrs but not 2hrs after dosing.
• Significant up-regulation of co-chaperone Hsp70 was also observed following
treatment with AT13387 in vitro (P=0.02) and in vivo.
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METHODS
• Cell proliferation assays performed in triplicate using EZ4U assay (BioMedica), 48 or 72 hrs after  
treatment. 
• Cell cycle analysis was performed 4,7,24 and 48hrs after treatment of cells with 250nM AT13387 using 
flow cytometry to determine propidium iodide incorporation.
• Apoptosis was assessed using Annexin-FITC vs propidium iodide staining and flow cytometry 7,13,24 
and 48hrs after treatment of cells with 250nM AT13387.
• Western blot analysis was performed using standard methods with ECL detection.
• Tolerability and efficacy of AT13387 assessed in Xenograft model (BALB/c (CAnN.Cg-Foxn1nu/Cr) nude 
mice and miapaca2 cells). Tumour volumes measured with external callipers.
• Statistical analysis was performed in SPSS and Statview. P values reported from T-tests. 
Hsp90 inhibition leads to cell cycle arrest in G0/G1 and G2/M phases of 
the cell cycle, but no clear evidence of apoptosis. Hsp90 downstream biomarkers are altered, following treatment 
with AT13387.
Figure 4: Effects of AT13387 treatment on Hsp90
client proteins and co-chaperone Hsp70 in A)
Miapaca2 cells (18hrs after treatment) and B)
miapaca2 xenograft tumours: C1 and C2 cyclodextrin
control animals; T1, tumor removed 2hrs and T2,
tumour removed 19hrs, after 80mg/kg AT13387.
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Suit-2 63
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MiaPaCa-2 58
FamPac 42
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CONCLUSION
AT13387 inhibits growth of pancreatic cancer cell lines, including those
resistant to gemcitabine, and suppresses the expression of Hsp90 client
proteins. In vivo AT13387 slows tumour growth and further investigations
will determine if AT13387 can improve inhibition of tumour growth when
used in combination with gemcitabine.
Untreated 
AT13387
Figure 1:  The effects of AT13387 on cell cycle distribution in A) Suit-2 and B) Suit-2 GR cells.  C) 
Analysis of apoptosis 24hrs after AT13387 treatment of Suit-2 cells; similar results were observed 
at 7, 13, 48 hours post  drug treatment. 
AT13387 treatment slows tumour growth in vivo
A
B
Figure 2: AT13387 tolerability: daily weights of mice
treated with AT13387(A). Example of exponential
regression curves of tumour growth in animal treated
with AT13387(B), or with vehicle control(C). Drug
administered once weekly at 80mg/kg. Exponential
regression analysis was used to fit a curve to data points
before treatment and over the first 10 days of treatment
and assign coefficients. Treatment groups were compared
using paired T-test (6 mice per group). Arrow marks start of
treatment.
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BACKGROUND
• Pancreatic cancer continues to have a poor prognosis with over 7700 deaths in the
UK per year.
• Gemcitabine the main standard of treatment for pancreatic cancer is still relatively
ineffective.
• Heat shock protein 90 (Hsp90), a molecular chaperone required for the stability and
function of signalling proteins that promote growth and/or survival of cancer cells,
affects a number of key pathways identified to be important in cancer, including the
PI3K/Akt and MAPK pathways [1].
• AT13387 (Astex therapeutics), a novel Hsp90 inhibitor, has efficacy against
melanoma, AML, colon and lung carcinoma in xenograft models and in a variety of
cancer types in vitro (IC50 10-400nM) [2].
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• Administ red as a single agent, AT13 t l rated in nude mice with no
mortality, per istent weight lo s or other i t i e ef ects.
• Although not significan the rate of tu ( s easured by coeffic ent of
expo ential regression) was reduced it treatment (n=6) compared to
vehicle treated controls (n=6) (p=0.073, ir -t t).
• AT13387 given in combination with Ge citabine as also tolerated and on-going
experiments are investigating the inhibition of tumour growth with this
combination.
AT13387 inhibited the proliferation of a
number of pancreatic cancer cell lines.
• IC50 values for proliferation inhibition by
AT13387 ranged from 29 - 100nM (Table 1).
• Suit-2GR, a gemcitabine resistant cell line
derived from Su -2 (with a gemcitabine IC50
value 60-fold higher than the parent c ll-line)
had similar sensitivity to AT13387. Table 1: Anti-proliferative 
activity of AT13387 
• Treatment of pancreatic cancer cells with AT13387 resulted in significant
down-regulation of phospho-S6 ribosomal protein and Raf -1 (both P<0.01)
and Akt/PKB, CDK4, phosphorylated -Erk and phosphorylated-Akt (all
P<0.001).
• In vivo down-regulation of CDK, phospho-S6 ribosomal protein and Akt was
observed in tumours from mice 19hrs but not 2hrs after dosing.
• Significant up-regulation of co-chaperone Hsp70 was also observed following
treatment with AT13387 in vitro (P=0.02) and in vivo.
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resistant to gemcitabine, and suppresses the expression of Hsp90 client
proteins. In vivo AT13387 slows tumour growth and further investigations
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Figure 1:  The effects of AT13387 on cell cycle distribution in A) Suit-2 and B) Suit-2 GR cells.  C) 
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Figure 2: AT13387 tolerability: daily weights of mice
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function of signalling proteins that promote growth and/or survival of cancer cells,
affects a number of key pathways identified to be important in cancer, including the
PI3K/Akt and MAPK pathways [1].
• AT13387 (Astex therapeutics), a novel Hsp90 inhibitor, has efficacy against
melanoma, AML, colon and lung carcinoma in xenograft models and in a variety of
cancer types in vitro (IC50 10-400nM) [2].
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Figure	5.21	A	graph	showing	the	tumour	volume	of	a	mouse	treated	with	AT13387	
80mg/kg	once	weekly,	with	total	treatment	of	up	to	3	weeks.	The	log	regression	
analysis	 co-efficient	 is	 plotted.	 The	 x-axis	 shows	 time	 from	 injection	 of	 tumour	
cells	and	the	y-axis	shows	tumour	volumes	in	mm3.		
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• Administered as a single agent, AT13387 was tolerated in nude mice with no
mortality, persistent weight loss or other significant side effects.
• Although not significant the rate of tumour growth (as measured by coefficient of
exponential regression) was reduced with AT13387 treatment (n=6) compared to
vehicle treated controls (n=6) (p=0.073, pair T-test).
• AT13387 given in combination with Gemcitabine was also tolerated and on-going
experiments are investigating the inhibition of tumour growth with this
combination.
AT13387 inhibited the proliferation of a
number of pancreatic cancer cell lines.
• IC50 values for proliferation inhibition by
AT13387 ranged from 29 - 100nM (Table 1).
• Suit-2GR, a gemcitabine resistant cell line
derived from Suit-2 (with a gemcitabine IC50
value 60-fold higher than the parent cell-line)
had similar sensitivity to AT13387. Table 1: Anti-proliferative 
activity of AT13387 
• Treatment of pancreatic cancer cells with AT13387 resulted in significant
down-regulation of phospho-S6 ribosomal protein and Raf -1 (both P<0.01)
and Akt/PKB, CDK4, phosphorylated -Erk and phosphorylated-Akt (all
P<0.001).
• In vivo down-regulation of CDK, phospho-S6 ribosomal protein and Akt was
observed in tumours from mice 19hrs but not 2hrs after dosing.
• Significant up-regulation of co-chaperone Hsp70 was also observed following
treatment with AT13387 in vitro (P=0.02) and in vivo.
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METHODS
• Cell proliferation assays performed in triplicate using EZ4U assay (BioMedica), 48 or 72 hrs after  
treatment. 
• Cell cycle analysis was performed 4,7,24 and 48hrs after treatment of cells with 250nM AT13387 using 
flow cytometry to determine propidium iodide incorporation.
• Apoptosis was assessed using Annexin-FITC vs propidium iodide staining and flow cytometry 7,13,24 
and 48hrs after treatment of cells with 250nM AT13387.
• Western blot analysis was performed using standard methods with ECL detection.
• Tolerability and efficacy of AT13387 assessed in Xenograft model (BALB/c (CAnN.Cg-Foxn1nu/Cr) nude 
mice and miapaca2 cells). Tumour volumes measured with external callipers.
• Statistical analysis was performed in SPSS and Statview. P values reported from T-tests. 
Hsp90 inhibition leads to cell cycle arrest in G0/G1 and G2/M phases of 
the cell cycle, but no clear evidence of apoptosis. Hsp90 downstream biomarkers are altered, following treatment 
with AT13387.
Figure 4: Effects of AT13387 treatment on Hsp90
client proteins and co-chaperone Hsp70 in A)
Miapaca2 cells (18hrs after treatment) and B)
miapaca2 xenograft tumours: C1 and C2 cyclodextrin
control animals; T1, tumor removed 2hrs and T2,
tumour removed 19hrs, after 80mg/kg AT13387.
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CONCLUSION
AT13387 inhibits growth of pancreatic cancer cell lines, including those
resistant to gemcitabine, and suppresses the expression of Hsp90 client
proteins. In vivo AT13387 slows tumour growth and further investigations
will determine if AT13387 can improve inhibition of tumour growth when
used in combination with gemcitabine.
Untreated 
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Figure 1:  The effects of AT13387 on cell cycle distribution in A) Suit-2 and B) Suit-2 GR cells.  C) 
Analysis of apoptosis 24hrs after AT13387 treatment of Suit-2 cells; similar results were observed 
at 7, 13, 48 hours post  drug treatment. 
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Figure 2: AT13387 tolerability: daily weights of mice
treated with AT13387(A). Example of exponential
regression curves of tumour growth in animal treated
with AT13387(B), or with vehicle control(C). Drug
administered once weekly at 80mg/kg. Exponential
regression analysis was used to fit a curve to data points
before treatment and over the first 10 days of treatment
and assign coefficients. Treatment groups were compared
using paired T-test (6 mice per group). Arrow marks start of
treatment.
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BACKGROUND
• Pancreatic cancer continues to have a poor prognosis with over 7700 deaths in the
UK per year.
• Gemcitabine the main standard of treatment for pancreatic cancer is still relatively
ineffective.
• Heat shock protein 90 (Hsp90), a molecular chaperone required for the stability and
function of signalling proteins that promote growth and/or survival of cancer cells,
affects a number of key pathways identified to be important in cancer, including the
PI3K/Akt and MAPK pathways [1].
• AT13387 (Astex therapeutics), a novel Hsp90 inhibitor, has efficacy against
melanoma, AML, colon and lung carcinoma in xenograft models and in a variety of
cancer types in vitro (IC50 10-400nM) [2].
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AT13387 inhibited the proliferation of a
number of pancreatic cancer cell lines.
• IC50 values for proliferation inhibition by
AT13387 ranged from 29 - 100nM (Table 1).
• Suit-2GR, a gemcitabine resistant cell line
derived from Su -2 (with a gemcitabine IC50
value 60-fold higher than the parent c ll-line)
had similar sensitivity to AT13387. Table 1: Anti-proliferative 
activity of AT13387 
• Treatment of pancreatic cancer cells with AT13387 resulted in significant
down-regulation of phospho-S6 ribosomal protein and Raf -1 (both P<0.01)
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P<0.001).
• In vivo down-regulation of CDK, phospho-S6 ribosomal protein and Akt was
observed in tumours from mice 19hrs but not 2hrs after dosing.
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• Cell proliferation assays performed in triplicate using EZ4U assay (BioMedica), 48 or 72 hrs after  
treatment. 
• Cell cycle analysis was performed 4,7,24 and 48hrs after treatment of cells with 250nM AT13387 using 
flow cytometry to determine propidium iodide incorporation.
• Apoptosis was assessed using Annexin-FITC vs propidium iodide staining and flow cytometry 7,13,24 
and 48hrs after treatment of cells with 250nM AT13387.
• Western blot analysis was performed using standard methods with ECL detection.
• Tolerability and efficacy of AT13387 assessed in Xenograft model (BALB/c (CAnN.Cg-Foxn1nu/Cr) nude 
mice and miapaca2 cells). Tumour volumes measured with external callipers.
• Statistical analysis was performed in SPSS and Statview. P values reported from T-tests. 
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Figure 1:  The effects of AT13387 on cell cycle distribution in A) Suit-2 and B) Suit-2 GR cells.  C) 
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Figure 2: AT13387 tolerability: daily weights of mice
treated with AT13387(A). Example of exponential
regression curves of tumour growth in animal treated
with AT13387(B), or with vehicle control(C). Drug
administered once weekly at 80mg/kg. Exponential
r gression analysis was used to fit a curve to data points
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and ass gn coefficients. Treatment groups were compared
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BACKGROUND
• Pancreatic cancer continues to have a poor prognosis with over 7700 deaths in the
UK per year.
• Gemcitabine the main standard of treatment for pancreatic cancer is still relatively
ineffective.
• Heat shock protein 90 (Hsp90), a molecular chaperone required for the stability and
function of signalling proteins that promote growth and/or survival of cancer cells,
affects a number of key pathways identified to be important in cancer, including the
PI3K/Akt and MAPK pathways [1].
• AT13387 (Astex therapeutics), a novel Hsp90 inhibitor, has efficacy against
melanoma, AML, colon and lung carcinoma in xenograft models and in a variety of
cancer types in vitro (IC50 10-400nM) [2].
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Treatment	
Mean	
coefficient	difference	
N	 P	value	
Group	1-	Vehicle	control	
cyclodextrin	
0.133	 6	 0.507	
Group	2-	AT13387		
treatment	
0.207	 6	 0.073	
Table	5.11	A	table	of	the	log	regression	analysis	coefficients	mean	difference	after	
treatment	 for	each	group	with	p	values	of	 significance	 in	difference	 for	 group	1	
(cyclodextrin	vehicle	control)	and	group	2	(AT13387	treatment).	
	
All	subjects	were	culled	by	day	16,	all	controls	by	day	15.		The	reasoning	for	all	culls	
was	 related	 to	 tumour	 volume.	 	 No	 mice	 experienced	 significant	 weight	 loss	 or	
adverse	effects	that	necessitated	cull	(see	table	5.12).	
	
Subject	 Day	of	treatment	 Reason	for	cull	
Mouse	2	 14	 Tumour	volume	
	
	
Mouse	4	
Mouse	5	
Mouse	6	
Mouse	1	 15	 Tumour	volume	
Mouse	3	 16	 Tumour	Volume	
Table	 5.12	 A	 table	 of	 day	 and	 reasoning	 for	 cull	 of	mice	 in	 AT13387	 treatment	
group.	
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CONCLUSION	
AT13387	was	tolerated	in	this	pancreatic	cancer	xenograft	model	and	appeared	to	
slow	 tumour	 growth	 in	 comparison	 to	 vehicle	 control	 but	 this	 effect	 was	 not	
statistically	significant.	
	
5.5	COMBINATION	TOLERBILITY	STUDIES	
After	 all	 single	 agents	 had	 been	 investigated	 for	 tolerability	 and	 efficacy	
combination	studies	were	undertaken.	 	Any	agent	that	would	potentially	be	taken	
forward	 into	 human	 trials	 would	 be	 trial	 in	 combination	 with	 the	 current	 gold	
standard	 treatment	 therefore	 the	 investigation	 of	 AT7519	 and	 AT13387	 in	
combination	with	gemcitabine	was	undertaken	for	tolerability	then	efficacy.	
	
5.5.1	AT7519	+	gemcitabine	combination	tolerability	
The	tolerability	of	the	combination	of	AT7519	and	gemcitabine	was	tested	prior	to	
exploring	 the	 efficacy	 of	 this	 combination.	 	 The	 dose	 of	 AT7519	 remained	 at	
7.5mg/kg	 twice	a	day	 for	5	days	per	week	as	 this	had	proved	 to	be	 tolerable	and	
efficacious	 in	previous	studies.	 	The	dose	of	gemcitabine	used	was	50mg/kg	twice	
weekly	 as	 a	 moderately	 efficaous	 dose	 that	 was	 well	 tolerated	 in	 single	 agent	
studies	 (see	 table	 5.13).	 	 The	 tolerability	 study	 was	 performed	 in	 non	 tumour	
bearing	mice	 for	 a	 total	 period	of	 2	weeks	 treatment	with	3	mice.	 	Daily	weights	
were	 performed	 as	 well	 as	 general	 health	 observations.	 	 Treatment	 dosing	 was	
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omitted	if	animals	had	encountered	>15%	total	body	weight	loss	and	terminated	if	
they	had	sustained	(72	hrs.)	weight	loss	>20%.	
	
	
Gemcitabine	
50mg/kg	twice	weekly	
AT7519	 7.5mg/kg	BD	(days	1-5)	 3	mice	
Table	5.13	A	table	showing	the	combination	tolerability	of	AT7519	+	gemcitabine:	
Treatments,	numbers	of	mice	and	dosing	regime	used	
	
The	combination	of	AT7519	and	gemcitabine	at	the	doses	tested	was	tolerated	with	
no	significant	weight	necessitating	missed	doses	or	culling	of	mice	(figures	5.22	and	
5.23).	
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Figure	 5.22	 A	 graph	 showing	 AT7519	 and	 gemcitabine	 combination	 tolerability:	
the	 x-axis	 shows	 time	of	 experiment	 in	days,	 the	 y-axis	 shows	mouse	weight	 in	
grams.	 	 The	 crosses	 represent	 a	 dose	 of	 AT7519,	 X	 represents	 a	 dose	 of	
gemcitabine.	Lines	of	best	fit	were	produced	with	a	2	point	moving	average.			
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Figure	 5.23	 A	 graph	 showing	 AT7519	 and	 gemcitabine	 combination	 tolerability	
exemplified	 by	 percentage	weight	 loss:	 the	 x-axis	 shows	 time	 of	 experiment	 in	
days,	 the	y-axis	 shows	percentage	weight	 loss.	 	 The	crosses	 represent	a	dose	of	
AT7519,	the	X	represents	a	dose	of	gemcitabine		
	
CONCLUSION	
The	combination	of	AT7519	and	gemcitabine	at	the	doses	tested	was	well	tolerated	
in	this	experiment	with	no	significant	weight	necessitating	missed	doses	or	culling	of	
mice.		This	dosing	regime	was	taken	forward	to	combination	efficacy	studies.	
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5.5.2	AT13387	+	gemcitabine	combination	tolerability	[1]	
The	 combination	 of	 AT13387	 and	 Gemcitabine	 was	 assessed	 prior	 to	 testing	
combination	efficacy	of	these	agents.		3	non	tumour	bearing	mice	were	dosed	for	a	
total	of	2	weeks.		The	dosing	of	each	agent	was	based	on	previous	tolerability	and	
efficacy	 studies	 on	 these	 as	 single	 agents.	 AT13387	 was	 dosed	 at	 80mg/kg	 once	
weekly	 (Tuesday)	 and	 gemcitabine	 50mg/kg	 twice	 weekly	 (Monday	 and	 Friday)	
(table	 5.14).	 Doses	 were	 omitted	 if	 animals	 sustained	 >15%	 weight	 loss	 and	 the	
experiment	terminated	if	sustained	(72	hrs.)	weight	loss	of	>20%	was	noted.	
	
	
Gemcitabine	
50mg/kg	twice	weekly	
AT13387	 80mg/kg	once	weekly	 3	mice	
Table	5.14	A	table	showing	the	combination	tolerability	of	AT13387	+	Gemcitabine	
[1]:	Treatments,	numbers	of	mice	and	dosing	regime	used.	
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Figure	5.24	A	graph	showing	AT13387	and	gemcitabine	combination	 tolerability:	
the	 x-axis	 shows	 time	of	 experiment	 in	days,	 the	 y-axis	 shows	mouse	weight	 in	
grams.		Blue	crosses	represent	a	dose	of	AT1387,	black	crosses	represents	a	dose	
of	gemcitabine.	Lines	of	best	fit	were	produced	with	a	2	point	moving	average.		
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Figure	 5.25	A	 graph	 showing	AT13387	 and	 gemcitabine	 combination	 tolerability	
[1]	exemplified	by	percentage	weight	loss:	the	x-axis	shows	time	of	experiment	in	
days,	 the	 y-axis	 shows	 percentage	 weight	 loss	 in	 each	 mouse.	 	 Blue	 crosses	
represent	a	dose	of	AT1387,	black	crosses	represents	a	dose	of	gemcitabine.	
	
	
	
!30$
!25$
!20$
!15$
!10$
!5$
0$
5$
10$
0$ 2$ 4$ 6$ 8$ 10$ 12$ 14$ 16$ 18$
%
"M
ou
se
"w
ei
gh
t"c
.f.
"d
ay
1"
ea
ch
"w
ee
k"
"
Time"(days)"
AT13387/Gemcitabine$combina9on$
AT13387/Gemcitabine1combina3on1
141
161
181
201
221
241
01 21 41 61 81 101 121 141 161 181
M
ou
se
&w
ei
gh
t&(
g)
&
Time&(days)&
dose1gemcitabine1
AT13387;11
AT13387;21
AT13387;31
21per.1Mov.1Avg.1(AT13387;1)1
21per.1Mov.1Avg.1(AT13387;2)1
21per.1Mov.1Avg.1(AT13387;3)1
missed1dose1of1gem1
Dose%AT13387%
	 223	
	
Figure	 5.26	A	 graph	 showing	AT13387	 and	 gemcitabine	 combination	 tolerability	
for	mouse	1:	the	x-axis	shows	time	of	experiment	in	days,	the	y-axis	shows	mouse	
weight	 in	 grams.	 	 Blue	 crosses	 represent	 a	 dose	 of	 AT1387,	 black	 crosses	
represents	a	dose	of	gemcitabine.		
	
	
Figure	 5.27	A	 graph	 showing	AT13387	 and	 gemcitabine	 combination	 tolerability	
for	mouse	2:	the	x-axis	shows	time	of	experiment	in	days,	the	y-axis	shows	mouse	
weight	 in	 grams.	 	 Blue	 crosses	 represent	 a	 dose	 of	 AT1387,	 black	 crosses	
represents	a	dose	of	gemcitabine.		
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Figure	5.28	A	graph	showing	AT13387	and	gemcitabine	combination	tolerability	
for	mouse	3:	the	x-axis	shows	time	of	experiment	in	days,	the	y-axis	shows	mouse	
weight	in	grams.		Blue	crosses	represent	a	dose	of	AT1387,	black	crosses	
represents	a	dose	of	gemcitabine.		
	
During	 this	 study	 significant	 weight	 loss	 was	 observed	 that	 necessitated	 missing	
doses.	 	 Two	gemcitabine	doses	 in	 1	 animal	 and	one	 gemcitabine	dose	 in	 another	
See	figures	5.24	to	5.28.			
	
CONCLUSION	
The	 combination	 of	 AT13387	 and	 Gemcitabine	 at	 the	 doses	 tested	 was	 not	 well	
tolerated	owing	to	weight	loss	that	necessitated	missing	doses.		In	light	of	this	fact	
this	 regime	 would	 not	 be	 taken	 forward	 into	 efficacy	 studies	 and	 a	 further	
tolerability	study	would	be	undertaken.			
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5.5.3	AT13387	+	gemcitabine	combination	tolerability	[2]	
The	 modifications	 to	 the	 dosing	 regime	 for	 AT13387	 and	 Gemcitabine	 were	
considered.		Owing	to	the	fact	that	issues	around	weight	loss	were	mostly	observed	
with	 the	 use	 of	 gemcitabine	 in	 previous	 experiments	 the	 decision	 was	 taken	 to	
reduce	the	dose	of	gemcitabine	to	25mg/kg.		3	non	tumour	bearing	nude	mice	were	
used	 to	 test	 this	 dose	modification.	 	 The	 dose	 of	 AT13387	 remained	 at	 80mg/kg	
once	weekly	(see	table	5.15).	
	
	
Gemcitabine	
25mg/kg	twice	weekly	
AT13387	 80mg/kg	once	weekly	 3	mice	
Table	5.15	A	 table	 showing	 the	combination	 tolerability	AT13387	+	Gemcitabine	
[2]:	Treatments,	numbers	of	mice	and	dosing	regime	used.	
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Figure	 5.29	 A	 graph	 showing	 AT13387	 and	 gemcitabine	 combination	
tolerability[2]:	 the	 x-axis	 shows	 time	 of	 experiment	 in	 days,	 the	 y-axis	 shows	
mouse	weight	in	grams.		Orange	crosses	represent	a	dose	of	AT1387,	black	crosses	
represents	a	dose	of	gemcitabine.		
	
	
14#
16#
18#
20#
22#
24#
0# 2# 4# 6# 8# 10# 12# 14# 16# 18#
M
ou
se
&w
ei
gh
t&(
g)
&
Time&(days)&
dose#gemcitabine#
AT1338781#
AT1338782#
AT1338783#
2#per.#Mov.#Avg.#(AT1338781)#
2#per.#Mov.#Avg.#(AT1338782)#
2#per.#Mov.#Avg.#(AT1338783)#
+&dose#AT13387&
	 227	
	
Figure	 5.30	A	 graph	 showing	AT13387	 and	 gemcitabine	 combination	 tolerability	
[2]	exemplified	by	percentage	weight	loss:	the	x-axis	shows	time	of	experiment	in	
days,	 the	 y-axis	 shows	 percentage	 weight	 loss	 in	 each	mouse.	 	 Orange	 crosses	
represent	a	dose	of	AT1387,	black	crosses	represents	a	dose	of	gemcitabine.		
	
In	 this	 study	 the	 combination	 of	 AT13387	 and	 gemcitabine	 was	 better	 tolerated	
with	 only	 one	 animal	 sustaining	 weight	 loss	 that	 necessitated	 a	 missed	 dose	 of	
gemcitabine	at	the	end	of	the	first	week	(see	figure	5.29	and	5.30).	
	
CONCLUSION	
The	 combination	 of	 AT13387	 at	 80mg/kg	 once	weekly	 and	Gemcitabine	 25mg/kg	
twice	 weekly	 was	 better	 tolerated	 than	 previous	 dosing	 schedules	 tested.	 	 This	
dosing	 regime	was	 deemed	 acceptable	 to	 take	 forward	 to	 efficacy	 studies	 of	 this	
combination	of	agents.	
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5.6	COMBINATION	EFFICACY	STUDIES	
	
5.6.1	AT7519	+	gemcitabine	combination	efficacy	
From	 combination	 tolerability	 studies	 and	 single	 agent	 efficacy	 studies	 this	
experiment	was	undertaken	with	the	aim	to	find	the	efficacious	dosing	schedule	for	
the	 combination	 of	 AT7519	 and	 gemcitabine	 and	 observe	 any	 superior	 effect	 to	
drugs	used	as	single	agents.	 	The	dosing	of	AT7519	7.5mg/kg	twice	daily	for	5	day	
per	week	and	50mg/kg	gemcitabine	twice	weekly	was	used.	 	Combined	treatment	
was	compared	to	vehicle	control	(saline)	and	single	agent	treatment	with	6	mice	per	
group	(see	table	5.16	for	summary	of	treatment	groups).	 	Dosing	was	commenced	
13	 days	 after	 tumours	 were	 injected	 subcutaneously	 and	were	 all	 measurable	 in	
order	 to	enable	volume	calculations.	 	 Treatment	was	carried	out	 for	3	weeks	and	
the	experimental	endpoints	as	previously	described	adverse	events	or	to	the	end	of	
the	 experiment	 which	 was	 terminated	 38	 post	 tumour	 introduction	 and	 25	 days	
post	treatment	commencing.	
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Group	 Agent	 Dose	 Number	of	animals	
1	 Vehicle	1	(saline)	 50mg/kg	twice	weekly	 6	
Vehicle	2	(saline)	 7.5mg/kg	BD	(1-5	days)	
2	 Gemcitabine	 50mg/kg	twice	weekly	 6	
Vehicle	2	(saline)	 7.5mg/kg	BD	(1-5	days)	
3	 Vehicle	1	(saline)	 50mg/kg	twice	weekly	 6	
AT7519	 7.5mg/kg	BD	(1-5	days)	
4	 Gemcitabine	 50mg/kg	twice	weekly	 6	
AT7519	 7.5mg/kg	BD	(1-5	days)	
Table	 5.16	 A	 table	 showing	 the	 combination	 efficacy	 study	 of	 AT7519	 +	
Gemcitabine:	Treatments,	numbers	of	mice	and	dosing	regime	used.	
	
In	the	combination	efficacy	study	of	AT7519	and	gemcitabine	a	reduction	in	tumour	
growth	 was	 observed	 that	 was	 superior	 to	 vehicle	 control	 (p=0.0041)	 as	 well	 as	
either	 AT7519	 (p=0.0173)	 or	 gemcitabine	 alone	 (p=0.0611)	 (data	 shown	 in	 table	
5.17	and	figures	5.31	and	5.32).	
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Treatment	 Mean	
coefficient	
difference	
N	 P	value	
compared	with	
control	
P	value	
compared	with	
gemcitabine	
P	value	
compared	
with	AT7519	
Saline	
	
0.05	 6	 -	 0.9991	 0.9906	
Gemcitabine	
	
0.162	 6	 0.0198	 -	 0.1477	
AT7519	
	
0.114	 6	 0.029	 0.9374	 -	
AT7519	+	
Gemcitabine	
0.249	 6	 0.0041	 0.0611	 0.0173	
Table	 5.17	 A	 table	 of	 mean	 coefficient	 difference	 for	 each	 group	 before	 and	 after	
treatment	with	p-values	for	paired	T-test	comparing	co-efficient	change.		
	
	
Figure	5.31	A	graph	showing	the	tumour	volume	of	a	mouse	treated	with	saline	
vehicle	control	with	log	regression	analysis	co-efficient	plotted.	The	x-axis	shows	
time	from	injection	of	tumour	cells	and	the	y-axis	shows	tumour	volumes	in	mm3.		
	
AT7519'+'Gemcitabine'
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ASSESSMENT OF THE CDK INHIBITOR AT7519 IN A XENOGRAFT 
MODEL OF PANCREATIC CANCER 
•  Pancreatic cancer continues to have a poor prognosis with over 70 000 deaths reported in Europe (2008). 
•  Chemotherapy is the treatment of choice in advanced disease and has a proven role in the adjuvant setting 
though current clinical agents, such as gemcitabine,  only prolong survival by a matter of weeks;  highlighting 
the need for more effective novel therapies 
•  The Cyclin Dependent Kinase (CDK)  family of protein kinases are pivotal 
  in cell cycle regulation 
•  AT7519 is a selective CDK inhibitor providing potent inhibition of CDK 1, 2, 4, 5 and 9 (Astex Therapeutics).  
Figures 3: Tumour volumes in mice treated with vehicle control (A), AT7519 (B) and 
gemcitabine (C).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 
AT7519 group than the control group (p=0.045). 
Initial xenograft experiments of AT7519 as a single agent showed 
a significant reduction in tumour growth compared with vehicle 
control 
(A) Saline Control (B) AT7519 (C) Gemcitabine 
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Figure 4: Mean difference in growth coefficients 
for treatments and controls. 
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Figure 1: Individual mice weights (g) for 3 mice 
dosed at  7.5mg/kg twice daily, weekdays for 2 
weeks with AT7519.  
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Figure 2: Individual mouse weights (g) for 3 mice dosed 
with  50mg/kg of gemcitabine twice per week and 
7.5mg/kg of AT7519 twice daily for 5 days.  Total 
treatment of 2 weeks. 
METHODS 
•  Cell proliferation assays  and isobolar analysis were performed in triplicate using 
EZ4U assay (BioMedica), measured 48 h or 72 h after drug treatment.  
•  Cell cycle analysis was performed 4 h,7 h,24 h and 48h after treatment of cells 
with 10mM AT7519, using flow cytometry to determine propidium iodide 
incorporation. 
•  Western blot analysis was performed using standard methods with ECL 
detection. 
•  Statistical analysis was performed using SPSS. 
•  In vivo studies using a murine xenograft model, BALB/c (CAnN.Cg-Foxn1nu/Cr) 
nude mice with MiaPaCa2 pancreatic cancer cells, tumour volumes measured 
with external callipers.!
A xenograft model of AT7519 in combination with gemcitabine showed 
superior reduction in tumour growth compared with gemcitabine and 
AT7519 as single age ts a d vehicle control 
   AT7519 inhibited the proliferation 
of a range of pancreatic cancer cell 
lines with  IC50 values from 0.2– 
2uM    
Figure 7: Anti-proliferative activity of 
AT17519 
!!!!
Cell! lines! resistant! to! gemcitabine! do! not! appear! to! be!
resistant!to!AT7519:!SuitT2!GR!(a!gemcitabine!resistant!cell!
line)! has! a! 60! fold! higher! gemcitabine! IC50! and! an!
equivalent!IC50!with!AT7519.!
Cell(line( IC50(AT7519( IC50(
Gemcitabine(
SuitT2! 2000nM! 10nM!
SuitT2!(GR)! 700nM! 625nM!
MiapacaT2! 390nM! 25nM!
PancT1! 275nM! 150nM!
CFpac! 180nM! 180nM!
FamPac! 210nM! 5.5nM!
Paca!2! 250nM! 5nM!
   Cell cycle analysis displayed a marked reduction 
of cells in the G0/G1 and S phases with an 
increase of cells in G2/M phase following 
treatment with AT7519 compared to 
untreated(p<0.0001) 
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Figure 8: Effects of AT7519 on cell cycle distribution of 
Suit-2 pancreatic cancer cell line. 
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 Isobolar analysis of AT7519 combined 
with gemcitabine suggested an additive 
effect 
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Figure 9: Isobolar graph of cells treated with 
gemcitabine for 24 h followed by combination of 
gemcitabine + AT7519 for 48 h.  
The line represents an additive effect.  The area 
under the curve would be lower if there was 
synergy and greater if there was antagonism. 
CONCLUSIONS(
Pancrea7c!cancer!cell!lines!develop!resistance!to!gemcitabine!(standard!chemotherapy)!aZer!rela7vely!brief!exposure!to!the!drug.!!!AT7519!inhibited!growth!
in!a!range!of!pancrea7c!!cancer!cell!lines!including!one!that!has!acquired!gemcitabine!resistance!and!was!eﬀec7ve!in!combina7on!with!gemcitabine.!
In!vivo!AT7519!was!eﬀec7ve!as!a!single!agent!in!a!xenograZ!model!and!had!superior!eﬀect!in!combina7on!with!gemcitabine!oﬀering!possible!future!
combina7on!therapy.!
AT7519(is((a(promising(agent(for(further(invesSgaSon(to(overcome(the(problem(of(acquired(gemcitabine(resistance(in(pancreaSc(cancer.!!!
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• Cell!cycle!analysis!supports!an!AT7519!G2/M!block!(as!!expected!if!cdc2!
ac7vity!is!inhibited).!!!
!
• CDK1!levels!were!unchanged,!but!phosphoryla7on!of!!pp1Ta!was!inhibited!
(shown!to!result!in!mito7c!collapse!!aZer!nuclear!envelope!breakdown)!
!
Figure 10: Effects of 
AT7519 on Suit- 2 
cells treated with 
AT7519 for 48 h. 
Western blot analysis demonstrated the effect 
on downstream targets of AT7519 
pp1Tα!
AT7519 was well tolerated as a single 
agent and in combination with 
gemctiabine in nude mice with no 
significant morbidity or mortality 
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Figures 5: Tumour volumes in mice treated with Saline vehicle control(A) and Gemcitabine 
+ AT7519 (B).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 
combination treatment  group than the control group (p=0.0041). 
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ASSESSMENT OF THE CDK INHIBITOR AT7519 IN A XENOGRAFT 
MODEL OF PANCREATIC CANCER 
•  Pancreatic cancer continues to have a poor prognosis with over 70 000 deaths reported in Europe (2008). 
•  Chemotherapy is the treatment of choice in advanced disease and has a proven role in the adjuvant setting 
though current clinical agents, such as gemcitabine,  only prolong survival by a matter of weeks;  highlighting 
the need for more effective novel therapies 
•  The Cyclin Dependent Kinase (CDK)  family of protein kinases are pivotal 
  in cell cycle regulation 
•  AT7519 is a selective CDK inhibitor providing potent inhibition of CDK 1, 2, 4, 5 and 9 (Astex Therapeutics).  
Figures 3: Tumour volumes in mice treated with vehicle control (A), AT7519 (B) and 
gemcitabine (C).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly gr ater for the 
AT7519 group than the control group (p=0.045). 
Initial xenograft experiments of AT7519 as a single agent showed 
a significant reduction i  tum ur g owth co pared ith vehicle 
control 
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Figure 1: Individual mice weights (g) for 3 mice 
dosed at  7.5mg/kg twice daily, weekdays for 2 
weeks with AT7519.  
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Figure 2: Individual mouse weights (g) for 3 mice dosed 
with  50mg/kg of gemcitabine twice per week and 
7.5mg/kg of AT7519 twice daily for 5 days.  Total 
treatment of 2 weeks. 
METHODS 
•  Cell proliferation assays  and isobolar analysis were performed in triplicate using 
EZ4U assay (BioMedica), measured 48 h or 72 h after drug treatment.  
•  Cell cycle analysis was performed 4 h,7 h,24 h and 48h after treatment of cells 
with 10mM AT7519, using flow cytometry to determine propidium iodide 
incorporation. 
•  Western blot analysis was performed using standard methods with ECL 
detection. 
•  Statistical analysis was performed using SPSS. 
•  In vivo studies using a murine xenograft model, BALB/c (CAnN.Cg-Foxn1nu/Cr) 
nude mice with MiaPaCa2 pancreatic cancer cells, tumour volumes measured 
with external callipers.!
A xenograft model of AT7519 in combination with gemcitabine showed 
superior reduction in tumour growth compared with gemcitabine and 
AT7519 as single agents and vehicle control 
   AT7519 inhibited the proliferation 
of a range of pancreatic cancer cell 
lines with  IC50 values from 0.2– 
2uM    
Figure 7: Anti-proliferative ctivity of 
AT17519 
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Cell! lines! resistant! to! gemcitabine! do! not! appear! to! be!
resistant!to!AT7519:!SuitT2!GR!(a!gemcitabine!resistant!cell!
line)! has! a! 60! fold! higher! gemcitabine! IC50! and! an!
equivalent!IC50!with!AT7519.!
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   Cell cycle analysis displayed a marked reduction 
of cells in the G0/G1 and S phases with an 
increase of cells in G2/M phase following 
tre tment with AT7519 compared to 
untreated(p<0.0001) 
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Figure 8: Effects of AT7519 on cell cycle distribution of 
Suit-2 pancreatic cancer cell line. 
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 Isobolar analysis of AT7519 combined 
with gemcitabine suggested an additive 
effect 
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Figure 9: Isobolar graph of cells treated with 
gemcitabine for 24 h followed by combination of 
gemcitabine + AT7519 for 48 h.  
The line represents an additive effect.  The area 
under the curve would be lower if there was 
synergy and greater if there was antagonism. 
CONCLUSIONS(
Pancrea7c!cancer!cell!lines!develop!resistance!to!gemcitabine!(standard!chemotherapy)!aZer!rela7vely!brief!exposure!to!the!drug.!!!AT7519!inhibited!growth!
in!a!range!of!pancrea7c!!cancer!cell!lines!including!one!that!has!acquired!gemcitabine!resistance!and!was!eﬀec7ve!in!combina7on!with!gemcitabine.!
In!vivo!AT7519!was!eﬀec7ve!as!a!single!agent!in!a!xenograZ!model!and!had!superior!eﬀect!in!combina7on!with!gemcitabine!oﬀering!possible!future!
combina7on!therapy.!
AT7519(is((a(promising(agent(for(further(invesSgaSon(to(overcome(the(problem(of(acquired(gemcitabine(resistance(in(pancreaSc(cancer.!!!
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cells treated with 
AT7519 for 48 h. 
Western blot analysis demonstrated the effect 
on downstream targets of AT7519 
pp1Tα!
AT7519 was well tolerated as a single 
agent and in combination with 
gemctiabine in nude mice with no 
significant morbidity or mortality 
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Figures 5: Tumour volumes in mice treated with Saline vehicle control(A) and Gemcitabine 
+ AT7519 (B).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greate  for the 
combination treatment  group than the control group (p=0.0041). 
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Figure	5.32	A	graph	showing	the	tumour	volume	of	a	mouse	treated	with	AT7519	
(7.5mg/kg	BD	 for	5	of	7	day	 treatment	period)	and	gemcitabine	 (50mg/kg	 twice	
weekly).	 Log	 regression	analysis	 co-efficients	 are	plotted.	 The	 x-axis	 shows	 time	
from	injection	of	tumour	cells	and	the	y-axis	shows	tumour	volumes	in	mm3.		
	
	
	
	
The	combination	of	AT7519	and	gemcitabine	was	relatively	well	tolerated	from	day	
23	a	small	number	of	subjects	started	to	display	signs	of	 ill	health	 likely	related	to	
the	on	going	tumour	burden	as	non	had	tumour	resolution,	this	only	affected	3	of	
the	combination	therapy	mice.	(Table	5.18	shows	why	mice	were	culled	prior	to	the	
end	of	the	experiment).	
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ASSESSMENT OF THE CDK INHIBITOR AT7519 IN A XENOGRAFT 
MODEL OF PANCREATIC CANCER 
•  Pancreatic cancer continues to have a poor prognosis with over 70 000 deaths reported in Europe (2008). 
•  Chemotherapy is the treatment of choice in advanced disease and has a proven role in the adjuvant setting 
though current clinical agents, such as gemcitabine,  only prolong survival by a matter of weeks;  highlighting 
the need for more effective novel therapies 
•  The Cyclin Dependent Kinase (CDK)  family of protein kinases are pivotal 
  in cell cycle regulation 
•  AT7519 is a selective CDK inhibitor providing potent inhibition of CDK 1, 2, 4, 5 and 9 (Astex Therapeutics).  
Figures 3: Tumour volumes in mice treated with vehicle control (A), AT7519 (B) and 
gemcitabine (C).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 
AT7519 group than the control group (p=0.045). 
Initial xenograft experiments of AT7519 as a single agent showed 
a significant reduction in tumour growth compared with vehicle 
control 
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Figure 1: Individual mice weights (g) for 3 mice 
dosed at  7.5mg/kg twice daily, weekdays for 2 
weeks with AT7519.  
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Figure 2: Individual mouse weights (g) for 3 mice dosed 
with  50mg/kg of gemcitabine twice per week and 
7.5mg/kg of AT7519 twice daily for 5 days.  Total 
treatment of 2 weeks. 
METHODS 
•  Cell proliferation assays  and isobolar analysis were performed in triplicate using 
EZ4U assay (BioMedica), measured 48 h or 72 h after drug treatment.  
•  Cell cycle analysis was performed 4 h,7 h,24 h and 48h after treatment of cells 
with 10mM AT7519, using flow cytometry to determine propidium iodide 
incorporation. 
•  Western blot analysis was performed using standard methods with ECL 
detection. 
•  Statistical analysis was performed using SPSS. 
•  In vivo studies using a murine xenograft model, BALB/c (CAnN.Cg-Foxn1nu/Cr) 
nude mice with MiaPaCa2 pancreatic cancer cells, tumour volumes measured 
with external callipers.!
A xenograft model of AT7519 in combination with gemcitabine showed 
superior reduction in tumour growth compared with gemcitabine and 
AT7519 as single agents and vehicle control 
   AT7519 inhibited the proliferation 
of a range of pancreatic cancer cell 
lines with  IC50 values from 0.2– 
2uM    
Figure 7: Anti-proliferative activity of 
AT17519 
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Cell! lines! resistant! to! gemcitabine! do! not! appear! to! be!
resistant!to!AT7519:!SuitT2!GR!(a!gemcitabine!resistant!cell!
line)! has! a! 60! fold! higher! gemcitabine! IC50! and! an!
equivalent!IC50!with!AT7519.!
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Figure 8: Effects of AT7519 on cell cycle distribution of 
Suit-2 pancreatic cancer cell line. 
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Figure 9: Isobolar graph of cells treated with 
gemcitabine for 24 h followed by combination of 
gemcitabine + AT7519 for 48 h.  
The line represents an additive effect.  The area 
under the curve would be lower if there was 
synergy and greater if there was antagonism. 
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Figures 5: Tumour volumes in mice treated with Saline vehicle control(A) and Gemcitabine 
+ AT7519 (B).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greater for the 
combination treatment  group than the control group (p=0.0041). 
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ASSESSMENT OF THE CDK INHIBITOR AT7519 IN A XENOGRAFT 
MODEL OF PANCREATIC CANCER 
•  Pancreatic cancer continues to have a poor prognosis with over 70 000 deaths reported in Europe (2008). 
•  Chemotherapy is the treatment of choice in advanced disease and has a proven role in the adjuvant setting 
though current clinical agents, such as gemcitabine,  only prolong survival by a matter of weeks;  highlighting 
the need for more effective novel therapies 
•  The Cyclin Dependent Kinase (CDK)  family of protein kinases are pivotal 
  in cell cycle regulation 
•  AT7519 is a selective CDK inhibitor providing potent inhibition of CDK 1, 2, 4, 5 and 9 (Astex Therapeutics).  
Figures 3: Tumour volumes in mice treated with vehicle control (A), AT7519 (B) and 
gemcitabine (C).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly gr ater for the 
AT7519 group than the control group (p=0.045). 
Initial xenograft experiments of AT7519 as a single agent showed 
a significant reduction i  tum ur g owth co pared ith vehicle 
control 
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Figure 4: Mean difference in growth coefficients 
for treatments and controls. 
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Figure 1: Individual mice weights (g) for 3 mice 
dosed at  7.5mg/kg twice daily, weekdays for 2 
weeks with AT7519.  
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Figure 2: Individual mouse weights (g) for 3 mice dosed 
with  50mg/kg of gemcitabine twice per week and 
7.5mg/kg of AT7519 twice daily for 5 days.  Total 
treatment of 2 weeks. 
METHODS 
•  Cell proliferation assays  and isobolar analysis were performed in triplicate using 
EZ4U assay (BioMedica), measured 48 h or 72 h after drug treatment.  
•  Cell cycle analysis was performed 4 h,7 h,24 h and 48h after treatment of cells 
with 10mM AT7519, using flow cytometry to determine propidium iodide 
incorporation. 
•  Western blot analysis was performed using standard methods with ECL 
detection. 
•  Statistical analysis was performed using SPSS. 
•  In vivo studies using a murine xenograft model, BALB/c (CAnN.Cg-Foxn1nu/Cr) 
nude mice with MiaPaCa2 pancreatic cancer cells, tumour volumes measured 
with external callipers.!
A xenograft model of AT7519 in combination with gemcitabine showed 
superior reduction in tumour growth compared with gemcitabine and 
AT7519 as single agents and vehicle control 
   AT7519 inhibited the proliferation 
of a range of pancreatic cancer cell 
lines with  IC50 values from 0.2– 
2uM    
Figure 7: Anti-proliferative ctivity of 
AT17519 
!!!!
Cell! lines! resistant! to! gemcitabine! do! not! appear! to! be!
resistant!to!AT7519:!SuitT2!GR!(a!gemcitabine!resistant!cell!
line)! has! a! 60! fold! higher! gemcitabine! IC50! and! an!
equivalent!IC50!with!AT7519.!
Cell(line( IC50(AT7519( IC50(
Gemcitabine(
SuitT2! 2000nM! 10nM!
SuitT2!(GR)! 700nM! 625nM!
MiapacaT2! 390nM! 25nM!
PancT1! 275nM! 150nM!
CFpac! 180nM! 180nM!
FamPac! 210nM! 5.5nM!
Paca!2! 250nM! 5nM!
   Cell cycle analysis displayed a marked reduction 
of cells in the G0/G1 and S phases with an 
increase of cells in G2/M phase following 
tre tment with AT7519 compared to 
untreated(p<0.0001) 
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Figure 8: Effects of AT7519 on cell cycle distribution of 
Suit-2 pancreatic cancer cell line. 
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 Isobolar analysis of AT7519 combined 
with gemcitabine suggested an additive 
effect 
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Figure 9: Isobolar graph of cells treated with 
gemcitabine for 24 h followed by combination of 
gemcitabine + AT7519 for 48 h.  
The line represents an additive effect.  The area 
under the curve would be lower if there was 
synergy and greater if there was antagonism. 
CONCLUSIONS(
Pancrea7c!cancer!cell!lines!develop!resistance!to!gemcitabine!(standard!chemotherapy)!aZer!rela7vely!brief!exposure!to!the!drug.!!!AT7519!inhibited!growth!
in!a!range!of!pancrea7c!!cancer!cell!lines!including!one!that!has!acquired!gemcitabine!resistance!and!was!eﬀec7ve!in!combina7on!with!gemcitabine.!
In!vivo!AT7519!was!eﬀec7ve!as!a!single!agent!in!a!xenograZ!model!and!had!superior!eﬀect!in!combina7on!with!gemcitabine!oﬀering!possible!future!
combina7on!therapy.!
AT7519(is((a(promising(agent(for(further(invesSgaSon(to(overcome(the(problem(of(acquired(gemcitabine(resistance(in(pancreaSc(cancer.!!!
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• Cell!cycle!analysis!supports!an!AT7519!G2/M!block!(as!!expected!if!cdc2!
ac7vity!is!inhibited).!!!
!
• CDK1!levels!were!unchanged,!but!phosphoryla7on!of!!pp1Ta!was!inhibited!
(shown!to!result!in!mito7c!collapse!!aZer!nuclear!env lope!breakdown)!
!
Figure 10: Effects of 
AT7519 on Suit- 2 
cells treated with 
AT7519 for 48 h. 
Western blot analysis demonstrated the effect 
on downstream targets of AT7519 
pp1Tα!
AT7519 was well tolerated as a single 
agent and in combination with 
gemctiabine in nude mice with no 
significant morbidity or mortality 
!
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Figures 5: Tumour volumes in mice treated with Saline vehicle control(A) and Gemcitabine 
+ AT7519 (B).   
Log regression analysis gave coefficients that declined after treatment. Paired T-tests 
comparing coefficient change showed that this decline was significantly greate  for the 
combination treatment  group than the control group (p=0.0041). 
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Subject	 Day	 Reason	for	cull	
Mouse	2	 23	 Tumour	volume	
Mouse	5	 23	 General	health	
Mouse	1	 24	 General	health	
Table	5.18	A	table	of	the	day	and	reasoning	for	cull	of	mice	prior	to	the	end	of	the	
experiment.		The	AT7519	+	Gemcitabine	treatment	group	mice	only	shown.	
	
	
CONCLUSION	
In	 this	 xenograft	 model	 of	 pancreatic	 cancer	 AT7519	 combined	 with	 gemcitabine	
was	 well	 tolerated	 and	 demonstrated	 significant	 reduction	 in	 tumour	 growth	
compared	with	vehicle	control	(p=0.0041),	AT7519	as	a	single	agent	(p=0.0173)	and	
to	a	lesser	extent	gemcitabine	as	a	single	agent	(p=0.0611).	
	
	
5.6.2	AT13387	+	gemcitabine	combination	efficacy	
Following	optimization	of	 the	 tolerated	 combination	of	AT13387	and	gemcitabine	
an	efficacy	study	was	undertaken	with	the	aim	to	demonstrate	an	efficacious	dosing	
schedule	of	the	combined	agents	superior	to	either	agent	alone.	
	
The	 dosing	 of	 AT13387	 780mg/kg	 once	 weekly	 and	 25mg/kg	 gemcitabine	 twice	
weekly	 was	 used	 (table	 5.19	 shows	 groupings	 used).	 	 In	 an	 attempt	 to	 avoid	
significant	weight	loss	dosing	of	the	agents	was	further	spaced	out	compared	with	
previous	experiments.	 	Gemcitabine	was	administered	on	Mondays	and	Saturdays	
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(previously	 Monday	 and	 Friday)	 and	 AT13387	 was	 administered	 on	 Tuesdays	 as	
previous	 experiments.	 	 	 	 Combined	 treatment	 was	 compared	 to	 vehicle	 control	
(saline	or	cyclodextrin)	and	single	agent	treatment	with	6	mice	per	group.	 	Dosing	
was	commenced	13	days	after	tumours	were	injected	subcutaneously	and	were	all	
measurable	in	order	to	enable	volume	calculations.		Treatment	was	carried	out	for	3	
weeks	and	the	experimental	endpoints	as	previously	described	adverse	events	or	to	
the	end	of	the	experiment	which	was	terminated	33	post	tumour	introduction	and	
20	days	post	treatment	commencing.	
	
Group	 Agent	 Dose	 Number	of	animals	
1	 Vehicle	1	(saline)	
	
25mg/kg	twice	weekly	 6	
Vehicle	2	
(cyclodextrin)	
	
80mg/kg	once	weekly	
2	 Gemcitabine	
	
25mg/kg	twice	weekly	 6	
Vehicle	2	
(cyclodextrin)	
	
80mg/kg	once	weekly	
3	 Vehicle	1	(saline)	
	
25mg/kg	twice	weekly	 6	
AT13387	
	
80mg/kg	once	weekly	
4	 Gemcitabine	
	
25mg/kg	twice	weekly	 6	
AT13387	
	
80mg/kg	once	weekly	
Table	 5.19	 A	 table	 of	 the	 AT13387	 +	 gemcitabine	 combination	 efficacy	 study:	
Treatments,	numbers	of	mice	and	dosing	regime.	
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Figure	5.33	A	graph	showing	the	tumour	volume	of	a	mouse	treated	with	
cyclodextrin	vehicle	control	with	log	regression	analysis	co-efficient	plotted.	The	
x-axis	shows	time	from	injection	of	tumour	cells	and	the	y-axis	shows	tumour	
volumes	in	mm3.		
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Figure	 5.34	 A	 graph	 showing	 tumour	 volume	 of	 mouse	 treated	 with	 AT13387	
(80mg/kg	once	weekly)	and	gemcitabine	(25mg/kg	twice	weekly).	Log	regression	
analysis	co-efficiens	are		plotted.	The	x-axis	shows	time	from	injection	of	tumour	
cells	and	the	y-axis	shows	tumour	volumes	in	mm3.		
	
	
Following	promising	 single	agent	 results	 supporting	a	 reduction	 in	 tumour	growth	
following	AT13387	treatment	the	compound	was	tested	in	vivo	in	combination	with	
gemcitabine.	 Once	 weekly	 dosing	 of	 AT13387	 at	 80mg/kg	 combined	 with	 twice-
weekly	dosing	of	gemcitabine	at	25mg/kg	was	tolerated	 in	vivo.	This	schedule	was	
selected	 as	 higher	 doses	 of	 gemcitabine	 combined	 with	 AT13387	 resulted	 in	
substantial	weight	 loss	which,	 although	 recoverable,	 resulted	 in	missed	 dosing	 at	
scheduled	time	points.		Tumour	growth	was	significantly	slowed	with	any	treatment	
versus	untreated	controls	(figure	5.33	and	5.34)		(P<0.004);	however,	the	tolerated	
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combined	 dosing	 did	 not	 improve	 growth	 inhibition	 over	 either	 AT13387	 or	
gemcitabine	administered	alone	(figure	5.35).		
	
	
Figure	 5.35	A	 graph	 showing	 the	 relative	 tumour	 volumes	 in	mice	 treated	with	
Saline	 vehicle	 control,	 Gemcitabine	 alone,	 AT13387	 alone	 and	 Gemcitabine	 +	
AT13387.	Treatment	 commenced	on	day	13.	The	x-axis	 shows	 time	 in	days	 from	
injection	of	cells	and	the	y-axis	shows	the	relative	tumour	volumes.		
	
Adverse	 events	 were	 encountered	 during	 this	 experiment.	 	 Three	 animals	 died	
unexpectedly	and	one	was	sacrificed	owing	to	ill	health	(2	had	combination	therapy	
and	 2	 single	 agent	AT13387).	 	Necropsy	was	 performed	on	 the	 animals	 that	 died	
unexpectedly	showed	ascites	and	dilated	bowel	in	all	3	animals.	
During	 the	 experiments	 3	 doses	 of	 gemcitabine	 and	 one	 dose	 of	 AT13387	 was	
missed	 in	 the	 combination	 experiment	 and	 one	 dosed	 was	 missed	 in	 the	
gemcitabine	single	agent	group	all	owing	to	weight	loss	>15%.	
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CONCLUSION	
AT13387	 and	 gemcitabine	 reduced	 tumour	 growth	 significantly	 compared	 to	
controls	but	was	no	better	than	single	agents	in	slowing	this	growth.		Furthermore	
there	 were	 issues	 around	 tolerability	 and	 adverse	 events	 that	 did	 not	 support	 a	
synergistic	or	even	additive	effect	of	these	agents.	
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CHAPTER	6:	DISCUSSION	
	
In	 this	 thesis	 I	 have	 shown	 the	 combination	 of	 gemcitabine	 and	 novel	 agents	
targeting	CDK	and	HSP	can	be	made	to	improve	response	in	models	of	PDAC.			
	
While	the	targeting	specific	molecules	and	pathways	has	been	previously		shown	to	
offer	 benefits	 for	 	 pancreatic	 cancer	 patients,	 	 this	 is	 a	 complex	 disease	 with	
multiple	 genetic	 and	 protein	 defects.	 	 Targeting	 pathways	 such	 as	 that	 of	 CDK	
inhibition	 and	 HSP90	 inhibition	 offers	 opportunities	 to	 target	 multiple	 pathways	
including	some	of	those	established	as	important	in	pancreatic	cancer.				
	
6.1	AT7519	–	A	NOVEL	CDK	INHIBITOR	
	
6.1.1	Inhibiton	of	cell	growth	in	vitro	
During	this	research	project	the	in	vitro	effects	of	AT7519	against	pancreatic	cancer	
cells	 lines	 was	 established.	 	 AT7519	 demonstrated	 ability	 to	 induce	 growth	
inhibition	across	a	range	of	pancreatic	cancer	cell	 lines.	 	The	effect	of	AT7519	was	
explored	in	standard	lines	and	an	in-house	developed	gemcitabine	resistant	line.		In	
light	 of	 the	 known	 chemoresistance	 demonstrated	 to	 gemcitabine	 the	 effects	 of	
novel	 agents	 in	 this	 cell	 line	 were	 important.	 	 It	 was	 observed	 that	 AT7519	
demonstrated	ability	to	 inhibit	growth	 in	this	resistant	 line	furthermore	 looking	at	
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the	 relative	 IC50	 values	 the	 resistant	 line	was	more	 sensitive	 to	AT7519	 then	 the	
parent	line,	the	converse	situation	was	true	when	these	cell	lines	were	treated	with	
gemcitabine.			
	
6.1.2	The	issue	of	gemcitabine	resistance	in	PDAC	
Gemcitabine	 resistance	 is	 an	 important	 issue	 to	 overcome	 in	 PDAC	 and	 the	
mechanisms	are	being	uncovered	as	in	vitro	and	in	vivo	study	is	taken	into	this	area.		
The	 action	 of	 gemcitabine	 is	 dependent	 on	 its	 uptake	 into	 cells	 via	 transporters	
including	 hENT1	 and	 2	 (human	 equilibrative	 nucleoside	 transporter	 1	 and	 2)	 and	
hCNT1	 and	 3	 (human	 concentrative	 nucleoside	 transporters	 1	 and	 3)	 then	
intracellular	metabolism	via	dCK	 (enzyme	deoxycytidine	kinase)	 leads	 to	an	active	
metabolite	 that	 is	 taken	 into	 the	 nucleus	 to	 cause	 DNA	 damage	 and	 ultimately	
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The	resistance	to	gemcitabine	seen	in	PDAC	can	be	attributed	both	to	its	ability	to	
reach	 the	 target	 cells	 and	 the	 cellular	 events	 leading	 to	 gemcitabine	metabolism	
including	the	levels	of	transporters	and	enzymes	aforementioned	(Mackey,	Mani	et	
al.	 1998;	 Andersson,	 Aho	 et	 al.	 2009).	 	 	 It	 has	 also	 been	 suggested	 that	 loss	 of	
function	of	p53	may	play	a	role	in	this	resistance.				
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Clearly	from	this	in	vitro	investigation	AT7519,	as	a	CDK	inhibitor,	was	not	subject	to	
the	 same	 cellular	 blocks	 to	 its	 activity	 and	 if	 anything	 was	more	 effective	 in	 the	
gemcitabine	resistant	line,	the	mechanisms	for	this	remain	unknown	but	this	offers	
promise	 for	 AT7519	 as	 a	 potential	 second	 line	 agent	 in	 patients	 who	 have	 not	
responded	 to	 gemcitabine	 therapy	 or	 AT7519	 to	 be	 given	 in	 combination	 with	
gemcitabine	to	attempt	to	overcome	the	resistance	currently	seen.				In	previous	in	
vitro	 studies	 of	 AT7519,	 colorectal	 cell	 lines	 with	 mutant	 p53	 were	 noted	 to	 be	
sensitive	to	AT7519	treatment,	perhaps	this	goes	some	way	to	explaining	why	the	
gemcitabine	resistant	line	investigated	here	was	more	sensitive	to	AT7519(Squires,	
Feltell	et	al.	2009).	
	
6.1.3	Cell	cycle	analysis	of	AT7519	
As	a	single	agent	AT7519	resulted	in	a	clear	cell	cycle	arrest	in	the	G2/M	phase,	with	
a	marked	 reduction	of	 cells	 in	G0/1	 and	 S	phases.	 	 	 	 Its	 activity	 observed	here	 in	
pancreatic	cancer	cell	lines	is	consistent	with	previous	investigations	of	this	agent	in	
other	 solid	 organ	 tumour	 types	 including	 colorectal	models	 (Squires,	 Feltell	 et	 al.	
2009).	 It	 is	 also	 in	 line	 with	 inhibition	 of	 substrates	 of	 CDKs	 1	 and	 2,	 supporting	
AT7519	as	a	potent	inhibitor	of	these	CDKs(Nyberg,	Michelson	et	al.	2002;	Donzelli	
and	 Draetta	 2003).	 When	 AT7519	 and	 gemcitabine	 were	 combined	 the	 effects	
observed	were	more	in	line	with	that	of	gemcitabine	as	a	single	agent,	specifically	S	
phase	accumulation.	Gemcitabine	is	an	S	phase	active	drug	and	evidence	suggests	it	
exerts	a	G1/S	phase	arrest	(Huang	and	Plunkett	1995).		It	has	been	noted	however,	
in	 some	 cell	 lines	 that	 this	 does	 not	 lead	 to	 an	 immediate	 apoptosis	 (Cappella,	
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Tomasoni	et	al.	2001).	 	Although	these	cells	do	experience	blocks	at	G2/M	and	G1	
again	and	have	been	observed	to	subsequently	be	highly	sensitive	to	programmed	
cell	death.		This	has	important	implications	in	combination	therapy	as	this	suggests	
that	additional	cell	cycle	agents	maybe	beneficial	on	these	already	sensitized	cells.		
The	 S	 phase	 accumulation	 observed	 was	 more	 marked	 using	 this	 combination	
compared	 to	 the	 actions	 of	 gemcitabine	 alone	 as	 a	 single	 agent.	 	 This	 raises	 two	
possibilities;	 AT7519	 may	 be	 enhancing	 the	 cell	 cycle	 effects	 of	 gemcitabine	 or	
exerting	effects	on	the	S	phase	checkpoint.	
	
From	 literature	 evidence	 the	 S	 phase	 checkpoint	 is	 in	 part	 dependent	 on	 CDK	 2	
activity,	therefore	AT7519	may	be	exerting	its	effects	on	CDK2	activity	more	notably	
in	 these	 cells	 that	 have	 been	 arrested	 by	 gemcitabine	 activity	 (Bartek	 and	 Lukas	
2003;	 Bartek,	 Lukas	 et	 al.	 2004).	 The	 cell	 cycle	 analysis	 reported	here	 shows	 that	
AT7519	has	different	effects	to	that	of	gemcitabine.		In	combination	the	two	drugs	
increased	apoptosis.	As	these	agents	have	effects	at	different	points	in	the	cell	cycle	
it	is	clear	that	dosing	schedule	has	a	potentially	important	role.			
	
6.1.4	Cytotoxic	effects	and	apoptosis	induced	by	AT7519	
AT7519	ability	to	induce	apoptosis	was	demonstrated	by	caspase	3	activity.		It	was	
noted	 in	vitro	 the	 increased	caspase-3	activity	was	seen	between	16	and	48	hours	
after	 treatment	 with	 AT7519.	 	 In	 this	 data	 presented	 it	 is	 worth	 noting	 that	 an	
exposure	time	of	more	than	24	hours	i.e.	equivalent	or	greater	than	one	cell	cycle,	
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was	required	to	observe	significant	apoptosis.		Perhaps	it	is	at	certain	points	in	the	
cell	cycle	that	AT7519	needs	to	be	present	 in	order	to	 induce	apoptosis.	 	Previous	
investigation	of	AT7519	in	Myeloma	cell	lines	also	noted	apoptosis	between	12	and	
48	 hours	 and	 this	 was	 also	 observed	 in	 colorectal	 cell	 lines(Squires,	 Feltell	 et	 al.	
2009;	Santo,	Vallet	et	al.	2010).	
	
6.1.5	Combination	treatment	of	AT7519	with	standard	therapy	
The	 importance	 of	 scheduling	 AT7519	 with	 gemcitabine	 to	 allow	 both	 agents	 to	
take	maximal	effect	was	further	demonstrated	by	isobolar	analysis.		When	AT7519	
and	 gemcitabine	 were	 combined	 in	 an	 isobolar	 model	 the	 initial	 experiments	
produced	results	consistent	with	antagonism.	 	 It	appeared	that	AT7519	prevented	
gemcitabine	from	having	its	expected	effect.		This	can	be	explained	by	the	fact	that	
Gemcitabine	as	a	nucleoside	analogue	needs	cells	to	be	actively	dividing	in	order	to	
have	 its	effect,	when	cells	are	 treated	with	AT7519	the	G2/M	block	prevents	 this.		
Interestingly	this	same	antagonism	was	not	indicated	in	the	cell	cycle	analysis	where	
gemcitabine	 still	 seemed	 to	be	having	an	effect,	 in	 fact	 the	S	phase	accumulation	
noted	was	more	marked	when	the	drugs	were	combined.	In	light	of	the	antagonism	
observed	 sequential	 addition	 of	 the	 agents	was	 tested.	 	 The	 results	 showed	 that	
when	 cells	 were	 treated	 with	 gemcitabine	 initially	 then	 the	 combination	 of	
gemcitabine	and	AT7519	at	least	an	additive	effect	was	achieved.		Although	this	is	a	
crude	demonstration	it	does	highlight	the	importance	of	agent	scheduling	to	allow	
both	agents	to	have	their	maximal	effect.		This	could	be	taken	further	with	trailing	
different	drug	schedules	but	the	value	of	this	in	an	in	vitro	model	is	questionable	in	
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light	of	the	fact	in	human	dosing	further	factors	play	a	role	in	drug	delivery	such	as	
tumour	microenvironment	therefore	potentially	make	this	effect	less	important.			
	
6.1.6	Current	literature	on	combination	treatment	
The	combination	of	gemcitabine	and	other	novel	CDK	inhibitors	has	been	reported	
in	the	 literature	 in	the	pre	clinical	setting.	 	Flavopiridol	 is	a	selective	CDK	 inhibitor	
with	 a	 profile	 similar	 to	 that	 of	 AT7519	 (inhibition	 of	 CDK	 1,2,4	 and	 7)	 and	 has	
demonstrated	activity	in	a	number	of	tumour	types	in	vitro	and	in	xenograft	models	
(Bible	 and	 Kaufmann	 1996;	 Carlson,	 Dubay	 et	 al.	 1996).	 	 Its	 combination	 therapy	
with	 gemcitabine	 and	 the	 importance	of	 drug	 sequencing	was	 investigated	 in	 the	
pre-clinical	setting.		It	was	noted	that	gemcitabine	followed	by	flavopiridol	resulted	
in	 the	maximum	 antitumour	 effect	 and	 the	 pro	 apoptotic	 effects	 of	 gemcitabine	
were	enhanced.		The	reverse	combination	did	not	show	any	superiority	over	either	
agent	 alone	 (Jung,	Motwani	 et	 al.	 2001).	 	 On	 the	 basis	 of	 this	 clinical	 trails	 have	
commenced	 with	 this	 combination	 using	 the	 drug	 sequencing	 indicated	 by	 pre	
clinical	studies	(Fekrazad,	Verschraegen	et	al.	2010).	
	
6.1.7	Downstream	effects	of	AT7519	
When	 downstream	 markers	 were	 investigated	 the	 effects	 of	 AT7519	 on	 key	
pathways	 in	 the	 cell	 cycle	 was	 demonstrated	 and	 again	 the	 importance	 of	 dose	
scheduling	investigated.		The	decreased	levels	of	cdc2	after	treatment	with	AT7519	
supports	the	G2/M	block	that	was	observed	 in	the	cell	cycle	work.	 	When	AT7519	
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was	 given	 in	 combination	 with	 Gemcitabine	 this	 decrease	 was	 less	 marked	 and	
when	gemcitabine	was	given	prior	to	AT7519	no	effect	on	cdc2	levels	were	noted.		
This	 can	 be	 explained	 by	 the	 effect	 of	 gemcitabine	 causing	 an	 S	 phase	 arrest,	
supported	 by	 the	 cell	 cycle	 activity	 of	 AT7519	 in	 combination	 with	 gemcitabine	
were	 this	marked	accumulation	of	cells	 in	S	phase	occurred.	 	Rb	phosphorylation,	
which	is	catalaysed	by	CDKs	(namely	CDK2)	was	decreased,	this	action	being	in	line	
with	the	expected	CDK	inhibition	AT7519	induced.		The	fact	that	AT7519	is	active	in	
inhibiting	the	phosphorylation	of	Rb,	a	critical	point	that	governs	the	G1/S	transition	
and	therefore	subsequent	DNA	replication,	offers	promise	in	its	potent	action	and	a	
potential	 synergy	with	 gemcitabine	 that	 is	 having	 effects	 at	 this	 point	 in	 the	 cell	
cycle.	 	 This	was	also	observed	 in	phospho	pp1-a	 	 and	phospho	NPM	proving	 that	
AT7519	 has	 an	 effect	 on	 CDK	 inhibition	 as	 all	 of	 these	 proteins	 have	
phosphorylation	that	 is	catalysed	by	CDKs.	 	The	decreased	 levels	of	Phospho	NPM	
were	also	investigated	when	cells	were	treated	with	the	combination	of	AT7519	and	
gemcitabine	and	 this	effect	was	again	present	by	more	marked	with	 combination	
treatment.	 	 This	 perhaps	 is	 explained	 by	 the	 fact	 that	 NPM	 is	 a	 nuclear	 residing	
protein,	 in	 the	 nucleolus	 or	 cytoplasm	 of	 the	 nucleus	 and	 perhaps	 the	 effects	 of	
gemcitabine	and	its	transport	within	the	nucleus	inhibit	its	phosphorylation	further.				
	
In	 targeting	 multiple	 pathways	 general	 CDK	 inhibitors	 such	 as	 AT7519	 provide	 a	
promising	 therapeutic	 option	 excerpting	 both	 direct	 cell	 cycle	 and	 transcription	
effects(Malumbres	 2012),	 evidence	 of	 actions	 on	 some	 of	 these	 known	 aberrant	
pathways	have	already	been	investigated.		Fry	et	al	demonstrated	the	activity	of	PD	
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000332991	on	tumour	xenografts,	this	CDK	inhibitor	specifically	targets	CDK	4	and	6	
and	therefore	the	downstream	phosphorylation	of	Rb(Fry,	Harvey	et	al.	2004).	
	
The	 observations	 on	 downstream	markers	 showed	AT7519	 is	 having	 an	 effect	 on	
the	 cell	 cycle	 although	 these	 were	 not	 significant	 enough	 at	 the	 expected	 IC50	
doses	 of	 AT7519	 to	 establish	 any	 protein	 that	 could	 be	 used	 as	 biomarkers	 for	
treatment	at	this	stage,	changes	in	NPM	were	observed	in	a	phase	I	study	of	AT7519	
but	not	 in	a	consistent	fashion	that	would	highlight	 it	as	a	potential	biomarker	for	
activity	(Mahadevan,	Plummer	et	al.	2011).	
	
6.1.8	In	vivo	investigation	of	AT7519	
In	a	murine	model	AT7519	was	 investigated	as	a	 single	agent	and	 in	 combination	
with	 gemcitabine.	 	 As	 a	 single	 agent	 in	 the	 xenograft	 model	 AT7519	 was	 well	
tolerated	and	there	was	no	observed	adverse	events	or	significant	weight	loss	in	no	
tumour	bearing	mice.		In	the	subsequent	efficacy	study	of	pancreatic	cancer	cell	line	
tumour	bearing	mice	AT7519	remained	well	tolerated	and	proved	to	be	efficacious.		
There	 was	 a	 significant	 reduction	 in	 tumour	 growth	 compared	 to	 control.	 The	
effects	 of	 AT7519	 on	 tumour	 xenografts	 in	 colorectal	 cell	 lines	 showed	 more	
marked	evidence	of	apoptosis	where	regression	of	tumours	was	noted	with	AT7519	
treatment(Squires,	Feltell	et	al.	2009),	the	effects	observed	in	this	model	were	more	
in	 line	 with	 the	 current	 evidence	 for	 CDK	 inhibitors	 in	 Xenograft	 models	 where	
reduction	in	growth	with	no	noted	regressions	have	been	noted	(Patel,	Senderowicz	
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et	 al.	 1998;	 McClue,	 Blake	 et	 al.	 2002).	 More	 recently	 a	 novel	 CDK	 inhibitor	
Dinaciclib	was	 demonstrated	 to	 inhibit	 pancreatic	 cancer	 progression	 in	 a	murine	
model	 and	 its	 CDK	 5	 inhibition	 hypothesized	 to	 affect	 Ras-mediated	 Ral	
activation(Feldmann,	Mishra	et	al.	2011).			
	
AT7519	was	also	tested	in	a	xenograft	model	in	combination	with	gemcitabine.		This	
study	would	to	be	pivotal	 in	supporting	the	use	of	AT7519	in	pancreatic	cancer	as	
any	novel	agent	would	be	tested	alongside	the	standard	therapy	if	it	were	advanced	
to	 human	 trials,	 therefore	 proving	 compatibility	 or	 synergy	 with	 the	 standard	
therapy	would	be	mandatory.		In	this	murine	model	the	combination	of	AT7519	and	
Gemcitabine	 was	 well	 tolerated	 and	 proved	 to	 be	 efficacious.	 	 The	 combination	
treated	mice	had	a	significant	reduction	in	tumour	growth	compared	to	control	and	
AT7519	as	a	 single	agent,	 there	was	also	a	 trend	 for	 superiority	over	gemcitabine	
alone	though	this	was	not	quite	statistically	significant	(	p	=	0.0611).	 	 	 	The	results	
gained	here	are	similar	to	that	of	other	work	done	on	CDK	inhibition	in	pancreatic	
cancer	 models.	 	 P276	 (a	 CDK	 4	 inhibitor)	 was	 tested	 in	 combination	 with	
gemcitabine	 in	a	comparable	animal	model.	 	 In	this	model	combination	treatment	
with	P276	and	gemcitabine	was	superior	to	control	and	either	as	a	single	agent	and	
no	significant	toxicity	was	encountered	(Subramaniam,	Periyasamy	et	al.	2012).		In	
this	model	PANC-1	(kras	mutated	line	relatively	resistant	to	gemcitabine)	was	used	
and	neither	the	novel	agent	or	gemcitabine	caused	any	significant	tumour	growth	
suppression	as	a	single	agent.		This	raises	an	interesting	discussion	point	regarding	
the	effects	seen	in	our	model.		If	it	were	repeated	in	a	more	gemcitabine	resistant	
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line	 such	as	PANC-1	or	 SUIT-2	GR	 the	effects	of	 the	 combination	 therapy	may	be	
more	marked.		
	
6.1.9		The	relevance	of	CDK	inhibtion	to	PDAC	
Gemcitabine	resistance	in	pancreatic	cancer	remains	an	important	issue	that	limits	
current	 therapeutic	 results.	 	 The	 inability	 of	 gemcitabine	 to	 induce	 apoptosis	 in	 a	
large	number	of	pancreatic	 tumours	 is	multifactorial	but	 the	 intimate	 relationship	
between	the	cell	cycle	and	programmed	cell	death	cannot	be	dismissed	for	example	
the	 central	 role	 of	 p53	 in	 both	 these	 processes	 which	 upon	 its	 loss	 of	 normal	
function	leads	to	cell	cycle	control	loss	and	alterations	in	the	pathway	to	apoptosis	
conferring	gemcitabine	resistance(Galmarini,	Clarke	et	al.	2002).	
	
Regarding	 the	 use	 of	 CDK	 inhibitors	 in	 pancreatic	 cancer	 the	 important	 question	
remains	that	which	CDKs	or	range	of	CDKs	should	be	target	and	would	provide	the	
optimum	therapeutic	option	for	this	disease.	 	Clearly	it	seems	attractive	to	targets	
multiple	CDKs	as	tumours	cells	by	their	nature	are	unable	to	stop	at	predetermined	
points	 in	 the	 cell	 cycle	 because	 of	 the	 loss	 of	 integrity	 of	 these	 checkpoints.		
Targeting	 multiple	 CDKs	 would	 recapture	 these	 stop	 check	 points	 that	 limit	 the	
tumour	cells	ability	to	pass	through	the	cell	cycle	and	may	then	allow	induction	of	
apoptosis.	 	 	 This	 would	 obviously	 be	more	 assured	 if	multiple	 targets	 were	 used	
rather	then	a	single	target	and	potentially	single	point	within	the	cell	cycle.		This	far	
most	 of	 the	 combined	 studies	 of	 chemotherapeutics	 and	CDK	 inhibitors	 has	 used	
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pan-CDK	 inhibitors	 such	 as	 flavopiridol	 although	 focus	 have	 shifted	 toward	
developing	compounds	that	are	more	potent	and	selective	in	their	action	(Dickson	
and	 Schwartz	 2009).	 	 The	 combination	 of	 chemotherpaturitcs	 and	 CDK	 inhibitors	
that	 have	 an	 effect	 on	 CDK1	 and	 2	 (like	 AT7519)	 may	 be	 the	 most	 desirable	
combinations	 owing	 to	 the	 synergistic	 effects	 noted	 in	 the	 literature	 with	 DNA	
damage	 causing	 chemotherapeutic	 agents	 (Ira,	 Pellicioli	 et	 al.	 2004;	 Maude	 and	
Enders	2005).		As	the	knowledge	on	the	genetic	basis	of	pancreatic	adenocarcinoma	
becomes	clearer	this	question	will	be	more	readily	answered,	certainly	the	effects	
demonstrated	 by	 AT7519	 offer	 promise	 and	 suggest	 that	 at	 least	 partly	 this	
selective	CDK	inhibitor	offers	a	useful	therapeutic	option	as	an	adjunct	to	standard	
therapy.	 	The	 information	to	date	on	CDK	 inhibitors	support	the	notion	that	using	
these	 agents	 in	 combination	 rather	 than	monotherapy	 offers	 the	 most	 desirable	
therapeutic	avenue	and	the	data	generated	from	this	work	supports	this.	
	
Collectively	these	results	support	the	notion	that	AT7519	could	be	a	useful	agent	in	
combination	 with	 gemcitabine	 to	 improve	 therapy	 in	 pancreatic	 cancer	 and	
overcome	 some	of	 the	 cell	 cycle	proteins	 involved	 in	 the	 resistance	of	 pancreatic	
cancers	 to	 gemcitabine.	 	 The	 anti-proliferative	 effects	 seen	 in	 vitro	 were	 further	
supported	by	in	vivo	efficacy	of	this	combined	therapy	that	was	well	tolerated.	
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6.1.10	Suggested	further	work	
AT7519	has	demonstrated	that	it	has	effects	against	PDAC	in	the	pre	clinical	setting.		
As	 an	 agent	 that	 has	 been	 investigated	 in	 early	 phase	 clinical	 trials	 in	 other	 solid	
organ	tumours	 it	would	be	appropriate	to	take	this	agent	forward	in	PDAC,	 in	this	
pre	clinical	model	its	efficacy	has	been	limited	but	this	may	be	enhanced	by	further	
biomarker	work	to	attempt	to	identify	subgroups	of	patients	that	may	benefit	most	
from	this	agent,	patients	with	innate	or	acquired	gemcitabine	resistance	may	derive	
benefit	from	the	addition	of	AT7519	in	the	advanced	cancer	setting.	
	
6.2	AT13387	–	A	NOVEL	HSP90	INHIBITOR		
	
6.2.1	Inhibition	of	cell	growth	in	vitro	
In	 this	 study	 the	effects	of	AT13387	were	examined	 in	vitro	 and	 in	vivo	both	as	a	
single	 agent	 and	 in	 combination	 with	 gemcitabine.	 	 AT13387	 induced	 growth	
inhibition	across	a	range	of	pancreatic	cancer	cell	lines	at	the	nanomolar	level.		The	
IC50	 values	 obtained	 in	 this	 study	 are	 comparable	 to	 the	 values	 that	 have	 been	
obtained	 in	 other	 cancer	 types	 (Graham,	 Curry	 et	 al.	 2012).	 	 The	 sensitivity	 of	 a	
gemcitabine	resistant	cell	 line	was	comparable	to	that	of	the	parent	line	but	more	
importantly	the	absolute	IC50	value	obtained	for	this	gemcitabine	resistant	cells	line	
was	significantly	less	than	that	of	gemcitabine	treatment.		This	offered	encouraging	
results	that	AT13387	may	be	a	potential	novel	therapy	to	overcome	the	problem	of	
gemcitabine	resistance	in	pancreatic	cancer.			The	sensitivity	of	the	parent	line	and	
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gemcitabine	resistant	line	were	similar	suggesting	that	AT13387	was	not	subject	to	
the	 same	underlying	 reasons	 for	gemcitabine	 resistance	 that	have	been	displayed	
and	chemoresistance	may	not	be	an	issue	for	this	agent.	One	advantage	of	HSP90	
inhibitors	may	be	that	HSP90	inhibition	leads	to	degradation	of	multiple	oncogenic	
client	proteins	and	effects	multiple	pathways	in	tumourgenesis	so	that	resistance	to	
their	action	may	not	be	an	issue.	
	
	When	cells	were	treated	with	AT13387	then	treatment	was	removed	cell	regrowth	
occurred.	 	 This	 suggested	 AT13387	 was	 having	 a	 cytostatic	 rather	 than	 cytotoxic	
effect.		This	effect	of	AT13387	is	notably	different	to	other	HSP90	inhibitors	but	may	
not	necessarily	be	a	disadvantage	when	used	in	the	setting	of	combination	therapy.		
The	 ability	 of	 AT13387	 to	 leave	 the	 cell	 in	 a	 quiescent	 state	may	 then	 allow	 the	
opportunity	 for	 chemotherapeutics	 to	 have	 an	 effect	 and	 give	 the	 final	 push	 to	
induce	apoptosis.					
	
6.2.2	Cell	cycle	effects	of	AT13387	
The	 cell	 cycle	 effects	 of	 AT13387	were	 demonstrated	with	 an	 increase	 of	 cells	 in	
G0/G1	and	G2/M	phases	after	 treatment.	 	 In	combination	with	gemcitabine	 the	S	
phase	 accumulation	 of	 cells	 exhibited	 by	 gemcitabine	 treatment	 alone	 was	
documented.	 	 The	 multiple	 pathways	 and	 proteins	 targeted	 by	 HSP90	 inhibition	
may	 account	 for	 there	 being	 no	 specific	 point	 in	 the	 cell	 cycle	 where	 cells	
accumulate.	 	The	encouraging	data	 from	this	cell	cycle	analysis	 is	 that	despite	 the	
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multiple	 points	 in	 the	 cell	 cycle	where	AT13387	 suspends	 cells	 it	 does	 not	 inhibit	
gemcitabine	having	an	effect	as	 the	same	effects	of	gemcitabine	as	a	single	agent	
are	observed	in	combination	with	AT13387.		
	
6.2.3	Investigation	of	apoptosis	in	AT13387	
When	 apoptosis	 was	 investigated	 it	 was	 demonstrated	 beyond	 40	 hours	 after	
treatment	 with	 AT13387.	 	 AT13387	 does	 not	 appear	 to	 produce	 apoptosis	 at	 an	
early	 stage,	 this	 is	 converse	 to	 the	observations	with	other	HSP90	 inhibitors	 (Kim,	
Kang	et	al.	2003)	and	the	actions	of	AT13387	observed	in	other	tumour	lines	(astex	
pharmaceuticals,	 data	 not	 published).	 	 The	 fact	 that	 AT13387	 interferes	 with	
protein	folding	and	subsequent	cell	division	on	a	number	of	levels	may	suggest	that	
the	 ability	 to	 push	 the	 cell	 forward	 to	 apoptosis	 takes	 some	 time,	 perhaps	
pancreatic	 cancer	 cells	 are	 more	 resistant	 to	 this	 final	 push	 to	 programmed	 cell	
death.		
	
6.2.4	Combination	treatment	with	standard	therapy	
While	inhibition	of	HSP90	may	prove	therapeutic	as	a	single	agent	it	is	also	likely	to	
find	use	in	combination	with	other	agents	as	the	effect	of	a	number	of	chemotoxic	
agents	has	been	reported	to	be	enhanced	by	other	HSP90	inhibitors	such	as	17AAG	
or	geldanacycim	(Burkitt,	Magee	et	al.	2007).	 	 It	has	also	been	suggested	that	 the	
global	effect	of	HSP90	 inhibition	 to	potentiate	 the	action	of	other	agents	may	act	
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through	mechanisms	 quite	 distinct	 from	 those	 employed	when	 acting	 as	 a	 single	
agent.			
	
The	effects	of	combining	AT13387	and	gemcitabine	 in	vitro	 in	an	 isobolar	analysis	
did	 not	 yield	 any	 clear	 results	 in	 these	 experiments,	 though	 these	 combination	
studies	did	allow	some	observations.	 	There	was	a	trend	for	enhanced	AT13387	in	
the	 presence	 of	 gemcitabine	 and	 perhaps	 this	 is	 more	 striking	 as	 in	 these	
experiments	 AT13387	 did	 not	 reach	 its	 IC50	 as	 a	 single	 agent	 but	 did	 in	 the	
presence	 of	 gemcitabine.	 	 Gemcitabine	 acts	 on	 the	 cell	 in	 S	 phase	 causing	
irreversible	DNA	damage	but	as	suggested	previously	this	may	not	occur	on	the	first	
cell	 cycle	 that	 gemcitabine	 comes	 into	 contact	 with	 the	 cell,	 perhaps	 the	 initial	
insult	of	gemcitabine	treatment	makes	the	cells	more	vulnerable	to	the	actions	of		
AT13387	 in	 subsequent	 cell	 cycles	 and	 therefore	 further	 investigation	 of	 this	
combination	with	sequential	drug	addition	may	shed	further	light	on	the	situation.	
	
6.2.5	Downstream	effects	of	AT13387	
AT13387	 induced	 inhibition	 of	 HSP90	 was	 evident	 from	 examination	 of	 client	
proteins.	 	 Both	 Akt	 and	 phospho	 Akt	 levels	 were	 reduced	 after	 treatment	 with	
AT13387,	this	effect	was	less	marked	when	cells	had	been	treated	with	gemcitabine	
prior	 to	 AT13387	 treatment.	 	 This	 is	 in	 line	 with	 the	 expected	 action	 of	 HSP90	
inhibition	as	suppression	of	survival	pathways	such	as	p13/Akt	is	often	observed	as	
one	of	the	earliest	effects	of	HSP90	inhibition	(Graham,	Curry	et	al.	2012).		The	fact	
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that	 after	 gemcitabine	 treatment	 the	 effects	 were	 less	 prominent	 suggests	 cells	
were	already	sustaining	the	DNA	damaged	caused	by	gemcitabine	treatment	and	a	
lesser	effect	of	AT13387	was	noted.		The	same	effect	was	true	on	phospho	S6	when	
AT13387	 was	 given	 as	 a	 single	 agent	 as	 decreased	 levels	 were	 observed.			
Combining	AT13387	with	gemcitabine	appeared	to	enhance	this	effect	irrespective	
of	the	order	in	which	the	agents	were	given.		From	literature	evidence	gemcitabine	
does	not	effect	S6	phosphorylation	 therefore	 this	enhanced	effect	on	phospho	S6	
offers	encouraging	results	and	suggests	the	addition	of	AT13387	opens	this	pathway	
to	 inhibit	 cellular	 proliferation	more	 so	 in	 combination	 treatment	 (Martin-Liberal,	
Gil-Martin	et	al.	2014)	
	
Client	proteins	 involved	 in	the	 important	MAPK	cascade	were	also	examined	after	
treatment	with	AT13387.	Raf-1	levels	were	decreased	in	cells	treated	with	AT13387.	
This	 effect	 was	 enhanced	 with	 the	 combination	 treatment	 with	 gemcitabine.	 In	
addition	to	these	above	many	cell	cycle	regulatory	proteins	are	affected	by	HSP90	
inhibitors,	 including	 CDK4,	 and	 in	 this	 study	 CDK4	 levels	 were	 reduced	 following	
treatment	with	AT13387,	this	effect	was	more	marked	and	noted	at	lower	doses	of	
AT13387	 when	 gemcitabine	 treatment	 was	 used	 in	 combination,	 irrespective	 of	
dosing	regime.	 	These	data	support	the	notion	that	AT13387	induced	HSP90	client	
protein	degradation	that	was	not	inhibited	or	antagonized	by	combination	therapy	
with	gemcitabine.				
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	Treatment	with	AT13387	 resulted	 in	 significant	up	 regulation	of	HSP70	both	as	 a	
single	agent	and	combined	with	gemcitabine,	as	a	co-chaperone	to	HSP90	inhibition	
this	is	in	line	with	actions	of	HSP90	inhibition	previously	recognized	in	the	literature.		
This	 effect	 was	 not	 inhibited	 by	 combination	 treatment	 or	 pre	 treatment	 with	
gemcitabine.	 	 	 	 The	 overexpression	 of	 HSP70	 relates	 to	 the	 heat	 shock	 response	
induced	 y	 this	 inhibitor	 and	 it	 is	 worth	 noting	 this	 could	 effect	 the	 agents	 anti-
cancer	 activity	 as	 overexpression	 of	 HSP70	 could	 induce	 pro-survival	 and	 anti-
apoptotic	 effects.	 	 This	may	 go	 some	way	 to	 explaining	 the	 only	modest	 tumour	
effects	observed	in	the	xenograft	model.	
	
6.2.6	In	vivo	investigation	of	AT13387	
The	 effects	 of	 AT13387	 as	 a	 single	 agent	 in	 a	 mouse	 xenograft	 model	 initially	
suggested	 potentially	 promising	 effects.	 	 The	 drug	 was	 well	 tolerated	 as	 a	 single	
agent	and	did	result	in	slowed	tumour	growth	compared	to	control	though	this	was	
not	 statistically	 significant.	 	When	 the	 agent	was	 combined	with	 gemcitabine	 the	
results	 were	 unfortunately	 less	 favorable.	 	 The	 combination	 of	 AT13387	 and	
gemcitabine	was	no	better	at	slowing	tumour	growth	than	either	agent	alone	and	
significant	 issues	 were	 encountered	 with	 tolerability	 and	 toxicity	 of	 these	 agents	
combined.		
	
The	tumour	half-life	of	AT13387	has	been	demonstrated	prolonged	in	a	lung	cancer	
cell	 line	 xenograft	 model.	 	 After	 a	 single	 dose	 tumour	 half-life	 was	 65	 hours	
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compared	 to	 around	 4	 hours	 in	 plasma/blood	 (Graham,	 Curry	 et	 al.	 2012).	 	 The	
effects	 on	 downstream	 markers	 were	 prolonged	 compared	 to	 other	 HSP90	
inhibitors	 such	 as	 17-AAG.	 	 In	 this	 same	 model	 tumour	 growth	 was	 significantly	
reduced	compared	to	controls.	 	An	advantage	of	this	prolonged	tumour	half-life	 is	
not	 only	 the	 prolonged	 tumour	 retention	 and	 potential	 window	 of	 action	 for	
AT13387	but	also	the	need	for	less	frequent	dosing	therefore	reducing	the	systemic	
effects/toxicities	that	treatment	may	produce.	
	
6.2.7	Current	literature	in	the	in	vivo	setting	
Dose	 limiting	 toxicity	 in	 HSP90	 xenograft	 models	 and	 human	 studies	 has	 been	
previously	 noted,	 mostly	 relating	 to	 gastrointestinal	 and	 liver	 toxicity	 (Banerji,	
Walton	et	 al.	 2005;	 Sequist,	Gettinger	 et	 al.	 2010).	 	 It	 is	 not	 surprising	bearing	 in	
mind	 the	 mechanism	 of	 action	 of	 HSP90	 inhibitors	 that	 global	 effects	 are	 seen	
frequently.	 	 In	 this	model	AT13387	 as	 a	 s	 ingle	 agent	was	well	 tolerated	perhaps	
owing	to	the	prolonged	tumour	half-life	therefore	less	frequent	dosing	regime	that	
was	employed.	 	 	 	Although	dose	 limiting	toxicity	was	experienced	 in	this	model	 in	
combined	 treatment	 of	 AT13387	 and	 gemcitabine	 in	 phase	 I	 studies	 of	 AT13387	
alone	 these	 have	 not	 been	 encountered	 at	 the	 same	 dosing	 levels	 offering	
encouragement	 that	 in	 human	 trials	 the	 same	 issues	may	 not	 be	 encountered	 in	
combination	 therapy.	 	 Even	 at	 higher	 doses	 of	 AT13387	 in	 humans	 the	 toxicities	
encountered	 were	 grade	 1-2(Do,	 Speranza	 et	 al.	 2015).	 	 The	 fact	 remains	 that	
HSP90	 inhibition	 signaling	pathways	have	not	been	 fully	 explored	hence	 could	be	
more	complicated	than	expected	and	systemic	toxicities	difficult	to	overcome.	
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A	number	of	HSP90	inhibitors	have	been	reported	to	inhibit	the	growth	of	tumours	
in	pancreatic	 xenograft	models	 alone	 (Moser,	 Lang	et	 al.	 2012)	or	 in	 combination	
with	 other	 agents	 (Cao,	 Jia	 et	 al.	 2008;	 Li,	 Zhang	 et	 al.	 2011).	 This	 supports	 the	
potential	use	of	HSP90	inhibition	in	pancreatic	cancer	treatment.	Here	AT13387	as	a	
single	agent	was	well	tolerated	and	showed	a	modest	effect	on	tumour	growth.		It	
was	disappointing	that	the	combined	treatment	of	AT13387	and	gemcitabine	in	this	
xenograft	 model	 showed	 no	 improvement	 over	 either	 single	 agent	 alone.	
Unfortunately	 poor	 tolerability	 of	 the	 combined	 regime	 resulted	 in	 a	 reduce	
gemcitabine	dosage	to	that	initial	planned	for	combination	studies	which	may	have	
impacted	on	 the	efficacy	 in	 this	model.	 Each	agent	 alone	produced	 some	modest	
weight	 loss	but	 the	 combined	 therapy	 resulted	 in	an	additive	effect	 in	 relation	 to	
this	 side	 effect	 that	 impacted	 on	 dosing	 and	 survival	 in	 the	 model.	 	 Further	
investigations	may	 reveal	 more	 favorable	 drug	 scheduling	 to	 improve	 tolerability	
and	efficacy	of	this	combination	therapy.	
	
	
6.2.8	AT13387	with	gemcitabine	
This	 study	 sought	 to	 investigate	 AT13387	 in	 combination	 with	 the	 current	 gold	
standard	 treatment	 for	pancreatic	 cancer,	 gemcitabine.	Combined	 treatment	with	
gemcitabine	and	AT13387	apparently	resulted	in	no	greater	effect	than	either	single	
agent	 in	both	 the	 in	vitro	and	 in	vivo	setting.	 	 It	appears	 that	 there	may	be	some	
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compensatory	or	competing	mechanisms	that	precludes	any	additive	or	synergistic	
effect	of	combining	these	agents.	It	was	notable	during	in	vitro	studies	that	the	up-
stream	protein	kinase	Raf-1	was	not	noticeably	elevated	by	gemcitabine	treatment	
and	if	anything	pre-treatment	with	gemcitabine	increased	the	effect	of	AT13387	to	
reduce	 raf-1	 protein	 levels	 further	 then	 the	 decrease	 seen	 with	 AT13387	 alone.	
Further	 investigation	 is	 required	 to	examine	 the	effects	on	other	members	of	 the	
pathway	 including	MEK.	These	data	suggest	a	potential	avenue	of	 investigation	of	
combining	 MEK	 inhibitors	 in	 this	 regime.	 There	 are	 a	 number	 of	 MEK	 inhibitors	
under	 investigation	 including	 a	 number	 of	 phase	 I/II	 clinical	 trials	 examining	MEK	
inhibitors	in	combination	with	gemcitabine	(Wong	2009;	Trujillo	2011).	
	
Although	 this	 data	 would	 not	 support	 adding	 AT13387	 to	 standard	 gemcitabine	
therapy,	 the	 continued	 activity	 of	 AT13887	 in	 the	 gemcitabine	 resistant	 Suit-2GR	
cells	indicates	that	this	agent	may	be	of	benefit	in	patients	who	have	not	responded	
to	gemcitabine	treatment	and	possibly	in	combination	with	other	alternative	agents	
that	 may	 enhance	 its	 activity	 such	 as	 MEK	 inhibitors.	 	 	 The	 fact	 remains	 that	
pancreatic	cancer	contains	multiple	molecular	aberrations	and	targeting	HSP90	and	
its	multiple	downstream	effects	may	offer	some	benefit	 in	 improving	outcomes	 in	
this	complex	disease.	
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6.2.9		Suggested	further	work	
With	the	above	in	mind	further	work	at	this	stage	would	not	revolve	around	taking	
this	agent	forward	in	the	clinical	setting	but	further	pre	clinical	work	n	AT13387	in	
combination	 with	 standard	 therapy.	 	 	 Further	 investigation	 of	 this	 agent	 in	
combination	with	 cell	 lines	 that	 are	 resistant	 to	 gemcitabine	 therapy	may	 offer	 a	
sub	 group	 that	 would	 have	 an	 enhanced	 benefit	 from	 this	 agent,	 biomarker	
discovery	 would	 be	 required	 in	 order	 to	 progress	 to	 clinical	 trials	 to	 properly	
identify	this	group	of	patients.		The	combination	of	gemcitabine	and	AT13387	in	the	
in	vivo	setting	seemed	to	induce	toxicity	that	limited	observations	on	efficacy	of	this	
combination,	it	may	be	beneficial	to	investigate	this	agent	along	with	newer	agents	
becoming	 standard	 therapy	 in	 PDAC	 such	 as	 capecitabine	 to	 investigate	 any	
enhanced	effects	of	these	agents	in	combination.	
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CHAPTER	7:	CONCLUSION	
	
In	 human	malignancies	 irregularities	 in	 the	 cell	 cycle	 are	 commonly	 encountered.		
The	knowledge	of	these	abnormalities	has	 lead	to	the	rationale	of	developing	this	
class	of	agents,	CDK	inhibitors.		Single	agent	activity	of	these	agents	may	be	limited	
but	their	combination	with	other	cyctotoxics	offers	a	promising	avenue	of	therapy	
not	only	to	overcome	issues	with	tumour	resistance	to	current	treatments	but	also	
to	develop	therapy	that	offers	a	targeted	approach	to	the	cell	cycle	perturbations	of	
malignancy.	
	
	In	this	study	AT7519,	a	novel	CDK	inhibitor,	showed	efficacy	as	a	single	agent	and	in	
combination	 with	 gemcitabine	 in	 vitro	 having	 anti-proliferative	 effects	 against	 a	
range	 of	 pancreatic	 cancer	 cell	 lines.	 	 In	 vivo	 AT7519	 demonstrated	 efficacy	 and	
tolerability	both	as	a	single	agent	and	in	combination	with	gemcitabine.		AT7519	is	a	
potential	agent	that	warrants	further	investigation	in	pancreatic	cancer	and	may	be	
beneficial	 in	 reducing	 the	 issues	 currently	 faced	 with	 chemoresistance	 standard	
therapies.			
	
HSP90	 is	 involved	 in	 the	 regulation	 of	many	 oncogenic	 proteins	 and	 its	 inhibition	
and	 the	 subsequent	 effects	 of	 multiple	 molecules	 and	 pathways	 is	 an	 attractive	
prospect	 in	 cancer	 therapy.	 	 This	 is	 particularly	 relevant	 to	 pancreatic	 cancer,	 as	
more	 is	understood	about	 the	cancer	biology	 the	complex	and	multiple	pathways	
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that	 are	 deranged,	 these	 need	 to	 be	 targeted	 in	 order	 to	 improve	 the	 poor	
outcomes	that	current	chemotherapeutics	provide.		
	
In	 this	 study	 AT13387,	 a	 novel	 HSP90	 inhibitor,	 showed	 activity	 in	 vitro	 against	
pancreatic	cancer	cell	lines	including	one	with	acquired	gemcitabine	resistance	and	
down	 stream	 effects	 consistent	 with	 HSP90	 inhibition	 were	 observed.	 	 In	 vivo	
AT13387	 slowed	 tumour	 growth	 as	 a	 single	 agent	 but	 performed	 poorly	 in	
combination	with	gemcitabine.	 	The	data	presented	does	not	support	the	addition	
of	At13387	to	current	gemcitabine	therapy	but	does	offer	some	possibilities	as	an	
alternative	 therapy	 for	patients	who	are	non-responders	 to	 current	 therapies	and	
may	be	of	benefit	in	combination	with	other	targeted	treatments.			
	
In	 light	of	the	ongoing	poor	prognosis	and	response	to	current	chemotherapeutics	
pancreatic	 cancer	 continues	 to	pose	 a	 significant	 health	problem	and	 is	 in	 urgent	
need	 of	 new	 and	 novel	 therapies	 which	 offer	 better	 outcomes	 for	 the	 patients	
affected.	 	 	Combining	 treatments	 is	desirable	as	previously	discussed	with	current	
understanding	of	the	multiple	pathways	related	to	pancreatic	cancer.	 	 	Combining	
chemotherapeutic	 agents	 has	 been	 this	 far	 disappointing	 with	 no	 significant	
improvements	 in	overall	survival	but	 increased	toxicity.	 	 	More	research	is	needed	
on	 the	 reasons	 for	 resistance	 to	 existing	 therapies	 and	 further	 clinical	 trials	 on	
combinations	 of	 gemcitabine	 with	 agents	 that	 would	 target	 cells	 resistant	 to	
gemcitabine.	 	 Combining	 standard	 chemotherapeutic	 agents	with	 novel	 therapies	
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that	 have	 a	 different	 mechanism	 of	 action	 offer	 an	 avenue	 to	 overcome	 these	
limitations.	
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AT7519,	A	novel	CDK	inhibitor	is	effective	against	pancreatic	cancer	cell	lines	and	
in	a	pancreatic	cancer	Xenograft	model	
Thomas	A,	Greenhalf	W,	Shaw	E,	 Jones	O,	Costello	E,	Dejani	K,	Davies	M,	Lyons	 J,	
Sibson	R,	Neoptolemos	JP,	Ghaneh	P	
Abstract	
Background	
Pancreatic	cancer	continues	to	carry	a	poor	prognosis.		Chemotherapy	is	used	
following	surgery	and	in	advanced	disease;	though	current	agents	e.g.	
gemcitabine+capecitabine	or	FOLFIRINOX,	provide	modest	survival	benefit.		There	is	
an	urgent	need	for	more	effective	therapies.	We	evaluated	a	novel	CDK	inhibitor,	
AT7519,	in	pancreatic	cancer.	
Methods	
Cell	proliferation	assays	for	IC50	values	and	isobolar	analysis	were	performed	using	
EZ4U	assay.		Cell	cycle	analysis	was	performed	with	flow	cytometry.		Standard	
western	blot	analysis	with	ECL	detection	was	completed	to	assess	downstream	
markers.		In	vivo	studies	were	conducted	using	a	murine	xenograft	model.			Tumour	
volume	was	assessed	with	external	callipers.		Experiments	were	performed	using	
AT7519	as	a	single	agent	and	in	combination	with	gemcitabine.	
Results	
AT7519	was	tolerated	as	a	single	agent	and	in	combination	with	gemcitabine.		Mice	
treated	with	AT7519	showed	decreased	tumour	growth	(p0.0446)	compared	with	
control	and	studies	in	combination	with	gemcitabine	are	near	completion.		AT7519	
inhibited	proliferation	in	pancreatic	cancer	cell	lines	including	gemcitabine	resistant	
lines.		AT7519	and	gemcitabine	in	combination	displayed	an	additive	effect	and	S	
phase	blockade.		Downstream	effects	were	observed	with	inhibition	of	
phosphorylation	of	Rb,	NPM	and	pp1-α.	
Conclusion	
AT7519	is	a	promising	agent	for	combination	therapy	in	pancreatic	cancer.		
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Introduction	
Pancreatic	cancer	continues	to	a	pose	significant	health	problem	being	the	6th	most	
common	cause	of	cancer	death	in	the	UK	equating	to	around	7	700	deaths	per	year	
cancer.		Despite	current	research	and	advances	in	understanding	pancreatic	cancer	
biology,	imaging	detection	methods	and	improved	surgical	outcomes,	the	prognosis	
remains	poor	with	a	five-year	survival	of	around	10%	in	resected	disease.	 	Despite	
advances	 in	 many	 other	 cancers	 leading	 to	 improved	 survival	 the	 incidence	 and	
mortality	 rates	 for	 pancreatic	 cancer	 have	 not	 seen	 any	 significant	 improvement	
over	the	last	30	years	and	are	predicted	to	remain	static	in	Europe	in	2012(Malvezzi,	
Bertuccio	et	al.	2012).	
The	 basis	 of	 current	 therapies	 for	 PDAC	 involves	 targeting	 of	 DNA	 replication	 by	
inhibition	 of	 thymidylate	 synthase	 and	 incorporation	 of	 fluorouridine	 derivatives	
into	 nascent	 DNA	 strands.	 	 The	 agents	 that	 are	 used	 are	 5-FU,	 capcetabine	 and	
gemcitabine	and	also	have	an	effect	on	transcription	and	DNA	methylation.		These	
therapies	 are	 used	 in	 both	 the	 adjuvant	 and	 advanced	 disease	 setting	 based	 on	
previous	 trial	 evidence	 (Burris,	 Moore	 et	 al.	 1997;	 Neoptolemos,	 Stocken	 et	 al.	
2004;	Oettle,	Post	et	al.	2007;	Sultana,	Smith	et	al.	2007;	Neoptolemos,	Stocken	et	
al.	2010;	Conroy,	Desseigne	et	al.	2011).	Despite	the	demonstrated	survival	benefits	
recurrence	 rates	 in	 resected	 disease	 remain	 high	 and	 in	 all	 disease	 settings	 long-
term	survival	 remains	poor	due	 in	part	 to	 chemoresistance.	 	Cancer	 cells	become	
resistant	to	therapy	by	a	number	of	hypothesised	means:	by	exclusion	of	drugs	from	
the	cancer	cells,	by	changes	in	enzymes	metabolising	drug	or	by	becoming	resistant	
to	apoptosis	and	cellular	stress.		Further	increases	in	survival	should	be	possible	by	
targeting	 these	 areas	 that	 lead	 to	 resistance	 or	 targeting	 multiple	 pathways	 in	
combination	with	standard	therapy.	 	Jones	et	al	 identified	12	pathways	commonly	
mutated	 in	 PDAC(Jones,	 Zhang	 et	 al.	 2008).	 	 Clearly	 this	 underpins	 the	 complex	
genetic	anomalies	that	exist	in	PDAC	and	supports	the	concept	that	targeting	single	
genes	or	proteins	will	likely	be	ineffective.		Therapy	that	targets	multiple	pathways	
at	different	levels	in	combination	with	standard	therapy	may	offer	the	most	chance	
of	 making	 significant	 differences	 to	 survival	 of	 patients.	 	 Genetic	 mutations	 that	
arise	 in	pancreatic	 cancer	often	have	effect	on	 crucial	 checkpoints	within	 the	 cell	
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cycle	and	CDK’s	being	pivotal	to	cell	cycle	regulation	could	offer	another	target	for	
inhibition	 in	 pancreatic	 cancer.	 CDK	 inhibition	 could	 offer	 future	 promise	 for	
therapy	in	PDAC.	
The	 replication	of	DNA	and	mitosis	are	 reliant	on	 the	activity	of	 cyclin-dependant	
protein	kinase	(CDK)	enzymes.		CDK’s	form	heterodimers	with	a	cyclin	subunit		and	
the	activity	of	this	molecular	complex	governs	cell	cycle	regulation.			
Cancer	cells,	by	definition,	are	prone	to	 inappropriate	cell	division	and	the	activity	
of	 CDK’s	 and	 cyclins	 are	 frequently	 deranged	 in	 cancer.	 	 This	 may	 be	 due	 to	
amplification	 of	 genes	 encoding	 for	 specific	 CDK’s	 or	 cyclins,	 other	 protein	
overexpression	mechanisms,	gene	deletion	or	gene	silencing	of	a	CDK	inhibitor	such	
as	p16INK4a(Malumbres	and	Barbacid	2001).			
Relationships	between	cdk’s	cell	cycle	regulation	and	tumour	suppressor	genes	are	
critical	in	cancer.		Aberrant	pRb	signalling	pathways	are	common	in	the	majority	of	
human	cancers	resulting	in	unchecked	entry	into	S	phase.		Overexpression	of	cyclin	
D1	or	deletion	of	p16INK4A	activates	 the	pRb	pathway	 in	 this	manner.	 	P53	 is	an	
essential	 regulator	 of	 the	G1	 checkpoint	 and	 arrests	 growth	 through	 induction	of	
p21	and	G2	arrest	by	promoting	transcription	of	GADD45	that	inhibits	cyclin	B-CDK1	
activation.	
The	role	of	aberrant	CDK	activity	and	potential	 inhibition	has	been	 investigated	 in	
many	human	cancers.	 	Novel	CDK	 inhibitors	have	also	been	 investigated	 in	PDAC.		
Brasca	 et	 al	 reported	 on	 a	 novel	 CDK	 inhibitor	 PHA-793887	 and	 its	 effects	 in	 a	
xenograft	model	of	pancreatic	cancer	using	the	tumour	line	Bx-PC3.		The	agent	was	
well	 tolerated	 and	 resulted	 in	 significant	 tumour	 growth	 inhibition	 (Brasca,	
Albanese	et	al.	2010).	
AT7519	is	a	general	CDK	inhibitor	developed	by	Astexs	pharmaceuticals	(Cambridge,	
UK).	 	 This	 compound	was	 developed	 using	 fragment-based	 X-ray	 crystallographic	
screening.	 	 Fragments	 are	 low-molecular	 weight	 compounds	 with	 low	 binding	
affinities	 and	 screening	 using	 X-ray	 crystallography	 yields	 small	 libraries	 of	
compounds	 that	 have	 much	 greater	 probability	 of	 yielding	 complimentary	
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fragments	and	targets(Hartshorn,	Murray	et	al.	2005).		Astexs	developed	a	panel	of	
molecules	and	investigated	pharmacokinetic	properties	leading	to	the	identification	
of	AT7519(Wyatt,	Woodhead	et	al.	2008).	
(Squires,	Feltell	et	al.	2009)	
AT7519	is	a	potent	inhibitor	of	CDK1,	2,	4,	6	and	9	and	also	inhibits	CDK	3	and	7	to	a	
lesser	degree(Squires,	Feltell	et	al.	2009).		Initial	in	vitro	experiments	across	a	range	
of	 cancer	 cell	 lines	 confirmed	 the	 antiproliferative	 activity	 of	 AT7519	 and	 TUNEL	
staining	 assays	 and	 colony	 formation	 confirmed	 induction	 of	 apoptosis	 in	 colonic	
and	ovarian	cancer	cell	 lines,	 interestingly	an	exposure	equivalent	or	greater	 than	
one	 cell	 cycle	 was	 required	 for	 induction	 of	 apoptosis	 suggesting	 that	 AT7519	
needed	 to	 be	 present	 during	 certain	 points	 in	 the	 cell	 cycle.	 	 In	 this	 initial	
investigation	a	xenograft	model	using	HCT116	(a	colonic	cancer	cell	line)	was	carried	
out	 that	 showed	 delayed	 tumour	 growth	 and	 tumour	 regression	 in	 an	 advanced	
cancer	 model	 compared	 to	 controls	 (p<0.05).	 	 CDK2	 substrates	 were	 also	 tested	
from	this	xenograft	model,	namely	 the	phosphorylation	of	NPM	and	Rb	and	were	
shown	to	decrease	after	certain	time	points	post	dose.	
The	 key	 to	 the	 future	 of	 chemotherapy	 in	 pancreatic	 cancer	 will	 be	 the	
identification	 of	 novel	 and	 effective	 agents,	 better	 biomarker	 technology	
underpinned	by	translational	research,	which	will	inform	the	design	of	future	trials.	
Ultimately	this	will	ensure	that	patients	will	be	able	to	receive	targeted	therapy	to	
achieve	the	most	benefit.	
In	this	study	were	investigated	the	efficacy	of	AT7519	in	pancreatic	cancer	cell	lines	
and	 in	 a	 pancreatic	 cancer	 xenograft	 model	 as	 a	 potential	 novel	 therapy	 to	 be	
remained sensitive to AT7519. Because functional Rb is
required for CDK4 inhibition to result in cell cycle arrest
(reviewed in ref. 32), this suggests that the anti-CDK4
activity of AT7519 alone is not responsible for the
antiproliferative effects. In contrast to the compound’s
potent activity against cycling tumor cell lines, AT7519 did
not affect the viability of noncycling MRC-5 cells at
concentrations up to 10 Amol/L. These data suggest that
the mechanism by which the compound exerts its effect is
cell cycle related and the compound is not generally
cytotoxic to cells that are not dividing.
The mechanism of action of AT7519 in cells has been
investigated by monitoring the phosphorylation state of
substrates specific for the various CDKs within treated
HCT116 cells (Fig. 1B). These studies indicated that
inhibition of cellular CDK1 and CDK2 by AT7519 was
observed at concentrations consistent with the observed
antiproliferative effects. Treatment with AT7519 for 24 h
was sufficient to inhibit phosphorylation of the CDK1
substrate PP1a (T320) and the CDK2 substrates Rb (T821)
and NPM (T199) in HCT116 cells. Additional studies
showed phosphorylation of NPM and Rb to be inhibited
following a 1 h exposure to AT7519 (data not shown),
suggesting that these inhibitory effects on substrate
phosphorylation were a direct effect of CDK inhibition
rather than a consequence of cell cycle arrest. No effect of
AT7519 was observed on the cyclin D-dependent phos-
phorylation site on Rb (S780) in cell-based systems despite
the observation in cell-free kinase assays that the com-
pound inhibited CDK4/cyclin D activity (Supplementary
Table S1).1 This supports the previous observation in Rb-
negative cells (MDA-MB 468) that inhibition of CDK4 by
AT7519 was not responsible for its antiproliferative effects.
Levels of the relevant cyclins, CDKs, and total proteins
remained unaffected by compound treatment. The effects
of the compound on phosphorylation of the COOH-
terminal domain repeats of RNA polymerase II were also
assessed. AT7519 inhibited phosphorylation of RNA
polymerase II on Ser2 of the COOH-terminal domain,
indicating that AT7519 has the potential to inhibit
transcription downstream of the polymerase, consistent
with the observed in vitro inhibition of CDK9. Inhibition of
total transcription was assayed using tritiated uridine
incorporation into RNA and showed that a 4 h treatment
of HCT116 cells with AT7519 was sufficient to inhibit
global transcription with an IC50 of 56 nmol/L (data not
shown), similar to the levels required for inhibition of
proliferation (Table 1).
AT7519 Inhibits Cell Cycle Progression in Human
Tumor Cell Lines
The effect of AT7519 on cell cycle progression was
investigated in HCT116 cells. Cells treated for 24 h with
increasing concentrations of AT7519 showed a significant
reduction in the number of cells in S phase and an increase
in the number of cells in G2-M (Fig. 2A). Colabeling with
bromodeoxyuridine and propidium iodide showed that
cells were also arrested in the G0-G1 phase of the cell cycle
(data not shown). An increase in cells containing sub-G1
Figure 1. Chemical structure of AT7519 (A). HCT116 cells were treated for 24 h with AT7519 and lysates were prepared for Western blotting.
Representative of three independent experiments (B).
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employed	 in	 combination	 with	 standard	 clinical	 agents	 currently	 used	 in	 the	
treatment	of	pancreatic	cancer.	
	
Materials	and	methods	
Cell	lines	and	reagents	
Pancreatic	 cancer	 cell	 lines	 SUIT-2,	 Miapaca-2,	 CFpac,	 Fampac	 and	 paca2	 were	
derived	from	stores	 in	the	department	of	Clinical	and	Molecular	Cancer	Medicine,	
University	 of	 Liverpool.	 	 Panc-1	 was	 supplied	 by	 LGC	 standards	 from	 the	 ATCC.		
SUIT-2	 (GR)	 (a	 gemcitabine	 resistant	 pancreatic	 cancer	 cell	 line	 derived	 from	 the	
parent	 line	 SUIT-2	 was	 developed	 in	 the	 department	 of	 molecular	 and	 clinical	
cancer	medicine	 by	 K	 Dejani.	 Cells	 were	 grown	 in	 RPMI	 supplemented	with	 10%	
foetal	 bovine	 serum	 and	 maintained	 at	 37oC	 in	 an	 atmosphere	 of	 5%	 CO2.	
Pancreatic	cell	lines	were	cultured	as	previously	described.		
AT7519	 is	 N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)	 1H-pyrazole-3-
carboxamide.	 AT7519	 was	 obtained	 from	 Astex	 Pharmaceuticals	 Ltd	 (Cambridge,	
UK).	 It	was	dissolved	first	 in	dimethyl	sulfoxide	(DMSO;	Sigma	Chemical,	USA)	at	a	
concentration	 of	 10	 mM,	 and	 then	 in	 culture	 medium	 immediately	 before	 use.	
Gemcitabine	 was	 obtained	 from	 stores	 in	 the	 department	 of	 clinical	 and	 cancer	
medicine,	University	of	Liverpool.		It	was	dissolved	in	PBS	(sigma	Chemical,	USA)	at	a	
concentration	of	0.1M	and	in	culture	medium	immediately	before	use.	
Cell	viability	and	proliferation	assays		
AT7519’s	 effects	on	 viability	of	 PDAC	 cell	 lines	 and	 isobolar	 analysis	 of	AT7519	 in	
combination	with	gemcitabine	was	assessed	using	the	cell	proliferation	assay	EZ4U	
(biomedical)	 measured	 at	 4,	 24,	 48,	 72	 and	 96	 hrs	 after	 drug	 treatment	 and	
performed	in	triplicate.		Cells	were	seeded	into	96-well	plates	at	1.5	x	104	per	well	
and	cultured	for	24	hrs	before	the	addition	of	the	agent	or	control	in	0.1%	DMSO	at	
varying	concentrations.	
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Isobolar	analysis	
An	 assessment	 of	 synergy	 (or	 antagonism)	 was	 carried	 out	 using	 isobolographic	
analysis	(berenbaum	1989,	tallarida	1989	1992).		Cells	were	plated	and	cultured	as	
per	 IC50	 cell	 proliferation	 assays	 above	 and	 cells	 were	 treated	 with	 variable	
concentrations	of	AT7519	and	gemcitabine	around	the	established	 IC50	values	for	
single	agents	or	control.		The	isobolar	analysis	was	also	performed	with	sequential	
addition	of	agents	with	gemcitabine	initially	then	addition	of	AT7519	after	24	hours.		
The	results	were	standardised	against	controls	and	an	isobolar	curve	generated	to	
display	 the	 relationship	 between	 the	 agents	 in	 combination	by	 plotting	 a	 straight	
line	 connecting	 the	 two	 agents	 IC50	 points	 representing	 an	 additive	 effect.	 	 	 The	
data	plotted	 indicted	the	effect	of	 the	drugs	 in	combination,	 if	below	the	additive	
line	synergy	was	demonstrated,	above	the	line	antagonism	and	on	the	additive	line	
the	drug	effects	were	purely	additive	i.e.	no	interaction.	
	
	
Cell	cycle	analysis	
Cell	 cycle	 analysis	 was	 performed	 using	 propidium	 iodide	 (PI)	 staining	 and	 flow	
cytometry.	Miapaca-2	cells	were	seeded	onto	6	well	plates	at	2.5	x	105	cells	 	per		
well,			grown	overnight			and	then	treated	with	AT7519,	gemcitabine	(+/-)	or	control	
(0.1%	DMSO	or	PBS)	 for	 various	 time	points	 	 at	doses	 	detailed	 in	 figure	 legends.		
Both	 adherent	 and	 floating	 cells	were	 collected	 and	washed	with	 twice	with	 PBS	
prior	 to	 fixation	 in	 70%	 ethanol	 overnight	 before	 staining	 with	 PI	 (50ug/ml)	 for	
15minutes	 at	 room	 temperature.	 	 Propidium	 iodide	 incorporation	 using	 assessed	
using	a	CyAn™	ADP	Analyzer	(Beckman	Coulter).	Duplicates	were	formed	each	time	
and	experiments	were	repeated	in	duplicate	on	different	days.	
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Detection	of	apoptosis	
To	 determine	 the	 timing	 and	 mechanism	 of	 cell	 death	 caspase	 3/7	 activity	 was	
assessed	using	 the	Caspase-Glo	3/7	 luminescent	assay	 (promega).	Miapaca-2	cells	
were	 seeded	 at	 5000	 cells/	well	 	 in	 96	well	 plates,	 left	 overnight	 to	 adhered	 and	
then	treated	with	10uM	AT7519	or	0.1%	DMSO	control	 for	6,	16,	24,	40,	48	or	72	
hours.	 	Caspase-Glo	reagent	was	added,	as	detailed	in	the	manufacturers	protocol	
using	100ul	volumes	and	incubated	for	1	hour.	Luminescence	was	then	measured	in	
a	microplate	reader	and	normalised	to	untreated	control.	A	single	experiment	was	
performed	with	6	replicates	for	each	time	point.		
	
Western	blotting		
Pancreatic	 cancer	 cells	 were	 cultured	 with	 AT7519	 a	 variable	 concentrations,	
harvested,	 washed	 and	 lysed	 using	 lysis	 buffer	 as	 previously	 described	 by	 Astexs	
pharmaceuticals	 (ref).	 The	 protein	 concentration	 of	 lysate	 was	 measured,	 mixed	
with	 gel	 electrophoresis	 loading	 buffer,	 boiled	 for	 5	 min,	 separated	 by	 sodium	
dodecyl	sulfate–polyacrylamide	gel	electrophoresis	(SDS–PAGE),	and	transferred	to	
nitrocellulose	membrane.	The	membranes	were	blocked	in	PBS	plus	5%	non	fat	milk	
powder	and	0.1%	Tween	20	for	1	h	before	incubating	with	the	antibodies	overnight	
at	 37oC.	 Immunoblotting	 was	 done	 with	 cdc2,	 Rb,	 pRb	 from	 Cell	 signalling	
Technology.	Decetction	was	performed	using	ECL	reagents.		Blots	were	stripped	and	
reprobed	 with	 b-actin	 (Santa	 Cruz	 Biotechnology)	 antibodies	 to	 ensure	 equal	
protein	loading.		
	
Xenograft	mouse	model	
To	 evaluate	 the	 in	 vivo	 tolerability	 and	 efficacy	 of	 AT7519,	 gemcitabine	 and	
combination	 therapy	BALB/c	 (CAnN.Cg-Foxn1nu/Cr)	 nude	mice	were	used	 (Harlan	
UK,	housed	in	pathogen	free	conditions,	6-8	weeks	old).		In	tolerability	studies	non-
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tumour	bearing	mice	were	used	and	treated	for	two	weeks	with	AT7519	7.5mg/kg	
BD	 5	 days	 per	week,	 gemcitabine	 50	 or	 75mg/kg	 2qw	 or	 AT7519	 7.5mg/kg	 BD	 5	
days	per	week	+	gemcitabine	50mg/kg	2qw.		Body	weights	and	general	observations	
were	performed	daily,	experimental	endpoints	were	a	 loss	of	>20%	of	day	1	body	
weight	 in	 two	or	more	 animals	 (sustained	over	 a	 72	 hr	 period)	 or	 death	of	more	
than	one	 animal.	 	 Animals	were	not	 dosed	 if	 their	was	 a	 >15%	body	weight	 loss.		
Necropsy	 for	 serum	 and	 organs	 was	 performed.	 	 For	 Efficacy	 studies	 mice	 were	
inoculated	with	Miapaca-2	pancreatic	cancer	cells.		Miapaca-2	were	supplied	by	LGC	
standards	from	the	ATCC	that	had	been	cultured	and	frozen	in	stocks	adequate	for	
all	 in	 vivo	 studies	 then	defrosted	 and	 cultured	 in	 T75	 flasks	 until	 90%	 confluence	
and	 no	 signs	 of	 infection.	 	 Cells	 were	 then	 harvested	 and	 diluted	 in	 PBS	 to	 a	
concentration	of	1	x	107/ml	and	added	to	an	equal	volume	of	matrigel	and	kept	on	
ice	until	subcutaneous	inoculation	of	each	mouse	with	200ul	into	the	shoulder	area	
bilaterally.	 	When	tumours	were	palpable/measurable,	mice	were	treated	i.p.	with	
saline	0.9%	vehicle,	AT7519	7.5mg/kg	BD	5	x	per	week	or	gemcitabine50mg/kg	2qw	
;	or	a	combination	of	AT7519	and	gemcitabine	at	the	same	doses.	Tumour	size	was	
measured	 every	 alternate	 days	 in	 three	 dimensions	 using	 callipers,	 and	 tumour	
volume	 was	 calculated.	 	 The	 experimental	 endpoints	 were	 tumours	 reaching	 a	
diameter	of	17mm3		or	became	ulcerated,		loss	of	>20%	of	day	1	body	weight	in	two	
or	more	animals	(sustained	over	a	72	hr	period)	or	death	of	more	than	one	animal.		
Animals	were	not	dosed	if	their	was	a	>15%	body	weight	loss.	Survival	and	tumour	
growth	were	evaluated	 from	the	 first	day	of	 treatment	until	death.	Necropsy	was	
performed	for	tumour,	serum	and	organs.		All	animal	studies	were	approved	by	the	
Home	office	animals	in	scientific	procedures	act.		
	
Analysis	
All	in	vitro	experiments	were	performed	in	triplicate	and	repeated	at	least	3	times;	
a	 representative	 experiment	 was	 selected	 for	 Figures.	 Statistical	 significance	 of	
differences	 for	 both	 in	 vitro	 and	 in	 vivo	 experiments	 were	 determined	 using	
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Student’s	 t-test,	with	minimal	 level	 of	 significance	 p=0.05.	 	 All	 statistical	 analyses	
were	determined	using	SPSS.		
	
Results	
	AT7519	inhibited	the	proliferation	of	pancreatic	cancer	cell	lines	with	IC50	values	
ranging	from	0.18–	2uM	(figure	1)	
AT7519	ability	 to	 inhibit	cell	proliferation	was	assessed	 in	7	pancreatic	cancer	cell	
lines.		Cell	lines	sensitive	and	resistant	to	conventional	therapy	were	assessed.		Cells	
were	cultured	with	increasing	concentrations	of	AT7519	(50nm		-	5000nM)	for	24,	
48	and	72	hours.		The	IC50	values	ranged	from	180nM	to	2uM	(72	hour	reading	IC50	
shown).	 	 	 The	gemcitabine	 resistant	 cell	 line	 Suit-2	GR	had	was	 found	 to	have	an	
IC50	of	 625nM	 to	 gemcitabine	 compared	 to	 10nM	 in	 the	 parent	 line	 Suit-2.	 	 The	
AT7519	 IC50	 was	 lower	 in	 the	 gemcitabine	 resistant	 cell	 line	 	 (700nM)	 than	 the	
parent	 line	 (2uM)	 suggesting	 the	 resistant	 mechanism	 for	 gemcitabine	 did	 not	
overlap	with	resistance	to	AT7519.		
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Cell	line	 IC50	AT7519	 IC50	Gemcitabine	
SUIT-2	 2uM	 10nM	
SUIT-2	(GR)	 700nM	 625nM	
Miapaca-2	 390nM	 25nM	
Panc-1	 275nM	 150nM	
CFpac	 180nM	 180nM	
FamPac	 210nM	 5.5nM	
Paca	2	 250nM	 5nM	
	
	
Figure	1.		Anti-proliferative	activity	of	AT17519	in	vitro		
[a]	IC50	values	across	a	range	of	pancreatic	cancer	cell	lines.			
[b]	Photography	of	cell	proliferation	in	untreated	cells	versus	AT7519	treated	cells	
(nm)	at	various	time	points.	
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Cell	cycle	analysis	showed	a	marked	reduction	of	cells	in	the	G0/G1	and	S	phases	
with	an	increase	in	cells	 in	G2/M	phase	following	treatment	with	AT7519	(figure	
2)	
Cell	 cycle	 analysis	 was	 performed	 on	 suit-2	 cells	 cultured	 with	 media	 alone	 or	
AT7519	 (10uM)	 for	 4,	 7,	 24	 and	 48	 hours.	 	 Following	 24	 hours	 treatment	 with	
AT7519	there	was	clear	arrest	in	G2/M	phase	with	a	reduction	in	the	proportion	of	
cells	in	G0/G1	and	S	phase	compared	to	untreated	cells	(p=<0.001).		When	AT7519	
was	combined	with	gemcitabine	 	 there	was	an	accumulation	of	cells	 in	S	phase	 in	
keeping	with	the	effects	of	gemcitabine	alone	but	AT7519	appeared	to	enhance	this	
effect.	
	
	
	
Figure	2.Effects	of	AT7519	on	the	cell	cycle	
[a]Cell	 cycle	 distribution	 of	 SUIT-2	 pancreatic	 cancer	 cell	 line	 untreated	 (media	
only),	treated	with	AT7519	(nm),	treated	with	AT7519	(nm)	and	gemcitabine	(nM)	
at	4,	7,	24	and	48	hours.	
[b]	 percentage	 of	 cells	 in	 different	 phases	 of	 the	 cell	 cycle	 treated	with	AT7519	
versus	untreated	control	SUIT-2	cells	at	24	hour	time	point.	
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Apoptosis	was	demonstrated	after	 treatment	with	AT7519	 in	 vitro	by	 caspase-3	
activity	(figure	3)	
Evidence	of	induction	of	apoptosis	by	AT7519	in	pancreatic	cancer	cell	lines	tested	
was	 limited.	 	 Caspase-3	 activity	 was	 investigated	 and	 at	 24	 hours	 induction	 of	
caspase-3	 was	 significantly	 increased	 in	 treated	 cells	 compared	 to	 untreated	
control.		
	
Figure	 3.	 caspase-3	 activity	 of	 untreated	 and	 AT7519	 treated	 Miapaca-2	
pancreatic	cancer	cells		at	6,	16,	24,	40,	48	and	72	hours.	
	
Isobolar	 analysis	 of	 AT7519	 combined	 with	 gemcitabine	 suggested	 an	 additive	
effect	(figure	4)	
Initial	 experiments	 performed	 demonstrated	 an	 antagonistic	 effect	 when	 AT7519	
and	gemcitabine	was	given	simultaneously	(data	not	shown)	consistent	with	a	need	
for	cells	 to	be	dividing	 in	order	 for	gemcitabine	 to	have	an	effect.	 	 In	 light	of	 this	
experiments	 were	 performed	 giving	 gemcitabine	 alone	 for	 the	 first	 24	 hrs	 of	
incubation	followed	by	the	addition	of	AT7519.	 	These	experiments	demonstrated	
at	 least	 an	 additive	 effect	 when	 AT7519	 and	 gemcitabine	 where	 given	 in	
combination	with	sequential	dosing.		
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Figure	 4.	 Isobolar	 graph	 of	 cells	 treated	with	 gemcitabine	 for	 24	 h	 followed	 by	
combination	of	gemcitabine	+	AT7519	for	48	h.		
The	line	represents	an	additive	effect.		The	area	under	the	curve	would	be	lower	if	
there	was	synergy	and	greater	if	there	was	antagonism	
	
Western	blot	analysis	demonstrated	the	effect	on	downstream	targets	of	AT7519	
(figure	5)	
Entry	of	cells	into	mitosis	is	regulated	by	CDK1	kinase	activation.		Cell	cycle	analysis	
supports	an	AT7519	G2/M	block	(as	expected	if	CDK1	activity	is	inhibited).		Western	
blot	analysis	 confirmed	decreased	CDK1	 levels	 further	 supporting	 the	G2/M	block	
effect	 of	 AT7519	 not	 observed	 with	 gemcitabine	 as	 a	 single	 agent.	 	 When	
gemcitabine	and	AT7519	were	used	in	combination	this	decrease	in	CDK1	was	not	
observed	 supporting	 the	 notion	 that	 cells	 need	 to	 be	 dividing	 in	 order	 for	 G2/M	
block	to	occur.		This	was	confirmed	by	sequential	addition	of	gemcitabine	alone	for	
24	 hours	 followed	 by	 AT7519,	 this	 lead	 to	 appropriate	 variation	 of	 CDK1.		
Phosphorylation	 of	 Rb	 is	 catalysed	 by	 cyclin-dependant	 kinases	 and	 inhibited	 by	
AT7519.	 	 Rb	 phosphorylation	 is	 almost	 eliminated	 despite	minimal	 changes	 in	 Rb	
levels.	
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Figure	5.	[a]Western	blot	showing	the	downstream	effects	on	cdc2	of	AT7519	and	
gemcitabine	as	single	agents	
[b]Combination:	 25nM	Gemcitabine	 and	 desired	 concentration	 of	 AT7519	 added	
together	
Sequential:	 Cells	 treated	 with	 25nM	 of	 Gemcitabine	 for	 24h	 followed	 by	 the	
addition	of	the	desired	concentration	of	AT7519	
[c]	 Western	 blot	 showing	 effect	 of	 AT7519	 (1uM-10uM)	 on	 Rb	 and	 phosph-Rb	
antibodies	
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AT7519	was	well	tolerated	as	a	single	agent	and	in	combination	with	gemcitabine	
in	nude	mice	(figure	6)	
To	test	the	tolerability	(and	establish	gemcitabine	dosing)	non-tumour	bearing	nude	
mice	were	treated	with	single	agents	and	combination	therapy	for	2	weeks	with	3	
mice	per	group.	 	AT7519	was	 tolerated	well	as	a	single	agent	at	7.5mg/kg	BD	5/7	
days	 and	 in	 combination	 studies.	 	One	 animal	 died	 due	 to	 an	 injury	 unrelated	 to	
AT7519	 treatment.	 	 Gemcitabine	was	 tolerated	 at	 50mg/kg	 2qw	 both	 as	 a	 single	
agent	and	in	combination	studies	(data	not	shown).	
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Figure	6.	[a]	Tolerability	of	AT7519	as	a	single	agent,	graphical	representation	of	
weight	 [b]Individual	 mouse	 weights	 (g)	 for	 3	 mice	 dosed	 with	 	 50mg/kg	 of	
gemcitabine	twice	per	week	and	7.5mg/kg	of	AT7519	twice	daily	for	5	days.		Total	
treatment	of	2	weeks.	
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In	 a	 xenograft	 model	 of	 pancreatic	 cancer,	 AT7519	 as	 a	 single	 agent	 and	 in	
combination	with	gemcitabine		showed	a	significant	reduction	in	tumour	growth	
compared	to	vehicle	control	(figure	7)	
SUIT-2	 pancreatic	 cancer	 cell	 line	 were	 successfully	 cultured	 and	 developed	
subcutaneous	 solid	 tumours	 in	 nude	 mice	 with	 matrigel.	 	 Tumours	 grew	 in	 an	
exponential	 fashion.	 	 From	 tolerability	 studies	 animals	 were	 dosed	 appropriately	
with	AT7519,	gemcitabine,	vehicle	control	(saline)	or	a	combination	of	AT7519	and	
gemcitabine.	 	 During	 the	 single	 agent	 efficacy	 study	AT7519	 significantly	 reduced	
the	 exponential	 tumour	 growth	 (p=0.043)	 as	 did	 gemcitabine	 (p=0.0038).	 	 There	
was	 no	 significant	 body	weight	 loss	 in	 the	 single	 agent	 dosing	 of	AT7519.	 	 In	 the	
combination	efficacy	study	of	AT7519	and	gemcitabine	a	further	beneficial	effect	of	
reduction	 in	 tumour	 growth	 was	 observed	 that	 was	 superior	 to	 vehicle	 control	
(p=0.0041)	either	AT7519	(p=0.0173)	or	gemcitabine	alone	(p=0.0611).	
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Treatment	 Mean	
coefficient	difference	 N	 P	value	
Vehicle	control	 0.162	 6	 0.502	
AT7519	 0.29	 6	 0.045	
Gemcitabine	 0.445	 6	 0.038	
Figures	7:		
	[a]Tumour	volumes	in	mice	treated	with	Saline	vehicle	control(A),	AT7519	(B)	and	
Gemcitabine	(C)	with	log	regression	analysis	co-efficient	plotted.		
[b]	 table	of	 Log	 regression	analysis	 coefficients	mean	difference	after	 treatment	
for	each	group	with	p	values	of	significance.	
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Treatment	 Mean	
coefficient	
difference	
N	 P	value	
compared	
with	
control	
P	value	
compared	
with	gem	
P	value	
compared	
with	
AT7519	
Vehicle	 0.05	 6	 -	 0.9991	 0.9906	
Gemcitabine	 0.162	 6	 0.0198	 -	 0.1477	
AT7519	 0.114	 6	 0.029	 0.9374	 -	
AT7519	+	
Gemcitabine	
0.249	 6	 0.0041	 0.0611	 0.0173	
	
Figures	8:	 [a]Tumour	volumes	 in	mice	 treated	with	 Saline	 vehicle	 control(A)	and	
Gemcitabine	+	AT7519	(B).		
[b]	Table	of	mean	coefficient	difference	for	each	group	before	and	after	treatment	
with	p-values	for	paired	T-test	comparing	co-efficient	change.	
	
Discussion			
Pivotal	to	the	regulation	of	the	cell	cycle	are	cyclins	and	cyclin	dependant	kinases.		
Cancer	cells	by	definition	are	subject	to	inappropriate	cell	division	and	aberrant	CDK	
activity	 has	 been	 documented	 as	 one	 of	 the	 hallmarks	 of	 cancer	 (Hanahan	 and	
Weinberg	 2011).	 	 The	 investigation	 of	 CDK	 inhibition	 and	 small	 molecule	 novel	
agents	 such	as	AT7519	 is	 appropriate	and	may	 improve	 survival	 in	PDAC(Lapenna	
and	Giordano	2009).	The	relative	chemoresistance	of	pancreatic	adenocarcinoma	to	
standard	 therapy	 remains	 a	 current	 problem	 and	 at	 least	 partly	 explains	 the	
relatively	poor	survival	associated	with	PDAC	both	in	the	resectable	and	advanced	
setting.	 	 With	 greater	 understanding	 of	 cancer	 biology	 and	 the	 need	 for	 new	
approaches	novel	 therapies	 remain	an	 important	avenue	 to	attempt	 to	overcome	
these	issues.		AT7519	a	novel	CDK	inhibitor	investigated	here	shows	efficacy	in	vitro	
against	 a	 range	 of	 pancreatic	 cancer	 cell	 lines	 and	 activity	 against	 a	 gemcitabine	
resistant	cell	line.		In	cell	cycle	analysis	AT7519	showed	activity	in	line	with	expected	
CDK	inhibition	as	for	mentioned	an	important	pathway	in	cancer	biology	and	its	cell	
cycle	 effects	 in	 combination	 with	 gemcitabine	 offers	 important	 information	
regarding	 the	 dosing	 schedule	 to	 devise	 maximal	 efficacy	 of	 this	 agent	 in	
combination	with	gemcitabine.		The	cytotoxicity	of	AT7519	has	been	demonstrated	
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by	in	vitro	assays	and	in	cell	cycle	studies	and	apoptosis	demonstrated	by	caspase	3	
activity.	 	 	When	downstream	markers	were	 investigated	 the	effects	of	AT7519	on	
key	pathways	in	the	cell	cycle	was	demonstrated	and	again	the	importance	of	dose	
scheduling	highlighted.		The	importance	of	scheduling	AT7519	with	gemcitabine	to	
allow	 both	 agents	 to	 take	 maximal	 effect	 was	 further	 demonstrated	 by	 isobar	
analysis	supporting	the	principle	that	gemcitabine	needs	cells	to	be	diving	in	order	
to	 have	 an	 effect.	 	 In	 a	 murine	 model	 AT7519	 was	 well	 tolerated	 and	 showed	
efficacy	 both	 as	 a	 single	 agent	 and	 in	 combination	with	 gemcitabine	 significantly	
reducing	tumour	burden.		
In	 targeting	 multiple	 pathways	 general	 CDK	 inhibitors	 such	 as	 AT7519	 provide	 a	
promising	 therapeutic	 option	 excerpting	 both	 direct	 cell	 cycle	 and	 transcription	
effects(Malumbres	 2012),	 evidence	 of	 actions	 on	 some	 of	 these	 known	 aberrant	
pathways	have	already	been	investigated.		Fry	et	al	demonstrated	the	activity	of	PD	
000332991	on	tumour	xenografts,	this	CDK	inhibitor	specifically	targets	CDK4	and	6	
and	 therefore	 the	 downstream	 phosphorylation	 of	 Rb(Fry,	 Harvey	 et	 al.	 2004).		
More	 recently	 a	 novel	 CDK	 inhibitor	 Dinaciclib	 was	 demonstrated	 to	 inhibit	
pancreatic	 cancer	 progression	 in	 a	 murine	 model	 and	 its	 CDK5	 inhibition	
hypothesised	to	affect	Ras-mediated	Ral	activation(Feldmann,	Mishra	et	al.	2011).		
Regarding	 the	 use	 of	 CDK	 inhibitors	 in	 pancreatic	 cancer	 the	 important	 question	
remains	that	which	CDKs	or	range	of	CDKs	should	be	target	and	would	provide	the	
optimum	therapeutic	option	for	this	disease.		As	the	knowledge	on	the	genetic	basis	
of	pancreatic	 adenocarcinoma	becomes	 clearer	 this	question	will	 be	more	 readily	
answered,	certainly	the	effects	demonstrated	by	AT7519	offer	promise	and	suggest	
that	at	least	partly	this	selective	CDK	inhibitor	offers	a	useful	therapeutic	option	as	
an	adjunct	to	standard	therapy.		The	information	to	date	on	CDK	inhibitors	support	
the	notion	that	using	these	agents	in	combination	rather	than	monotherapy	offers	
the	most	desirable	therapeutic	avenue.			
	
Combining	 therapies	 is	 desirable	 as	 previously	 discussed	 with	 current	
understanding	of	the	multiple	pathways	related	to	pancreatic	cancer(Jones,	Zhang	
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et	al.	2008;	Greenhalf	and	Thomas	2011).		More	research	is	needed	on	the	reasons	
for	 resistance	 to	 existing	 therapies	 and	 further	 clinical	 trials	 on	 combinations	 of	
gemcitabine	with	agents	that	would	target	cells	resistant	to	gemcitabine.	
	
Conclusion		
The	 key	 to	 the	 future	 of	 adjuvant	 therapy	 in	 pancreatic	 cancer	 will	 be	 the	
identification	 of	 novel	 and	 effective	 agents,	 better	 biomarker	 technology	
underpinned	by	 translational	 research	 that	will	 inform	 the	design	 of	 future	 trials.	
AT7519	 inhibited	 growth	 in	 pancreatic	 cancer	 cell	 lines	 including	 one	 that	 has	
acquired	gemcitabine	resistance	and	was	effective	in	combination	with	gemcitabine	
both	 in	vitro	and	 in	vivo.	 	AT7519	 is	a	promising	agent	for	 further	 investigation	to	
overcome	the	problem	of	acquired	gemcitabine	resistance	in	pancreatic	cancer.	
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